<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Establishment Labs Holdings Inc. Investor Day 2025 June 12, 2025<br><br>Speaker 1: So, we're gonna have an introduction from Peter. And then Jeff Earhardt who heads up North America for us is gonna give us an overview of The United States and the progress we're making here. Speaker 1: We have two panels of plastic surgeons to talk about aesthetics and reconstruction and their experience with Motiva in The United States. And in the half of the meeting, Roberto is going to talk a little bit about our innovation pipeline, and then we have a very timely couple of presentations from a couple of surgeons on GLP-1s in plastic surgery.</td><td>ì„¤ë¦½ ë©ìŠ¤ í™€ë”©ìŠ¤(Establishment Labs Holdings Inc.) íˆ¬ììì˜ ë‚  2025ë…„ 6ì›” 12ì¼<br><br>ë°œí‘œì 1: í”¼í„°ì˜ ì†Œê°œë¡œ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ê·¸ ë‹¤ìŒ ì €í¬ ë¶ë¯¸ ì§€ì—­ì„ ë‹´ë‹¹í•˜ëŠ” ì œí”„ ì–´í•˜íŠ¸(Jeff Earhardt)ê°€ ë¯¸êµ­ ì‹œì¥ê³¼ ì €í¬ê°€ ì´ê³³ì—ì„œ ì´ë£¨ê³  ìˆëŠ” ì§„ì „ì— ëŒ€í•´ ê°œìš”ë¥¼ ì„¤ëª…ë“œë¦´ ì˜ˆì •ì…ë‹ˆë‹¤. <br><br>ë°œí‘œì 1: ë¯¸ìš© ë° ì¬ê±´ ë¶„ì•¼ì™€ ë¯¸êµ­ì—ì„œì˜ ëª¨í‹°ë°”(Motiva) ê²½í—˜ì— ëŒ€í•´ ë…¼ì˜í•  ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ë¡œ êµ¬ì„±ëœ ë‘ ê°œì˜ íŒ¨ë„ì´ ìˆìŠµë‹ˆë‹¤. íšŒì˜ í›„ë°˜ë¶€ì—ëŠ” ë¡œë² ë¥´í† ê°€ ì €í¬ í˜ì‹  íŒŒì´í”„ë¼ì¸ì— ëŒ€í•´ ë§ì”€ë“œë¦´ ì˜ˆì •ì´ë©°, ì„±í˜•ì™¸ê³¼ì—ì„œì˜ GLP-1ì— ê´€í•œ ë§¤ìš° ì‹œì˜ì ì ˆí•œ ë‘ ëª…ì˜ ì™¸ê³¼ì˜ì‚¬ ë°œí‘œê°€ ìˆì„ ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And finally, we're going to have a panel with the plastic surgeons to talk about these new markets and answer some questions you might have. And then finally, we're going to have a session with management where you guys can pepper us all with your questions at the end. We will have time for Q and A throughout with the surgeons and so we have microphones and since we are webcasting, please wait for those before you ask your questions. Speaker 1: We hope to wrap up by about 04:00, so we're going try to keep moving along. And with that, it's my pleasure to turn the call over to Peter Caldini, our CEO. You, Raj.</td><td>ë§ˆì§€ë§‰ìœ¼ë¡œ, ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ê³¼ í•¨ê»˜ ì´ëŸ¬í•œ ìƒˆë¡œìš´ ì‹œì¥ì— ëŒ€í•´ ë…¼ì˜í•˜ê³  ì—¬ëŸ¬ë¶„ì´ ê°€ì§€ê³  ê³„ì‹¤ ìˆ˜ ìˆëŠ” ì§ˆë¬¸ë“¤ì— ë‹µë³€í•˜ëŠ” íŒ¨ë„ ì„¸ì…˜ì„ ì§„í–‰í•˜ê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§ˆì§€ë§‰ì—ëŠ” ê²½ì˜ì§„ê³¼ì˜ ì„¸ì…˜ì„ í†µí•´ ì—¬ëŸ¬ë¶„ê»˜ì„œ ì €í¬ì—ê²Œ ë‹¤ì–‘í•œ ì§ˆë¬¸ì„ í•˜ì‹¤ ìˆ˜ ìˆëŠ” ì‹œê°„ì„ ë§ˆë ¨í–ˆìŠµë‹ˆë‹¤. ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ê³¼ì˜ ì„¸ì…˜ ì „ë°˜ì— ê±¸ì³ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°€ì§ˆ ì˜ˆì •ì´ë©°, ë§ˆì´í¬ê°€ ì¤€ë¹„ë˜ì–´ ìˆê³  ì›¹ìºìŠ¤íŒ… ì¤‘ì´ë¯€ë¡œ ì§ˆë¬¸í•˜ì‹œê¸° ì „ì— ë§ˆì´í¬ë¥¼ ê¸°ë‹¤ë ¤ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. <br><br>ë°œí‘œì 1: ì˜¤í›„ 4ì‹œê²½ì— ë§ˆë¬´ë¦¬í•  ì˜ˆì •ì´ë¯€ë¡œ ê³„ì† ì§„í–‰í•´ ë‚˜ê°€ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ ì €í¬ CEOì¸ í”¼í„° ì¹¼ë””ë‹ˆì—ê²Œ ë°œí‘œë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ë¼ì§€, ë¶€íƒë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 2: Much of the day is going to be focusing on our performance and what's going on in The U. S. Business. I think when you look at the performance to date and we've been off to a great start in The U. S. Speaker 2: And I think you're going hear directly from, Jeff Earhart who runs our commercial operations. In The, U. S, you're also going hear from a lot of surgeons, you're going to hear firsthand from what their experiences have been with, Motiva. But as I mentioned before, I mean we're off to a great start. And in a lot of stances we're actually exceeding our<br><br>expectations in The US market.</td><td>ë°œí‘œì 2: ì˜¤ëŠ˜ í•˜ë£¨ì˜ ëŒ€ë¶€ë¶„ì€ ì €í¬ì˜ ì‹¤ì ê³¼ ë¯¸êµ­ ì‚¬ì—… í˜„í™©ì— ì´ˆì ì„ ë§ì¶œ ì˜ˆì •ì…ë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ì˜ ì‹¤ì ì„ ë³´ë©´ ë¯¸êµ­ì—ì„œ í›Œë¥­í•œ ì¶œë°œì„ ë³´ì´ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. <br><br>ë°œí‘œì 2: ë¯¸êµ­ ìƒì—… ìš´ì˜ì„ ë‹´ë‹¹í•˜ëŠ” ì œí”„ ì–´í•˜íŠ¸(Jeff Earhart)ë¡œë¶€í„° ì§ì ‘ ë“¤ìœ¼ì‹¤ ìˆ˜ ìˆì„ ê²ƒì´ë©°, ë§ì€ ì™¸ê³¼ì˜ì‚¬ë“¤ë¡œë¶€í„°ë„ ë“¤ìœ¼ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ëª¨í‹°ë°”(Motiva)ì— ëŒ€í•œ ê·¸ë“¤ì˜ ê²½í—˜ì„ ì§ì ‘ ë“¤ìœ¼ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì €í¬ëŠ” í›Œë¥­í•œ ì¶œë°œì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§ì€ ê²½ìš°ì— ì‹¤ì œë¡œ ë¯¸êµ­ ì‹œì¥ì—ì„œ ì €í¬ì˜ ê¸°ëŒ€ì¹˜ë¥¼ ë›°ì–´ë„˜ëŠ” ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 2: And you know a lot of that and I think it's important to highlight is the strong results as well as the momentum we have in The U. S. Is really driven by and it's really benefiting from over twenty years of successful global innovation at Establishment Labs. A lot of what Juan Jose Chacona has created is really coming to market in The U. S. Speaker 2: You know, we've sold over 4,000,000 devices worldwide. We have over 200 patents approved as well as pending. And we also have a number of publications, really a testament to the focus on science driven innovation.</td><td>ë°œí‘œì 2: ê·¸ë¦¬ê³  ê°•ì¡°í•˜ê³  ì‹¶ì€ ì¤‘ìš”í•œ ì ì€, ë¯¸êµ­ì—ì„œì˜ ê°•ë ¥í•œ ì‹¤ì ê³¼ ëª¨ë©˜í…€ì´ ì‹¤ì œë¡œ Establishment Labsì˜ 20ë…„ ì´ìƒì— ê±¸ì¹œ ì„±ê³µì ì¸ ê¸€ë¡œë²Œ í˜ì‹ ì— ì˜í•´ ì£¼ë„ë˜ê³  ìˆìœ¼ë©°, ì´ë¡œë¶€í„° í˜œíƒì„ ë°›ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. Juan Jose Chaconaê°€ ì°½ì¡°í•œ ë§ì€ ê²ƒë“¤ì´ ì‹¤ì œë¡œ ë¯¸êµ­ ì‹œì¥ì— ì¶œì‹œë˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 2: ì €í¬ëŠ” ì „ ì„¸ê³„ì ìœ¼ë¡œ 400ë§Œ ê°œ ì´ìƒì˜ ê¸°ê¸°ë¥¼ íŒë§¤í–ˆìŠµë‹ˆë‹¤. ìŠ¹ì¸ëœ íŠ¹í—ˆì™€ ì¶œì› ì¤‘ì¸ íŠ¹í—ˆë¥¼ í•©ì³ 200ê°œ ì´ìƒì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ë‹¤ìˆ˜ì˜ ë…¼ë¬¸ì„ ë°œí‘œí–ˆëŠ”ë°, ì´ëŠ” ê³¼í•™ ì¤‘ì‹¬ì˜ í˜ì‹ ì— ëŒ€í•œ ì§‘ì¤‘ì„ ë³´ì—¬ì£¼ëŠ” ì¦ê±°ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And we're also the only truly global breast aesthetics company in the industry with a broad reach across over 90 markets worldwide. So while we're new to The U. Speaker 2: S. Market, we clearly have a lot of history. And what we've been doing is really leveraging a lot of the learnings and capabilities that we've built over the last twenty years in our launch in The U. S. Market. Speaker 2: Now we have a very broad portfolio of differentiated products that, quite frankly, are unmatched in the industry. We are the clear leaders when it comes to innovation, and we also have the safest products in the market.</td><td>ê·¸ë¦¬ê³  ì €í¬ëŠ” ì „ ì„¸ê³„ 90ê°œ ì´ìƒì˜ ì‹œì¥ì— ê´‘ë²”ìœ„í•˜ê²Œ ì§„ì¶œí•œ ì—…ê³„ ìœ ì¼ì˜ ì§„ì •í•œ ê¸€ë¡œë²Œ ìœ ë°© ë¯¸ìš© íšŒì‚¬ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ê°€ ë¯¸êµ­ ì‹œì¥ì—ëŠ” ìƒˆë¡œ ì§„ì…í–ˆì§€ë§Œ, ë¶„ëª…íˆ ì˜¤ëœ ì—­ì‚¬ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ê°€ í•˜ê³  ìˆëŠ” ê²ƒì€ ì§€ë‚œ 20ë…„ê°„ êµ¬ì¶•í•´ì˜¨ ë§ì€ í•™ìŠµê³¼ ì—­ëŸ‰ì„ ë¯¸êµ­ ì‹œì¥ ì§„ì¶œì— ì‹¤ì œë¡œ í™œìš©í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>í˜„ì¬ ì €í¬ëŠ” ì†”ì§íˆ ë§í•´ì„œ ì—…ê³„ì—ì„œ íƒ€ì˜ ì¶”ì¢…ì„ ë¶ˆí—ˆí•˜ëŠ” ë§¤ìš° ê´‘ë²”ìœ„í•œ ì°¨ë³„í™”ëœ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” í˜ì‹  ë¶„ì•¼ì—ì„œ ëª…í™•í•œ ë¦¬ë”ì´ë©°, ë˜í•œ ì‹œì¥ì—ì„œ ê°€ì¥ ì•ˆì „í•œ ì œí’ˆë“¤ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We've been able to create a spectrum of products that go from reconstruction with flora to our breast augmentation when you look at round and Ergo and Ergo II to our minimally invasive platform, which is really the wave of the future with Preservay and then the premium segment, Mia. We're able to provide value and differentiation at different price points and it's all grounded on superior performance and superior safety. As you go across the spectrum, we add value to our surgeons, increased features to our patients and ultimately, economics to establishment labs. Speaker 2: And I think when you look at The U. S. Business today, we're on the early stage of<br><br>the innovation.</td><td>ì €í¬ëŠ” í”Œë¡œë¼ë¥¼ ì´ìš©í•œ ì¬ê±´ìˆ ë¶€í„° ë¼ìš´ë“œ, ì—ë¥´ê³ , ì—ë¥´ê³  IIë¥¼ í†µí•œ ìœ ë°©í™•ëŒ€ìˆ , ê·¸ë¦¬ê³  ë¯¸ë˜ì˜ íŠ¸ë Œë“œì¸ ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì¸ í”„ë¦¬ì €ë² ì´, ê·¸ë¦¬ê³  í”„ë¦¬ë¯¸ì—„ ì„¸ê·¸ë¨¼íŠ¸ì¸ ë¯¸ì•„ì— ì´ë¥´ê¸°ê¹Œì§€ ë‹¤ì–‘í•œ ì œí’ˆ ìŠ¤í™íŠ¸ëŸ¼ì„ êµ¬ì¶•í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ë‹¤ì–‘í•œ ê°€ê²©ëŒ€ì—ì„œ ê°€ì¹˜ì™€ ì°¨ë³„í™”ë¥¼ ì œê³µí•  ìˆ˜ ìˆìœ¼ë©°, ì´ ëª¨ë“  ê²ƒì€ ìš°ìˆ˜í•œ ì„±ëŠ¥ê³¼ ì•ˆì „ì„±ì„ ê¸°ë°˜ìœ¼ë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì œí’ˆ ìŠ¤í™íŠ¸ëŸ¼ ì „ë°˜ì— ê±¸ì³ ì €í¬ëŠ” ì™¸ê³¼ì˜ì‚¬ë“¤ì—ê²Œ ê°€ì¹˜ë¥¼, í™˜ìë“¤ì—ê²ŒëŠ” í–¥ìƒëœ ê¸°ëŠ¥ì„, ê·¸ë¦¬ê³  ê¶ê·¹ì ìœ¼ë¡œ ì˜ë£Œê¸°ê´€ì—ëŠ” ê²½ì œì  íš¨ìµì„ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 2: ì˜¤ëŠ˜ë‚  ë¯¸êµ­ ì‚¬ì—…ì„ ì‚´í´ë³´ë©´, ì €í¬ëŠ” í˜ì‹ ì˜ ì´ˆê¸° ë‹¨ê³„ì— ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>We only have, right now, Round and ErgoOne, and we also have in terms of Flora for the recon market. So we're in the early stages of this pipeline, and you're going to see over the next two to three years a super cycle of innovation that's really going to help drive the revenue growth, share growth to become a dominant player The U. Speaker 2: S. Market. You're going to hear more about that from Jeff. As I mentioned, we have the safest product in the market. I think a number of people have seen this five year data from the FDA study. Speaker 2: We have less than one percent device related complications.</td><td>í˜„ì¬ ì €í¬ëŠ” Roundì™€ ErgoOneë§Œ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì¬ê±´ ì‹œì¥ì„ ìœ„í•œ Floraë„ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” ì´ íŒŒì´í”„ë¼ì¸ì˜ ì´ˆê¸° ë‹¨ê³„ì— ìˆìœ¼ë©°, í–¥í›„ 2-3ë…„ì— ê±¸ì³ í˜ì‹ ì˜ ìŠˆí¼ ì‚¬ì´í´ì„ ë³´ê²Œ ë˜ì‹¤ ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ë§¤ì¶œ ì„±ì¥ê³¼ ì‹œì¥ ì ìœ ìœ¨ ì„±ì¥ì„ ê²¬ì¸í•˜ì—¬ ë¯¸êµ­ ì‹œì¥ì—ì„œ ì§€ë°°ì ì¸ í”Œë ˆì´ì–´ê°€ ë˜ëŠ” ë° ì •ë§ë¡œ ë„ì›€ì´ ë  ê²ƒì…ë‹ˆë‹¤.<br><br>í™”ì 2: ì´ì— ëŒ€í•´ì„œëŠ” Jeffë¡œë¶€í„° ë” ìì„¸í•œ ë‚´ìš©ì„ ë“¤ìœ¼ì‹œê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì œê°€ ì–¸ê¸‰í–ˆë“¯ì´, ì €í¬ëŠ” ì‹œì¥ì—ì„œ ê°€ì¥ ì•ˆì „í•œ ì œí’ˆì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ì€ ë¶„ë“¤ì´ FDA ì—°êµ¬ì˜ 5ë…„ ë°ì´í„°ë¥¼ ë³´ì…¨ì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤.<br><br>í™”ì 2: ì €í¬ëŠ” ê¸°ê¸° ê´€ë ¨ í•©ë³‘ì¦ì´ 1% ë¯¸ë§Œì…ë‹ˆë‹¤.</td></tr>
<tr><td>And in a lot of respects, we're almost 10 times better performance than what you've seen of competitive products in the same type of FDA study in The U. S. So really the foundation, not only driving true innovation, science driven innovation, it's also around a strong safety platform. Now, we have a global very broad global footprint. Speaker 2: We're across 90 countries, some through a direct business where it's our own people, our own sales and distribution capabilities where we commercialize the product. And in a number of markets, we have distributors. A key milestone, obviously, is when we got approval for The U. S. Market. Speaker 2: We're off to a tremendous start The U. S.</td><td>ê·¸ë¦¬ê³  ì—¬ëŸ¬ ë©´ì—ì„œ ë³¼ ë•Œ, ì €í¬ëŠ” ë¯¸êµ­ ë‚´ ë™ì¼í•œ ìœ í˜•ì˜ FDA ì—°êµ¬ì—ì„œ ê²½ìŸ ì œí’ˆë“¤ì´ ë³´ì—¬ì¤€ ê²ƒë³´ë‹¤ ê±°ì˜ 10ë°° ë” ë‚˜ì€ ì„±ëŠ¥ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì§„ì •í•œ í˜ì‹ , ê³¼í•™ ê¸°ë°˜ í˜ì‹ ì„ ì¶”ì§„í•  ë¿ë§Œ ì•„ë‹ˆë¼ ê°•ë ¥í•œ ì•ˆì „ì„± í”Œë«í¼ì„ ê¸°ë°˜ìœ¼ë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì €í¬ëŠ” ë§¤ìš° ê´‘ë²”ìœ„í•œ ê¸€ë¡œë²Œ ì‚¬ì—… ê¸°ë°˜ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>í™”ì 2: ì €í¬ëŠ” 90ê°œêµ­ì— ì§„ì¶œí•´ ìˆìœ¼ë©°, ì¼ë¶€ëŠ” ìì²´ ì¸ë ¥ê³¼ ì˜ì—… ë° ìœ í†µ ì—­ëŸ‰ì„ í†µí•´ ì œí’ˆì„ ìƒìš©í™”í•˜ëŠ” ì§ì ‘ ì‚¬ì—… ë°©ì‹ìœ¼ë¡œ, ê·¸ë¦¬ê³  ì—¬ëŸ¬ ì‹œì¥ì—ì„œëŠ” ìœ í†µì—…ì²´ë¥¼ í†µí•´ ìš´ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¶„ëª…íˆ ì¤‘ìš”í•œ ì´ì •í‘œëŠ” ë¯¸êµ­ ì‹œì¥ ìŠ¹ì¸ì„ ë°›ì€ ê²ƒì…ë‹ˆë‹¤.<br><br>í™”ì 2: ì €í¬ëŠ” ë¯¸êµ­ì—ì„œ ì—„ì²­ë‚œ ì¶œë°œì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And a lot of it is driven by the unique products, the pipeline that we're bringing to The U. S. As well as we have a best in class organization in The U. Speaker 2: S. And probably one of the best in the aesthetics industry. When you look at the OUS market, I think there's always a number of questions in terms of the macroeconomic environment. There's been a little bit of choppiness, I think, in recent past. But what we've seen, especially with the tariff discussions, we haven't seen any significant impact in the type<br><br>of demand.</td><td>ê·¸ë¦¬ê³  ì´ëŠ” ëŒ€ë¶€ë¶„ ë¯¸êµ­ì— ë„ì…í•˜ê³  ìˆëŠ” ë…íŠ¹í•œ ì œí’ˆë“¤ê³¼ íŒŒì´í”„ë¼ì¸ì— ì˜í•´ ì£¼ë„ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì €í¬ëŠ” ë¯¸êµ­ ë‚´ì—ì„œ ì—…ê³„ ìµœê³  ìˆ˜ì¤€ì˜ ì¡°ì§ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì•„ë§ˆë„ ë¯¸ìš© ì—…ê³„ì—ì„œ ìµœê³  ì¤‘ í•˜ë‚˜ì¼ ê²ƒì…ë‹ˆë‹¤. <br><br>í•´ì™¸ ì‹œì¥ì„ ì‚´í´ë³´ë©´, ê±°ì‹œê²½ì œ í™˜ê²½ê³¼ ê´€ë ¨í•´ì„œ í•­ìƒ ì—¬ëŸ¬ ê°€ì§€ ì˜ë¬¸ì ë“¤ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ìµœê·¼ì— ì•½ê°„ì˜ ë³€ë™ì„±ì´ ìˆì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ íŠ¹íˆ ê´€ì„¸ ë…¼ì˜ì™€ ê´€ë ¨í•´ì„œ ì €í¬ê°€ í™•ì¸í•œ ë°”ë¡œëŠ”, ìˆ˜ìš” ì¸¡ë©´ì—ì„œ ì–´ë– í•œ ì¤‘ëŒ€í•œ ì˜í–¥ë„ ë³´ì§€ ëª»í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 2: But as an organization, we're going to continue to be very vigilant in terms of managing it, finding if there's any changes in that, course correcting, reallocating resources to different markets. When you look at the OUS market, a lot of this year is going be focusing on enhancing our operational commercial capabilities, while at the same time continuing to drive the minimally invasive platform to drive share in a lot of our markets, primarily in our direct markets. So, when I joined Establishment Lab, what really got me excited was really marrying the tremendous technology, the innovation that we have, and the strong and enhanced execution capabilities.</td><td>í™”ì 2: í•˜ì§€ë§Œ ì¡°ì§ìœ¼ë¡œì„œ ìš°ë¦¬ëŠ” ì´ë¥¼ ê´€ë¦¬í•˜ê³ , ë³€í™”ê°€ ìˆëŠ”ì§€ íŒŒì•…í•˜ë©°, ë°©í–¥ì„ ìˆ˜ì •í•˜ê³ , ë‹¤ë¥¸ ì‹œì¥ìœ¼ë¡œ ìì›ì„ ì¬ë°°ë¶„í•˜ëŠ” ë° ìˆì–´ ê³„ì†í•´ì„œ ë§¤ìš° ê²½ê³„ì‹¬ì„ ëŠ¦ì¶”ì§€ ì•Šì„ ê²ƒì…ë‹ˆë‹¤. í•´ì™¸ ì‹œì¥ì„ ì‚´í´ë³´ë©´, ì˜¬í•´ ìƒë‹¹ ë¶€ë¶„ì€ ìš´ì˜ ë° ìƒì—…ì  ì—­ëŸ‰ì„ ê°•í™”í•˜ëŠ” ë° ì§‘ì¤‘í•˜ëŠ” ë™ì‹œì—, ì£¼ë¡œ ì§ì ‘ ì‹œì¥ì—ì„œ ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì„ ì§€ì†ì ìœ¼ë¡œ ì¶”ì§„í•˜ì—¬ ë§ì€ ì‹œì¥ì—ì„œ ì ìœ ìœ¨ì„ í™•ëŒ€í•˜ëŠ” ë° ì´ˆì ì„ ë§ì¶œ ê²ƒì…ë‹ˆë‹¤. ì œê°€ ì—ìŠ¤íƒœë¸”ë¦¬ì‹œë¨¼íŠ¸ ë©ì— í•©ë¥˜í–ˆì„ ë•Œ ì •ë§ í¥ë¯¸ì§„ì§„í–ˆë˜ ê²ƒì€ ìš°ë¦¬ê°€ ë³´ìœ í•œ ë›°ì–´ë‚œ ê¸°ìˆ ê³¼ í˜ì‹ ì„ ê°•ë ¥í•˜ê³  í–¥ìƒëœ ì‹¤í–‰ ì—­ëŸ‰ê³¼ ê²°í•©í•˜ëŠ” ê²ƒì´ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So if you look at our priorities this year, number one, our objective is to deliver on our financial targets from a revenue standpoint as well as profitability. And, these are our priorities that we really use to really reallocate and allocate our resources within the organization around these priorities. Speaker 2: And, you know, a lot of that is not just financial, it's also personnel. So obviously, The U. S. Is one of our key priorities for this year and beyond, and we want to make sure that we continue to provide the resources within the organization to make sure we continue to fuel that growth in The U. S.</td><td>ì˜¬í•´ ì €í¬ì˜ ìš°ì„ ìˆœìœ„ë¥¼ ì‚´í´ë³´ë©´, ì²« ë²ˆì§¸ë¡œ ë§¤ì¶œ ê´€ì ì—ì„œë¿ë§Œ ì•„ë‹ˆë¼ ìˆ˜ìµì„± ê´€ì ì—ì„œë„ ì¬ë¬´ ëª©í‘œë¥¼ ë‹¬ì„±í•˜ëŠ” ê²ƒì´ ì €í¬ì˜ ëª©í‘œì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ìš°ì„ ìˆœìœ„ë“¤ì€ ì €í¬ê°€ ì¡°ì§ ë‚´ì—ì„œ ì´ëŸ¬í•œ ìš°ì„ ìˆœìœ„ë¥¼ ì¤‘ì‹¬ìœ¼ë¡œ ìì›ì„ ì¬ë°°ë¶„í•˜ê³  ë°°ë¶„í•˜ëŠ” ë° ì‹¤ì œë¡œ ì‚¬ìš©í•˜ëŠ” ê¸°ì¤€ì…ë‹ˆë‹¤.<br><br>í™”ì 2: ê·¸ë¦¬ê³  ì•„ì‹œë‹¤ì‹œí”¼, ê·¸ ì¤‘ ìƒë‹¹ ë¶€ë¶„ì€ ì¬ë¬´ì ì¸ ê²ƒë¿ë§Œ ì•„ë‹ˆë¼ ì¸ë ¥ê³¼ë„ ê´€ë ¨ì´ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë¶„ëª…íˆ ë¯¸êµ­ì€ ì˜¬í•´ì™€ ê·¸ ì´í›„ì˜ í•µì‹¬ ìš°ì„ ìˆœìœ„ ì¤‘ í•˜ë‚˜ì´ë©°, ì €í¬ëŠ” ë¯¸êµ­ì—ì„œì˜ ì„±ì¥ì„ ì§€ì†ì ìœ¼ë¡œ ê²¬ì¸í•  ìˆ˜ ìˆë„ë¡ ì¡°ì§ ë‚´ì—ì„œ ê³„ì†í•´ì„œ ìì›ì„ ì œê³µí•˜ê³ ì í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 2: Minimally invasive is a key driver for us in the OUS markets with Prezervay and Mia. And then it's really focusing on driving efficiency and profitability in the organization. We've made a lot of great strides in this area. And it's not just about driving profitability, it's what I<br>said before, enhancing a lot of our commercial and operational capabilities so we continue to drive top line growth in the marketplace. And then the real foundation for this company and the legacy that JJ has created is around the innovation pipeline. Speaker 2: We have a lot of great products and ready to be launched in The U. S.</td><td>**ë°œí‘œì 2**: ìµœì†Œì¹¨ìŠµ ê¸°ìˆ ì€ Prezervayì™€ Miaë¥¼ í†µí•´ í•´ì™¸ ì‹œì¥ì—ì„œ ì €í¬ì˜ í•µì‹¬ ì„±ì¥ ë™ë ¥ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¡°ì§ì˜ íš¨ìœ¨ì„±ê³¼ ìˆ˜ìµì„± í–¥ìƒì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë¶„ì•¼ì—ì„œ ë§ì€ í›Œë¥­í•œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë‹¨ìˆœíˆ ìˆ˜ìµì„± í–¥ìƒë§Œì„ ìœ„í•œ ê²ƒì´ ì•„ë‹ˆë¼, ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ ì‹œì¥ì—ì„œ ì§€ì†ì ì¸ ë§¤ì¶œ ì„±ì¥ì„ ê²¬ì¸í•  ìˆ˜ ìˆë„ë¡ ìƒì—…ì  ë° ìš´ì˜ ì—­ëŸ‰ì„ í¬ê²Œ ê°•í™”í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ íšŒì‚¬ì˜ ì§„ì •í•œ ê¸°ë°˜ì´ì JJê°€ êµ¬ì¶•í•œ ìœ ì‚°ì€ í˜ì‹  íŒŒì´í”„ë¼ì¸ì…ë‹ˆë‹¤.<br><br>**ë°œí‘œì 2**: ë¯¸êµ­ì—ì„œ ì¶œì‹œí•  ì¤€ë¹„ê°€ ëœ ë§ì€ í›Œë¥­í•œ ì œí’ˆë“¤ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>But we're also<br><br>looking at what's the next generation things that we're working on. You're going to hear a lot more about that from Roberto. So how are we tracking so far this year? Speaker 2: You know as we mentioned before, very confident in our guidance of $2.05 to $2.1 You know we believe with a strong start in The U. S, we're going to be meaningfully exceeding our 35,000,000 We're off to a good pace in Q2. We expect to exceed $9,500,000 in revenue. And then you look at the OUS market, we're expecting mid single digit growth and as I mentioned before, we really haven't seen any dynamics related to the macroeconomic environment.</td><td>í•˜ì§€ë§Œ ì €í¬ëŠ” ë˜í•œ í˜„ì¬ ì‘ì—… ì¤‘ì¸ ì°¨ì„¸ëŒ€ ê¸°ìˆ ë“¤ì´ ë¬´ì—‡ì¸ì§€ë„ ì‚´í´ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ì— ëŒ€í•´ì„œëŠ” Robertoë¡œë¶€í„° ë” ìì„¸í•œ ë‚´ìš©ì„ ë“¤ìœ¼ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ì˜¬í•´ ì§€ê¸ˆê¹Œì§€ ì €í¬ê°€ ì–´ë–»ê²Œ ì§„í–‰ë˜ê³  ìˆëŠ”ì§€ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 2: ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì €í¬ëŠ” 2.05ë‹¬ëŸ¬ì—ì„œ 2.1ë‹¬ëŸ¬ì˜ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œì˜ ê°•ë ¥í•œ ì¶œë°œê³¼ í•¨ê»˜, ì €í¬ëŠ” 3,500ë§Œ ë‹¬ëŸ¬ë¥¼ ì˜ë¯¸ ìˆê²Œ ì´ˆê³¼í•  ê²ƒìœ¼ë¡œ ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. 2ë¶„ê¸°ì—ë„ ì¢‹ì€ ì†ë„ë¡œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë§¤ì¶œì—ì„œ 950ë§Œ ë‹¬ëŸ¬ë¥¼ ì´ˆê³¼í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  í•´ì™¸ ì‹œì¥ì„ ë³´ë©´, ì €í¬ëŠ” ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´ ê±°ì‹œê²½ì œ í™˜ê²½ê³¼ ê´€ë ¨ëœ ì–´ë–¤ ì—­í•™ë„ ì‹¤ì œë¡œ ë³´ì§€ ëª»í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We launched PRESIVE in Latin America and EMEA and we're off to a great start, very strong initial demand, a lot of commitments from surgeons and clinics. Speaker 2: We continue to enhance our gross margin with the growth in The U. S, but also as we expand our portfolio into the minimally invasive platform. And we've done a lot of work as it relates to operating expenses. Since going back to 2023, we've reduced close to 30% operating expenses in our corporate structure as well as OUS, while at the same time we're building up our capabilities in The U. S. Speaker 2: Market. And a key target and we're still on target to achieve this in 2025 is to be EBITDA positive.</td><td>ì €í¬ëŠ” ë¼í‹´ ì•„ë©”ë¦¬ì¹´ì™€ EMEA ì§€ì—­ì—ì„œ PRESIVEë¥¼ ì¶œì‹œí–ˆìœ¼ë©°, ë§¤ìš° ì¢‹ì€ ì¶œë°œì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì´ˆê¸° ìˆ˜ìš”ê°€ ë§¤ìš° ê°•ë ¥í•˜ê³ , ì™¸ê³¼ì˜ì‚¬ë“¤ê³¼ í´ë¦¬ë‹‰ë“¤ë¡œë¶€í„° ë§ì€ ì•½ì†ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 2: ì €í¬ëŠ” ë¯¸êµ­ ë‚´ ì„±ì¥ê³¼ í•¨ê»˜ ì´ ë§ˆì§„ì„ ì§€ì†ì ìœ¼ë¡œ ê°œì„ í•˜ê³  ìˆìœ¼ë©°, ìµœì†Œ ì¹¨ìŠµ í”Œë«í¼ìœ¼ë¡œ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ í™•ì¥í•˜ë©´ì„œë„ ì´ë¥¼ ë‹¬ì„±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš´ì˜ë¹„ìš©ê³¼ ê´€ë ¨í•´ì„œë„ ë§ì€ ì‘ì—…ì„ í•´ì™”ìŠµë‹ˆë‹¤. 2023ë…„ìœ¼ë¡œ ëŒì•„ê°€ì„œ ë³´ë©´, ì €í¬ëŠ” ê¸°ì—… êµ¬ì¡°ì™€ í•´ì™¸ ì‚¬ì—…ë¶€ë¬¸ì—ì„œ ìš´ì˜ë¹„ìš©ì„ ê±°ì˜ 30% ê°ì¶•í–ˆìœ¼ë©°, ë™ì‹œì— ë¯¸êµ­ ì‹œì¥ì—ì„œì˜ ì—­ëŸ‰ì„ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 2: ê·¸ë¦¬ê³  í•µì‹¬ ëª©í‘œì´ì 2025ë…„ì— ë‹¬ì„±í•  ì˜ˆì •ì¸ ëª©í‘œëŠ” EBITDA í‘ì ì „í™˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Looking beyond 2025, you know, with the continued growth in The U. S, with the pipeline that we have, we're expecting to continue 20% growth over the next three years. We're going to continue as an organization focusing on driving efficiency and healthy growth. Speaker 2: There's going to be a lot of focus on the minimally invasive platform that will enable us to become a clear leader in the industry and also a lot of focus on driving to cash flow positive in 2026. So that's a quick summary of where we are as an organization.</td><td>2025ë…„ì„ ë„˜ì–´ì„œ ë³´ë©´, ë¯¸êµ­ì—ì„œì˜ ì§€ì†ì ì¸ ì„±ì¥ê³¼ ë³´ìœ í•˜ê³  ìˆëŠ” íŒŒì´í”„ë¼ì¸ì„ í†µí•´ í–¥í›„ 3ë…„ê°„ 20% ì„±ì¥ì„ ì§€ì†í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¡°ì§ìœ¼ë¡œì„œ íš¨ìœ¨ì„± ì œê³ ì™€ ê±´ì „í•œ ì„±ì¥ ì¶”ì§„ì— ê³„ì† ì§‘ì¤‘í•  ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 2: ì—…ê³„ì—ì„œ í™•ì‹¤í•œ ë¦¬ë”ê°€ ë  ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì— ë§ì€ ì§‘ì¤‘ì„ í•  ê²ƒì´ë©°, ë˜í•œ 2026ë…„ í˜„ê¸ˆíë¦„ í‘ì ë‹¬ì„±ì„ ìœ„í•´ ë§ì€ ë…¸ë ¥ì„ ê¸°ìš¸ì¼ ê²ƒì…ë‹ˆë‹¤. ì´ìƒì´ ì¡°ì§ìœ¼ë¡œì„œ ìš°ë¦¬ê°€ í˜„ì¬ ì–´ë””ì— ìˆëŠ”ì§€ì— ëŒ€í•œ ê°„ëµí•œ ìš”ì•½ì…ë‹ˆë‹¤.</td></tr>
<tr><td>A lot of great progress in the last two years in terms of achieving profitability, but it's really built on a lot of the innovation and successful innovation we've had in the last twenty years. So with that, I'm<br><br>going to pass it over to, Jeff. Speaker 3: Thanks, Pete. As Pete said, we are very excited about the progress that we've made with the launch here in The United States. Almost as happy as I am about whoever put that highly sensationalized photo of me up on the screen. But we had five key priorities as we entered the launch year here in 2025. The one being to staff The U. Speaker 3: S. Organization with best in class talent.</td><td>ì§€ë‚œ 2ë…„ê°„ ìˆ˜ìµì„± ë‹¬ì„± ì¸¡ë©´ì—ì„œ ë§ì€ í›Œë¥­í•œ ì§„ì „ì„ ì´ë£¨ì—ˆì§€ë§Œ, ì´ëŠ” ì‹¤ì œë¡œ ì§€ë‚œ 20ë…„ê°„ ìš°ë¦¬ê°€ ì´ë£¬ ë§ì€ í˜ì‹ ê³¼ ì„±ê³µì ì¸ í˜ì‹ ì„ ê¸°ë°˜ìœ¼ë¡œ êµ¬ì¶•ëœ ê²ƒì…ë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Jeffì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Speaker 3: ê³ ë§™ìŠµë‹ˆë‹¤, Pete. Peteê°€ ë§í–ˆë“¯ì´, ìš°ë¦¬ëŠ” ì—¬ê¸° ë¯¸êµ­ì—ì„œì˜ ì¶œì‹œì™€ í•¨ê»˜ ì´ë£¬ ì§„ì „ì— ëŒ€í•´ ë§¤ìš° ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤. í™”ë©´ì— ì œ ë§¤ìš° ì„ ì •ì ì¸ ì‚¬ì§„ì„ ì˜¬ë¦° ë¶„ë§Œí¼ì´ë‚˜ ê¸°ì©ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ëŠ” 2025ë…„ ì¶œì‹œ ì—°ë„ì— ë“¤ì–´ì„œë©´ì„œ 5ê°€ì§€ í•µì‹¬ ìš°ì„ ìˆœìœ„ë¥¼ ê°€ì§€ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ëŠ” ë¯¸êµ­ ì¡°ì§ì— ìµœê³  ìˆ˜ì¤€ì˜ ì¸ì¬ë¥¼ ë°°ì¹˜í•˜ëŠ” ê²ƒì´ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And I'm super excited to say that every single person in the field sales organization came from a competitive plastic surgery organization in The U. S. Marketplace. Speaker 3: And most of them from a most of them had implant experience in their background. The reason why that's so important is because they not only come with relationships with plastic surgeons that we're obviously trying to target, but it also shortens the training time for them to come on board and ultimately become effective in the field and start to drive revenue.</td><td>ê·¸ë¦¬ê³  í˜„ì¥ ì˜ì—… ì¡°ì§ì˜ ëª¨ë“  êµ¬ì„±ì›ì´ ë¯¸êµ­ ì‹œì¥ì˜ ê²½ìŸ ì„±í˜•ì™¸ê³¼ ì¡°ì§ ì¶œì‹ ì´ë¼ëŠ” ì ì„ ë§ì”€ë“œë¦¬ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì©ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ê·¸ë¦¬ê³  ê·¸ë“¤ ëŒ€ë¶€ë¶„ì´ ì„í”Œë€íŠ¸ ê²½í—˜ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë§¤ìš° ì¤‘ìš”í•œ ì´ìœ ëŠ” ê·¸ë“¤ì´ ìš°ë¦¬ê°€ ëª…ë°±íˆ íƒ€ê²Ÿìœ¼ë¡œ í•˜ê³  ìˆëŠ” ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ê³¼ì˜ ê´€ê³„ë¥¼ ê°€ì§€ê³  ìˆì„ ë¿ë§Œ ì•„ë‹ˆë¼, ê·¸ë“¤ì´ í•©ë¥˜í•˜ì—¬ í˜„ì¥ì—ì„œ íš¨ê³¼ì ìœ¼ë¡œ ì—…ë¬´ë¥¼ ìˆ˜í–‰í•˜ê³  ê¶ê·¹ì ìœ¼ë¡œ ë§¤ì¶œì„ ê²¬ì¸í•˜ê¸° ì‹œì‘í•˜ëŠ” ë° í•„ìš”í•œ êµìœ¡ ì‹œê°„ì„ ë‹¨ì¶•ì‹œì¼œ ì£¼ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Another key thing that we needed to do is to build out a very easy to navigate interface for our customers in order to handle the kind of transactional volume that we anticipate in The U. S. And I'm happy to say that more than 75% of our orders go through our ordering platform, which means it's not being touched by an actual customer service agent, right? Speaker 3: So it goes through automatically. So less errors, but also you end up with the need for a smaller customer service headcount, right? So it saves us money and makes us more efficient. And related to that is that we wanted to build out permanent consignments in our targeted and our biggest and best customers in The U. S.</td><td>ë˜ ë‹¤ë¥¸ í•µì‹¬ ê³¼ì œëŠ” ë¯¸êµ­ì—ì„œ ì˜ˆìƒë˜ëŠ” ê±°ë˜ëŸ‰ì„ ì²˜ë¦¬í•  ìˆ˜ ìˆë„ë¡ ê³ ê°ë“¤ì´ ë§¤ìš° ì‰½ê²Œ íƒìƒ‰í•  ìˆ˜ ìˆëŠ” ì¸í„°í˜ì´ìŠ¤ë¥¼ êµ¬ì¶•í•˜ëŠ” ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. ê¸°ì˜ê²Œë„ ì €í¬ ì£¼ë¬¸ì˜ 75% ì´ìƒì´ ì£¼ë¬¸ í”Œë«í¼ì„ í†µí•´ ì²˜ë¦¬ë˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì‹¤ì œ ê³ ê° ì„œë¹„ìŠ¤ ë‹´ë‹¹ìì˜ ê°œì… ì—†ì´ ì²˜ë¦¬ëœë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤.<br><br>í™”ì 3: ë”°ë¼ì„œ ìë™ìœ¼ë¡œ ì²˜ë¦¬ë©ë‹ˆë‹¤. ì˜¤ë¥˜ê°€ ì¤„ì–´ë“¤ ë¿ë§Œ ì•„ë‹ˆë¼ ê³ ê° ì„œë¹„ìŠ¤ ì¸ë ¥ ê·œëª¨ë„ ì¶•ì†Œí•  ìˆ˜ ìˆì–´ ë¹„ìš©ì„ ì ˆê°í•˜ê³  íš¨ìœ¨ì„±ì„ ë†’ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ì™€ ê´€ë ¨í•˜ì—¬ ì €í¬ëŠ” ë¯¸êµ­ ë‚´ íƒ€ê²Ÿ ê³ ê°ë“¤ê³¼ ìµœëŒ€ ìš°ëŸ‰ ê³ ê°ë“¤ì—ê²Œ ì˜êµ¬ ìœ„íƒíŒë§¤ ì„œë¹„ìŠ¤ë¥¼ êµ¬ì¶•í•˜ê³ ì í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 3: 200 is our number, not quite midway through the year. We are well over 100 consignments placed. Reason why that's important is because that saves you a lot of money and time and efficiency in the ordering and the flow of product back and between the accounts,<br><br>right. It's very costly to ship the devices back and But also, of course, if the product is on the shelf, you are more likely to be used in that plastic surgeon's practice.</td><td>í™”ì 3: 200ê°œê°€ ì €í¬ ëª©í‘œ ìˆ˜ì¹˜ì´ê³ , ì—°ì¤‘ ì¤‘ë°˜ì— ì•„ì§ ë„ë‹¬í•˜ì§€ ëª»í–ˆì§€ë§Œ 100ê°œ ì´ìƒì˜ ìœ„íƒ íŒë§¤ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì¤‘ìš”í•œ ì´ìœ ëŠ” ì£¼ë¬¸ ê³¼ì •ê³¼ ê±°ë˜ì²˜ ê°„ ì œí’ˆ ìœ í†µì—ì„œ ìƒë‹¹í•œ ë¹„ìš©ê³¼ ì‹œê°„ì„ ì ˆì•½í•˜ê³  íš¨ìœ¨ì„±ì„ ë†’ì¼ ìˆ˜ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>ë§ìŠµë‹ˆë‹¤. ê¸°ê¸°ë¥¼ ë‹¤ì‹œ ë°°ì†¡í•˜ëŠ” ë°ëŠ” ë¹„ìš©ì´ ë§ì´ ë“¤ì§€ë§Œ, ë¬¼ë¡  ì œí’ˆì´ ì§„ì—´ëŒ€ì— ìˆìœ¼ë©´ í•´ë‹¹ ì„±í˜•ì™¸ê³¼ ë³‘ì›ì—ì„œ ì‚¬ìš©ë  ê°€ëŠ¥ì„±ì´ í›¨ì”¬ ë†’ì•„ì§‘ë‹ˆë‹¤.</td></tr>
<tr><td>And then from an actual executional focus with the field and the commercial organization, Two major initiatives here, surgeon training and engagement as well as raising overall brand awareness in the target patient population, which I will talk more about in just a minute. Speaker 3: And of course, ultimately, are trying to drive towards the $35,000,000 plus target that we have for this year for 2025 in The U. S. I'm sure that you saw the $6,200,000 that we announced in Q1. And as Pete just mentioned, right now based on our current run rate, we'll be between 9,500,000.0 and $10,000,000 for Q2. So I am sure you are doing the calculation quickly in your head.</td><td>ê·¸ë¦¬ê³  í˜„ì¥ ë° ì˜ì—… ì¡°ì§ê³¼ì˜ ì‹¤ì œ ì‹¤í–‰ ì¤‘ì‹¬ ê´€ì ì—ì„œ ë³´ë©´, ë‘ ê°€ì§€ ì£¼ìš” ì´ë‹ˆì…”í‹°ë¸Œê°€ ìˆìŠµë‹ˆë‹¤. ì™¸ê³¼ì˜ êµìœ¡ ë° ì°¸ì—¬ í™•ëŒ€, ê·¸ë¦¬ê³  ëª©í‘œ í™˜ìêµ°ì—ì„œì˜ ì „ë°˜ì ì¸ ë¸Œëœë“œ ì¸ì§€ë„ ì œê³ ì…ë‹ˆë‹¤. ì´ì— ëŒ€í•´ì„œëŠ” ì ì‹œ í›„ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ê·¸ë¦¬ê³  ë¬¼ë¡  ê¶ê·¹ì ìœ¼ë¡œëŠ” ì˜¬í•´ 2025ë…„ ë¯¸êµ­ì—ì„œ 3,500ë§Œ ë‹¬ëŸ¬ ì´ìƒì´ë¼ëŠ” ëª©í‘œ ë‹¬ì„±ì„ ìœ„í•´ ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. 1ë¶„ê¸°ì— ë°œí‘œí•œ 620ë§Œ ë‹¬ëŸ¬ë¥¼ ë³´ì…¨ì„ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  Peteê°€ ë°©ê¸ˆ ì–¸ê¸‰í–ˆë“¯ì´, í˜„ì¬ ì§„í–‰ë¥ ì„ ê¸°ì¤€ìœ¼ë¡œ 2ë¶„ê¸°ì—ëŠ” 950ë§Œ ë‹¬ëŸ¬ì—ì„œ 1,000ë§Œ ë‹¬ëŸ¬ ì‚¬ì´ê°€ ë  ê²ƒì…ë‹ˆë‹¤. ì§€ê¸ˆ ë¨¸ë¦¿ì†ìœ¼ë¡œ ë¹ ë¥´ê²Œ ê³„ì‚°í•˜ê³  ê³„ì‹¤ ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 3: That means clearly we are going to meaningfully exceed the $35,000,000 in The U. S. This year. So from a surgeon training and engagement standpoint, this is really our major executional focus in the field. We've taken last year, we took four groups and it's usually 20 to<br>25 surgeons down to our facility in Costa Rica. Speaker 3: This year, we'll do another eight, groups to the facility there.</td><td>ë°œí‘œì 3: ì´ëŠ” ì˜¬í•´ ë¯¸êµ­ì—ì„œ 3,500ë§Œ ë‹¬ëŸ¬ë¥¼ ì˜ë¯¸ ìˆê²Œ ì´ˆê³¼í•  ê²ƒì„ì„ ëª…í™•íˆ ë³´ì—¬ì¤ë‹ˆë‹¤. ë”°ë¼ì„œ ì™¸ê³¼ì˜ êµìœ¡ ë° ì°¸ì—¬ ê´€ì ì—ì„œ, ì´ê²ƒì´ í˜„ì¥ì—ì„œ ìš°ë¦¬ì˜ ì£¼ìš” ì‹¤í–‰ ì¤‘ì ì‚¬í•­ì…ë‹ˆë‹¤. ì‘ë…„ì— ìš°ë¦¬ëŠ” 4ê°œ ê·¸ë£¹ì„ ëŒ€ìƒìœ¼ë¡œ í–ˆìœ¼ë©°, ë³´í†µ 20ëª…ì—ì„œ 25ëª…ì˜ ì™¸ê³¼ì˜ë¥¼ ì½”ìŠ¤íƒ€ë¦¬ì¹´ì— ìˆëŠ” ìš°ë¦¬ ì‹œì„¤ë¡œ ëª¨ì…¨ìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 3: ì˜¬í•´ì—ëŠ” ê·¸ê³³ ì‹œì„¤ë¡œ ì¶”ê°€ë¡œ 8ê°œ ê·¸ë£¹ì„ ëª¨ì‹¤ ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And so in total, we'll be over 200 surgeons by the end of the year that have spent basically two days with an immersion program effectively learning about the data, the science, taking a tour of our manufacturing facility and trying to understand the quality of the devices and the care that goes into creating those devices. And then that culminates on the day where they actually either get to participate or they observe live surgery in our surgery suite that's inside our facility, but nobody else in the industry has that kind of experience or that capability. So we are leveraging that significantly.</td><td>ê·¸ë˜ì„œ ì´í•©ì ìœ¼ë¡œ, ì—°ë§ê¹Œì§€ 200ëª… ì´ìƒì˜ ì™¸ê³¼ì˜ë“¤ì´ ê¸°ë³¸ì ìœ¼ë¡œ ì´í‹€ê°„ì˜ ëª°ì… í”„ë¡œê·¸ë¨ì„ í†µí•´ ë°ì´í„°ì™€ ê³¼í•™ì— ëŒ€í•´ í•™ìŠµí•˜ê³ , ì €í¬ ì œì¡° ì‹œì„¤ì„ ê²¬í•™í•˜ë©°, ê¸°ê¸°ì˜ í’ˆì§ˆê³¼ ê·¸ëŸ¬í•œ ê¸°ê¸°ë¥¼ ì œì‘í•˜ëŠ” ë° ë“¤ì–´ê°€ëŠ” ì„¸ì‹¬í•œ ê´€ë¦¬ì— ëŒ€í•´ ì´í•´í•˜ëŠ” ì‹œê°„ì„ ê°€ì§ˆ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŠ” ì‹¤ì œë¡œ ì €í¬ ì‹œì„¤ ë‚´ë¶€ì— ìˆëŠ” ìˆ˜ìˆ ì‹¤ì—ì„œ ì‹¤ì œ ìˆ˜ìˆ ì— ì°¸ì—¬í•˜ê±°ë‚˜ ê´€ì°°í•˜ëŠ” ë‚ ë¡œ ë§ˆë¬´ë¦¬ë©ë‹ˆë‹¤. ì—…ê³„ì˜ ë‹¤ë¥¸ ì–´ë–¤ íšŒì‚¬ë„ ì´ëŸ° ì¢…ë¥˜ì˜ ê²½í—˜ì´ë‚˜ ì—­ëŸ‰ì„ ë³´ìœ í•˜ê³  ìˆì§€ ì•ŠìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” ì´ë¥¼ ìƒë‹¹íˆ ì ê·¹ì ìœ¼ë¡œ í™œìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And of course, as they leave the experience in Costa Rica, they are obviously more comfortable and they understand the devices. Speaker 3: And when a surgeon is more comfortable with a device that feels very confident in them, they ultimately, of course, tend to use more devices immediately thereafter. For those who can't attend Costa Rica, we have preceptor ships or master classes and this is various investigators around the country that will essentially give them the same experience sans the manufacturing to our piece of the equation.</td><td>ë¬¼ë¡  ì½”ìŠ¤íƒ€ë¦¬ì¹´ì—ì„œì˜ ê²½í—˜ì„ ë§ˆì¹˜ê³  ëŒì•„ê°ˆ ë•Œ, ì˜ì‚¬ë“¤ì€ í™•ì‹¤íˆ ë” í¸ì•ˆí•´í•˜ê³  ê¸°ê¸°ë“¤ì„ ì´í•´í•˜ê²Œ ë©ë‹ˆë‹¤. <br><br>ë°œí‘œì 3: ì™¸ê³¼ì˜ì‚¬ê°€ ê¸°ê¸°ì— ëŒ€í•´ ë” í¸ì•ˆí•´í•˜ê³  ê·¸ ê¸°ê¸°ì— ëŒ€í•´ ë§¤ìš° ìì‹ ê°ì„ ëŠë¼ê²Œ ë˜ë©´, ê¶ê·¹ì ìœ¼ë¡œ ë‹¹ì—°íˆ ê·¸ ì§í›„ ë” ë§ì€ ê¸°ê¸°ë“¤ì„ ì‚¬ìš©í•˜ëŠ” ê²½í–¥ì´ ìˆìŠµë‹ˆë‹¤. ì½”ìŠ¤íƒ€ë¦¬ì¹´ì— ì°¸ì„í•  ìˆ˜ ì—†ëŠ” ë¶„ë“¤ì„ ìœ„í•´ì„œëŠ” í”„ë¦¬ì…‰í„°ì‹­ì´ë‚˜ ë§ˆìŠ¤í„° í´ë˜ìŠ¤ë¥¼ ì œê³µí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì „êµ­ì˜ ë‹¤ì–‘í•œ ì—°êµ¬ìë“¤ì´ ì œì¡° ë¶€ë¶„ì„ ì œì™¸í•˜ê³ ëŠ” ë³¸ì§ˆì ìœ¼ë¡œ ë™ì¼í•œ ê²½í—˜ì„ ì œê³µí•˜ëŠ” í”„ë¡œê·¸ë¨ì…ë‹ˆë‹¤.</td></tr>
<tr><td>So again, two days where they get hands on experience, understand maybe the subtleties and technique and how to use these devices to get the best outcomes for their patients. Of course, we are doing all the normal things like attending, the regional, national, local, society events, doing advisory panels and speaker events, all the stuff that you would anticipate that we'd be doing. The other major thing that we're doing is to try to drive overall brand awareness in The United States. Speaker 3: Obviously, haven't had an offering here until the launch in the fall. And if you're following anything in plastic surgery, I think you'll see that everyone is talking about Motiva on social, right?</td><td>ë”°ë¼ì„œ ë‹¤ì‹œ ë§ì”€ë“œë¦¬ë©´, ì´í‹€ ë™ì•ˆ ì˜ì‚¬ë“¤ì´ ì§ì ‘ ì²´í—˜í•˜ê³ , ë¯¸ë¬˜í•œ ì°¨ì´ì ê³¼ ê¸°ìˆ ì„ ì´í•´í•˜ë©°, í™˜ìë“¤ì—ê²Œ ìµœìƒì˜ ê²°ê³¼ë¥¼ ì œê³µí•˜ê¸° ìœ„í•´ ì´ëŸ¬í•œ ê¸°ê¸°ë“¤ì„ ì–´ë–»ê²Œ ì‚¬ìš©í•˜ëŠ”ì§€ ë°°ìš°ëŠ” ì‹œê°„ì„ ê°–ê²Œ ë©ë‹ˆë‹¤. ë¬¼ë¡  ì €í¬ëŠ” ì§€ì—­, ì „êµ­, ì§€ì—­ í•™íšŒ í–‰ì‚¬ ì°¸ì„, ìë¬¸ íŒ¨ë„ ë° ì—°ì‚¬ í–‰ì‚¬ ê°œìµœ ë“± ì—¬ëŸ¬ë¶„ì´ ì˜ˆìƒí•˜ì‹œëŠ” ëª¨ë“  ì¼ë°˜ì ì¸ í™œë™ë“¤ì„ ìˆ˜í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ê°€ í•˜ê³  ìˆëŠ” ë˜ ë‹¤ë¥¸ ì£¼ìš” í™œë™ì€ ë¯¸êµ­ ë‚´ ì „ë°˜ì ì¸ ë¸Œëœë“œ ì¸ì§€ë„ë¥¼ ë†’ì´ë ¤ëŠ” ë…¸ë ¥ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ë¶„ëª…íˆ ê°€ì„ ì¶œì‹œ ì „ê¹Œì§€ëŠ” ë¯¸êµ­ì—ì„œ ì œí’ˆì„ ì œê³µí•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì„±í˜•ì™¸ê³¼ ë¶„ì•¼ì˜ ë™í–¥ì„ ë”°ë¼ë³´ê³  ê³„ì‹œë‹¤ë©´, ëª¨ë“  ì‚¬ëŒë“¤ì´ ì†Œì…œë¯¸ë””ì–´ì—ì„œ Motivaì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>So we have our own execution website, our own postings that we do have significant pickup and reposting by not only surgeons but patients as well. But I think most powerfully, we have had more than 700 surgeons organically posting about Motiva, why they are choosing Motiva, why they are adding Motiva to their practices and that's really driven tremendous awareness because of course they have their own followings within their social activities as well. And then patients are also sharing their journey.</td><td>ì €í¬ëŠ” ìì²´ ì‹¤í–‰ ì›¹ì‚¬ì´íŠ¸ì™€ ìì²´ ê²Œì‹œë¬¼ì„ ìš´ì˜í•˜ê³  ìˆìœ¼ë©°, ì™¸ê³¼ì˜ì‚¬ë¿ë§Œ ì•„ë‹ˆë¼ í™˜ìë“¤ë¡œë¶€í„°ë„ ìƒë‹¹í•œ ê´€ì‹¬ê³¼ ì¬ê²Œì‹œë¥¼ ë°›ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ê°€ì¥ ê°•ë ¥í•œ ê²ƒì€ 700ëª… ì´ìƒì˜ ì™¸ê³¼ì˜ì‚¬ë“¤ì´ ìë°œì ìœ¼ë¡œ ëª¨í‹°ë°”ì— ëŒ€í•´ ê²Œì‹œí•˜ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ê·¸ë“¤ì´ ì™œ ëª¨í‹°ë°”ë¥¼ ì„ íƒí•˜ëŠ”ì§€, ì™œ ìì‹ ì˜ ì§„ë£Œì— ëª¨í‹°ë°”ë¥¼ ì¶”ê°€í•˜ëŠ”ì§€ì— ëŒ€í•´ í¬ìŠ¤íŒ…í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì •ë§ë¡œ ì—„ì²­ë‚œ ì¸ì§€ë„ í–¥ìƒì„ ì´ëŒì–´ëƒˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ê·¸ë“¤ë„ ê°ìì˜ ì†Œì…œ í™œë™ ë‚´ì—ì„œ ìì‹ ë§Œì˜ íŒ”ë¡œì›Œë¥¼ ë³´ìœ í•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  í™˜ìë“¤ë„ ìì‹ ë“¤ì˜ ì—¬ì •ì„ ê³µìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 3: So we do have an influencer program that we provide a small stipend to influencers who have a certain following and then of course that we vet their content to make sure that's on label and appropriate. And we have a number of those folks that are taking advantage of that program. But again, organically, we've had tremendous pickup in the marketplace by patients talking about their journey that we had absolutely zero to do with. Probably most notably is Lindsay Arnold of Dancing with the Stars fame, very early on posted about getting breast<br><br>augmentation with Motiva, why she chose Motiva. So it's been really powerful for us to raise overall awareness.</td><td>ë°œí‘œì 3: ì €í¬ëŠ” ì¼ì •í•œ íŒ”ë¡œì›Œë¥¼ ë³´ìœ í•œ ì¸í”Œë£¨ì–¸ì„œë“¤ì—ê²Œ ì†Œì•¡ì˜ ì§€ì›ê¸ˆì„ ì œê³µí•˜ëŠ” ì¸í”Œë£¨ì–¸ì„œ í”„ë¡œê·¸ë¨ì„ ìš´ì˜í•˜ê³  ìˆìœ¼ë©°, ë¬¼ë¡  ê·¸ë“¤ì˜ ì½˜í…ì¸ ê°€ ë¼ë²¨ì— ë¶€í•©í•˜ê³  ì ì ˆí•œì§€ ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ í”„ë¡œê·¸ë¨ì„ í™œìš©í•˜ëŠ” ë¶„ë“¤ì´ ìƒë‹¹ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ìì—°ìŠ¤ëŸ½ê²Œ í™˜ìë“¤ì´ ìì‹ ì˜ ê²½í—˜ë‹´ì„ ì´ì•¼ê¸°í•˜ë©´ì„œ ì‹œì¥ì—ì„œ ì—„ì²­ë‚œ ê´€ì‹¬ì„ ë°›ê³  ìˆëŠ”ë°, ì´ëŠ” ì €í¬ê°€ ì „í˜€ ê´€ì—¬í•˜ì§€ ì•Šì€ ê²ƒì…ë‹ˆë‹¤. ê°€ì¥ ì£¼ëª©í•  ë§Œí•œ ì‚¬ë¡€ëŠ” ì•„ë§ˆë„ 'ëŒ„ì‹± ìœ„ë“œ ë” ìŠ¤íƒ€ì¦ˆ'ë¡œ ìœ ëª…í•œ ë¦°ì§€ ì•„ë†€ë“œê°€ ì´ˆê¸°ì— ëª¨í‹°ë°”ë¡œ ìœ ë°©í™•ëŒ€ìˆ ì„ ë°›ì€ ê²ƒê³¼ ëª¨í‹°ë°”ë¥¼ ì„ íƒí•œ ì´ìœ ì— ëŒ€í•´ í¬ìŠ¤íŒ…í•œ ê²ƒì¼ ê²ë‹ˆë‹¤. ì´ëŠ” ì „ë°˜ì ì¸ ì¸ì§€ë„ ì œê³ ì— ì •ë§ ê°•ë ¥í•œ íš¨ê³¼ë¥¼ ê°€ì ¸ë‹¤ì£¼ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 3: We have had one major execution here and that's a partnership that we created with Megan Trainor who was already going to get Motiva, had made the decision to do it, started posting about it. So then we engaged with her and created a partnership by which she did<br>some posts as well as a podcast with her surgeon talking about Motiva and why she chose Motiva. A list celebrities in the past absolutely did not talk about their surgical procedures and certainly not breast implant, but I think you are seeing a real shift in the marketplace right now even yesterday.</td><td>í™”ì 3: ì €í¬ëŠ” ì—¬ê¸°ì„œ í•œ ê°€ì§€ ì£¼ìš”í•œ ì‹¤í–‰ ì‚¬ë¡€ê°€ ìˆì—ˆëŠ”ë°, ë°”ë¡œ ë©”ê°„ íŠ¸ë ˆì´ë„ˆ(Megan Trainor)ì™€ ë§ºì€ íŒŒíŠ¸ë„ˆì‹­ì…ë‹ˆë‹¤. ê·¸ë…€ëŠ” ì´ë¯¸ ëª¨í‹°ë°”ë¥¼ ì„ íƒí•˜ê¸°ë¡œ ê²°ì •ì„ ë‚´ë¦° ìƒíƒœì˜€ê³ , ì´ì— ëŒ€í•´ í¬ìŠ¤íŒ…ì„ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ê°€ ê·¸ë…€ì™€ ì ‘ì´‰í•˜ì—¬ íŒŒíŠ¸ë„ˆì‹­ì„ ì²´ê²°í–ˆê³ , ì´ë¥¼ í†µí•´ ê·¸ë…€ëŠ” ëª‡ ê°€ì§€ í¬ìŠ¤íŠ¸ë¥¼ ì˜¬ë ¸ì„ ë¿ë§Œ ì•„ë‹ˆë¼ ìì‹ ì˜ ì§‘ë„ì˜ì™€ í•¨ê»˜ ëª¨í‹°ë°”ì— ëŒ€í•´, ê·¸ë¦¬ê³  ì™œ ëª¨í‹°ë°”ë¥¼ ì„ íƒí–ˆëŠ”ì§€ì— ëŒ€í•´ íŒŸìºìŠ¤íŠ¸ë„ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. ê³¼ê±° Aê¸‰ ì…€ëŸ¬ë¸Œë¦¬í‹°ë“¤ì€ ì ˆëŒ€ë¡œ ìì‹ ë“¤ì˜ ìˆ˜ìˆ  ì‹œìˆ ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ì§€ ì•Šì•˜ê³ , íŠ¹íˆ ìœ ë°© ì„í”Œë€íŠ¸ì— ëŒ€í•´ì„œëŠ” ë”ìš± ê·¸ë¬ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì§€ê¸ˆ ì‹œì¥ì—ì„œ ì‹¤ì§ˆì ì¸ ë³€í™”ê°€ ì¼ì–´ë‚˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì‹¬ì§€ì–´ ì–´ì œë„ ê·¸ë¬ê³ ìš”.</td></tr>
<tr><td>I think in The New York Times, they are talking about the era of openness or transparency, the era of transparency where people are now starting to talk about their procedures and Motiva is certainly front and center in a<br><br>Speaker 1: lot of<br><br><br>Speaker 3: those things. On the Meghan Trainor execution itself, her original post, which is a video, more than 1,700,000 views of that, 90 pickups in various media outlets, talking about her journey and her program with us and nearly 5,000,000,000 impressions already. So this started in March and will run through September. So tremendous awareness being built by the Meghan Trainor initiative.</td><td>ë‰´ìš•íƒ€ì„ì¦ˆì—ì„œëŠ” ê°œë°©ì„± ë˜ëŠ” íˆ¬ëª…ì„±ì˜ ì‹œëŒ€, ì¦‰ ì‚¬ëŒë“¤ì´ ì´ì œ ìì‹ ë“¤ì˜ ì‹œìˆ ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ê¸° ì‹œì‘í•˜ëŠ” íˆ¬ëª…ì„±ì˜ ì‹œëŒ€ì— ëŒ€í•´ ë‹¤ë£¨ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  MotivaëŠ” í™•ì‹¤íˆ ì´ëŸ¬í•œ ë§ì€ ë¶„ì•¼ì—ì„œ ìµœì „ì„ ì— ì„œ ìˆìŠµë‹ˆë‹¤.<br><br>í™”ì 1: ë§ì€<br><br>í™”ì 3: ê·¸ëŸ° ê²ƒë“¤ì—ì„œ ë§ì´ì£ . Meghan Trainor ìº í˜ì¸ ì‹¤í–‰ ìì²´ë¥¼ ë³´ë©´, ê·¸ë…€ì˜ ì›ë³¸ ê²Œì‹œë¬¼ì€ ë¹„ë””ì˜¤ì¸ë°, 170ë§Œ íšŒ ì´ìƒì˜ ì¡°íšŒìˆ˜ë¥¼ ê¸°ë¡í–ˆê³ , ë‹¤ì–‘í•œ ë¯¸ë””ì–´ ë§¤ì²´ì—ì„œ 90ê±´ì˜ í”½ì—…ì´ ìˆì—ˆìœ¼ë©°, ê·¸ë…€ì˜ ì—¬ì •ê³¼ ì €í¬ì™€ í•¨ê»˜í•˜ëŠ” í”„ë¡œê·¸ë¨ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ë©´ì„œ ì´ë¯¸ ê±°ì˜ 50ì–µ ê±´ì˜ ë…¸ì¶œì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ ìº í˜ì¸ì€ 3ì›”ì— ì‹œì‘ë˜ì–´ 9ì›”ê¹Œì§€ ì§„í–‰ë  ì˜ˆì •ì…ë‹ˆë‹¤. ë”°ë¼ì„œ Meghan Trainor ì´ë‹ˆì…”í‹°ë¸Œë¥¼ í†µí•´ ì—„ì²­ë‚œ ì¸ì§€ë„ê°€ êµ¬ì¶•ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>On top of that, we had a special landing page created where a patient could go and take advantage of a $250 offer, as a discount off of their procedure if they got it within a certain timeframe. Speaker 3: We've had more than 3,400 people actually go in, do the lead form, which then sends their information to the surgeon that they've selected from our Find a Surgeon Finder and 700 of them have actually already had the procedure which is really tremendous because typically it's is three plus years of consideration before somebody ultimately ends up getting<br><br>an augmentation.</td><td>ì´ì— ë”í•´, í™˜ìë“¤ì´ íŠ¹ì • ê¸°ê°„ ë‚´ì— ì‹œìˆ ì„ ë°›ì„ ê²½ìš° ì‹œìˆ ë¹„ì—ì„œ 250ë‹¬ëŸ¬ë¥¼ í• ì¸ë°›ì„ ìˆ˜ ìˆëŠ” íŠ¹ë³„ ëœë”© í˜ì´ì§€ë¥¼ ì œì‘í–ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ì‹¤ì œë¡œ 3,400ëª… ì´ìƒì´ í•´ë‹¹ í˜ì´ì§€ì— ì ‘ì†í•˜ì—¬ ë¦¬ë“œ í¼ì„ ì‘ì„±í–ˆìœ¼ë©°, ì´ë¥¼ í†µí•´ ê·¸ë“¤ì˜ ì •ë³´ê°€ ì €í¬ 'ì˜ì‚¬ ì°¾ê¸°' ì„œë¹„ìŠ¤ì—ì„œ ì„ íƒí•œ ì™¸ê³¼ì˜ì—ê²Œ ì „ë‹¬ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ ì¤‘ 700ëª…ì´ ì‹¤ì œë¡œ ì´ë¯¸ ì‹œìˆ ì„ ë°›ì•˜ëŠ”ë°, ì´ëŠ” ì •ë§ ë†€ë¼ìš´ ê²°ê³¼ì…ë‹ˆë‹¤. ì¼ë°˜ì ìœ¼ë¡œ ì‚¬ëŒë“¤ì´ ìµœì¢…ì ìœ¼ë¡œ í™•ëŒ€ìˆ ì„ ë°›ê¸°ê¹Œì§€ëŠ” 3ë…„ ì´ìƒì˜ ê²€í†  ê¸°ê°„ì„ ê±°ì¹˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>This is three months and we have had 700 of those folks take advantage of the offer and actually have the surgery done and then we know that we have that they have had the surgery done because they have to report it through our device tracking, right. So it's completely verifiable. And then so overall brand awareness, all those things combined, we<br>have had a 40% increase in search on our own site and 130,000 active visitors and when they come to our site they are filling out the lead form so their information goes to a surgeon they select that offers Motiva and over 120,000 of them have searched actively for a surgeon in their area that does Motiva.</td><td>ì´ëŠ” 3ê°œì›”ê°„ì˜ ê²°ê³¼ì´ë©°, 700ëª…ì˜ ê³ ê°ì´ ì´ ì œì•ˆì„ í™œìš©í•˜ì—¬ ì‹¤ì œë¡œ ìˆ˜ìˆ ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ë“¤ì´ ìˆ˜ìˆ ì„ ë°›ì•˜ë‹¤ëŠ” ê²ƒì„ í™•ì‹¤íˆ ì•Œ ìˆ˜ ìˆëŠ” ì´ìœ ëŠ” ì €í¬ ê¸°ê¸° ì¶”ì  ì‹œìŠ¤í…œì„ í†µí•´ ë³´ê³ í•´ì•¼ í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì™„ì „íˆ ê²€ì¦ ê°€ëŠ¥í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì „ë°˜ì ì¸ ë¸Œëœë“œ ì¸ì§€ë„ì™€ ì´ ëª¨ë“  ê²ƒë“¤ì„ ì¢…í•©í•˜ë©´, ì €í¬ ìì²´ ì‚¬ì´íŠ¸ì—ì„œ ê²€ìƒ‰ëŸ‰ì´ 40% ì¦ê°€í–ˆê³  130,000ëª…ì˜ í™œì„± ë°©ë¬¸ìê°€ ìˆì—ˆìŠµë‹ˆë‹¤. ê·¸ë“¤ì´ ì €í¬ ì‚¬ì´íŠ¸ì— ë°©ë¬¸í•˜ë©´ ë¦¬ë“œ ì–‘ì‹ì„ ì‘ì„±í•˜ê²Œ ë˜ì–´ ìˆì–´ì„œ, ê·¸ë“¤ì˜ ì •ë³´ê°€ ê·¸ë“¤ì´ ì„ íƒí•œ Motivaë¥¼ ì œê³µí•˜ëŠ” ì™¸ê³¼ì˜ì‚¬ì—ê²Œ ì „ë‹¬ë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  120,000ëª… ì´ìƒì´ ìì‹ ì˜ ì§€ì—­ì—ì„œ Motivaë¥¼ ì‹œìˆ í•˜ëŠ” ì™¸ê³¼ì˜ì‚¬ë¥¼ ì ê·¹ì ìœ¼ë¡œ ê²€ìƒ‰í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So really great pull through on the awareness campaign there. Speaker 3: And at this point, we're in more than 1,000 practices around The United States, only the hotbeds of South Dakota and Maine do we not have a practice, yet. I think we will probably very soon. So when somebody does look for Motiva, there is a high probability that there is a surgeon that provides Motiva that's readily in their area. Most importantly obviously is the<br>order trend and we have had just a beautiful order trend chart like if I could have laid this out a year ago, said I would like the chart to look like this, this is exactly what you would have suggested, right?</td><td>ì¸ì§€ë„ ìº í˜ì¸ì—ì„œ ì •ë§ í›Œë¥­í•œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 3: í˜„ì¬ ì €í¬ëŠ” ë¯¸êµ­ ì „ì—­ 1,000ê°œ ì´ìƒì˜ ë³‘ì›ì— ì§„ì¶œí•´ ìˆìœ¼ë©°, ì‚¬ìš°ìŠ¤ë‹¤ì½”íƒ€ì™€ ë©”ì¸ì£¼ë§Œ ì•„ì§ ë³‘ì›ì´ ì—†ëŠ” ìƒí™©ì…ë‹ˆë‹¤. ì•„ë§ˆ ê³§ ì´ ì§€ì—­ì—ë„ ì§„ì¶œí•  ê²ƒìœ¼ë¡œ ìƒê°ë©ë‹ˆë‹¤. ë”°ë¼ì„œ ëˆ„êµ°ê°€ ëª¨í‹°ë°”ë¥¼ ì°¾ì„ ë•Œ, í•´ë‹¹ ì§€ì—­ì—ì„œ ëª¨í‹°ë°”ë¥¼ ì œê³µí•˜ëŠ” ì™¸ê³¼ì˜ë¥¼ ì°¾ì„ í™•ë¥ ì´ ë§¤ìš° ë†’ìŠµë‹ˆë‹¤. <br><br>ê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€ ë‹¹ì—°íˆ ì£¼ë¬¸ ì¶”ì„¸ì¸ë°, ì €í¬ëŠ” ì •ë§ ì•„ë¦„ë‹¤ìš´ ì£¼ë¬¸ ì¶”ì„¸ ì°¨íŠ¸ë¥¼ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ë§Œì•½ 1ë…„ ì „ì— ì œê°€ ì´ëŸ° ì°¨íŠ¸ë¥¼ ê·¸ë ¤ë³´ë¼ê³  í–ˆë‹¤ë©´, ë°”ë¡œ ì´ëŸ° ëª¨ìŠµì„ ì œì•ˆí–ˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>So very consistent order trend month over month and this ends in April. Speaker 3: But I can tell you if I extended it into June, the trend would look exactly the same. So really great pickup in the marketplace. And then lastly for me and Pete mentioned the super cycle of innovation. I think a big reason why we've had such success of attracting talent from competitive organizations as well as surgeon interest in Motiva is, yes, we've meaningfully brought forward products that are what we believe are better than the existing technology<br>that's in the marketplace today.</td><td>ë”°ë¼ì„œ ë§¤ì›” ë§¤ìš° ì¼ê´€ëœ ì£¼ë¬¸ ì¶”ì„¸ë¥¼ ë³´ì´ê³  ìˆìœ¼ë©°, ì´ëŠ” 4ì›”ê¹Œì§€ ì§€ì†ë˜ì—ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 3: í•˜ì§€ë§Œ 6ì›”ê¹Œì§€ ì—°ì¥í•´ì„œ ë³´ë”ë¼ë„ ì¶”ì„¸ëŠ” ì •í™•íˆ ë™ì¼í•  ê²ƒì´ë¼ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì‹œì¥ì—ì„œ ì •ë§ í›Œë¥­í•œ íšŒë³µì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  ë§ˆì§€ë§‰ìœ¼ë¡œ ì €ì™€ Peteê°€ ì–¸ê¸‰í•œ í˜ì‹ ì˜ ìŠˆí¼ ì‚¬ì´í´ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê²½ìŸì‚¬ë¡œë¶€í„° ì¸ì¬ë¥¼ ìœ ì¹˜í•˜ê³  ì™¸ê³¼ì˜ë“¤ì˜ Motivaì— ëŒ€í•œ ê´€ì‹¬ì„ ëŒì–´ë‚´ëŠ” ë° ì´ë ‡ê²Œ í° ì„±ê³µì„ ê±°ë‘” ì£¼ìš” ì´ìœ ëŠ”, ë„¤, ì €í¬ê°€ í˜„ì¬ ì‹œì¥ì— ìˆëŠ” ê¸°ì¡´ ê¸°ìˆ ë³´ë‹¤ ë” ìš°ìˆ˜í•˜ë‹¤ê³  ë¯¿ëŠ” ì œí’ˆë“¤ì„ ì˜ë¯¸ ìˆê²Œ ì•ë‹¹ê²¨ ì¶œì‹œí–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>But as we expose the surgeons to this super cycle of innovation and they think about the competitive companies and we have people in our organization that have all come from those companies that we could say this with confidence, which is all the competitors in this space have basically played out whatever innovation that<br><br>they were working at. Speaker 3: It's on market now. We're just at the beginning of this cycle, right? So every year for the next three years essentially depending on how the FDA processes go, we'll be bringing out either a new technology or a new indication. And that's going to start here very soon with the beginning of 2026.</td><td>í•˜ì§€ë§Œ ì™¸ê³¼ì˜ë“¤ì´ ì´ëŸ¬í•œ í˜ì‹ ì˜ ìŠˆí¼ ì‚¬ì´í´ì— ë…¸ì¶œë˜ê³  ê²½ìŸì‚¬ë“¤ì— ëŒ€í•´ ìƒê°í•  ë•Œ, ê·¸ë¦¬ê³  ì €í¬ ì¡°ì§ì—ëŠ” ê·¸ëŸ° ëª¨ë“  íšŒì‚¬ë“¤ ì¶œì‹ ì˜ ì‚¬ëŒë“¤ì´ ìˆê¸° ë•Œë¬¸ì— í™•ì‹ ì„ ê°€ì§€ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆëŠ” ê²ƒì€, ì´ ë¶„ì•¼ì˜ ëª¨ë“  ê²½ìŸì‚¬ë“¤ì´ ê¸°ë³¸ì ìœ¼ë¡œ ê·¸ë“¤ì´ ì‘ì—…í•˜ê³  ìˆë˜ í˜ì‹ ì„ ëª¨ë‘ ì¶œì‹œí–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>í™”ì 3: ì§€ê¸ˆ ì‹œì¥ì— ë‚˜ì™€ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì´ì œ ì´ ì‚¬ì´í´ì˜ ì‹œì‘ì ì— ìˆìŠµë‹ˆë‹¤. ë§ì£ ? ë”°ë¼ì„œ FDA ìŠ¹ì¸ ê³¼ì •ì´ ì–´ë–»ê²Œ ì§„í–‰ë˜ëŠëƒì— ë”°ë¼ ë‹¤ë¥´ê² ì§€ë§Œ, í–¥í›„ 3ë…„ ë™ì•ˆ ë§¤ë…„ ìƒˆë¡œìš´ ê¸°ìˆ ì´ë‚˜ ìƒˆë¡œìš´ ì ì‘ì¦ì„ ì¶œì‹œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì€ 2026ë…„ ì´ˆë¶€í„° ê³§ ì‹œì‘ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>We'll be launching pressurvey tools here in The United States. Speaker 3: Later that year, we should. We'll file this fall for the recon indication. So typically, it's at a year, it could be a little faster, it could be a little slower, right, FDA willing. We'll have the recon indications, so then we'll launch that. The next cycle, the next year, then we'll be able to bring forward Ergo two and Diamond, which gives us the ability to launch EMEA in The United States. Speaker 3: So at least three to five years of new innovation that we'll be able to bring to the market that will meaningfully impact and improve the plastic surgery, marketplace.</td><td>ë¯¸êµ­ì—ì„œ ì‚¬ì „ ìˆ˜ìˆ  ë„êµ¬ë“¤ì„ ì¶œì‹œí•  ì˜ˆì •ì…ë‹ˆë‹¤. <br><br>ë°œí‘œì 3: ì˜¬í•´ ë§ì—ëŠ” ì¬ê±´ ì ì‘ì¦ì— ëŒ€í•´ ì‹ ì²­ì„œë¥¼ ì œì¶œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ì¼ë°˜ì ìœ¼ë¡œ 1ë…„ ì •ë„ ì†Œìš”ë˜ë©°, FDAì˜ ìŠ¹ì¸ì— ë”°ë¼ ì¡°ê¸ˆ ë” ë¹ ë¥´ê±°ë‚˜ ëŠ¦ì–´ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì¬ê±´ ì ì‘ì¦ì„ ë°›ê²Œ ë˜ë©´ í•´ë‹¹ ì œí’ˆì„ ì¶œì‹œí•  ê²ƒì…ë‹ˆë‹¤. ë‹¤ìŒ ì‚¬ì´í´, ì¦‰ ë‚´ë…„ì—ëŠ” Ergo twoì™€ Diamondë¥¼ ì¶œì‹œí•  ìˆ˜ ìˆì„ ê²ƒì´ë©°, ì´ë¥¼ í†µí•´ ë¯¸êµ­ì—ì„œ EMEA ì§€ì—­ìœ¼ë¡œ ì§„ì¶œí•  ìˆ˜ ìˆëŠ” ì—­ëŸ‰ì„ ê°–ì¶”ê²Œ ë©ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: í–¥í›„ ìµœì†Œ 3ë…„ì—ì„œ 5ë…„ê°„ ì‹œì¥ì— ì„ ë³´ì¼ ìˆ˜ ìˆëŠ” ìƒˆë¡œìš´ í˜ì‹  ê¸°ìˆ ë“¤ì´ ìˆìœ¼ë©°, ì´ëŠ” ì„±í˜•ì™¸ê³¼ ì‹œì¥ì— ì˜ë¯¸ ìˆëŠ” ì˜í–¥ì„ ë¯¸ì¹˜ê³  ê°œì„ ì‹œí‚¬ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And with that, I'd like to go ahead and bring up Ben Newcott, who is the Head of our Surgeon Engagement, and he'll introduce our surgeon panel. Speaker 4: Okay, thanks Jeff. I'd like to bring up the, U. S. Augmentation panel. It's a pleasure to be here today. Speaker 4: This has been a wonderful launch so far, and we thought it would be best to bring up several of our experts to talk to you today. Doctor Mark Epstein is a plastic surgeon in private practice in Long Island, New York. Doctor Anna Steeve is right here in Manhattan. And Doctor Troy Pittman splits time between here and Washington DC.</td><td>ê·¸ëŸ¼ ì´ì œ ì €í¬ ì™¸ê³¼ì˜ ì°¸ì—¬ ë¶€ë¬¸ ì±…ì„ìì¸ Ben Newcottì„ ëª¨ì‹œê² ìŠµë‹ˆë‹¤. ê·¸ê°€ ì™¸ê³¼ì˜ íŒ¨ë„ì„ ì†Œê°œí•´ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤ Jeff. ë¯¸êµ­ í™•ëŒ€ìˆ  íŒ¨ë„ì„ ì†Œê°œí•´ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì´ ìë¦¬ì— í•¨ê»˜í•  ìˆ˜ ìˆì–´ì„œ ê¸°ì©ë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ì§€ê¸ˆê¹Œì§€ ì •ë§ í›Œë¥­í•œ ì¶œì‹œë¥¼ ë³´ì—¬ì™”ìœ¼ë©°, ì˜¤ëŠ˜ ì—¬ëŸ¬ë¶„ê»˜ ë§ì”€ë“œë¦´ ìˆ˜ ìˆëŠ” ëª‡ ë¶„ì˜ ì „ë¬¸ê°€ë“¤ì„ ëª¨ì‹œëŠ” ê²ƒì´ ìµœì„ ì´ë¼ê³  ìƒê°í–ˆìŠµë‹ˆë‹¤. Mark Epstein ë°•ì‚¬ëŠ” ë‰´ìš• ë¡±ì•„ì¼ëœë“œì—ì„œ ê°œì¸ ë³‘ì›ì„ ìš´ì˜í•˜ëŠ” ì„±í˜•ì™¸ê³¼ ì „ë¬¸ì˜ì…ë‹ˆë‹¤. Anna Steeve ë°•ì‚¬ëŠ” ë°”ë¡œ ì—¬ê¸° ë§¨í•´íŠ¼ì— ê³„ì‹œê³ ìš”. ê·¸ë¦¬ê³  Troy Pittman ë°•ì‚¬ëŠ” ì´ê³³ê³¼ ì›Œì‹±í„´ DCë¥¼ ì˜¤ê°€ë©° ì§„ë£Œí•˜ê³  ê³„ì‹­ë‹ˆë‹¤.</td></tr>
<tr><td>So you're gonna get a little, you'll get an insight into different types of practices in different areas, not just, New York proper. Speaker 4: Doctor Epstein is a long time investigator of ours. He is going to show you some wonderfully stable results at six and seven years out. He's been working hard over the last couple of days to get a couple of postoperative photos in there at seven years, is really cool to see. Doctor. Steve is going talk about this cultural moment that we are in right now in breast augmentation and aesthetics. Speaker 4: And Doctor.</td><td>ì´ë¥¼ í†µí•´ ë‰´ìš• ë³¸í† ë¿ë§Œ ì•„ë‹ˆë¼ ë‹¤ì–‘í•œ ì§€ì—­ì˜ ì„œë¡œ ë‹¤ë¥¸ ìœ í˜•ì˜ ì§„ë£Œ ê´€í–‰ì— ëŒ€í•œ í†µì°°ì„ ì–»ìœ¼ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ì—¡ìŠ¤íƒ€ì¸ ë°•ì‚¬ëŠ” ì €í¬ì˜ ì˜¤ëœ ì—°êµ¬ìì…ë‹ˆë‹¤. ê·¸ëŠ” 6ë…„ ë° 7ë…„ ê²½ê³¼ ì‹œì ì—ì„œ ë§¤ìš° ì•ˆì •ì ì¸ ê²°ê³¼ë“¤ì„ ë³´ì—¬ë“œë¦´ ì˜ˆì •ì…ë‹ˆë‹¤. ì§€ë‚œ ë©°ì¹  ë™ì•ˆ 7ë…„ ê²½ê³¼ í›„ ìˆ˜ìˆ  ì‚¬ì§„ ëª‡ ì¥ì„ ì¶”ê°€ë¡œ í™•ë³´í•˜ê¸° ìœ„í•´ ì—´ì‹¬íˆ ë…¸ë ¥í•´ì™”ìœ¼ë©°, ì´ë¥¼ ë³´ì‹œë©´ ì •ë§ í¥ë¯¸ë¡œìš°ì‹¤ ê²ƒì…ë‹ˆë‹¤.<br><br>ìŠ¤í‹°ë¸Œ ë°•ì‚¬ëŠ” í˜„ì¬ ìœ ë°©í™•ëŒ€ìˆ ê³¼ ë¯¸ìš© ë¶„ì•¼ì—ì„œ ìš°ë¦¬ê°€ ë§ì´í•˜ê³  ìˆëŠ” ë¬¸í™”ì  ì „í™˜ì ì— ëŒ€í•´ ë§ì”€ë“œë¦´ ì˜ˆì •ì…ë‹ˆë‹¤.<br><br>ê·¸ë¦¬ê³  ë°•ì‚¬ë‹˜ê»˜ì„œëŠ”...</td></tr>
<tr><td>Pittman is going to talk about this long journey of tissue preservation that started when he was a resident at Georgetown and now extends into his future here. So, I'm not gonna get up in between each speaker, but I will have a handheld microphone over there on the side. Feel free to jump in if you want. We'll have some time for Q and A after the three doctors. Speaker 4: I've got some prepared questions in the case that, you know, the audience doesn't have a lot to ask. But with that, I'd like to bring up Doctor. Mark Epstein. Thank you. Speaker 5: Which moves him forward. The green? Speaker 3: Forward. Backward. Got it. Speaker 5: Well, thank you.</td><td>í”¼íŠ¸ë¨¼ì€ ì¡°ì§€íƒ€ìš´ì—ì„œ ë ˆì§€ë˜íŠ¸ì˜€ì„ ë•Œ ì‹œì‘ë˜ì–´ í˜„ì¬ ì´ê³³ì—ì„œì˜ ë¯¸ë˜ë¡œ ì´ì–´ì§€ëŠ” ì¡°ì§ ë³´ì¡´ì˜ ê¸´ ì—¬ì •ì— ëŒ€í•´ ì´ì•¼ê¸°í•  ì˜ˆì •ì…ë‹ˆë‹¤. ê° ì—°ì‚¬ ì‚¬ì´ì— ì œê°€ ì¼ì–´ë‚˜ì§€ëŠ” ì•Šê² ì§€ë§Œ, ì €ìª½ ì˜†ì— í•¸ë“œí—¬ë“œ ë§ˆì´í¬ê°€ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì›í•˜ì‹œë©´ ì–¸ì œë“ ì§€ ì°¸ì—¬í•´ ì£¼ì„¸ìš”. ì„¸ ëª…ì˜ ì˜ì‚¬ ë¶„ë“¤ì´ ëë‚œ í›„ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°€ì§ˆ ì˜ˆì •ì…ë‹ˆë‹¤. <br><br>ë°œí‘œì 4: ì²­ì¤‘ë¶„ë“¤ì´ ì§ˆë¬¸ì´ ë§ì§€ ì•Šì„ ê²½ìš°ë¥¼ ëŒ€ë¹„í•´ì„œ ë¯¸ë¦¬ ì¤€ë¹„í•œ ì§ˆë¬¸ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ë§ˆí¬ ì—¡ìŠ¤íƒ€ì¸ ë°•ì‚¬ë‹˜ì„ ëª¨ì‹œê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ê·¸ê²ƒì´ ê·¸ë¥¼ ì•ìœ¼ë¡œ ì›€ì§ì´ê²Œ í•©ë‹ˆë‹¤. ë…¹ìƒ‰ì´ìš”?<br><br>ë°œí‘œì 3: ì•ìœ¼ë¡œ. ë’¤ë¡œ. ì•Œê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>I'm honored to be here and to be able to present my seven year experience with Motiva Implants. My relevant disclosures, I've designed some instrumentation for breast augmentation. I'm on an advisory panel for Canfield Scientific who makes three d imaging for breast augmentation. I'm a principal investigator, one of 22 on the breast augmentation cosmetic side. Speaker 5: And I've been performing the surgeries for about I have seven years experience. A little bit about me. I studied biomedical electrical engineering and computer science at Northwestern. I'm certified by the American Board of Surgery and Plastic Surgery. I've been in<br><br>practice just over thirty years.</td><td>ì €ëŠ” ì´ ìë¦¬ì— ì°¸ì„í•˜ì—¬ Motiva Implantsì™€ í•¨ê»˜í•œ 7ë…„ê°„ì˜ ê²½í—˜ì„ ë°œí‘œí•  ìˆ˜ ìˆê²Œ ë˜ì–´ ì˜ê´‘ì…ë‹ˆë‹¤. ê´€ë ¨ ê³µì‹œì‚¬í•­ìœ¼ë¡œ, ì €ëŠ” ìœ ë°©í™•ëŒ€ìˆ ìš© ê¸°êµ¬ë¥¼ ì¼ë¶€ ì„¤ê³„í–ˆìœ¼ë©°, ìœ ë°©í™•ëŒ€ìˆ ìš© 3D ì´ë¯¸ì§•ì„ ì œì‘í•˜ëŠ” Canfield Scientificì˜ ìë¬¸ìœ„ì›ìœ¼ë¡œ í™œë™í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €ëŠ” ìœ ë°©í™•ëŒ€ ë¯¸ìš© ë¶„ì•¼ 22ëª…ì˜ ì£¼ìš” ì—°êµ¬ì ì¤‘ í•œ ëª…ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ê·¸ë¦¬ê³  ì €ëŠ” ì•½ 7ë…„ê°„ì˜ ê²½í—˜ì„ ë°”íƒ•ìœ¼ë¡œ ìˆ˜ìˆ ì„ ì‹œí–‰í•´ì™”ìŠµë‹ˆë‹¤. ì €ì— ëŒ€í•´ ê°„ë‹¨íˆ ì†Œê°œí•˜ë©´, Northwesternì—ì„œ ìƒì˜í•™ ì „ê¸°ê³µí•™ê³¼ ì»´í“¨í„° ê³¼í•™ì„ ì „ê³µí–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì™¸ê³¼í•™íšŒì™€ ì„±í˜•ì™¸ê³¼í•™íšŒ ì¸ì¦ì„ ë°›ì•˜ìœ¼ë©°, 30ë…„ì´ ì¡°ê¸ˆ ë„˜ëŠ” ê¸°ê°„ ë™ì•ˆ ì§„ë£Œë¥¼ í•´ì˜¤ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 5: I perform thousands of breast augmentations. I employ both two and three d imaging in my breast augmentation practice since 02/2008. And I've been performing a true one day recovery breast dog that's arms over your head out to dinner and shopping the same day<br>of surgery for the past twenty one years. I also was a co author, this was the article in a peer reviewed publication which describes the technology, how it works for three-dimensional breast augmentation imaging. So how did I get involved in all this? Speaker 5: I was contacted by JJ Chacon, who was at the time the CEO of Establishment Labs in 2017. I had never heard of Motiva implants. I said, Okay, the study sounds cool.</td><td>ë°œí‘œì 5: ì €ëŠ” ìˆ˜ì²œ ê±´ì˜ ìœ ë°©í™•ëŒ€ìˆ ì„ ì‹œí–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2008ë…„ 2ì›”ë¶€í„° ìœ ë°©í™•ëŒ€ìˆ  ì§„ë£Œì—ì„œ 2Dì™€ 3D ì´ë¯¸ì§•ì„ ëª¨ë‘ í™œìš©í•˜ê³  ìˆìœ¼ë©°, ì§€ë‚œ 21ë…„ê°„ ì§„ì •í•œ ë‹¹ì¼ íšŒë³µ ìœ ë°©í™•ëŒ€ìˆ ì„ ì‹œí–‰í•´ì™”ìŠµë‹ˆë‹¤. ì´ëŠ” ìˆ˜ìˆ  ë‹¹ì¼ì— íŒ”ì„ ë¨¸ë¦¬ ìœ„ë¡œ ì˜¬ë¦¬ê³  ì €ë…ì‹ì‚¬ì™€ ì‡¼í•‘ì„ í•  ìˆ˜ ìˆëŠ” ìˆ˜ìˆ ì…ë‹ˆë‹¤. ë˜í•œ ì €ëŠ” 3ì°¨ì› ìœ ë°©í™•ëŒ€ ì´ë¯¸ì§• ê¸°ìˆ ê³¼ ê·¸ ì‘ë™ ì›ë¦¬ë¥¼ ì„¤ëª…í•˜ëŠ” ë™ë£Œì‹¬ì‚¬ í•™ìˆ ì§€ ë…¼ë¬¸ì˜ ê³µë™ì €ìì´ê¸°ë„ í•©ë‹ˆë‹¤. <br><br>ë°œí‘œì 5: ê·¸ë ‡ë‹¤ë©´ ì œê°€ ì–´ë–»ê²Œ ì´ ì¼ì— ì°¸ì—¬í•˜ê²Œ ë˜ì—ˆì„ê¹Œìš”? 2017ë…„ ë‹¹ì‹œ Establishment Labsì˜ CEOì˜€ë˜ JJ Chaconì´ ì €ì—ê²Œ ì—°ë½ì„ í–ˆìŠµë‹ˆë‹¤. ì €ëŠ” Motiva ì„í”Œë€íŠ¸ì— ëŒ€í•´ ë“¤ì–´ë³¸ ì ì´ ì—†ì—ˆìŠµë‹ˆë‹¤. ì €ëŠ” "ì¢‹ìŠµë‹ˆë‹¤, ì—°êµ¬ê°€ í¥ë¯¸ë¡œì›Œ ë³´ì´ë„¤ìš”"ë¼ê³  ë§í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Let me do a little research. I went on the website. Speaker 5: I did a deep dive. And what I found is that Establishment Labs was doing an incredible job with the rheology, the way silicone gel flows, the mechanical properties. It was a complete departure from everything I had known and experienced with breast implants for the past few decades. I like the smooth silk surface technology, the QID, which is the RFID device inside. But what really fascinated me the most was the mechanical properties of the gel and the fact that they match the shell to the gel to create a monoblock.</td><td>ì œê°€ ì¡°ê¸ˆ ì¡°ì‚¬ë¥¼ í•´ë³´ì•˜ìŠµë‹ˆë‹¤. ì›¹ì‚¬ì´íŠ¸ì— ë“¤ì–´ê°€ ë´¤ìŠµë‹ˆë‹¤. ë°œí‘œì 5: ì €ëŠ” ì‹¬ì¸µ ë¶„ì„ì„ í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì œê°€ ë°œê²¬í•œ ê²ƒì€ Establishment Labsê°€ ìœ ë³€í•™, ì¦‰ ì‹¤ë¦¬ì½˜ ê²”ì´ íë¥´ëŠ” ë°©ì‹ê³¼ ê¸°ê³„ì  íŠ¹ì„±ì—ì„œ ë†€ë¼ìš´ ì„±ê³¼ë¥¼ ê±°ë‘ê³  ìˆë‹¤ëŠ” ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì§€ë‚œ ìˆ˜ì‹­ ë…„ê°„ ì œê°€ ìœ ë°© ì„í”Œë€íŠ¸ì— ëŒ€í•´ ì•Œê³  ê²½í—˜í–ˆë˜ ëª¨ë“  ê²ƒê³¼ëŠ” ì™„ì „íˆ ë‹¤ë¥¸ ì ‘ê·¼ë²•ì´ì—ˆìŠµë‹ˆë‹¤. ì €ëŠ” ë§¤ë„ëŸ¬ìš´ ì‹¤í¬ í‘œë©´ ê¸°ìˆ ê³¼ RFID ì¥ì¹˜ê°€ ë‚´ì¥ëœ QIDë¥¼ ì¢‹ì•„í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €ë¥¼ ê°€ì¥ ë§¤ë£Œì‹œí‚¨ ê²ƒì€ ê²”ì˜ ê¸°ê³„ì  íŠ¹ì„±ê³¼ ê·¸ë“¤ì´ ì‰˜ê³¼ ê²”ì„ ë§¤ì¹­ì‹œì¼œ ëª¨ë…¸ë¸”ë¡ì„ ë§Œë“ ë‹¤ëŠ” ì‚¬ì‹¤ì´ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 5: So the implant moves as a unit rather than all the other implants I've seen where the gel moves separately inside the shell independently. And that creates Eddy currents, which have certain effects on the soft tissue interaction and the ultimate aesthetic result, which I'll discuss a little bit later. So what my initial observations in the study were, patients coming in, they want an implant for their breast, and I'm trying to sell them on the idea of having an experimental device, not approved in this country, to put into their breast. I thought it was<br>going to be an uphill battle. So my nurses would room the patient.</td><td>í™”ì 5: ë”°ë¼ì„œ ì„í”Œë€íŠ¸ê°€ í•˜ë‚˜ì˜ ë‹¨ìœ„ë¡œ ì›€ì§ì…ë‹ˆë‹¤. ì œê°€ ë³¸ ë‹¤ë¥¸ ëª¨ë“  ì„í”Œë€íŠ¸ë“¤ê³¼ëŠ” ë‹¬ë¦¬ ì ¤ì´ ì‰˜ ë‚´ë¶€ì—ì„œ ë…ë¦½ì ìœ¼ë¡œ ë³„ë„ë¡œ ì›€ì§ì´ì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì™€ë¥˜ë¥¼ ìƒì„±í•˜ë©°, ì´ëŠ” ì—°ì¡°ì§ ìƒí˜¸ì‘ìš©ê³¼ ìµœì¢…ì ì¸ ë¯¸ìš© ê²°ê³¼ì— íŠ¹ì •í•œ ì˜í–¥ì„ ë¯¸ì¹©ë‹ˆë‹¤. ì´ì— ëŒ€í•´ì„œëŠ” ë‚˜ì¤‘ì— ì¢€ ë” ìì„¸íˆ ë…¼ì˜í•˜ê² ìŠµë‹ˆë‹¤. ì—°êµ¬ì—ì„œ ì œê°€ ì²˜ìŒ ê´€ì°°í•œ ë°”ëŠ”, í™˜ìë“¤ì´ ë‚´ì›í•˜ì—¬ ìœ ë°© ì„í”Œë€íŠ¸ë¥¼ ì›í•˜ëŠ”ë°, ì €ëŠ” ê·¸ë“¤ì—ê²Œ ì´ ë‚˜ë¼ì—ì„œ ìŠ¹ì¸ë˜ì§€ ì•Šì€ ì‹¤í—˜ì  ê¸°ê¸°ë¥¼ ìœ ë°©ì— ì‚½ì…í•˜ëŠ” ê²ƒì— ëŒ€í•´ ì„¤ë“í•´ì•¼ í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ í˜ë“  ì‹¸ì›€ì´ ë  ê²ƒì´ë¼ê³  ìƒê°í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì œ ê°„í˜¸ì‚¬ë“¤ì´ í™˜ìë¥¼ ì§„ë£Œì‹¤ë¡œ ì•ˆë‚´í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 5: They'd have a few of the Allergan implants on a table with the Motiva next to it. I'd walk in the room before I could open my mouth. Several of them said, I want the little blue implant. So it was very easy, actually, to enroll patients. Almost everyone wanted to be in the study. Speaker 5: We had no issues with the device and placement during the study. And patient satisfaction afterwards was just about universal. What I found now, after seven years, is that the results are extremely stable. And I'm going to show photos of that. What I mean is the lower pole of the breast is not stretching, which preserves the upper fullness. Speaker 5: And the breasts feel extremely natural.</td><td>ë°œí‘œì 5: ê·¸ë“¤ì€ í…Œì´ë¸” ìœ„ì— ì•¨ëŸ¬ê°„ ì„í”Œë€íŠ¸ ëª‡ ê°œì™€ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ë¥¼ ë‚˜ë€íˆ ë†“ì•„ë‘ì—ˆìŠµë‹ˆë‹¤. ì œê°€ ë°©ì— ë“¤ì–´ê°€ì„œ ì…ì„ ì—´ê¸°ë„ ì „ì— í™˜ìë“¤ ì¤‘ ëª‡ ëª…ì´ "ì € ì‘ì€ íŒŒë€ìƒ‰ ì„í”Œë€íŠ¸ë¥¼ ì›í•´ìš”"ë¼ê³  ë§í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì‹¤ì œë¡œ í™˜ì ë“±ë¡ì´ ë§¤ìš° ì‰¬ì› ìŠµë‹ˆë‹¤. ê±°ì˜ ëª¨ë“  í™˜ìê°€ ì—°êµ¬ì— ì°¸ì—¬í•˜ê¸°ë¥¼ ì›í–ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ì—°êµ¬ ê¸°ê°„ ë™ì•ˆ ê¸°ê¸°ë‚˜ ì‚½ì… ê³¼ì •ì—ì„œ ì–´ë–¤ ë¬¸ì œë„ ì—†ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìˆ˜ìˆ  í›„ í™˜ì ë§Œì¡±ë„ëŠ” ê±°ì˜ ì „ì²´ì ìœ¼ë¡œ ë†’ì•˜ìŠµë‹ˆë‹¤. 7ë…„ì´ ì§€ë‚œ ì§€ê¸ˆ ì œê°€ ë°œê²¬í•œ ê²ƒì€ ê²°ê³¼ê°€ ê·¹ë„ë¡œ ì•ˆì •ì ì´ë¼ëŠ” ì ì…ë‹ˆë‹¤. ì´ì— ëŒ€í•œ ì‚¬ì§„ì„ ë³´ì—¬ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì œê°€ ë§í•˜ëŠ” ê²ƒì€ ìœ ë°© í•˜ë¶€ê°€ ëŠ˜ì–´ë‚˜ì§€ ì•Šì•„ì„œ ìƒë¶€ì˜ ë³¼ë¥¨ê°ì„ ë³´ì¡´í•œë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ê·¸ë¦¬ê³  ìœ ë°©ì´ ê·¹ë„ë¡œ ìì—°ìŠ¤ëŸ½ê²Œ ëŠê»´ì§‘ë‹ˆë‹¤.</td></tr>
<tr><td>It's very hard to feel the implant. Normally, when you see an augmented breast, you can feel the breast tissue, and then you can feel a firmer implant underneath. In these breasts, they feel completely normal. My wife is one of the study participants. Speaker 5: She was enrolled when we were dating, so it fell according to FDA guidelines. And she has very thin, compromised tissue. And her breasts, you cannot feel the implant. It just feels like a breast. Patients feel that they have a much more natural breast than with any other device, and ninety nine percent of the patients are absolutely thrilled with the results.</td><td>ì„í”Œë€íŠ¸ë¥¼ ëŠë¼ê¸°ê°€ ë§¤ìš° ì–´ë µìŠµë‹ˆë‹¤. ì¼ë°˜ì ìœ¼ë¡œ í™•ëŒ€ëœ ê°€ìŠ´ì„ ë³´ë©´ ìœ ë°© ì¡°ì§ì„ ëŠë‚„ ìˆ˜ ìˆê³ , ê·¸ ì•„ë˜ì—ì„œ ë” ë‹¨ë‹¨í•œ ì„í”Œë€íŠ¸ë¥¼ ëŠë‚„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ëŸ¬í•œ ê°€ìŠ´ë“¤ì€ ì™„ì „íˆ ìì—°ìŠ¤ëŸ½ê²Œ ëŠê»´ì§‘ë‹ˆë‹¤. ì œ ì•„ë‚´ë„ ì—°êµ¬ ì°¸ì—¬ì ì¤‘ í•œ ëª…ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ì•„ë‚´ëŠ” ì €í¬ê°€ ì—°ì¸ ê´€ê³„ì˜€ì„ ë•Œ ë“±ë¡ë˜ì—ˆê¸° ë•Œë¬¸ì— FDA ê°€ì´ë“œë¼ì¸ì— ë”°ë¥¸ ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•„ë‚´ëŠ” ë§¤ìš° ì–‡ê³  ì†ìƒëœ ì¡°ì§ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì•„ë‚´ì˜ ê°€ìŠ´ì—ì„œëŠ” ì„í”Œë€íŠ¸ë¥¼ ì „í˜€ ëŠë‚„ ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ê·¸ëƒ¥ ê°€ìŠ´ì²˜ëŸ¼ ëŠê»´ì§‘ë‹ˆë‹¤. í™˜ìë“¤ì€ ë‹¤ë¥¸ ì–´ë–¤ ê¸°ê¸°ë³´ë‹¤ë„ í›¨ì”¬ ë” ìì—°ìŠ¤ëŸ¬ìš´ ê°€ìŠ´ì„ ê°€ì§€ê²Œ ë˜ì—ˆë‹¤ê³  ëŠë¼ë©°, í™˜ìì˜ 99%ê°€ ê²°ê³¼ì— ì ˆëŒ€ì ìœ¼ë¡œ ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 5: No one has gone back to me later and said, hey, I want these out. I want you to put in an Allergan, a Mentor, a Sientra. And device related complications are extremely low. The safety data far exceeds that of any of the competitive devices. So what we've seen here, what I've observed, is a disruption of the market on two fronts. Speaker 5: My initial understanding of a market disruptor is a low quality product at a reduced price that disrupts the higher quality product at a more premium price. But that's not what's happening here at all. You have disruption on two fronts. of all, you have sustaining innovation.</td><td>ë°œí‘œì 5: ë‚˜ì¤‘ì— ë‹¤ì‹œ ì™€ì„œ ì´ê²ƒë“¤ì„ ë¹¼ë‹¬ë¼ê³  í•œ ì‚¬ëŒì€ ì•„ë¬´ë„ ì—†ì—ˆìŠµë‹ˆë‹¤. ì•ŒëŸ¬ê°„ì´ë‚˜ ë©˜í† , ì‹œì—”íŠ¸ë¼ ì œí’ˆìœ¼ë¡œ ë°”ê¿”ë‹¬ë¼ê³  í•œ ì‚¬ëŒë„ ì—†ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê¸°ê¸° ê´€ë ¨ í•©ë³‘ì¦ì€ ê·¹íˆ ë‚®ìŠµë‹ˆë‹¤. ì•ˆì „ì„± ë°ì´í„°ëŠ” ê²½ìŸ ê¸°ê¸°ë“¤ì„ í›¨ì”¬ ëŠ¥ê°€í•©ë‹ˆë‹¤. ì—¬ê¸°ì„œ ì œê°€ ê´€ì°°í•œ ë°”ë¡œëŠ”, ë‘ ê°€ì§€ ì¸¡ë©´ì—ì„œ ì‹œì¥ íŒŒê´´ê°€ ì¼ì–´ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 5: ì‹œì¥ íŒŒê´´ìì— ëŒ€í•œ ì œ ì´ˆê¸° ì´í•´ëŠ” ì €í’ˆì§ˆ ì œí’ˆì´ ì €ë ´í•œ ê°€ê²©ìœ¼ë¡œ ê³ í’ˆì§ˆì˜ í”„ë¦¬ë¯¸ì—„ ê°€ê²© ì œí’ˆì„ íŒŒê´´í•˜ëŠ” ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì—¬ê¸°ì„œëŠ” ì „í˜€ ê·¸ëŸ° ì¼ì´ ì¼ì–´ë‚˜ì§€ ì•Šê³  ìˆìŠµë‹ˆë‹¤. ë‘ ê°€ì§€ ì¸¡ë©´ì—ì„œ íŒŒê´´ê°€ ì¼ì–´ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ì„ , ì§€ì†ì  í˜ì‹ ì´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The competitive devices, there has been no research, no development, nothing new significant in many, many years, whereas Establishment Labs is continually pushing the limit, improving the devices, finding new ways to solve problems with women's health and breast augmentation. Speaker 5: So the technology is superior to the competitive devices. And the other thing and this is really fascinating using the minimally invasive technology, they've created new market disruption. So now you have all these patients out there who've been happy with their padded bras, didn't want breast implants because they didn't want to look like they had implants.</td><td>ê²½ìŸ ì œí’ˆë“¤ì˜ ê²½ìš°, ìˆ˜ë…„ê°„ ì—°êµ¬ë„, ê°œë°œë„, ì˜ë¯¸ ìˆëŠ” ìƒˆë¡œìš´ ê²ƒë„ ì „í˜€ ì—†ì—ˆë˜ ë°˜ë©´, Establishment LabsëŠ” ì§€ì†ì ìœ¼ë¡œ í•œê³„ë¥¼ ë›°ì–´ë„˜ìœ¼ë©° ê¸°ê¸°ë¥¼ ê°œì„ í•˜ê³ , ì—¬ì„± ê±´ê°•ê³¼ ìœ ë°© í™•ëŒ€ìˆ ì˜ ë¬¸ì œë¥¼ í•´ê²°í•˜ëŠ” ìƒˆë¡œìš´ ë°©ë²•ë“¤ì„ ì°¾ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ë”°ë¼ì„œ ì´ ê¸°ìˆ ì€ ê²½ìŸ ì œí’ˆë“¤ë³´ë‹¤ ìš°ìˆ˜í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë˜ ë‹¤ë¥¸ ì ì€ ì •ë§ í¥ë¯¸ë¡œìš´ë°, ìµœì†Œ ì¹¨ìŠµ ê¸°ìˆ ì„ ì‚¬ìš©í•˜ì—¬ ìƒˆë¡œìš´ ì‹œì¥ íŒŒê´´ë¥¼ ë§Œë“¤ì–´ëƒˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ì œ íŒ¨ë“œ ë¸Œë¼ì— ë§Œì¡±í•˜ë©° ì„í”Œë€íŠ¸ë¥¼ í•œ ê²ƒì²˜ëŸ¼ ë³´ì´ê³  ì‹¶ì§€ ì•Šì•„ì„œ ìœ ë°© ì„í”Œë€íŠ¸ë¥¼ ì›í•˜ì§€ ì•Šì•˜ë˜ ëª¨ë“  í™˜ìë“¤ì´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>They want just a little modest enhancement, but they don't want to go through a big surgery. And now you can offer them a MIA procedure with a very small incision, quick procedure, easy recovery, and they can achieve their goal without having to wear a padded bra. Speaker 5: That technology has now been expanded to the Preserve, where you can use a little larger implant. Now, the patients will think about it in terms of the small incision, but after<br>breast surgery, most patients don't care about the incision.</td><td>ê·¸ë“¤ì€ ë‹¨ì§€ ì•½ê°„ì˜ ì†Œí­ ê°œì„ ì„ ì›í•  ë¿, í° ìˆ˜ìˆ ì„ ë°›ê³  ì‹¶ì–´í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ì œ ë§¤ìš° ì‘ì€ ì ˆê°œ, ë¹ ë¥¸ ì‹œìˆ , ì‰¬ìš´ íšŒë³µì´ ê°€ëŠ¥í•œ MIA ì‹œìˆ ì„ ì œì•ˆí•  ìˆ˜ ìˆìœ¼ë©°, íŒ¨ë“œ ë¸Œë¼ë¥¼ ì°©ìš©í•˜ì§€ ì•Šê³ ë„ ëª©í‘œë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 5: ì´ ê¸°ìˆ ì€ ì´ì œ Preserveë¡œ í™•ì¥ë˜ì–´ ì¡°ê¸ˆ ë” í° ì„í”Œë€íŠ¸ë¥¼ ì‚¬ìš©í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. í™˜ìë“¤ì€ ì‘ì€ ì ˆê°œë¼ëŠ” ì¸¡ë©´ì—ì„œ ìƒê°í•˜ê² ì§€ë§Œ, ìœ ë°© ìˆ˜ìˆ  í›„ì—ëŠ” ëŒ€ë¶€ë¶„ì˜ í™˜ìë“¤ì´ ì ˆê°œ ë¶€ìœ„ì— ëŒ€í•´ì„œëŠ” í¬ê²Œ ì‹ ê²½ ì“°ì§€ ì•ŠìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The real beauty about this is that you are preserving the circumammary ligament, which is like a gasket that the breast is affixed to the chest with, and you're preserving all the internal ligaments and structure to the breast, so you're eliminating all the malpositions and other shape contour problems that normally occur after breast surgery. Aside from the minimally invasive technique, all other breast aug procedures are disruptive. It doesn't matter what size the incision is. Speaker 5: They all result in disruption of the ligamentous structure. The minimally invasive preserved that's why they call it the preservation space preserved the ligamentous structure.</td><td>ì´ ê¸°ìˆ ì˜ ì§„ì •í•œ ì¥ì ì€ ìœ ë°©ì´ í‰ë¶€ì— ê³ ì •ë˜ëŠ” ê°œìŠ¤í‚·ê³¼ ê°™ì€ ì—­í• ì„ í•˜ëŠ” ìœ ë¥œì£¼ìœ„ì¸ëŒ€ë¥¼ ë³´ì¡´í•˜ê³ , ìœ ë°©ì˜ ëª¨ë“  ë‚´ë¶€ ì¸ëŒ€ì™€ êµ¬ì¡°ë¥¼ ë³´ì¡´í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì¼ë°˜ì ìœ¼ë¡œ ìœ ë°© ìˆ˜ìˆ  í›„ ë°œìƒí•˜ëŠ” ëª¨ë“  ìœ„ì¹˜ ì´ìƒê³¼ ê¸°íƒ€ í˜•íƒœ ìœ¤ê³½ ë¬¸ì œë¥¼ ì œê±°í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ìµœì†Œì¹¨ìŠµ ê¸°ë²•ì„ ì œì™¸í•˜ê³ ëŠ”, ë‹¤ë¥¸ ëª¨ë“  ìœ ë°©í™•ëŒ€ìˆ ì€ íŒŒê´´ì ì…ë‹ˆë‹¤. ì ˆê°œ í¬ê¸°ê°€ ì–´ë–»ë“  ìƒê´€ì—†ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ëª¨ë“  ìˆ˜ìˆ ì´ ì¸ëŒ€ êµ¬ì¡°ì˜ íŒŒê´´ë¥¼ ì´ˆë˜í•©ë‹ˆë‹¤. ìµœì†Œì¹¨ìŠµ ë³´ì¡´ìˆ ì´ ì¸ëŒ€ êµ¬ì¡°ë¥¼ ë³´ì¡´í•˜ê¸° ë•Œë¬¸ì— ì´ë¥¼ ë³´ì¡´ ê³µê°„(preservation space) ë³´ì¡´ìˆ ì´ë¼ê³  ë¶€ë¥´ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And that is the key reason why I'm going to be moving to that this summer as soon as it's available. There's also been a major paradigm shift in my practice, and I see it in a lot of my colleagues, where we went from subpectoral breast augmentation that was my gold standard<br><br>for over thirty years. I wouldn't consider going above the muscle because I didn't like the way the competitive implants were in the upper part of the breast. Speaker 5: Without that muscle coverage, you didn't have the blending of soft tissue that you wanted. And I was very concerned how the long term results would be. And because of that, we accepted other problems going under the muscle.</td><td>í™”ì 5: ê·¼ìœ¡ ë®ê°œê°€ ì—†ìœ¼ë©´ ì›í•˜ëŠ” ì—°ì¡°ì§ì˜ ìì—°ìŠ¤ëŸ¬ìš´ ë¸”ë Œë”©ì„ ì–»ì„ ìˆ˜ ì—†ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¥ê¸°ì ì¸ ê²°ê³¼ê°€ ì–´ë–¨ì§€ ë§¤ìš° ìš°ë ¤ìŠ¤ëŸ¬ì› ìŠµë‹ˆë‹¤. ê·¸ ë•Œë¬¸ì— ìš°ë¦¬ëŠ” ê·¼ìœ¡ ì•„ë˜ë¡œ ë“¤ì–´ê°€ëŠ” ë‹¤ë¥¸ ë¬¸ì œë“¤ì„ ë°›ì•„ë“¤ì˜€ë˜ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Now we can go above the muscle, which is now the new gold standard. And the concern about the transition is no longer there. Speaker 5: This week, I did a 74 year old woman who's so thin, she doesn't have two fat cells to rub together. And we went above the muscle in the subfascial plane and put Motiva Ergonomix in, and she looks amazing and so happy. So we can perform this now in people with thin tissue where we couldn't do it with competitive implants. We can create narrower cleavage because normally when you go under the muscle, the muscle acts as a barrier and limits how far<br>medially you can place that implant.</td><td>ì´ì œ ê·¼ìœ¡ ìœ„ë¡œ ì‹œìˆ í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìœ¼ë©°, ì´ê²ƒì´ ìƒˆë¡œìš´ ê³¨ë“œ ìŠ¤íƒ ë‹¤ë“œê°€ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì „í™˜ì— ëŒ€í•œ ìš°ë ¤ëŠ” ë” ì´ìƒ ì—†ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ì´ë²ˆ ì£¼ì— ì €ëŠ” 74ì„¸ ì—¬ì„± í™˜ìë¥¼ ì‹œìˆ í–ˆëŠ”ë°, ì´ ë¶„ì€ ë„ˆë¬´ ë§ˆë¥´ì…”ì„œ ì§€ë°© ì„¸í¬ê°€ ê±°ì˜ ì—†ì„ ì •ë„ì˜€ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê·¼ë§‰í•˜ í‰ë©´ì—ì„œ ê·¼ìœ¡ ìœ„ë¡œ ì ‘ê·¼í•˜ì—¬ Motiva Ergonomixë¥¼ ì‚½ì…í–ˆê³ , ê²°ê³¼ê°€ ë†€ë¼ìš¸ ì •ë„ë¡œ ì¢‹ì•˜ìœ¼ë©° í™˜ìë¶„ë„ ë§¤ìš° ë§Œì¡±í•´í•˜ì…¨ìŠµë‹ˆë‹¤. ì´ì œ ê²½ìŸì‚¬ ì„í”Œë€íŠ¸ë¡œëŠ” í•  ìˆ˜ ì—†ì—ˆë˜ ì–‡ì€ ì¡°ì§ì„ ê°€ì§„ í™˜ìë“¤ì—ê²Œë„ ì´ ì‹œìˆ ì„ ì‹œí–‰í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ ë” ì¢ì€ ê°€ìŠ´ê³¨ ê°„ê²©ì„ ë§Œë“¤ ìˆ˜ ìˆëŠ”ë°, ì¼ë°˜ì ìœ¼ë¡œ ê·¼ìœ¡ ì•„ë˜ë¡œ ë“¤ì–´ê°ˆ ë•ŒëŠ” ê·¼ìœ¡ì´ ì¥ë²½ ì—­í• ì„ í•˜ì—¬ ì„í”Œë€íŠ¸ë¥¼ ë‚´ì¸¡ìœ¼ë¡œ ë°°ì¹˜í•  ìˆ˜ ìˆëŠ” ë²”ìœ„ê°€ ì œí•œë˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>But now I can go on top of the muscle and bring the cleavage in a little bit closer. Speaker 5: And I don't have animation deformities, which is when the woman contracts her pec muscle, you see the implants move. And also a faster recovery. In my practice, it's a one day recovery under the muscle, but for 99% of other practices out there, this is going to be a substantial improvement in recovery. So let me show my results. This is my patient in the study, number one. Speaker 5: And she has ergonomic implants, three forty cc's. If you look at her, you will see the upper pole and the lower pole. They don't change from four months to seven years.</td><td>í•˜ì§€ë§Œ ì´ì œ ê·¼ìœ¡ ìœ„ì— ìœ„ì¹˜ì‹œì¼œì„œ ìœ ë°© ì‚¬ì´ì˜ ê°„ê²©ì„ ì¡°ê¸ˆ ë” ê°€ê¹ê²Œ ë§Œë“¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 5: ê·¸ë¦¬ê³  ì• ë‹ˆë©”ì´ì…˜ ë³€í˜•ì´ ì—†ìŠµë‹ˆë‹¤. ì´ëŠ” ì—¬ì„±ì´ ê°€ìŠ´ê·¼ìœ¡ì„ ìˆ˜ì¶•ì‹œí‚¬ ë•Œ ì„í”Œë€íŠ¸ê°€ ì›€ì§ì´ëŠ” í˜„ìƒì„ ë§í•©ë‹ˆë‹¤. ë˜í•œ íšŒë³µì´ ë” ë¹ ë¦…ë‹ˆë‹¤. ì œ ì§„ë£Œì—ì„œëŠ” ê·¼ìœ¡ ì•„ë˜ ìˆ˜ìˆ ì˜ ê²½ìš° í•˜ë£¨ íšŒë³µì´ì§€ë§Œ, ë‹¤ë¥¸ 99%ì˜ ì§„ë£Œì†Œë“¤ì—ê²ŒëŠ” ì´ê²ƒì´ íšŒë³µì— ìˆì–´ ìƒë‹¹í•œ ê°œì„ ì´ ë  ê²ƒì…ë‹ˆë‹¤. ê·¸ëŸ¼ ì œ ê²°ê³¼ë¥¼ ë³´ì—¬ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ë¶„ì€ ì—°êµ¬ì— ì°¸ì—¬í•œ ì œ í™˜ì 1ë²ˆì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ê·¸ë¦¬ê³  ì´ë¶„ì€ ì¸ì²´ê³µí•™ì  ì„í”Œë€íŠ¸ 340ccë¥¼ ì‚¬ìš©í–ˆìŠµë‹ˆë‹¤. ì´ë¶„ì„ ë³´ì‹œë©´ ìƒë¶€ì™€ í•˜ë¶€ë¥¼ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. 4ê°œì›”ì—ì„œ 7ë…„ê¹Œì§€ ë³€í™”ê°€ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And here's another similar patient, also ergonomic implants. Again, at seven years. Speaker 5: Look at the stability. You don't see stretching of the lower pole. The crease is not dropping. You're not losing fullness in the upper pole. The breast is staying the same seven<br><br>years out. Speaker 5: Now we're going to some of my six year follow ups, because we just started seven years in May, so I've only got a few in the seven year area. Again, same degree of stability. Another patient, two eighty five cc ergonomics. Again, very stable. And these are all different types of breasts. Speaker 5: Here's a patient with a little bit more compromise to her soft tissue.</td><td>ê·¸ë¦¬ê³  ì—¬ê¸° ë˜ ë‹¤ë¥¸ ìœ ì‚¬í•œ í™˜ìì…ë‹ˆë‹¤. ì—­ì‹œ ì¸ì²´ê³µí•™ì  ì„í”Œë€íŠ¸ë¥¼ ì‚¬ìš©í–ˆìŠµë‹ˆë‹¤. ë§ˆì°¬ê°€ì§€ë¡œ 7ë…„ í›„ì˜ ëª¨ìŠµì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ì•ˆì •ì„±ì„ ë³´ì‹­ì‹œì˜¤. í•˜ë¶€ ê·¹ì˜ ëŠ˜ì–´ì§ì´ ë³´ì´ì§€ ì•ŠìŠµë‹ˆë‹¤. ìœ ë°© í•˜ë¶€ ì£¼ë¦„ì´ ì²˜ì§€ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ìƒë¶€ ê·¹ì˜ ë³¼ë¥¨ê°ì„ ìƒì§€ ì•Šê³  ìˆìŠµë‹ˆë‹¤. ìœ ë°©ì´ 7ë…„ì´ ì§€ë‚œ í›„ì—ë„ ë™ì¼í•œ ìƒíƒœë¥¼ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ì´ì œ 6ë…„ ì¶”ì  ê´€ì°° ì‚¬ë¡€ë“¤ì„ ë³´ì—¬ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 7ë…„ ì¶”ì  ê´€ì°°ì€ 5ì›”ì— ë§‰ ì‹œì‘í–ˆê¸° ë•Œë¬¸ì— 7ë…„ êµ¬ê°„ì—ì„œëŠ” ëª‡ ì‚¬ë¡€ë§Œ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì°¬ê°€ì§€ë¡œ ë™ì¼í•œ ìˆ˜ì¤€ì˜ ì•ˆì •ì„±ì„ ë³´ì…ë‹ˆë‹¤. ë˜ ë‹¤ë¥¸ í™˜ìë¡œ, 285cc ì¸ì²´ê³µí•™ì  ì„í”Œë€íŠ¸ë¥¼ ì‚¬ìš©í–ˆìŠµë‹ˆë‹¤. ì—­ì‹œ ë§¤ìš° ì•ˆì •ì ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ë“¤ì€ ëª¨ë‘ ì„œë¡œ ë‹¤ë¥¸ ìœ í˜•ì˜ ìœ ë°©ë“¤ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ì—¬ê¸°ëŠ” ì—°ì¡°ì§ì´ ë‹¤ì†Œ ì†ìƒëœ í™˜ìì…ë‹ˆë‹¤.</td></tr>
<tr><td>Again, very, very stable results. So thank you. Anyone has any questions, my contact information is here, or you can reach me through Establishment Labs. If you go on my website, epsteinplasticsurgery.com, under Motiva in the video gallery is a nice eight minute video where I explain the rheology in very, very simple terms that anyone can understand without a technical background. Speaker 5: So if you want to know what the magic of the gel is, it's an eight minute video, but it's definitely well worth watching. Thank you. Speaker 6: So I'm going to talk a little bit about the culture shift in breast augmentation in the new era of breast aesthetics.</td><td>ë‹¤ì‹œ í•œë²ˆ ë§ì”€ë“œë¦¬ì§€ë§Œ, ë§¤ìš° ì•ˆì •ì ì¸ ê²°ê³¼ì…ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. ì§ˆë¬¸ì´ ìˆìœ¼ì‹œë©´ ì œ ì—°ë½ì²˜ ì •ë³´ê°€ ì—¬ê¸° ìˆê³ , ë˜ëŠ” Establishment Labsë¥¼ í†µí•´ì„œë„ ì—°ë½í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì œ ì›¹ì‚¬ì´íŠ¸ epsteinplasticsurgery.comì— ê°€ì…”ì„œ Motiva ì„¹ì…˜ì˜ ë¹„ë””ì˜¤ ê°¤ëŸ¬ë¦¬ë¥¼ ë³´ì‹œë©´, ê¸°ìˆ ì  ë°°ê²½ ì§€ì‹ì´ ì—†ëŠ” ë¶„ë“¤ë„ ì´í•´í•  ìˆ˜ ìˆë„ë¡ ë§¤ìš° ê°„ë‹¨í•œ ìš©ì–´ë¡œ ìœ ë³€í•™ì„ ì„¤ëª…í•˜ëŠ” 8ë¶„ì§œë¦¬ ì¢‹ì€ ì˜ìƒì´ ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ì ¤ì˜ ë§ˆë²•ì´ ë¬´ì—‡ì¸ì§€ ì•Œê³  ì‹¶ìœ¼ì‹œë‹¤ë©´, 8ë¶„ì§œë¦¬ ì˜ìƒì´ì§€ë§Œ ì •ë§ ë³¼ ê°€ì¹˜ê°€ ìˆìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 6: ì´ì œ ìœ ë°© ë¯¸ìš©ì˜ ìƒˆë¡œìš´ ì‹œëŒ€ì—ì„œ ìœ ë°©í™•ëŒ€ìˆ ì˜ ë¬¸í™”ì  ë³€í™”ì— ëŒ€í•´ ì¡°ê¸ˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>My practice is based here in New York City. We have a luxury practice. And I'm going to talk a little bit about the Park Avenue look and the experience that women are expecting. So this is our typical Park Avenue patient. Speaker 6: She has her Hermes bag on one arm and her son on the other. She's looking for the most natural looking results in breast augmentation with minimal downtime. Cost is no object and she wants the best available option on the market. To her right is a patient who flew from out of country for this Park Avenue look desiring that natural looking breast with minimal downtime.</td><td>ì œ ì§„ë£Œì†ŒëŠ” ë‰´ìš•ì‹œì— ìœ„ì¹˜í•´ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ëŸ­ì…”ë¦¬ ì§„ë£Œì†Œë¥¼ ìš´ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  íŒŒí¬ ì• ë¹„ë‰´ ë£©ê³¼ ì—¬ì„±ë“¤ì´ ê¸°ëŒ€í•˜ëŠ” ê²½í—˜ì— ëŒ€í•´ ì¡°ê¸ˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ë¶„ì´ ì €í¬ì˜ ì „í˜•ì ì¸ íŒŒí¬ ì• ë¹„ë‰´ í™˜ìì…ë‹ˆë‹¤. <br><br>ë°œí‘œì 6: ê·¸ë…€ëŠ” í•œ íŒ”ì—ëŠ” ì—ë¥´ë©”ìŠ¤ ê°€ë°©ì„, ë‹¤ë¥¸ í•œ íŒ”ì—ëŠ” ì•„ë“¤ì„ ì•ˆê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë…€ëŠ” ìµœì†Œí•œì˜ íšŒë³µ ê¸°ê°„ìœ¼ë¡œ ê°€ì¥ ìì—°ìŠ¤ëŸ¬ì›Œ ë³´ì´ëŠ” ìœ ë°© í™•ëŒ€ìˆ  ê²°ê³¼ë¥¼ ì›í•©ë‹ˆë‹¤. ë¹„ìš©ì€ ë¬¸ì œê°€ ë˜ì§€ ì•Šìœ¼ë©°, ì‹œì¥ì—ì„œ êµ¬í•  ìˆ˜ ìˆëŠ” ìµœê³ ì˜ ì˜µì…˜ì„ ì›í•©ë‹ˆë‹¤. ê·¸ë…€ ì˜¤ë¥¸ìª½ì— ìˆëŠ” í™˜ìëŠ” ì´ íŒŒí¬ ì• ë¹„ë‰´ ë£©ì„ ìœ„í•´ í•´ì™¸ì—ì„œ ë‚ ì•„ì˜¨ ë¶„ìœ¼ë¡œ, ìµœì†Œí•œì˜ íšŒë³µ ê¸°ê°„ìœ¼ë¡œ ìì—°ìŠ¤ëŸ¬ì›Œ ë³´ì´ëŠ” ê°€ìŠ´ì„ ì›í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Shown here, she's three months post operative and she chose Motiva for its natural shape, currently the only slightly teardrop shaped available implant in the market. Speaker 6: And the option to have these implants placed above the muscle with very minimal downtime. Before Motiva implants, my patients typically had no knowledge of their breast implant brand. Now my patient intake forms look like this. Patients requesting Motiva Implants. Patients requesting maybe fat transfer or Motiva Implants which is interesting because typically patients perceive fat transfer as a more safe alternative to implants.</td><td>ì—¬ê¸° ë³´ì‹œëŠ” í™˜ìëŠ” ìˆ˜ìˆ  í›„ 3ê°œì›”ì´ ì§€ë‚œ ìƒíƒœì´ë©°, ìì—°ìŠ¤ëŸ¬ìš´ ëª¨ì–‘ì„ ìœ„í•´ Motivaë¥¼ ì„ íƒí–ˆìŠµë‹ˆë‹¤. í˜„ì¬ ì‹œì¥ì—ì„œ ìœ ì¼í•˜ê²Œ ì•½ê°„ì˜ í‹°ì–´ë“œë¡­ í˜•íƒœë¥¼ ì œê³µí•˜ëŠ” ì„í”Œë€íŠ¸ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 6: ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ì„í”Œë€íŠ¸ë¥¼ ê·¼ìœ¡ ìœ„ì— ì‚½ì…í•  ìˆ˜ ìˆëŠ” ì˜µì…˜ìœ¼ë¡œ íšŒë³µ ì‹œê°„ì´ ë§¤ìš° ì§§ìŠµë‹ˆë‹¤. Motiva ì„í”Œë€íŠ¸ ì´ì „ì—ëŠ” ì œ í™˜ìë“¤ì´ ì¼ë°˜ì ìœ¼ë¡œ ìì‹ ì˜ ìœ ë°© ì„í”Œë€íŠ¸ ë¸Œëœë“œì— ëŒ€í•´ ì „í˜€ ì•Œì§€ ëª»í–ˆìŠµë‹ˆë‹¤. ì´ì œ ì œ í™˜ì ì ‘ìˆ˜ ì–‘ì‹ì€ ì´ë ‡ê²Œ ìƒê²¼ìŠµë‹ˆë‹¤. Motiva ì„í”Œë€íŠ¸ë¥¼ ìš”ì²­í•˜ëŠ” í™˜ìë“¤. ì§€ë°© ì´ì‹ì´ë‚˜ Motiva ì„í”Œë€íŠ¸ë¥¼ ìš”ì²­í•˜ëŠ” í™˜ìë“¤ì¸ë°, ì´ëŠ” í¥ë¯¸ë¡œìš´ í˜„ìƒì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì¼ë°˜ì ìœ¼ë¡œ í™˜ìë“¤ì€ ì§€ë°© ì´ì‹ì„ ì„í”Œë€íŠ¸ë³´ë‹¤ ë” ì•ˆì „í•œ ëŒ€ì•ˆìœ¼ë¡œ ì¸ì‹í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 6: And here we have patients categorizing Motiva Implants alongside fat transfer. They truly feel it is a safer option and when we look at the data, it is. In the six months since the FDA approval, I had a total of one hundred and sixty seven breast implant based cases. One hundred and fifty five of those patients chose Motiva. As you can imagine, most of these patients actually had their initial surgery booked expecting a different implant brand. Speaker 6: So many of these patients chose to change their implant brand after they already had a procedure plan.</td><td>í™”ì 6: ê·¸ë¦¬ê³  ì—¬ê¸°ì„œ í™˜ìë“¤ì´ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ë¥¼ ì§€ë°© ì´ì‹ê³¼ í•¨ê»˜ ë¶„ë¥˜í•˜ê³  ìˆìŒì„ ë³¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í™˜ìë“¤ì€ ì´ê²ƒì´ ë” ì•ˆì „í•œ ì˜µì…˜ì´ë¼ê³  ì§„ì •ìœ¼ë¡œ ëŠë¼ê³  ìˆìœ¼ë©°, ë°ì´í„°ë¥¼ ì‚´í´ë³´ë©´ ì‹¤ì œë¡œ ê·¸ë ‡ìŠµë‹ˆë‹¤. FDA ìŠ¹ì¸ í›„ 6ê°œì›” ë™ì•ˆ ì €ëŠ” ì´ 167ê±´ì˜ ìœ ë°© ì„í”Œë€íŠ¸ ê¸°ë°˜ ìˆ˜ìˆ  ì‚¬ë¡€ë¥¼ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. ì´ ì¤‘ 155ëª…ì˜ í™˜ìê°€ ëª¨í‹°ë°”ë¥¼ ì„ íƒí–ˆìŠµë‹ˆë‹¤. ìƒìƒí•˜ì‹œê² ì§€ë§Œ, ì´ë“¤ í™˜ì ëŒ€ë¶€ë¶„ì€ ì‹¤ì œë¡œ ë‹¤ë¥¸ ì„í”Œë€íŠ¸ ë¸Œëœë“œë¥¼ ì˜ˆìƒí•˜ê³  ì´ˆê¸° ìˆ˜ìˆ ì„ ì˜ˆì•½í–ˆì—ˆìŠµë‹ˆë‹¤. <br><br>í™”ì 6: ë”°ë¼ì„œ ì´ë“¤ í™˜ì ì¤‘ ë§ì€ ìˆ˜ê°€ ì´ë¯¸ ìˆ˜ìˆ  ê³„íšì„ ì„¸ìš´ í›„ì—ë„ ì„í”Œë€íŠ¸ ë¸Œëœë“œë¥¼ ë³€ê²½í•˜ê¸°ë¡œ ì„ íƒí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Since this timeline, my practice has shifted to be 99% Motiva implants and the only patients that I don't use Motiva implants for are typically those who either have too large of implant required that doesn't come in the Motiva profile. We're certainly seeing a shift in the type of implants that women are requesting. Most patients are requesting smaller<br>volumes, more subtle volume changes, maybe that one cup up type appearance that the Motiva Mini Implants offer. I have two primary demographics.</td><td>ì´ ì‹œì  ì´í›„ë¡œ ì œ ì§„ë£ŒëŠ” 99%ê°€ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ë¡œ ì „í™˜ë˜ì—ˆìœ¼ë©°, ëª¨í‹°ë°” ì„í”Œë€íŠ¸ë¥¼ ì‚¬ìš©í•˜ì§€ ì•ŠëŠ” í™˜ìë“¤ì€ ì¼ë°˜ì ìœ¼ë¡œ ëª¨í‹°ë°” í”„ë¡œíŒŒì¼ì—ì„œ ì œê³µë˜ì§€ ì•ŠëŠ” ë„ˆë¬´ í° ì„í”Œë€íŠ¸ê°€ í•„ìš”í•œ ê²½ìš°ì— í•œì •ë©ë‹ˆë‹¤. ì—¬ì„±ë“¤ì´ ìš”ì²­í•˜ëŠ” ì„í”Œë€íŠ¸ ìœ í˜•ì— í™•ì‹¤í•œ ë³€í™”ë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ëŒ€ë¶€ë¶„ì˜ í™˜ìë“¤ì€ ë” ì‘ì€ ë³¼ë¥¨, ë” ìì—°ìŠ¤ëŸ¬ìš´ ë³¼ë¥¨ ë³€í™”, ì•„ë§ˆë„ ëª¨í‹°ë°” ë¯¸ë‹ˆ ì„í”Œë€íŠ¸ê°€ ì œê³µí•˜ëŠ” í•œ ì»µ ì •ë„ ì˜¬ë¼ê°€ëŠ” ì™¸ê´€ì„ ìš”ì²­í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €ëŠ” ë‘ ê°€ì§€ ì£¼ìš” ê³ ê°ì¸µì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 6: The is a young woman who has never had children, is looking for just a little bit more volume and she's shown above here and she has the round shaped implant placed above the muscle in the mini profile. The bottom patient is a postpartum woman who felt like she lost all shape and volume after breastfeeding. This is a mom who wants to be very discreet and wants most women and other women around her not to know she's had breast augmentation. She chose the ergo profile and again had the implants placed above the muscle. Neither of these two patients are patients who would have been candidates for their implants to be placed<br><br>above the muscle prior to Motiva implants.</td><td>í™”ì 6: ì´ í™˜ìëŠ” ì¶œì‚° ê²½í—˜ì´ ì—†ëŠ” ì Šì€ ì—¬ì„±ìœ¼ë¡œ, ì•½ê°„ì˜ ë³¼ë¥¨ ì¦ê°€ë¥¼ ì›í•˜ê³  ìˆìœ¼ë©° ìœ„ì— ë³´ì‹œëŠ” ë°”ì™€ ê°™ìŠµë‹ˆë‹¤. ê·¸ë…€ëŠ” ë¯¸ë‹ˆ í”„ë¡œíŒŒì¼ì˜ ì›í˜• ì„í”Œë€íŠ¸ë¥¼ ê·¼ìœ¡ ìœ„ì— ì‚½ì…í–ˆìŠµë‹ˆë‹¤. ì•„ë˜ìª½ í™˜ìëŠ” ì¶œì‚° í›„ ëª¨ìœ ìˆ˜ìœ ë¥¼ í†µí•´ ëª¨ë“  í˜•íƒœì™€ ë³¼ë¥¨ì„ ìƒì—ˆë‹¤ê³  ëŠë¼ëŠ” ì‚°í›„ ì—¬ì„±ì…ë‹ˆë‹¤. ì´ ë¶„ì€ ë§¤ìš° ì‹ ì¤‘í•˜ê²Œ ì ‘ê·¼í•˜ê¸°ë¥¼ ì›í–ˆê³ , ëŒ€ë¶€ë¶„ì˜ ì—¬ì„±ë“¤ê³¼ ì£¼ë³€ ë‹¤ë¥¸ ì—¬ì„±ë“¤ì´ ìì‹ ì´ ìœ ë°©í™•ëŒ€ìˆ ì„ ë°›ì•˜ë‹¤ëŠ” ê²ƒì„ ì•Œì§€ ëª»í•˜ê¸°ë¥¼ ë°”ëìŠµë‹ˆë‹¤. ê·¸ë…€ëŠ” ì—ë¥´ê³  í”„ë¡œíŒŒì¼ì„ ì„ íƒí–ˆê³  ì—­ì‹œ ì„í”Œë€íŠ¸ë¥¼ ê·¼ìœ¡ ìœ„ì— ì‚½ì…í–ˆìŠµë‹ˆë‹¤. ì´ ë‘ í™˜ì ëª¨ë‘ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ ì´ì „ì—ëŠ” ì„í”Œë€íŠ¸ë¥¼ ê·¼ìœ¡ ìœ„ì— ì‚½ì…í•  ìˆ˜ ìˆëŠ” í›„ë³´ìê°€ ì•„ë‹ˆì—ˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 6: So for me, there's been certainly a market expansion in women who are considering this a safer and less invasive alternative with minimal downtime. This is just a testimonial from the Motiva breast augmentation patient. She had actually been booked for surgery And after her, after the FDA announcement of approval, she had decided that she preferred to wait for Motiva Implant. So they were FDA approved but not available So we actually moved her surgical date. Speaker 6: And I think the most compelling thing here is she says that she wanted to minimize recovery time. So we adjusted her surgical plan.</td><td>í™”ì 6: ì €ì—ê²ŒëŠ” í™•ì‹¤íˆ ì´ê²ƒì„ ë” ì•ˆì „í•˜ê³  ëœ ì¹¨ìŠµì ì´ë©° ìµœì†Œí•œì˜ íšŒë³µ ì‹œê°„ì„ ìš”í•˜ëŠ” ëŒ€ì•ˆìœ¼ë¡œ ê³ ë ¤í•˜ëŠ” ì—¬ì„±ë“¤ì˜ ì‹œì¥ í™•ëŒ€ê°€ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ ëª¨í‹°ë°” ìœ ë°©í™•ëŒ€ìˆ  í™˜ìì˜ ì‹¤ì œ í›„ê¸°ì…ë‹ˆë‹¤. ê·¸ë…€ëŠ” ì‹¤ì œë¡œ ìˆ˜ìˆ  ì˜ˆì•½ì„ í•´ë†“ì€ ìƒíƒœì˜€ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  FDA ìŠ¹ì¸ ë°œí‘œ í›„ì—, ê·¸ë…€ëŠ” ëª¨í‹°ë°” ì„í”Œë€íŠ¸ë¥¼ ê¸°ë‹¤ë¦¬ëŠ” ê²ƒì„ ì„ í˜¸í•œë‹¤ê³  ê²°ì •í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ FDA ìŠ¹ì¸ì€ ë°›ì•˜ì§€ë§Œ ì•„ì§ ì´ìš©í•  ìˆ˜ ì—†ëŠ” ìƒí™©ì´ì—ˆê¸° ë•Œë¬¸ì— ì‹¤ì œë¡œ ê·¸ë…€ì˜ ìˆ˜ìˆ  ë‚ ì§œë¥¼ ì—°ê¸°í–ˆìŠµë‹ˆë‹¤. <br><br>í™”ì 6: ê·¸ë¦¬ê³  ì—¬ê¸°ì„œ ê°€ì¥ ì„¤ë“ë ¥ ìˆëŠ” ë¶€ë¶„ì€ ê·¸ë…€ê°€ íšŒë³µ ì‹œê°„ì„ ìµœì†Œí™”í•˜ê³  ì‹¶ë‹¤ê³  ë§í•œ ê²ƒì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ê·¸ë…€ì˜ ìˆ˜ìˆ  ê³„íšì„ ì¡°ì •í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And because of the Motiva technology, she was able to qualify for over the muscle implants which was less invasive and preferred for her. You can see on the other side her before and after results pre op days after the procedure and six months after the procedure compared to a patient who had traditional implants. And I think the most telling thing here is to look at where it's days after. Speaker 6: You can see the Motiva breast implant patient who has her implants placed above the muscle days after the procedure looks great. The traditional brand, you can see days after the procedure placed under the muscle, her breasts look distorted.</td><td>ëª¨í‹°ë°” ê¸°ìˆ  ë•ë¶„ì— ê·¸ë…€ëŠ” ê·¼ìœ¡ ìœ„ ì„í”Œë€íŠ¸ ì‹œìˆ ì„ ë°›ì„ ìˆ˜ ìˆì—ˆìœ¼ë©°, ì´ëŠ” ëœ ì¹¨ìŠµì ì´ê³  ì„ í˜¸ë˜ëŠ” ë°©ë²•ì´ì—ˆìŠµë‹ˆë‹¤. ë°˜ëŒ€í¸ì—ì„œ ìˆ˜ìˆ  ì „í›„ ê²°ê³¼ë¥¼ ë³´ì‹¤ ìˆ˜ ìˆëŠ”ë°, ìˆ˜ìˆ  ì „, ì‹œìˆ  ë©°ì¹  í›„, ê·¸ë¦¬ê³  ì‹œìˆ  6ê°œì›” í›„ì˜ ëª¨ìŠµì„ ê¸°ì¡´ ì„í”Œë€íŠ¸ë¥¼ ë°›ì€ í™˜ìì™€ ë¹„êµí•´ ë³´ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œ ê°€ì¥ ì£¼ëª©í•  ì ì€ ì‹œìˆ  ë©°ì¹  í›„ì˜ ìƒíƒœë¥¼ ë³´ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 6: ê·¼ìœ¡ ìœ„ì— ì„í”Œë€íŠ¸ë¥¼ ì‚½ì…í•œ ëª¨í‹°ë°” ìœ ë°© ì„í”Œë€íŠ¸ í™˜ìì˜ ê²½ìš°, ì‹œìˆ  ë©°ì¹  í›„ì—ë„ í›Œë¥­í•œ ê²°ê³¼ë¥¼ ë³´ì´ëŠ” ê²ƒì„ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë°˜ë©´ ê¸°ì¡´ ë¸Œëœë“œì˜ ê²½ìš°, ê·¼ìœ¡ ì•„ë˜ì— ì‚½ì…í•œ ì‹œìˆ  ë©°ì¹  í›„ ìœ ë°©ì´ ì¼ê·¸ëŸ¬ì ¸ ë³´ì´ëŠ” ê²ƒì„ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And this lasts a significant amount of time for women, three to six months, six months to a year, depending on the implant size. So Motiva is really changing the game in terms of the ability for these patients to have quick, quick changes and less recovery time and fairly immediate results with excellent sustained results over time as Doctor. Epstein has showed and also superior safety. Speaker 6: I'll hand things over to Doctor. Pittman who's going to expand a little bit more on that difference between above and below the muscle. Speaker 7: Thank you. It's a pleasure to be here today. So let's talk about the quest for the<br><br>perfect breast. It's really filled with dogma, devices, and drama.</td><td>ì—¬ì„±ì˜ ê²½ìš° ì´ëŸ¬í•œ ìƒíƒœê°€ ìƒë‹¹í•œ ê¸°ê°„ ë™ì•ˆ ì§€ì†ë˜ëŠ”ë°, ì„í”Œë€íŠ¸ í¬ê¸°ì— ë”°ë¼ 3ê°œì›”ì—ì„œ 6ê°œì›”, 6ê°œì›”ì—ì„œ 1ë…„ê¹Œì§€ ì§€ì†ë©ë‹ˆë‹¤. ë”°ë¼ì„œ MotivaëŠ” í™˜ìë“¤ì´ ë¹ ë¥¸ ë³€í™”ì™€ ì§§ì€ íšŒë³µ ì‹œê°„, ê·¸ë¦¬ê³  ê±°ì˜ ì¦‰ê°ì ì¸ ê²°ê³¼ë¥¼ ì–»ì„ ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ì¸¡ë©´ì—ì„œ ì •ë§ë¡œ ê²Œì„ì˜ íŒë„ë¥¼ ë°”ê¾¸ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ Epstein ë°•ì‚¬ê°€ ë³´ì—¬ì£¼ì‹  ë°”ì™€ ê°™ì´ ì‹œê°„ì´ ì§€ë‚˜ë„ ìš°ìˆ˜í•˜ê³  ì§€ì†ì ì¸ ê²°ê³¼ì™€ ë›°ì–´ë‚œ ì•ˆì „ì„±ì„ ì œê³µí•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 6: ê·¼ìœ¡ ìœ„ì™€ ê·¼ìœ¡ ì•„ë˜ì˜ ì°¨ì´ì ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹¤ Pittman ë°•ì‚¬ì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 7: ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì´ ìë¦¬ì— ì°¸ì„í•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. ê·¸ëŸ¼ ì™„ë²½í•œ ê°€ìŠ´ì— ëŒ€í•œ íƒêµ¬ì— ëŒ€í•´ ì´ì•¼ê¸°í•´ ë³´ê² ìŠµë‹ˆë‹¤. ì´ëŠ” ì •ë§ë¡œ ë„ê·¸ë§ˆ, ê¸°ê¸°, ê·¸ë¦¬ê³  ë“œë¼ë§ˆë¡œ ê°€ë“ ì°¨ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And so I think, you know, you've heard all of the unique things about Motiva today, and I think it becomes even more special and more unique and more disruptive when you know where we came from. Speaker 7: This is my mentor, doctor Scott Spear. I trained with him at Georgetown. He I'm sure any of us would be here today without him. I know I certainly would not be here today without him. He was really an innovator. Speaker 7: He's kind of the the godfather of breast surgery. And Scott was not dogmatic. He was very into technology, new ideas, which is sometimes unusual amongst plastic surgeons. We kind of are taught things one way, and we just do that over and over again.</td><td>ê·¸ë˜ì„œ ì €ëŠ” ì˜¤ëŠ˜ ì—¬ëŸ¬ë¶„ê»˜ì„œ Motivaì˜ ëª¨ë“  ë…íŠ¹í•œ íŠ¹ì§•ë“¤ì— ëŒ€í•´ ë“¤ìœ¼ì…¨ë‹¤ê³  ìƒê°í•˜ë©°, ì €í¬ê°€ ì–´ë””ì„œ ì¶œë°œí–ˆëŠ”ì§€ë¥¼ ì•Œê²Œ ë˜ë©´ ì´ê²ƒì´ ë”ìš± íŠ¹ë³„í•˜ê³  ë”ìš± ë…íŠ¹í•˜ë©° ë”ìš± íŒŒê´´ì ì¸ í˜ì‹ ì´ ëœë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 7: ì´ë¶„ì€ ì œ ë©˜í† ì´ì‹  ìŠ¤ì½§ ìŠ¤í”¼ì–´(Scott Spear) ë°•ì‚¬ë‹˜ì…ë‹ˆë‹¤. ì €ëŠ” ì¡°ì§€íƒ€ìš´ì—ì„œ ë°•ì‚¬ë‹˜ê³¼ í•¨ê»˜ ìˆ˜ë ¨ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ë°•ì‚¬ë‹˜ ì—†ì´ëŠ” ì €í¬ ì¤‘ ëˆ„êµ¬ë„ ì˜¤ëŠ˜ ì´ ìë¦¬ì— ìˆì§€ ëª»í–ˆì„ ê²ƒì´ë¼ê³  í™•ì‹ í•©ë‹ˆë‹¤. ì € ì—­ì‹œ ë°•ì‚¬ë‹˜ ì—†ì´ëŠ” ë¶„ëª…íˆ ì˜¤ëŠ˜ ì´ ìë¦¬ì— ìˆì§€ ëª»í–ˆì„ ê²ƒì…ë‹ˆë‹¤. ë°•ì‚¬ë‹˜ì€ ì •ë§ë¡œ í˜ì‹ ê°€ì…¨ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 7: ë°•ì‚¬ë‹˜ì€ ìœ ë°© ìˆ˜ìˆ ì˜ ëŒ€ë¶€ë¼ê³  í•  ìˆ˜ ìˆëŠ” ë¶„ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìŠ¤ì½§ ë°•ì‚¬ë‹˜ì€ ë…ë‹¨ì ì´ì§€ ì•Šìœ¼ì…¨ìŠµë‹ˆë‹¤. ê¸°ìˆ ê³¼ ìƒˆë¡œìš´ ì•„ì´ë””ì–´ì— ë§¤ìš° ì ê·¹ì ì´ì…¨ëŠ”ë°, ì´ëŠ” ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ ì‚¬ì´ì—ì„œëŠ” ë•Œë¡œ í”í•˜ì§€ ì•Šì€ ì¼ì…ë‹ˆë‹¤. ì €í¬ëŠ” ë³´í†µ í•œ ê°€ì§€ ë°©ì‹ìœ¼ë¡œ ë°°ìš°ê³ , ê·¸ê²ƒì„ ê³„ì† ë°˜ë³µí•˜ëŠ” ê²½í–¥ì´ ìˆê±°ë“ ìš”.</td></tr>
<tr><td>But he was extremely excited about Motiva, and unfortunately, before his untimely death, he was going to be the principal investigator for The US trial. Speaker 7: So in 02/2014, I was director of breast reconstruction at Georgetown, and we thought, don't we try something new? Why don't we try to start reconstructing breasts with the implants in front of the muscle without cutting the muscle, without stretching the muscle? It<br>was much more comfortable for patients and this really became although we were told we were crazy, this really became a game changer in breast reconstruction. Not disrupting that pectoralis muscle, not lifting it off the chest wall, recovery was much quicker.</td><td>í•˜ì§€ë§Œ ê·¸ëŠ” Motivaì— ëŒ€í•´ ë§¤ìš° í¥ë¯¸ë¥¼ ë³´ì˜€ê³ , ì•ˆíƒ€ê¹ê²Œë„ ê·¸ì˜ ê°‘ì‘ìŠ¤ëŸ¬ìš´ ì‚¬ë§ ì „ì— ë¯¸êµ­ ì„ìƒì‹œí—˜ì˜ ì£¼ìš” ì—°êµ¬ì±…ì„ìê°€ ë  ì˜ˆì •ì´ì—ˆìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 7: 2014ë…„ 2ì›”ì— ì €ëŠ” ì¡°ì§€íƒ€ìš´ ëŒ€í•™êµì˜ ìœ ë°©ì¬ê±´ìˆ  ë””ë ‰í„°ì˜€ëŠ”ë°, ìš°ë¦¬ëŠ” ìƒˆë¡œìš´ ì‹œë„ë¥¼ í•´ë³´ìê³  ìƒê°í–ˆìŠµë‹ˆë‹¤. ê·¼ìœ¡ì„ ì ˆê°œí•˜ì§€ ì•Šê³ , ê·¼ìœ¡ì„ ëŠ˜ë¦¬ì§€ ì•Šê³ , ì„í”Œë€íŠ¸ë¥¼ ê·¼ìœ¡ ì•ìª½ì— ìœ„ì¹˜ì‹œì¼œ ìœ ë°©ì„ ì¬ê±´í•´ë³´ëŠ” ê²ƒì€ ì–´ë–¨ê¹Œìš”? <br><br>í™˜ìë“¤ì—ê²Œ í›¨ì”¬ ë” í¸ì•ˆí–ˆê³ , ì‚¬ëŒë“¤ì´ ìš°ë¦¬ë¥¼ ë¯¸ì³¤ë‹¤ê³  ë§í–ˆì§€ë§Œ, ì´ê²ƒì€ ì •ë§ë¡œ ìœ ë°©ì¬ê±´ìˆ ì˜ íŒë„ë¥¼ ë°”ê¾¸ëŠ” í˜ì‹ ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ëŒ€í‰ê·¼ì„ ì†ìƒì‹œí‚¤ì§€ ì•Šê³ , í‰ë²½ì—ì„œ ë“¤ì–´ì˜¬ë¦¬ì§€ ì•ŠìŒìœ¼ë¡œì¨ íšŒë³µì´ í›¨ì”¬ ë¹¨ë¼ì¡ŒìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Women could actually have their mastectomy surgery and their reconstruction with an implant at the same time and be home in their own bed that night. Speaker 7: The implant anatomically should replace the breast. Everything we do in plastic surgery is about recreating like with like. And so I always joked with the patients that God put the breast in front of the muscle because she thought it was way more comfortable that way. And so with this faster recovery, we're gonna talk about animation deformity. It was a game<br><br>changer in reconstruction, but because of the implant technology at the time, there was a question about long term rippling.</td><td>ì—¬ì„±ë“¤ì€ ì‹¤ì œë¡œ ìœ ë°©ì ˆì œìˆ ê³¼ ì„í”Œë€íŠ¸ë¥¼ ì´ìš©í•œ ì¬ê±´ìˆ ì„ ë™ì‹œì— ë°›ê³  ë‹¹ì¼ ë°¤ ì§‘ì—ì„œ ì ë“¤ ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 7: ì„í”Œë€íŠ¸ëŠ” í•´ë¶€í•™ì ìœ¼ë¡œ ìœ ë°©ì„ ëŒ€ì²´í•´ì•¼ í•©ë‹ˆë‹¤. ì„±í˜•ì™¸ê³¼ì—ì„œ ìš°ë¦¬ê°€ í•˜ëŠ” ëª¨ë“  ê²ƒì€ ê°™ì€ ê²ƒìœ¼ë¡œ ê°™ì€ ê²ƒì„ ì¬í˜„í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €ëŠ” í•­ìƒ í™˜ìë“¤ì—ê²Œ ë†ë‹´ìœ¼ë¡œ í•˜ë‚˜ë‹˜ì´ ìœ ë°©ì„ ê·¼ìœ¡ ì•ìª½ì— ë‘ì‹  ê²ƒì€ ê·¸ìª½ì´ í›¨ì”¬ ë” í¸ì•ˆí•˜ë‹¤ê³  ìƒê°í•˜ì…¨ê¸° ë•Œë¬¸ì´ë¼ê³  ë§í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ë¹ ë¥¸ íšŒë³µê³¼ í•¨ê»˜, ìš°ë¦¬ëŠ” ì• ë‹ˆë©”ì´ì…˜ ë³€í˜•ì— ëŒ€í•´ ì´ì•¼ê¸°í•  ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì€ ì¬ê±´ìˆ ì—ì„œ ê²Œì„ ì²´ì¸ì €ì˜€ì§€ë§Œ, ë‹¹ì‹œì˜ ì„í”Œë€íŠ¸ ê¸°ìˆ ë¡œ ì¸í•´ ì¥ê¸°ì ì¸ ì£¼ë¦„ í˜•ì„±ì— ëŒ€í•œ ì˜ë¬¸ì´ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 7: These were mastectomy patients who often had very thin flaps, very thin skin, And putting the older devices in, they oftentimes were afflicted with rippling or capsular contracture, scar tissue that forms around the muscle. And we were really required to use some type of mesh or human skin or pig skin or something to really try to support that implant to try and prevent capsular contracture and rippling. Here's our evolution of breast augmentation. So we started with implants in front of the muscle and when the moratorium<br>happened and surgeons were using saline implants on a regular basis, those looked like water balloons under the skin.</td><td>í™”ì 7: ì´ë“¤ì€ ìœ ë°©ì ˆì œìˆ  í™˜ìë“¤ë¡œ ì¢…ì¢… ë§¤ìš° ì–‡ì€ í”¼íŒê³¼ ë§¤ìš° ì–‡ì€ í”¼ë¶€ë¥¼ ê°€ì§€ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ê¸°ì¡´ ê¸°ê¸°ë¥¼ ì‚½ì…í•  ë•Œ, ì´ë“¤ì€ ì¢…ì¢… ì£¼ë¦„ í˜„ìƒì´ë‚˜ í”¼ë§‰ êµ¬ì¶•, ì¦‰ ê·¼ìœ¡ ì£¼ë³€ì— í˜•ì„±ë˜ëŠ” í‰í„° ì¡°ì§ìœ¼ë¡œ ê³ ìƒí–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” í”¼ë§‰ êµ¬ì¶•ê³¼ ì£¼ë¦„ì„ ë°©ì§€í•˜ê¸° ìœ„í•´ ì„í”Œë€íŠ¸ë¥¼ ì§€ì§€í•˜ë ¤ë©´ ì–´ë–¤ ì¢…ë¥˜ì˜ ë©”ì‹œë‚˜ ì¸ê°„ í”¼ë¶€ ë˜ëŠ” ë¼ì§€ í”¼ë¶€ ê°™ì€ ê²ƒì„ ì‚¬ìš©í•´ì•¼ í–ˆìŠµë‹ˆë‹¤. ë‹¤ìŒì€ ìœ ë°© í™•ëŒ€ìˆ ì˜ ë°œì „ ê³¼ì •ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê·¼ìœ¡ ì•ìª½ì— ì„í”Œë€íŠ¸ë¥¼ ì‚½ì…í•˜ëŠ” ê²ƒìœ¼ë¡œ ì‹œì‘í–ˆê³ , ëª¨ë¼í† ë¦¬ì—„ì´ ë°œìƒí•˜ì—¬ ì™¸ê³¼ì˜ë“¤ì´ ì •ê¸°ì ìœ¼ë¡œ ì‹ì—¼ìˆ˜ ì„í”Œë€íŠ¸ë¥¼ ì‚¬ìš©í•˜ê²Œ ë˜ì—ˆì„ ë•Œ, ê·¸ê²ƒë“¤ì€ í”¼ë¶€ ì•„ë˜ ë¬¼í’ì„ ì²˜ëŸ¼ ë³´ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And so everything transitioned to putting the implants under the muscle to hide the implant. Speaker 7: And that carried through after the moratorium something called a dual plane or as Kylie Jenner puts it, half under the muscle. That's where the muscle is the implant is under the muscle at the top and under the breast at the bottom. The problem with a dual plane is you have this downward force vector. Particularly active women who work out a lot. Their muscle is constantly contracting against the implant, and it drives those implants down and out and leads to higher revision rates. Speaker 7: Now we're back to in front of the muscle. And why?</td><td>ìŠ¤í”¼ì»¤ 7: ê·¸ë˜ì„œ ëª¨ë“  ê²ƒì´ ì„í”Œë€íŠ¸ë¥¼ ê·¼ìœ¡ ì•„ë˜ì— ì‚½ì…í•˜ì—¬ ì„í”Œë€íŠ¸ë¥¼ ìˆ¨ê¸°ëŠ” ë°©í–¥ìœ¼ë¡œ ì „í™˜ë˜ì—ˆìŠµë‹ˆë‹¤.<br><br>ìŠ¤í”¼ì»¤ 7: ê·¸ë¦¬ê³  ì´ëŠ” ëª¨ë¼í† ë¦¬ì—„ ì´í›„ì—ë„ ì´ì¤‘ í‰ë©´(dual plane) ë˜ëŠ” ì¹´ì¼ë¦¬ ì œë„ˆê°€ í‘œí˜„í•˜ëŠ” 'ë°˜ê·¼ìœ¡í•˜(half under the muscle)'ë¼ê³  ë¶ˆë¦¬ëŠ” ë°©ì‹ìœ¼ë¡œ ì´ì–´ì¡ŒìŠµë‹ˆë‹¤. ì´ëŠ” ì„í”Œë€íŠ¸ê°€ ìƒë¶€ì—ì„œëŠ” ê·¼ìœ¡ ì•„ë˜ì—, í•˜ë¶€ì—ì„œëŠ” ìœ ë°© ì•„ë˜ì— ìœ„ì¹˜í•˜ëŠ” ë°©ì‹ì…ë‹ˆë‹¤. ì´ì¤‘ í‰ë©´ì˜ ë¬¸ì œì ì€ í•˜í–¥ë ¥ ë²¡í„°ê°€ ë°œìƒí•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. íŠ¹íˆ ìš´ë™ì„ ë§ì´ í•˜ëŠ” í™œë™ì ì¸ ì—¬ì„±ë“¤ì˜ ê²½ìš°, ê·¼ìœ¡ì´ ì„í”Œë€íŠ¸ì— ëŒ€í•´ ì§€ì†ì ìœ¼ë¡œ ìˆ˜ì¶•í•˜ë©´ì„œ ì„í”Œë€íŠ¸ë¥¼ ì•„ë˜ìª½ê³¼ ë°”ê¹¥ìª½ìœ¼ë¡œ ë°€ì–´ë‚´ì–´ ì¬ìˆ˜ìˆ ë¥ ì„ ë†’ì´ê²Œ ë©ë‹ˆë‹¤.<br><br>ìŠ¤í”¼ì»¤ 7: ì´ì œ ìš°ë¦¬ëŠ” ë‹¤ì‹œ ê·¼ìœ¡ ì•ìª½ìœ¼ë¡œ ëŒì•„ì™”ìŠµë‹ˆë‹¤. ê·¸ ì´ìœ ëŠ” ë¬´ì—‡ì¼ê¹Œìš”?</td></tr>
<tr><td>Let's talk a little bit about FDA and the implants. In 1962, Kronin and Jiro, they invented the breast implant, which was really out of, even at the end of World War II, Japanese prostitutes were injecting their breasts with free silicone because they thought that American GI soldiers would like a bigger breasted woman. And so in 1962, Croton and Giraud thought, okay, we can invent something that will actually enhance the breast. Speaker 7: In 1976, congress passed the Medical Device Amendment to the Food and Drug Cosmetic Act.</td><td>FDAì™€ ì„í”Œë€íŠ¸ì— ëŒ€í•´ ì¡°ê¸ˆ ì´ì•¼ê¸°í•´ë³´ê² ìŠµë‹ˆë‹¤. 1962ë…„, í¬ë¡œë‹Œ(Kronin)ê³¼ ì§€ë¡œ(Jiro)ê°€ ìœ ë°© ì„í”Œë€íŠ¸ë¥¼ ë°œëª…í–ˆëŠ”ë°, ì´ëŠ” ì‹¤ì œë¡œ ì œ2ì°¨ ì„¸ê³„ëŒ€ì „ ë§ê¸°ì— ì¼ë³¸ ë§¤ì¶˜ë¶€ë“¤ì´ ë¯¸êµ° ë³‘ì‚¬ë“¤ì´ ê°€ìŠ´ì´ í° ì—¬ì„±ì„ ì„ í˜¸í•  ê²ƒì´ë¼ê³  ìƒê°í•˜ì—¬ ììœ  ì‹¤ë¦¬ì½˜ì„ ê°€ìŠ´ì— ì£¼ì…í–ˆë˜ ê²ƒì—ì„œ ë¹„ë¡¯ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ 1962ë…„ í¬ë¡œíŠ¼(Croton)ê³¼ ì§€ë¡œë“œ(Giraud)ëŠ” ì‹¤ì œë¡œ ê°€ìŠ´ì„ í™•ëŒ€í•  ìˆ˜ ìˆëŠ” ì œí’ˆì„ ë°œëª…í•  ìˆ˜ ìˆë‹¤ê³  ìƒê°í–ˆìŠµë‹ˆë‹¤.<br><br>í™”ì 7: 1976ë…„ ì˜íšŒëŠ” ì‹í’ˆì˜ì•½í’ˆí™”ì¥í’ˆë²•ì— ëŒ€í•œ ì˜ë£Œê¸°ê¸° ê°œì •ë²•ì„ í†µê³¼ì‹œì¼°ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>That was the act that said you had to put the ingredients of everything on on wrappers, but these medical devices, they didn't really know what to do with them, and so every device that existed in 1976 was kind of grandfathered into that without any requirements with studies. In 1988, this was right after the Dow Corning lawsuit, which happened in 1984. In 1988, the FDA said, well, we should classify the implants as class three devices. So FDA categorizes class three devices is something that is potentially harmful to the person receiving the medical device or the person putting it in.</td><td>1976ë…„ì— ì œì •ëœ ì´ ë²•ì•ˆì€ ëª¨ë“  ì œí’ˆì˜ í¬ì¥ì§€ì— ì„±ë¶„ì„ í‘œì‹œí•˜ë„ë¡ ì˜ë¬´í™”í•œ ë²•ì´ì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì˜ë£Œê¸°ê¸°ì˜ ê²½ìš° ì–´ë–»ê²Œ ì²˜ë¦¬í•´ì•¼ í• ì§€ ëª…í™•í•˜ì§€ ì•Šì•˜ê¸° ë•Œë¬¸ì—, 1976ë…„ì— ì¡´ì¬í–ˆë˜ ëª¨ë“  ì˜ë£Œê¸°ê¸°ë“¤ì€ ë³„ë„ì˜ ì—°êµ¬ ìš”êµ¬ì‚¬í•­ ì—†ì´ ê¸°ì¡´ ê·œì • í•˜ì—ì„œ ìŠ¹ì¸ëœ ê²ƒìœ¼ë¡œ ê°„ì£¼ë˜ì—ˆìŠµë‹ˆë‹¤. 1984ë…„ ë‹¤ìš°ì½”ë‹ ì†Œì†¡ ì§í›„ì¸ 1988ë…„, FDAëŠ” ì„í”Œë€íŠ¸ë¥¼ 3ë“±ê¸‰ ì˜ë£Œê¸°ê¸°ë¡œ ë¶„ë¥˜í•´ì•¼ í•œë‹¤ê³  ë°œí‘œí–ˆìŠµë‹ˆë‹¤. FDAëŠ” 3ë“±ê¸‰ ì˜ë£Œê¸°ê¸°ë¥¼ ì˜ë£Œê¸°ê¸°ë¥¼ ë°›ëŠ” í™˜ìë‚˜ ì‹œìˆ í•˜ëŠ” ì˜ì‚¬ì—ê²Œ ì ì¬ì ìœ¼ë¡œ í•´ë¡œìš¸ ìˆ˜ ìˆëŠ” ì œí’ˆìœ¼ë¡œ ë¶„ë¥˜í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 7: So that's a little bit of an incendiary comment, And it wasn't that the devices were being reclassified. This was the time they were truly classified. Fast forward to 1990, the big Connie Chung face to face interview, where Connie Chung interviewed women who said, I have illness from my implants. My implants are comfortable. This was really the boiling point. Speaker 7: And in 1991, the FDA said, we need studies. Everybody has ninety days. Every implant manufacturer has ninety days to submit their plan for a study. Now these studies take years to actually complete and years to devise.</td><td>í™”ì 7: ì´ëŠ” ë‹¤ì†Œ ì„ ë™ì ì¸ ë°œì–¸ì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê¸°ê¸°ë“¤ì´ ì¬ë¶„ë¥˜ë˜ê³  ìˆì—ˆë˜ ê²ƒì´ ì•„ë‹ˆë¼, ì´ë•Œ ì§„ì •ìœ¼ë¡œ ë¶„ë¥˜ê°€ ì´ë£¨ì–´ì§„ ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. 1990ë…„ìœ¼ë¡œ ë„˜ì–´ê°€ì„œ, ì½”ë‹ˆ ì²­ì˜ ëŒ€ë©´ ì¸í„°ë·°ê°€ ìˆì—ˆëŠ”ë°, ì½”ë‹ˆ ì²­ì´ "ì„í”Œë€íŠ¸ë¡œ ì¸í•´ ì§ˆë³‘ì´ ìƒê²¼ìŠµë‹ˆë‹¤. ì œ ì„í”Œë€íŠ¸ëŠ” í¸ì•ˆí•©ë‹ˆë‹¤"ë¼ê³  ë§í•˜ëŠ” ì—¬ì„±ë“¤ì„ ì¸í„°ë·°í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì •ë§ë¡œ ì„ê³„ì ì´ì—ˆìŠµë‹ˆë‹¤.<br><br>í™”ì 7: ê·¸ë¦¬ê³  1991ë…„ì— FDAëŠ” "ìš°ë¦¬ì—ê²Œ ì—°êµ¬ê°€ í•„ìš”í•©ë‹ˆë‹¤. ëª¨ë“  íšŒì‚¬ëŠ” 90ì¼ì˜ ì‹œê°„ì´ ìˆìŠµë‹ˆë‹¤. ëª¨ë“  ì„í”Œë€íŠ¸ ì œì¡°ì—…ì²´ëŠ” ì—°êµ¬ ê³„íšì„ ì œì¶œí•  90ì¼ì˜ ì‹œê°„ì´ ìˆìŠµë‹ˆë‹¤"ë¼ê³  ë§í–ˆìŠµë‹ˆë‹¤. ì´ì œ ì´ëŸ¬í•œ ì—°êµ¬ë“¤ì€ ì‹¤ì œë¡œ ì™„ë£Œí•˜ëŠ” ë° ìˆ˜ë…„ì´ ê±¸ë¦¬ê³  ê³ ì•ˆí•˜ëŠ” ë°ë„ ìˆ˜ë…„ì´ ê±¸ë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>So ninety days is kind of unreasonable, but the FDA went forward and said, you can't sell your implants if you don't have your ninety day study in, and what happened? Speaker 7: We ended up in a moratorium where no silicone implants could be used outside of breast reconstruction, outside of a study, and so everyone started getting saline implants. So 02/2006, after probably more studies that have been done on any medical device, the implants come back on. 1997, BIA ALCL is introduced. There's an FDA alert, and the WHO by 2016 recognized ALCL as an actual disease. And so we fought so long. Speaker 7: The implants came back on the market. Now there was something new.</td><td>90ì¼ì´ë¼ëŠ” ê¸°ê°„ì€ ë‹¤ì†Œ ë¹„í•©ë¦¬ì ì´ì—ˆì§€ë§Œ, FDAëŠ” ê³„ì† ì§„í–‰í•˜ì—¬ 90ì¼ ì—°êµ¬ ê²°ê³¼ê°€ ì—†ìœ¼ë©´ ì„í”Œë€íŠ¸ë¥¼ íŒë§¤í•  ìˆ˜ ì—†ë‹¤ê³  ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ê·¸ ê²°ê³¼ ì–´ë–¤ ì¼ì´ ì¼ì–´ë‚¬ì„ê¹Œìš”?<br><br>ë°œí‘œì 7: ê²°êµ­ ìœ ë°©ì¬ê±´ìˆ ì„ ì œì™¸í•˜ê³ ëŠ”, ì—°êµ¬ ëª©ì ì´ ì•„ë‹Œ í•œ ì‹¤ë¦¬ì½˜ ì„í”Œë€íŠ¸ë¥¼ ì‚¬ìš©í•  ìˆ˜ ì—†ëŠ” ëª¨ë¼í† ë¦¬ì—„ ìƒí™©ì— ë†“ì´ê²Œ ë˜ì—ˆê³ , ê·¸ë˜ì„œ ëª¨ë“  ì‚¬ëŒë“¤ì´ ì‹ì—¼ìˆ˜ ì„í”Œë€íŠ¸ë¥¼ ì‚¬ìš©í•˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. 2006ë…„ 2ì›”, ì•„ë§ˆë„ ì–´ë–¤ ì˜ë£Œê¸°ê¸°ë³´ë‹¤ë„ ë§ì€ ì—°êµ¬ê°€ ì§„í–‰ëœ í›„ì— ì„í”Œë€íŠ¸ê°€ ì‹œì¥ì— ë‹¤ì‹œ ì¶œì‹œë˜ì—ˆìŠµë‹ˆë‹¤. 1997ë…„ì— BIA ALCLì´ ë„ì…ë˜ì—ˆìŠµë‹ˆë‹¤. FDA ê²½ê³ ê°€ ìˆì—ˆê³ , 2016ë…„ WHOê°€ ALCLì„ ì‹¤ì œ ì§ˆë³‘ìœ¼ë¡œ ì¸ì •í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê·¸ë ‡ê²Œ ì˜¤ë«ë™ì•ˆ ì‹¸ì› ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 7: ì„í”Œë€íŠ¸ê°€ ì‹œì¥ì— ë‹¤ì‹œ ì¶œì‹œë˜ì—ˆìŠµë‹ˆë‹¤. ì´ì œ ìƒˆë¡œìš´ ë¬¸ì œê°€ ìƒê²¼ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>You could<br><br>get cancer from breast implants. And that's exactly what the lay press actually came up. That was the words that they used. Speaker 7: They were highly linked to the Allergan biocell texture devices. The FDA hosted a general meeting where women who were afflicted with either ALCL, BII, which really is breast implant illness, which came out of the internet. There were these very emotional testimonies at that meeting. And so that ended up in a voluntary recall of implants. And so you see where I'm going with this. Speaker 7: It's the same thing happening again. And here we are in 2019 thinking, are we going to be in another moratorium? Enter Motiva.</td><td>ë‹¤ìŒê³¼ ê°™ì´ ë²ˆì—­í•˜ê² ìŠµë‹ˆë‹¤:<br><br>ìœ ë°© ì„í”Œë€íŠ¸ë¡œ ì¸í•´ ì•”ì— ê±¸ë¦´ ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ë°”ë¡œ ì¼ë°˜ ì–¸ë¡ ì—ì„œ ì‹¤ì œë¡œ ë‚˜ì˜¨ ë‚´ìš©ì…ë‹ˆë‹¤. ê·¸ë“¤ì´ ì‚¬ìš©í•œ í‘œí˜„ì´ ë°”ë¡œ ê·¸ê²ƒì´ì—ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 7: ì´ë“¤ì€ ì•ŒëŸ¬ê°„(Allergan) ë°”ì´ì˜¤ì…€ í…ìŠ¤ì²˜ ê¸°ê¸°ì™€ ë†’ì€ ì—°ê´€ì„±ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. FDAëŠ” ALCLì´ë‚˜ BII, ì¦‰ ì¸í„°ë„·ì—ì„œ ë‚˜ì˜¨ ìœ ë°© ì„í”Œë€íŠ¸ ì§ˆí™˜(breast implant illness)ìœ¼ë¡œ ê³ í†µë°›ëŠ” ì—¬ì„±ë“¤ì´ ì°¸ì„í•˜ëŠ” ê³µê°œ íšŒì˜ë¥¼ ì£¼ìµœí–ˆìŠµë‹ˆë‹¤. ê·¸ íšŒì˜ì—ì„œëŠ” ë§¤ìš° ê°ì •ì ì¸ ì¦ì–¸ë“¤ì´ ìˆì—ˆìŠµë‹ˆë‹¤. ê·¸ ê²°ê³¼ ì„í”Œë€íŠ¸ì˜ ìë°œì  ë¦¬ì½œë¡œ ì´ì–´ì¡ŒìŠµë‹ˆë‹¤. ì œê°€ ì–´ë””ë¡œ ê°€ê³ ì í•˜ëŠ”ì§€ ì•„ì‹œê² ì£ .<br><br>ë°œí‘œì 7: ë˜‘ê°™ì€ ì¼ì´ ë‹¤ì‹œ ì¼ì–´ë‚˜ê³  ìˆëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ê¸° 2019ë…„ì— ìš°ë¦¬ëŠ” ë˜ ë‹¤ë¥¸ ëª¨ë¼í† ë¦¬ì—„ì— ì§ë©´í•˜ê²Œ ë  ê²ƒì¸ê°€ í•˜ê³  ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë•Œ ëª¨í‹°ë°”(Motiva)ê°€ ë“±ì¥í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This has been a game changer for augmentation because we all of the things that I said with reconstruction, these problems are solved. We<br>don't worry about long term rippling. Speaker 7: We don't worry about capsular contracture and we don't need a mesh. This is the animation deformity that doctor Epstein and doctor Steve<br><br>Speaker 6: Right. Together. Together. Together. Speaker 7: No. This lady joked when I saw her in the office that this was her bar trick, but in all honesty, she plays with the New York Philharmonic and this is incredibly bothersome to her because as she's playing her instrument, her breasts are bouncing around.</td><td>ì´ê²ƒì€ í™•ëŒ€ìˆ ì— ìˆì–´ì„œ ê²Œì„ ì²´ì¸ì €ê°€ ë˜ì—ˆìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì œê°€ ì¬ê±´ìˆ ì— ëŒ€í•´ ë§ì”€ë“œë¦° ëª¨ë“  ê²ƒë“¤, ì´ëŸ¬í•œ ë¬¸ì œë“¤ì´ í•´ê²°ë˜ì—ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë” ì´ìƒ ì¥ê¸°ì ì¸ ì£¼ë¦„ í˜„ìƒì„ ê±±ì •í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.<br><br>**í™”ì 7:** ìš°ë¦¬ëŠ” í”¼ë§‰ êµ¬ì¶•ì„ ê±±ì •í•˜ì§€ ì•Šìœ¼ë©° ë©”ì‹œë„ í•„ìš”í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì—¡ìŠ¤íƒ€ì¸ ë°•ì‚¬ì™€ ìŠ¤í‹°ë¸Œ ë°•ì‚¬ê°€...<br><br>**í™”ì 6:** ë§ìŠµë‹ˆë‹¤. í•¨ê»˜. í•¨ê»˜. í•¨ê»˜.<br><br>**í™”ì 7:** ì•„ë‹™ë‹ˆë‹¤. ì´ ì—¬ì„±ë¶„ì€ ì œê°€ ì§„ë£Œì‹¤ì—ì„œ ëµˆì—ˆì„ ë•Œ ì´ê²ƒì´ ìì‹ ì˜ ë°” íŠ¸ë¦­ì´ë¼ê³  ë†ë‹´ì„ í•˜ì…¨ì§€ë§Œ, ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´ ê·¸ë…€ëŠ” ë‰´ìš• í•„í•˜ëª¨ë‹‰ì—ì„œ ì—°ì£¼í•˜ì‹œëŠ” ë¶„ì´ê³  ì•…ê¸°ë¥¼ ì—°ì£¼í•  ë•Œ ê°€ìŠ´ì´ ì›€ì§ì´ê¸° ë•Œë¬¸ì— ì´ê²ƒì´ ê·¸ë…€ì—ê²Œ ë§¤ìš° ê´´ë¡œìš´ ì¼ì…ë‹ˆë‹¤.</td></tr>
<tr><td>With preservation breast augmentation, we're able to put those implants in front of the muscle. The patient here on the left, this is the ideal patient. These are women just like doctor Steve said. Speaker 7: These are women that work out. They want to not have their implants bouncing around. They don't want their muscles disrupted. These are all thin women who, with the old devices, would be afflicted with rippling and the potential for capsular contracture. And that's<br><br>all I have. Speaker 4: Thank you. Thank you very much, panel. We don't have much time for questions, but, doctor Steve, I wanted to ask one of you. And if the audience has any, please feel free.</td><td>ë³´ì¡´ì  ìœ ë°© í™•ëŒ€ìˆ ì„ í†µí•´ ì„í”Œë€íŠ¸ë¥¼ ê·¼ìœ¡ ì•ìª½ì— ì‚½ì…í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì™¼ìª½ì— ìˆëŠ” í™˜ìê°€ ì´ìƒì ì¸ í™˜ìì…ë‹ˆë‹¤. ìŠ¤í‹°ë¸Œ ë°•ì‚¬ë‹˜ì´ ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ ì´ëŸ° ì—¬ì„±ë“¤ì€<br><br>ë°œí‘œì 7: ìš´ë™ì„ í•˜ëŠ” ì—¬ì„±ë“¤ì…ë‹ˆë‹¤. ì„í”Œë€íŠ¸ê°€ ì›€ì§ì´ëŠ” ê²ƒì„ ì›í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¼ìœ¡ì´ ë°©í•´ë°›ëŠ” ê²ƒì„ ì›í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ëª¨ë‘ ë§ˆë¥¸ ì—¬ì„±ë“¤ë¡œ, ê¸°ì¡´ ê¸°ê¸°ë¡œëŠ” ì£¼ë¦„ í˜„ìƒê³¼ í”¼ë§‰ êµ¬ì¶•ì˜ ê°€ëŠ¥ì„±ì— ì‹œë‹¬ë ¸ì„ ê²ƒì…ë‹ˆë‹¤. ì œ ë°œí‘œëŠ” ì—¬ê¸°ê¹Œì§€ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ê°ì‚¬í•©ë‹ˆë‹¤. íŒ¨ë„ ì—¬ëŸ¬ë¶„ ëŒ€ë‹¨íˆ ê°ì‚¬í•©ë‹ˆë‹¤. ì§ˆë¬¸ ì‹œê°„ì´ ë§ì§€ ì•Šì§€ë§Œ, ìŠ¤í‹°ë¸Œ ë°•ì‚¬ë‹˜ê»˜ í•œ ê°€ì§€ ì§ˆë¬¸ì„ ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ì²­ì¤‘ ì—¬ëŸ¬ë¶„ë„ ì§ˆë¬¸ì´ ìˆìœ¼ì‹œë©´ ì–¸ì œë“ ì§€ í•´ì£¼ì„¸ìš”.</td></tr>
<tr><td>But we we seem to be sitting in the middle of a cultural moment. Speaker 4: The culture, the era of transparency, as Real Self has said, we are The New York Times put out an article about the Kylie and Kris Jenner effect, which could be impacting our space right now. I would love to just get your thoughts on the mindset of patients you see coming into your practice, and maybe you could comment on whether volumes have changed up or down over the last year, what the climate is like, but what's that cultural conversation? That's the real heart of this question.</td><td>í•˜ì§€ë§Œ ìš°ë¦¬ëŠ” ë¬¸í™”ì  ì „í™˜ì ì˜ í•œê°€ìš´ë°ì— ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. <br><br>í™”ì 4: ë¬¸í™”ì ìœ¼ë¡œ, Real Selfê°€ ë§í–ˆë“¯ì´ íˆ¬ëª…ì„±ì˜ ì‹œëŒ€ì— ìš°ë¦¬ëŠ” ì‚´ê³  ìˆìŠµë‹ˆë‹¤. ë‰´ìš•íƒ€ì„ìŠ¤ì—ì„œ ì¹´ì¼ë¦¬ì™€ í¬ë¦¬ìŠ¤ ì œë„ˆ íš¨ê³¼ì— ëŒ€í•œ ê¸°ì‚¬ë¥¼ ëƒˆëŠ”ë°, ì´ê²ƒì´ ì§€ê¸ˆ ìš°ë¦¬ ì—…ê³„ì— ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì„ ìƒë‹˜ì˜ ì§„ë£Œì‹¤ì— ì˜¤ëŠ” í™˜ìë“¤ì˜ ë§ˆì¸ë“œì…‹ì— ëŒ€í•œ ìƒê°ì„ ë“£ê³  ì‹¶ê³ , ì§€ë‚œ 1ë…„ê°„ ì‹œìˆ  ê±´ìˆ˜ê°€ ì¦ê°€í–ˆëŠ”ì§€ ê°ì†Œí–ˆëŠ”ì§€, í˜„ì¬ ë¶„ìœ„ê¸°ê°€ ì–´ë–¤ì§€ì— ëŒ€í•´ì„œë„ ì½”ë©˜íŠ¸í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? í•˜ì§€ë§Œ ê·¸ ë¬¸í™”ì  ëŒ€í™”ê°€ ë¬´ì—‡ì¸ì§€, ê·¸ê²ƒì´ ì´ ì§ˆë¬¸ì˜ ì§„ì§œ í•µì‹¬ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 6: I think that culture is shifting totally into that culture of transparency and women so generously sharing their stories for other women to learn. And I think that's where a lot of all of the work that you've done for your direct to consumer works really well because those women who are sharing their stories are talking about Motiva Implants. And patients like Kylie Jenner who opened up and she certainly has influence. I don't think there's a negative impact that she has not received Motiva Implants because she had her implants placed at a time when they weren't available here.</td><td>í™”ì 6: ì €ëŠ” ê·¸ ë¬¸í™”ê°€ ì™„ì „íˆ íˆ¬ëª…ì„±ì˜ ë¬¸í™”ë¡œ ë³€í™”í•˜ê³  ìˆê³ , ì—¬ì„±ë“¤ì´ ë‹¤ë¥¸ ì—¬ì„±ë“¤ì´ ë°°ìš¸ ìˆ˜ ìˆë„ë¡ ìì‹ ë“¤ì˜ ì´ì•¼ê¸°ë¥¼ ë§¤ìš° ê´€ëŒ€í•˜ê²Œ ê³µìœ í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ë°”ë¡œ ì§ì ‘ ì†Œë¹„ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•˜ì‹  ëª¨ë“  ì‘ì—…ì´ ì •ë§ ì˜ ì‘ë™í•˜ëŠ” ì´ìœ ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ìì‹ ë“¤ì˜ ì´ì•¼ê¸°ë¥¼ ê³µìœ í•˜ëŠ” ê·¸ ì—¬ì„±ë“¤ì´ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¹´ì¼ë¦¬ ì œë„ˆì™€ ê°™ì€ í™˜ìë“¤ì´ ë§ˆìŒì„ ì—´ê³  ì´ì•¼ê¸°í–ˆëŠ”ë°, ê·¸ë…€ëŠ” í™•ì‹¤íˆ ì˜í–¥ë ¥ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ë…€ê°€ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ë¥¼ ë°›ì§€ ì•Šì•˜ë‹¤ê³  í•´ì„œ ë¶€ì •ì ì¸ ì˜í–¥ì´ ìˆë‹¤ê³  ìƒê°í•˜ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ê·¸ë…€ëŠ” ëª¨í‹°ë°” ì„í”Œë€íŠ¸ê°€ ì—¬ê¸°ì„œ ì´ìš© ê°€ëŠ¥í•˜ì§€ ì•Šì•˜ë˜ ì‹œê¸°ì— ì„í”Œë€íŠ¸ ì‹œìˆ ì„ ë°›ì•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>So, think the sort of juncture between that culture of transparency and women seeing Motiva Implants as the safest option is going to be great for brand recognition and women talking more and more about this. Speaker 6: And you're, I think you're going to see that patients start to demand this brand because it's the safest one available. Speaker 8: Yes. Yeah, thank you. Sam Wiever, BTIG. Appreciate the panelists' presentations. Clearly, guys are convinced on the move to above the muscle, but curious where the rest of the<br><br>surgical community is on that shift. Speaker 8: Is there a learning curve associated with above the muscle and subfascial placement? And is that unique to Motiva?</td><td>íˆ¬ëª…ì„± ë¬¸í™”ì™€ ì—¬ì„±ë“¤ì´ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ë¥¼ ê°€ì¥ ì•ˆì „í•œ ì˜µì…˜ìœ¼ë¡œ ì¸ì‹í•˜ëŠ” ê²ƒ ì‚¬ì´ì˜ ì ‘ì ì´ ë¸Œëœë“œ ì¸ì§€ë„ì— ë§¤ìš° ê¸ì •ì ì¸ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒì´ë©°, ì—¬ì„±ë“¤ì´ ì´ì— ëŒ€í•´ ì ì  ë” ë§ì´ ì´ì•¼ê¸°í•˜ê²Œ ë  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 6: ê·¸ë¦¬ê³  í™˜ìë“¤ì´ ì´ ë¸Œëœë“œë¥¼ ìš”êµ¬í•˜ê¸° ì‹œì‘í•  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ê²ƒì´ í˜„ì¬ ì´ìš© ê°€ëŠ¥í•œ ê°€ì¥ ì•ˆì „í•œ ì œí’ˆì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 8: ë„¤, ë§ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. BTIGì˜ ìƒ˜ ìœ„ë²„ì…ë‹ˆë‹¤. íŒ¨ë„ë¦¬ìŠ¤íŠ¸ë“¤ì˜ ë°œí‘œì— ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ë¶„ëª…íˆ ì—¬ëŸ¬ë¶„ë“¤ì€ ê·¼ìœ¡ ìœ„ ì‚½ì…ìœ¼ë¡œì˜ ì „í™˜ì„ í™•ì‹ í•˜ê³  ê³„ì‹œëŠ”ë°, ì´ëŸ¬í•œ ë³€í™”ì— ëŒ€í•´ ë‚˜ë¨¸ì§€ ì™¸ê³¼ ì˜ë£Œì§„ë“¤ì€ ì–´ë–¤ ì…ì¥ì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 8: ê·¼ìœ¡ ìœ„ ì‚½ì…ê³¼ ê·¼ë§‰í•˜ ì‚½ì…ì— í•™ìŠµ ê³¡ì„ ì´ ìˆë‚˜ìš”? ê·¸ë¦¬ê³  ì´ê²ƒì´ ëª¨í‹°ë°”ë§Œì˜ ê³ ìœ í•œ íŠ¹ì§•ì¸ê°€ìš”?</td></tr>
<tr><td>Can you use that technique with other implants? Speaker 5: That's a great question. For anyone who does subpectoral, they'd be experienced doing dual plane, and when you do dual plane, you're essentially doing a subfascial dissection, partway up the muscle. And the technical skills involved to go, whether you're subfascial or above the fascia and go subglangeal, is very simple. So I would say one hundred percent of surgeons who are capable of going under the muscle can easily adopt on the fly and pivot to above the muscle without any difficulty.</td><td>ë‹¤ë¥¸ ì„í”Œë€íŠ¸ì—ë„ ì´ ê¸°ë²•ì„ ì‚¬ìš©í•  ìˆ˜ ìˆë‚˜ìš”?<br><br>ë°œí‘œì 5: ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. ëŒ€í‰ê·¼í•˜ ìˆ˜ìˆ ì„ í•˜ëŠ” ì˜ì‚¬ë¼ë©´ ì´ì¤‘í‰ë©´(dual plane) ìˆ˜ìˆ  ê²½í—˜ì´ ìˆì„ ê²ƒì´ê³ , ì´ì¤‘í‰ë©´ ìˆ˜ìˆ ì„ í•  ë•ŒëŠ” ë³¸ì§ˆì ìœ¼ë¡œ ê·¼ìœ¡ ì¼ë¶€ê¹Œì§€ ê·¼ë§‰í•˜ ë°•ë¦¬ë¥¼ í•˜ê²Œ ë©ë‹ˆë‹¤. ê·¼ë§‰í•˜ë“  ê·¼ë§‰ ìœ„ë“  ìƒê´€ì—†ì´ ìœ ì„ í•˜ë¡œ ê°€ëŠ” ê¸°ìˆ ì  ìŠ¤í‚¬ì€ ë§¤ìš° ê°„ë‹¨í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ê·¼ìœ¡ ì•„ë˜ë¡œ ë“¤ì–´ê°ˆ ìˆ˜ ìˆëŠ” ì™¸ê³¼ì˜ì‚¬ë¼ë©´ 100% ëª¨ë‘ ì¦‰ì„ì—ì„œ ì‰½ê²Œ ì ì‘í•˜ì—¬ ì–´ë ¤ì›€ ì—†ì´ ê·¼ìœ¡ ìœ„ìª½ìœ¼ë¡œ ì „í™˜í•  ìˆ˜ ìˆë‹¤ê³  ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The question is, the surgeons need to be educated, just as I present my own transition, from being a staunch there is no indication to ever go above the muscle to now, I really can't think of an indication to go below the muscle. Speaker 5: And that will just take a matter of time. I think Peter Caldini's prediction of 20% growth over three years is extremely conservative. I'm with the patients, I'm with the consumers, and have been, since approval, one hundred percent of my patients have booked the implant.</td><td>ì§ˆë¬¸ì€, ì™¸ê³¼ì˜ë“¤ì´ êµìœ¡ì„ ë°›ì•„ì•¼ í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì œ ìì‹ ì˜ ì „í™˜ ê³¼ì •ì„ ë³´ë©´, ê·¼ìœ¡ ìœ„ë¡œ ì˜¬ë¼ê°ˆ ì ì‘ì¦ì´ ì „í˜€ ì—†ë‹¤ê³  í™•ê³ íˆ ë¯¿ì—ˆë˜ ì €ì—ì„œ, ì´ì œëŠ” ê·¼ìœ¡ ì•„ë˜ë¡œ ë“¤ì–´ê°ˆ ì ì‘ì¦ì„ ì •ë§ ìƒê°í•  ìˆ˜ ì—†ëŠ” ìƒí™©ìœ¼ë¡œ ë°”ë€Œì—ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ê·¸ë¦¬ê³  ê·¸ê²ƒì€ ë‹¨ì§€ ì‹œê°„ ë¬¸ì œì¼ ê²ƒì…ë‹ˆë‹¤. Peter Caldiniì˜ 3ë…„ê°„ 20% ì„±ì¥ ì˜ˆì¸¡ì€ ê·¹ë„ë¡œ ë³´ìˆ˜ì ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì €ëŠ” í™˜ìë“¤ê³¼ í•¨ê»˜í•˜ê³  ìˆê³ , ì†Œë¹„ìë“¤ê³¼ í•¨ê»˜í•˜ê³  ìˆìœ¼ë©°, ìŠ¹ì¸ ì´í›„ë¡œ ì œ í™˜ìë“¤ì˜ 100%ê°€ ì„í”Œë€íŠ¸ë¥¼ ì˜ˆì•½í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Half my practice is revision, half is primary, And interestingly enough, patients who come in with ruptured implants that are entitled to a replacement device for free under warranty by a competitive company are still selecting Motiva. So my prediction, which was back in 2017, holds today, I think in three years or so, somewhere between 6080% of the implants in this country will be Motiva. Speaker 5: And that will continue to increase because there is such a strong disparity in technology results. And patients are now calling my office, and they're asking for Motiva. In the past, they didn't ask for Allergan or Mentor. I can't think of one time that had happened.</td><td>ì œ ì§„ë£Œì˜ ì ˆë°˜ì€ ì¬ìˆ˜ìˆ ì´ê³  ì ˆë°˜ì€ ì¼ì°¨ ìˆ˜ìˆ ì…ë‹ˆë‹¤. í¥ë¯¸ë¡­ê²Œë„ ì„í”Œë€íŠ¸ê°€ íŒŒì—´ë˜ì–´ ê²½ìŸì‚¬ì˜ ë³´ì¦ í•˜ì— ë¬´ë£Œë¡œ êµì²´ìš© ê¸°ê¸°ë¥¼ ë°›ì„ ìê²©ì´ ìˆëŠ” í™˜ìë“¤ì¡°ì°¨ ì—¬ì „íˆ ëª¨í‹°ë°”ë¥¼ ì„ íƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. 2017ë…„ì— í–ˆë˜ ì œ ì˜ˆì¸¡ì´ ì˜¤ëŠ˜ë‚ ì—ë„ ìœ íš¨í•˜ë‹¤ê³  ìƒê°í•˜ëŠ”ë°, ì•½ 3ë…„ ì •ë„ í›„ì—ëŠ” ì´ ë‚˜ë¼ ì„í”Œë€íŠ¸ì˜ 60-80% ì •ë„ê°€ ëª¨í‹°ë°”ê°€ ë  ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ê·¸ë¦¬ê³  ì´ëŠ” ê³„ì† ì¦ê°€í•  ê²ƒì…ë‹ˆë‹¤. ê¸°ìˆ ê³¼ ê²°ê³¼ ë©´ì—ì„œ ë§¤ìš° í° ê²©ì°¨ê°€ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ì œ í™˜ìë“¤ì´ ì œ ë³‘ì›ì— ì „í™”ë¥¼ ê±¸ì–´ ëª¨í‹°ë°”ë¥¼ ìš”ì²­í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê³¼ê±°ì—ëŠ” ì•ŒëŸ¬ê°„ì´ë‚˜ ë©˜í† ë¥¼ ìš”ì²­í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ê·¸ëŸ° ì¼ì´ ìˆì—ˆë˜ ì ì€ í•œ ë²ˆë„ ê¸°ì–µë‚˜ì§€ ì•ŠìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Now they're asking for Motiva. Speaker 5: The patients know about it. They're online. They're seeing the social media. And it's snowballing very fast. Speaker 4: It's clear that happy patients talk about how happy they are, and they now have platforms to do it. The TikTok, the social media craze is able to move this information in ways like never before. Doctor. Pittman, I thought you might have a comment, but one other thing is maybe one other point of contextualizing this is why did implants start going under the muscle in the place and anything else you might have to add?</td><td>ì´ì œ ê·¸ë“¤ì´ ëª¨í‹°ë°”ì— ëŒ€í•´ ë¬¸ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 5: í™˜ìë“¤ì´ ì´ì— ëŒ€í•´ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë“¤ì€ ì˜¨ë¼ì¸ì— ìˆê³ , ì†Œì…œ ë¯¸ë””ì–´ë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ë§¤ìš° ë¹ ë¥´ê²Œ ëˆˆë©ì´ì²˜ëŸ¼ ë¶ˆì–´ë‚˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ë§Œì¡±í•œ í™˜ìë“¤ì´ ìì‹ ë“¤ì´ ì–¼ë§ˆë‚˜ ë§Œì¡±í•˜ëŠ”ì§€ì— ëŒ€í•´ ì´ì•¼ê¸°í•œë‹¤ëŠ” ê²ƒì€ ë¶„ëª…í•˜ë©°, ì´ì œ ê·¸ë“¤ì€ ê·¸ë ‡ê²Œ í•  ìˆ˜ ìˆëŠ” í”Œë«í¼ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. í‹±í†¡, ì†Œì…œ ë¯¸ë””ì–´ ì—´í’ì´ ì´ì „ê³¼ëŠ” ì „í˜€ ë‹¤ë¥¸ ë°©ì‹ìœ¼ë¡œ ì´ëŸ¬í•œ ì •ë³´ë¥¼ ì „íŒŒí•  ìˆ˜ ìˆê²Œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>í”¼íŠ¸ë§Œ ë°•ì‚¬ë‹˜, ì½”ë©˜íŠ¸ê°€ ìˆìœ¼ì‹¤ ê²ƒ ê°™ì€ë°ìš”. í•˜ì§€ë§Œ í•œ ê°€ì§€ ë” ë§ì”€ë“œë¦¬ìë©´, ì´ë¥¼ ë§¥ë½í™”í•˜ëŠ” ë˜ ë‹¤ë¥¸ ê´€ì ì€ ì™œ ì„í”Œë€íŠ¸ê°€ ê·¼ìœ¡ ì•„ë˜ë¡œ ë“¤ì–´ê°€ê¸° ì‹œì‘í–ˆëŠ”ì§€, ê·¸ë¦¬ê³  ì¶”ê°€ë¡œ ë§ì”€í•˜ì‹¤ ë‹¤ë¥¸ ë‚´ìš©ì´ ìˆëŠ”ì§€ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 7: Well, think to expand upon what doctor Epstein was saying to your question is any surgeon can place the implant in front of the muscle. What's absolutely essential though is that you respect the boundaries of the breast when you're putting it in front of the muscle Because if you make a big pocket in front of the muscle, that implant can go anywhere. It can go into the armpit. And so I think one of the things that Motiva and Establishment Labs has done with their education program is saying, we have a great device. The device can be placed in front of the muscle, but they're very specific about the anatomy and if you're gonna do this operation successfully, this is how you do it.</td><td>ë°œí‘œì 7: ì—¡ìŠ¤íƒ€ì¸ ë°•ì‚¬ë‹˜ì´ ë§ì”€í•˜ì‹  ë‚´ìš©ì„ ë” ìì„¸íˆ ì„¤ëª…í•˜ìë©´, ì–´ë–¤ ì™¸ê³¼ì˜ì‚¬ë“  ê·¼ìœ¡ ì•ìª½ì— ì„í”Œë€íŠ¸ë¥¼ ì‚½ì…í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ê·¼ìœ¡ ì•ìª½ì— ì‚½ì…í•  ë•Œ ì ˆëŒ€ì ìœ¼ë¡œ ì¤‘ìš”í•œ ê²ƒì€ ìœ ë°©ì˜ ê²½ê³„ë¥¼ ì¡´ì¤‘í•´ì•¼ í•œë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ê·¼ìœ¡ ì•ìª½ì— í° ì£¼ë¨¸ë‹ˆë¥¼ ë§Œë“¤ë©´ ì„í”Œë€íŠ¸ê°€ ì–´ë””ë“  ì´ë™í•  ìˆ˜ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê²¨ë“œë‘ì´ ìª½ìœ¼ë¡œë„ ê°ˆ ìˆ˜ ìˆì£ . ë”°ë¼ì„œ Motivaì™€ Establishment Labsê°€ êµìœ¡ í”„ë¡œê·¸ë¨ì„ í†µí•´ ê°•ì¡°í•˜ê³  ìˆëŠ” ê²ƒ ì¤‘ í•˜ë‚˜ëŠ”, ìš°ë¦¬ëŠ” í›Œë¥­í•œ ì˜ë£Œê¸°ê¸°ë¥¼ ë³´ìœ í•˜ê³  ìˆê³  ì´ ê¸°ê¸°ëŠ” ê·¼ìœ¡ ì•ìª½ì— ì‚½ì…í•  ìˆ˜ ìˆì§€ë§Œ, í•´ë¶€í•™ì  êµ¬ì¡°ì— ëŒ€í•´ ë§¤ìš° êµ¬ì²´ì ìœ¼ë¡œ ì ‘ê·¼í•´ì•¼ í•˜ë©°, ì´ ìˆ˜ìˆ ì„ ì„±ê³µì ìœ¼ë¡œ ìˆ˜í–‰í•˜ë ¤ë©´ ì´ë ‡ê²Œ í•´ì•¼ í•œë‹¤ëŠ” ì ì„ ëª…í™•íˆ í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 7: And I think that's what makes the commitment from the company. If you put if you have really great devices and they're not used correctly, it can be a big disaster. And so they've really doubled down on education and innovation. Speaker 4: Got a question over here. I can repeat the question if you want to. Speaker 9: Josh Jennings from TD Cowen. Echo the thank you for the presentations and the education. Doctor. Epstein, you just mentioned that you were patiently or maybe enthusiastically awaiting the approvals of the pressurvey minimally invasive instrumentation.</td><td>**ë°œí‘œì 7**: ê·¸ë¦¬ê³  ì €ëŠ” ê·¸ê²ƒì´ íšŒì‚¬ì˜ ì˜ì§€ë¥¼ ë³´ì—¬ì£¼ëŠ” ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì •ë§ í›Œë¥­í•œ ê¸°ê¸°ë“¤ì„ ë³´ìœ í•˜ê³  ìˆì§€ë§Œ ì˜¬ë°”ë¥´ê²Œ ì‚¬ìš©ë˜ì§€ ì•ŠëŠ”ë‹¤ë©´, í° ì¬ì•™ì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ê·¸ë“¤ì€ êµìœ¡ê³¼ í˜ì‹ ì— ì •ë§ë¡œ ë‘ ë°°ì˜ ë…¸ë ¥ì„ ê¸°ìš¸ì´ê³  ìˆìŠµë‹ˆë‹¤.<br><br>**ë°œí‘œì 4**: ì—¬ê¸° ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. ì›í•˜ì‹œë©´ ì§ˆë¬¸ì„ ë°˜ë³µí•´ ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>**ë°œí‘œì 9**: TD Cowenì˜ ì¡°ì‹œ ì œë‹ìŠ¤ì…ë‹ˆë‹¤. ë°œí‘œì™€ êµìœ¡ì— ëŒ€í•´ ê°ì‚¬ ì¸ì‚¬ë¥¼ ì „í•©ë‹ˆë‹¤. ì—¡ìŠ¤íƒ€ì¸ ë°•ì‚¬ë‹˜, ë°©ê¸ˆ ì „ì— í”„ë ˆì„œë² ì´ ìµœì†Œì¹¨ìŠµ ê¸°êµ¬ì˜ ìŠ¹ì¸ì„ ì°¸ì„ì„± ìˆê²Œ, ì•„ë‹ˆë©´ ì—´ì •ì ìœ¼ë¡œ ê¸°ë‹¤ë¦¬ê³  ê³„ì‹ ë‹¤ê³  ë§ì”€í•˜ì…¨ëŠ”ë°ìš”.</td></tr>
<tr><td>I was hoping to just hear from the panelists about, your potential adoption trends and how<br><br>quickly minimally invasive approach with Preservaes could become standard of care in your practice. Speaker 5: For primary augmentation, I anticipate my adoption to be one hundred percent. And again, it's not about the small incision. Preservaes is a two centimeter incision. Two centimeter on the breast or four centimeter where you can't see it, trust me, the women are not going to care. Going forward, before the surgery, they say, Oh, that's better, but trust me, after, that's not going to be the selling point. Speaker 5: The selling point is the fact that you are preserving all the anatomy.</td><td>íŒ¨ë„ ë¶„ë“¤ê»˜ ìµœì†Œ ì¹¨ìŠµì  ì ‘ê·¼ë²•ì¸ Preservaesì˜ ì ì¬ì  ë„ì… íŠ¸ë Œë“œì™€ ì´ê²ƒì´ ê·€í•˜ì˜ ì§„ë£Œì—ì„œ í‘œì¤€ ì¹˜ë£Œë²•ì´ ë˜ëŠ” ì†ë„ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œê¸°ë¥¼ ë°”ëë‹ˆë‹¤.<br><br>ë°œí‘œì 5: 1ì°¨ í™•ëŒ€ìˆ ì˜ ê²½ìš°, ì œê°€ ë„ì…í•  ë¹„ìœ¨ì€ 100%ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë‹¤ì‹œ ë§í•˜ì§€ë§Œ, ì´ê²ƒì€ ì‘ì€ ì ˆê°œì— ê´€í•œ ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. PreservaesëŠ” 2ì„¼í‹°ë¯¸í„° ì ˆê°œì…ë‹ˆë‹¤. ìœ ë°©ì— 2ì„¼í‹°ë¯¸í„°ë“  ë³´ì´ì§€ ì•ŠëŠ” ê³³ì— 4ì„¼í‹°ë¯¸í„°ë“ , ë¯¿ì–´ì£¼ì„¸ìš”, ì—¬ì„±ë“¤ì€ ì‹ ê²½ ì“°ì§€ ì•Šì„ ê²ƒì…ë‹ˆë‹¤. ìˆ˜ìˆ  ì „ì—ëŠ” "ì•„, ê·¸ê²Œ ë” ì¢‹ë„¤ìš”"ë¼ê³  ë§í•˜ì§€ë§Œ, ë¯¿ì–´ì£¼ì„¸ìš”, ìˆ˜ìˆ  í›„ì—ëŠ” ê·¸ê²ƒì´ íŒë§¤ í¬ì¸íŠ¸ê°€ ë˜ì§€ ì•Šì„ ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 5: íŒë§¤ í¬ì¸íŠ¸ëŠ” ëª¨ë“  í•´ë¶€í•™ì  êµ¬ì¡°ë¥¼ ë³´ì¡´í•œë‹¤ëŠ” ì‚¬ì‹¤ì…ë‹ˆë‹¤.</td></tr>
<tr><td>You have a boundary. And as Doctor. Pittman just said, what he said is extremely, extremely important. When you go beyond the border of the breast, beyond that circumambulatory ligament, the footprint of the breast, what's going to happen is you are going to create potentially uncorrectable problems. Speaker 5: And women are going to have to be reined in a little bit about when they come in and they say, But I want this size implant. If I tell the patients, if I were to do that, I would have to over dissect past your breast to fit this implant, and you are going to have problems, and that stops that discussion.</td><td>ë‹¤ìŒì€ í•´ë‹¹ ë°œì–¸ì˜ í•œêµ­ì–´ ë²ˆì—­ì…ë‹ˆë‹¤:<br><br>"ê²½ê³„ê°€ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í”¼íŠ¸ë§Œ ë°•ì‚¬ë‹˜ì´ ë°©ê¸ˆ ë§ì”€í•˜ì‹  ê²ƒì€ ê·¹íˆ, ê·¹íˆ ì¤‘ìš”í•©ë‹ˆë‹¤. ìœ ë°©ì˜ ê²½ê³„ë¥¼ ë„˜ì–´ì„œ, ê·¸ ë‘˜ë ˆì¸ëŒ€ë¥¼ ë„˜ì–´ì„œ, ìœ ë°©ì˜ ì¡±ì (footprint)ì„ ë„˜ì–´ì„œê²Œ ë˜ë©´, ì ì¬ì ìœ¼ë¡œ êµì • ë¶ˆê°€ëŠ¥í•œ ë¬¸ì œë“¤ì„ ì•¼ê¸°í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ê·¸ë¦¬ê³  ì—¬ì„± í™˜ìë“¤ì´ ì™€ì„œ 'í•˜ì§€ë§Œ ì €ëŠ” ì´ ì‚¬ì´ì¦ˆì˜ ì„í”Œë€íŠ¸ë¥¼ ì›í•´ìš”'ë¼ê³  ë§í•  ë•Œ, ì–´ëŠ ì •ë„ ì œì¬ë¥¼ ê°€í•´ì•¼ í•©ë‹ˆë‹¤. ì œê°€ í™˜ìë“¤ì—ê²Œ ë§í•˜ëŠ” ê²ƒì€, ë§Œì•½ ì œê°€ ê·¸ë ‡ê²Œ í•œë‹¤ë©´, ì´ ì„í”Œë€íŠ¸ë¥¼ ë§ì¶”ê¸° ìœ„í•´ ë‹¹ì‹ ì˜ ìœ ë°©ì„ ë„˜ì–´ì„œ ê³¼ë„í•˜ê²Œ ë°•ë¦¬í•´ì•¼ í•˜ê³ , ê·¸ëŸ¬ë©´ ë¬¸ì œê°€ ìƒê¸¸ ê²ƒì´ë¼ê³  í•©ë‹ˆë‹¤. ê·¸ëŸ¬ë©´ ê·¸ ë…¼ì˜ëŠ” ê±°ê¸°ì„œ ëë‚©ë‹ˆë‹¤."<br><br>**ì°¸ê³ **: ì´ ë‚´ìš©ì€ ìœ ë°© ì„±í˜•ìˆ˜ìˆ ì— ê´€í•œ ì˜í•™ì  ë…¼ì˜ë¡œ ë³´ì´ë©°, ìˆ˜ìµ ë°œí‘œì™€ëŠ” ê´€ë ¨ì´ ì—†ì–´ ë³´ì…ë‹ˆë‹¤. í˜¹ì‹œ ë‹¤ë¥¸ ë¬¸ì„œë¥¼ ì˜ë„í•˜ì‹  ê²ƒì€ ì•„ë‹Œì§€ í™•ì¸í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>When you're doing the PrezuVet, you'll be telling them it will not be possible to put in that large an implant. And if you do, you're going to need a procedure that's going to destroy your breast. So they have to make a decision. Speaker 5: Do they want to go down a rabbit hole of multiple revisions later or have a procedure that they're going to get a lot of good years and not be paying for multiple revisions. So this is going to rein in a lot of these ones who do the Kylie Jenner. You cannot fit a four forty five cc implant within the border of her breast. It's impossible. So I think this is going to do a better service for women's health.</td><td>PrezuVetì„ ì‹œí–‰í•  ë•Œ, í™˜ìë“¤ì—ê²Œ ê·¸ë ‡ê²Œ í° ì„í”Œë€íŠ¸ë¥¼ ì‚½ì…í•˜ëŠ” ê²ƒì€ ë¶ˆê°€ëŠ¥í•˜ë‹¤ê³  ë§í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ë§Œì•½ ê·¸ë ‡ê²Œ í•œë‹¤ë©´, ìœ ë°©ì„ ì†ìƒì‹œí‚¤ëŠ” ì‹œìˆ ì´ í•„ìš”í•  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ í™˜ìë“¤ì€ ê²°ì •ì„ ë‚´ë ¤ì•¼ í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ë‚˜ì¤‘ì— ì—¬ëŸ¬ ë²ˆì˜ ì¬ìˆ˜ìˆ ì´ë¼ëŠ” ì•…ìˆœí™˜ì„ ê²ªì„ ê²ƒì¸ì§€, ì•„ë‹ˆë©´ ì˜¤ë«ë™ì•ˆ ì¢‹ì€ ê²°ê³¼ë¥¼ ì–»ê³  ì—¬ëŸ¬ ë²ˆì˜ ì¬ìˆ˜ìˆ  ë¹„ìš©ì„ ì§€ë¶ˆí•˜ì§€ ì•Šì•„ë„ ë˜ëŠ” ì‹œìˆ ì„ ë°›ì„ ê²ƒì¸ì§€ ë§ì…ë‹ˆë‹¤. ì´ê²ƒì€ ì¹´ì¼ë¦¬ ì œë„ˆ ê°™ì€ ì‹œìˆ ì„ í•˜ëŠ” ë§ì€ ê²½ìš°ë“¤ì„ ì–µì œí•  ê²ƒì…ë‹ˆë‹¤. ê·¸ë…€ì˜ ìœ ë°© ê²½ê³„ ë‚´ì— 445cc ì„í”Œë€íŠ¸ë¥¼ ë§ì¶”ëŠ” ê²ƒì€ ë¶ˆê°€ëŠ¥í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ê²ƒì´ ì—¬ì„± ê±´ê°•ì— ë” ë‚˜ì€ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 5: Some women will have to be reigned in a little bit on their expectations. Speaker 6: And I think when you look at the two primary patient populations, women who are young, have never had children, they've often never had surgery before. Women who are mothers, they have kids. And both of those patient populations, I call all my patients the night before surgery and they say to me, I'm not worried about the surgery. I'm worried about the general anesthesia and I'm worried I'm not going to wake up. And so I think from that perspective, one of the very unique components of Preservay is it can be done without general anesthesia. Speaker 6: And that again leans into the safety.</td><td>í™”ì 5: ì¼ë¶€ ì—¬ì„±ë“¤ì€ ê¸°ëŒ€ì¹˜ë¥¼ ì¡°ê¸ˆ ë‚®ì¶°ì•¼ í•  ê²ƒì…ë‹ˆë‹¤.<br><br>í™”ì 6: ë‘ ê°€ì§€ ì£¼ìš” í™˜ìêµ°ì„ ì‚´í´ë³´ë©´, ì Šê³  ì•„ì´ë¥¼ ê°€ì ¸ë³¸ ì ì´ ì—†ëŠ” ì—¬ì„±ë“¤ì€ ì¢…ì¢… ìˆ˜ìˆ  ê²½í—˜ë„ ì—†ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì–´ë¨¸ë‹ˆì¸ ì—¬ì„±ë“¤ì€ ì•„ì´ë“¤ì´ ìˆì£ . ì´ ë‘ í™˜ìêµ° ëª¨ë‘ì—ê²Œ ì €ëŠ” ìˆ˜ìˆ  ì „ë‚  ë°¤ ì „í™”ë¥¼ ë“œë¦¬ëŠ”ë°, ê·¸ë“¤ì´ ì €ì—ê²Œ í•˜ëŠ” ë§ì€ "ìˆ˜ìˆ ì€ ê±±ì •ë˜ì§€ ì•Šì•„ìš”. ì „ì‹ ë§ˆì·¨ê°€ ê±±ì •ë˜ê³  ê¹¨ì–´ë‚˜ì§€ ëª»í• ê¹Œ ë´ ê±±ì •ë¼ìš”"ë¼ê³  í•©ë‹ˆë‹¤. ê·¸ëŸ° ê´€ì ì—ì„œ ë³¼ ë•Œ, Preservayì˜ ë§¤ìš° ë…íŠ¹í•œ êµ¬ì„± ìš”ì†Œ ì¤‘ í•˜ë‚˜ëŠ” ì „ì‹ ë§ˆì·¨ ì—†ì´ë„ ì‹œìˆ ì´ ê°€ëŠ¥í•˜ë‹¤ëŠ” ì ì…ë‹ˆë‹¤.<br><br>í™”ì 6: ê·¸ë¦¬ê³  ì´ëŠ” ë‹¤ì‹œ ì•ˆì „ì„±ìœ¼ë¡œ ì´ì–´ì§‘ë‹ˆë‹¤.</td></tr>
<tr><td>There's a lot of women out there who just simply would not have an elective aesthetic procedure if they have to go to sleep for it. And so I think in that way there is market expansion that we haven't even touched yet. Speaker 4: We'll get to market expansion in a future panel here today, but any other questions from the audience? Speaker 5: Can I bring up one point? Speaker 4: One more point and then we'll move One<br><br><br>Speaker 5: point in economics that I use as a selling point when I'm talking about Motiva. I tell patients the rupture rate on these implants is a lot less than other implants. When it's a young patient, implants are not going to last forever.</td><td>ìˆ˜ë©´ ë§ˆì·¨ë¥¼ í•´ì•¼ í•œë‹¤ë©´ ì„ íƒì  ë¯¸ìš© ì‹œìˆ ì„ ì ˆëŒ€ ë°›ì§€ ì•Šê² ë‹¤ëŠ” ì—¬ì„±ë“¤ì´ ì •ë§ ë§ìŠµë‹ˆë‹¤. ê·¸ëŸ° ì˜ë¯¸ì—ì„œ ìš°ë¦¬ê°€ ì•„ì§ ê±´ë“œë¦¬ì§€ë„ ëª»í•œ ì‹œì¥ í™•ì¥ ê°€ëŠ¥ì„±ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ì‹œì¥ í™•ì¥ì— ëŒ€í•´ì„œëŠ” ì˜¤ëŠ˜ ì´í›„ íŒ¨ë„ì—ì„œ ë‹¤ë£¨ê² ìŠµë‹ˆë‹¤ë§Œ, ì²­ì¤‘ì„ì—ì„œ ë‹¤ë¥¸ ì§ˆë¬¸ ìˆìœ¼ì‹ ê°€ìš”?<br><br>ë°œí‘œì 5: í•œ ê°€ì§€ ë§ì”€ë“œë ¤ë„ ë ê¹Œìš”?<br><br>ë°œí‘œì 4: í•œ ê°€ì§€ë§Œ ë” í•˜ì‹œê³  ê·¸ ë‹¤ìŒì— ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 5: Motivaì— ëŒ€í•´ ì´ì•¼ê¸°í•  ë•Œ ì œê°€ íŒë§¤ í¬ì¸íŠ¸ë¡œ ì‚¬ìš©í•˜ëŠ” ê²½ì œí•™ì  ê´€ì ì´ í•˜ë‚˜ ìˆìŠµë‹ˆë‹¤. í™˜ìë“¤ì—ê²Œ ì´ ì„í”Œë€íŠ¸ì˜ íŒŒì—´ë¥ ì´ ë‹¤ë¥¸ ì„í”Œë€íŠ¸ë“¤ë³´ë‹¤ í›¨ì”¬ ë‚®ë‹¤ê³  ë§ì”€ë“œë¦½ë‹ˆë‹¤. ì Šì€ í™˜ìì˜ ê²½ìš°, ì„í”Œë€íŠ¸ê°€ ì˜ì›íˆ ì§€ì†ë˜ì§€ëŠ” ì•Šê±°ë“ ìš”.</td></tr>
<tr><td>Most women are going to see more than one operation in their lifetime. I tell them, when the ten year safety data comes out, my prediction is it's going to be a dramatic difference. Speaker 5: But on that assumption, you're going to need less revisions, less surgeries in your lifespan. It now becomes a fiscally less expensive procedure than with a competitive device,<br><br>even though I charge more for Motiva, and that has swayed no one. Everyone still pays the premium price. I haven't had one person pick a competitive device since approval. Speaker 4: You're opening a can of worms talking about price for this audience, but thank you, US panel on breast augmentation.</td><td>ëŒ€ë¶€ë¶„ì˜ ì—¬ì„±ë“¤ì€ í‰ìƒì— ê±¸ì³ í•œ ë²ˆ ì´ìƒì˜ ìˆ˜ìˆ ì„ ë°›ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì €ëŠ” ê·¸ë“¤ì—ê²Œ 10ë…„ ì•ˆì „ì„± ë°ì´í„°ê°€ ë‚˜ì˜¤ë©´ ê·¹ì ì¸ ì°¨ì´ë¥¼ ë³´ì¼ ê²ƒì´ë¼ê³  ì˜ˆì¸¡í•œë‹¤ê³  ë§í•©ë‹ˆë‹¤.<br><br>**ë°œì–¸ì 5:** í•˜ì§€ë§Œ ê·¸ ê°€ì • í•˜ì—ì„œëŠ” ì¬ìˆ˜ìˆ ì´ ì¤„ì–´ë“¤ê³ , í‰ìƒ ë™ì•ˆ ë°›ëŠ” ìˆ˜ìˆ  íšŸìˆ˜ê°€ ì¤„ì–´ë“¤ê²Œ ë©ë‹ˆë‹¤. ì´ì œ ì´ê²ƒì€ ê²½ìŸ ì œí’ˆ ëŒ€ë¹„ ì¬ì •ì ìœ¼ë¡œ ë” ì €ë ´í•œ ì‹œìˆ ì´ ë˜ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>ì œê°€ Motivaì— ë” ë†’ì€ ê°€ê²©ì„ ì±…ì •í•¨ì—ë„ ë¶ˆêµ¬í•˜ê³  ë§ì´ì£ . ê·¸ë¦¬ê³  ì´ê²ƒì´ ì•„ë¬´ë„ ì„¤ë“í•˜ì§€ ëª»í•œ ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. ëª¨ë“  ì‚¬ëŒì´ ì—¬ì „íˆ í”„ë¦¬ë¯¸ì—„ ê°€ê²©ì„ ì§€ë¶ˆí•©ë‹ˆë‹¤. ìŠ¹ì¸ ì´í›„ë¡œ ê²½ìŸ ì œí’ˆì„ ì„ íƒí•œ ì‚¬ëŒì€ í•œ ëª…ë„ ì—†ì—ˆìŠµë‹ˆë‹¤.<br><br>**ë°œì–¸ì 4:** ì´ ì²­ì¤‘ì„ ëŒ€ìƒìœ¼ë¡œ ê°€ê²©ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ëŠ” ê²ƒì€ ë³µì¡í•œ ë¬¸ì œë¥¼ ê±´ë“œë¦¬ëŠ” ê²ƒì´ì§€ë§Œ, ê°ì‚¬í•©ë‹ˆë‹¤. ìœ ë°©í™•ëŒ€ìˆ ì— ê´€í•œ ë¯¸êµ­ íŒ¨ë„ì´ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With that I'll bring Jeff back up to talk about reconstruction. Speaker 3: Thanks again to the panel. So moving on to breast reconstruction opportunity in The United States. Obviously, we do not have the indication yet, so therefore we can't promote. We are seeing a very small amount of off label usage already and it typically follows where somebody is using our flora tissue expander, which obviously is approved for reconstruction. But we anticipate that we would get approval sometime, as I said before, we are going to submit late this fall and then FDA typically takes about a year, but it could be a little bit faster given that we're already on market and approved for augmentation.</td><td>ì´ì œ Jeffë¥¼ ë‹¤ì‹œ ëª¨ì‹œê³  ì¬ê±´ìˆ ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 3: íŒ¨ë„ ì—¬ëŸ¬ë¶„ê»˜ ë‹¤ì‹œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ê·¸ëŸ¼ ë¯¸êµ­ ë‚´ ìœ ë°© ì¬ê±´ìˆ  ê¸°íšŒì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¶„ëª…íˆ ì €í¬ëŠ” ì•„ì§ ì ì‘ì¦ì„ ë°›ì§€ ëª»í–ˆê¸° ë•Œë¬¸ì— í™ë³´í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. í˜„ì¬ ë§¤ìš° ì†ŒëŸ‰ì˜ ì˜¤í”„ë¼ë²¨ ì‚¬ìš©ì„ ë³´ê³  ìˆìœ¼ë©°, ì´ëŠ” ì¼ë°˜ì ìœ¼ë¡œ ì¬ê±´ìˆ ì— ì´ë¯¸ ìŠ¹ì¸ëœ ì €í¬ í”Œë¡œë¼ ì¡°ì§ í™•ì¥ê¸°ë¥¼ ì‚¬ìš©í•˜ëŠ” ê²½ìš°ì— ë”°ë¼ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ëŠ” ì–¸ì  ê°€ ìŠ¹ì¸ì„ ë°›ì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ ì˜¬ ê°€ì„ ë§ì— ì œì¶œí•  ì˜ˆì •ì´ê³ , FDAëŠ” ë³´í†µ ì•½ 1ë…„ ì •ë„ ì†Œìš”ë˜ì§€ë§Œ ì €í¬ê°€ ì´ë¯¸ ì‹œì¥ì— ì¶œì‹œë˜ì–´ í™•ëŒ€ìˆ ì— ëŒ€í•´ ìŠ¹ì¸ì„ ë°›ì•˜ë‹¤ëŠ” ì ì„ ê³ ë ¤í•˜ë©´ ì¡°ê¸ˆ ë” ë¹¨ë¼ì§ˆ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 3: And this reconstruction is a it's reloading here. It is a significant opportunity for us because the reconstruction market is very stable and grows at about two percent absolutely steadily. So if you longitudinally look through the data and you take out the noise of the COVID years, it just sort of marches on at about a two percent growth rate every year. And although the procedure count is significantly lower than augmentation, given that the price points in the hospital are usually 25% to 30% higher as well as you have the opportunity to include tissue expanders into that case.</td><td>í™”ì 3: ê·¸ë¦¬ê³  ì´ ì¬ê±´ìˆ ì€... ì—¬ê¸°ì„œ ë‹¤ì‹œ ë¡œë”©ë˜ê³  ìˆë„¤ìš”. ì´ê²ƒì€ ì €í¬ì—ê²Œ ìƒë‹¹í•œ ê¸°íšŒì…ë‹ˆë‹¤. ì¬ê±´ìˆ  ì‹œì¥ì€ ë§¤ìš° ì•ˆì •ì ì´ê³  ì•½ 2%ì”© ê¾¸ì¤€íˆ ì„±ì¥í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë°ì´í„°ë¥¼ ì¢…ë‹¨ì ìœ¼ë¡œ ì‚´í´ë³´ê³  ì½”ë¡œë‚˜ ì‹œê¸°ì˜ ë…¸ì´ì¦ˆë¥¼ ì œê±°í•˜ë©´, ë§¤ë…„ ì•½ 2%ì˜ ì„±ì¥ë¥ ë¡œ ê¾¸ì¤€íˆ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹œìˆ  ê±´ìˆ˜ëŠ” í™•ëŒ€ìˆ ì— ë¹„í•´ í˜„ì €íˆ ë‚®ì§€ë§Œ, ë³‘ì›ì—ì„œì˜ ê°€ê²©ëŒ€ê°€ ë³´í†µ 25%ì—ì„œ 30% ë” ë†’ê³ , ë˜í•œ í•´ë‹¹ ì¼€ì´ìŠ¤ì— ì¡°ì§ í™•ì¥ê¸°ë¥¼ í¬í•¨í•  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ìˆë‹¤ëŠ” ì ì„ ê³ ë ¤í•˜ë©´ ë§ì…ë‹ˆë‹¤.</td></tr>
<tr><td>So that procedure actually could end up being worth, from a revenue standpoint, about three times what an augmentation case could. Speaker 3: So you net through all that and the actual revenue opportunity is at least as much, if not slightly more than the augmentation opportunity. And again, so we anticipate approval sometime in 2026 with the full launch then in early twenty twenty seven. And the Motiva device, as you've currently heard and you're going to hear from some reconstruction surgeons here in<br><br>just a minute, is very well suited for this patient type.</td><td>ë”°ë¼ì„œ í•´ë‹¹ ì‹œìˆ ì€ ì‹¤ì œë¡œ ìˆ˜ìµ ê´€ì ì—ì„œ ë³¼ ë•Œ ìœ ë°©í™•ëŒ€ìˆ  ì¼€ì´ìŠ¤ ëŒ€ë¹„ ì•½ 3ë°° ì •ë„ì˜ ê°€ì¹˜ë¥¼ ê°€ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ì´ ëª¨ë“  ê²ƒì„ ì¢…í•©í•´ë³´ë©´, ì‹¤ì œ ìˆ˜ìµ ê¸°íšŒëŠ” ìµœì†Œí•œ ìœ ë°©í™•ëŒ€ ê¸°íšŒë§Œí¼, ë˜ëŠ” ê·¸ë³´ë‹¤ ì•½ê°„ ë” í´ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ë©´, ì €í¬ëŠ” 2026ë…„ ì¤‘ ìŠ¹ì¸ì„ ë°›ê³  2027ë…„ ì´ˆì— ë³¸ê²©ì ì¸ ì¶œì‹œë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ê»˜ì„œ ì´ë¯¸ ë“¤ìœ¼ì…¨ê³  ê³§ ì¬ê±´ ì™¸ê³¼ì˜ë“¤ë¡œë¶€í„° ì§ì ‘ ë“¤ìœ¼ì‹œê²Œ ë  Motiva ë””ë°”ì´ìŠ¤ëŠ” ì´ëŸ¬í•œ í™˜ì ìœ í˜•ì— ë§¤ìš° ì í•©í•©ë‹ˆë‹¤.</td></tr>
<tr><td>So the surface technology really creates a soft pliable capsule that's great in that patient type, the 100% filled monoblock technology, all really combines for a great offering, for the patient from an implant selection standpoint. And then with the Fluor Tissue Expander, it's the only one MRI conditional. Speaker 3: So it can be used, during radiation. And so you get the opportunity to get a more targeted radiation protocol for that patient so it's much safer and can be more effective because of that.</td><td>ë”°ë¼ì„œ í‘œë©´ ê¸°ìˆ ì€ í•´ë‹¹ í™˜ì ìœ í˜•ì— ë§¤ìš° ì í•©í•œ ë¶€ë“œëŸ½ê³  ìœ ì—°í•œ ìº¡ìŠì„ ë§Œë“¤ì–´ë‚´ë©°, 100% ì¶©ì „ëœ ëª¨ë…¸ë¸”ë¡ ê¸°ìˆ ê³¼ ê²°í•©ë˜ì–´ ì„í”Œë€íŠ¸ ì„ íƒ ê´€ì ì—ì„œ í™˜ìì—ê²Œ í›Œë¥­í•œ ì˜µì…˜ì„ ì œê³µí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  Fluor ì¡°ì§ í™•ì¥ê¸°ì˜ ê²½ìš°, ìœ ì¼í•˜ê²Œ MRI ì¡°ê±´ë¶€ ìŠ¹ì¸ì„ ë°›ì€ ì œí’ˆì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ë”°ë¼ì„œ ë°©ì‚¬ì„  ì¹˜ë£Œ ì¤‘ì—ë„ ì‚¬ìš©í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ í•´ë‹¹ í™˜ìì—ê²Œ ë³´ë‹¤ í‘œì í™”ëœ ë°©ì‚¬ì„  ì¹˜ë£Œ í”„ë¡œí† ì½œì„ ì ìš©í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ì–»ê²Œ ë˜ë¯€ë¡œ í›¨ì”¬ ë” ì•ˆì „í•˜ê³  ë”ìš± íš¨ê³¼ì ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And you are already seeing really prestigious institutions like MD Anderson starting the publications, to put publications out relative to the things that I just discussed and I think we are going to hear some of that from Doctor. Hammond. Obviously there is other publications already around the rest of the world saying these same things but when you have an institution like MD Anderson, it really solidifies the fact that this is really great data and a great offering for these patients. Speaker 3: So with that, I'll go ahead and bring, Ben back up to introduce our recon panel. Speaker 4: Okay. Thanks a lot, Jeff.</td><td>ê·¸ë¦¬ê³  ì´ë¯¸ MD Andersonê³¼ ê°™ì€ ì •ë§ ê¶Œìœ„ ìˆëŠ” ê¸°ê´€ë“¤ì´ ì œê°€ ë°©ê¸ˆ ë…¼ì˜í•œ ë‚´ìš©ë“¤ê³¼ ê´€ë ¨ëœ ë…¼ë¬¸ ë°œí‘œë¥¼ ì‹œì‘í•˜ê³  ìˆëŠ” ê²ƒì„ ë³´ê³  ê³„ì‹œë©°, Hammond ë°•ì‚¬ë¡œë¶€í„° ê·¸ëŸ° ë‚´ìš©ë“¤ì„ ì¼ë¶€ ë“¤ì„ ìˆ˜ ìˆì„ ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë¬¼ë¡  ì „ ì„¸ê³„ì ìœ¼ë¡œ ì´ë¯¸ ê°™ì€ ë‚´ìš©ì„ ë‹¤ë£¨ëŠ” ë‹¤ë¥¸ ë…¼ë¬¸ë“¤ë„ ìˆì§€ë§Œ, MD Andersonê³¼ ê°™ì€ ê¸°ê´€ì—ì„œ ë‚˜ì˜¬ ë•ŒëŠ” ì´ê²ƒì´ ì •ë§ í›Œë¥­í•œ ë°ì´í„°ì´ê³  ì´ëŸ¬í•œ í™˜ìë“¤ì—ê²Œ í›Œë¥­í•œ ì¹˜ë£Œ ì˜µì…˜ì´ë¼ëŠ” ì‚¬ì‹¤ì„ í™•ì‹¤íˆ ì…ì¦í•´ ì£¼ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ê·¸ëŸ¼ ì´ì œ Benì„ ë‹¤ì‹œ ëª¨ì…”ì„œ ì¬ê±´ìˆ  íŒ¨ë„ì„ ì†Œê°œí•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ë„¤, ê³ ë§™ìŠµë‹ˆë‹¤, Jeff.</td></tr>
<tr><td>Doctors Hammond and Karp would love for you to join me on the stage, in those two middle seats if possible. So great tremendous opportunity for us here in The US in breast reconstruction. I'm happy to present these two panelists today. Speaker 4: Doctor Dennis Hammond is a we like to call him a serial investigator. He's been involved in almost, every clinical trial in this space, in The US. Going back twenty years now, he'll talk about his experience. But he's also a co developer of our FLORA technology, so he'll give you a good insight into, the why, how, and what, of that device. He's from Grand Rapids, Michigan. Speaker 4: He joins us today. And then we'll bring up Doctor. Nolan Karp.</td><td>í•´ë¨¼ë“œ ë°•ì‚¬ë‹˜ê³¼ ì¹´í”„ ë°•ì‚¬ë‹˜, ê°€ëŠ¥í•˜ì‹œë‹¤ë©´ ê°€ìš´ë° ë‘ ìë¦¬ì— ì €ì™€ í•¨ê»˜ ë¬´ëŒ€ì— ì˜¬ë¼ì™€ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ ìœ ë°© ì¬ê±´ìˆ  ë¶„ì•¼ì— ìˆì–´ ì €í¬ì—ê²ŒëŠ” ì •ë§ ì—„ì²­ë‚œ ê¸°íšŒì…ë‹ˆë‹¤. ì˜¤ëŠ˜ ì´ ë‘ ë¶„ì˜ íŒ¨ë„ë¦¬ìŠ¤íŠ¸ë¥¼ ì†Œê°œí•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ë°ë‹ˆìŠ¤ í•´ë¨¼ë“œ ë°•ì‚¬ë‹˜ì€ ì €í¬ê°€ 'ì—°ì‡„ ì—°êµ¬ì'ë¼ê³  ë¶€ë¥´ëŠ” ë¶„ì…ë‹ˆë‹¤. ì§€ë‚œ 20ë…„ê°„ ì´ ë¶„ì•¼ì˜ ê±°ì˜ ëª¨ë“  ì„ìƒì‹œí—˜ì— ì°¸ì—¬í•´ ì˜¤ì…¨ìœ¼ë©°, ê·¸ì˜ ê²½í—˜ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ì˜ˆì •ì…ë‹ˆë‹¤. ë˜í•œ ì €í¬ FLORA ê¸°ìˆ ì˜ ê³µë™ ê°œë°œìì´ê¸°ë„ í•˜ì‹œë¯€ë¡œ, í•´ë‹¹ ê¸°ê¸°ì˜ ì´ìœ , ë°©ë²•, ê·¸ë¦¬ê³  ë‚´ìš©ì— ëŒ€í•´ ì¢‹ì€ í†µì°°ì„ ì œê³µí•´ ì£¼ì‹¤ ê²ƒì…ë‹ˆë‹¤. ë¯¸ì‹œê°„ì£¼ ê·¸ëœë“œë˜í”¼ì¦ˆì—ì„œ ì˜¤ì…¨ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ì˜¤ëŠ˜ ì €í¬ì™€ í•¨ê»˜í•´ ì£¼ì…¨ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì œ ë†€ë€ ì¹´í”„ ë°•ì‚¬ë‹˜ì„ ëª¨ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>He is also I should have said they're both investigators on the implant trial, so it'll be a little forward looking on<br><br>what you might expect. But, we obviously don't have that indication yet for implants, but Doctor. Speaker 4: Nolan Karp is here at NYU right here in the city. So, with that, I'll bring up, Doctor. Hammond. Thank you. Speaker 10: Good morning, everyone. I am Dennis Hammond from Grand Rapids, Michigan. And I'm in private practice in Grand Rapids and I've been in practice for thirty three years, but I've had a very active academic side to my practice, mostly because of my previous training.</td><td>ê·¸ëŠ” ë˜í•œ - ì œê°€ ë§ì”€ë“œë ¸ì–´ì•¼ í–ˆëŠ”ë° - ë‘ ë¶„ ëª¨ë‘ ì„í”Œë€íŠ¸ ì‹œí—˜ì˜ ì—°êµ¬ìë“¤ì´ì‹œë¯€ë¡œ, ì—¬ëŸ¬ë¶„ì´ ê¸°ëŒ€í•  ìˆ˜ ìˆëŠ” ê²ƒì— ëŒ€í•´ ì¡°ê¸ˆ ë¯¸ë˜ì§€í–¥ì ì¸ ê´€ì ì„ ì œì‹œí•´ ì£¼ì‹¤ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ëŠ” ì•„ì§ ì„í”Œë€íŠ¸ì— ëŒ€í•œ í•´ë‹¹ ì ì‘ì¦ì„ ë³´ìœ í•˜ê³  ìˆì§€ ì•ŠìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë‹¥í„° Speaker 4: ë†€ë€ ì¹´í”„(Nolan Karp) ë°•ì‚¬ë‹˜ì´ ì—¬ê¸° ë‰´ìš•ì‹œì˜ NYUì— ê³„ì‹­ë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ í•´ë¨¼ë“œ(Hammond) ë°•ì‚¬ë‹˜ì„ ëª¨ì‹œê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. <br><br>Speaker 10: ì•ˆë…•í•˜ì„¸ìš”, ì—¬ëŸ¬ë¶„. ì €ëŠ” ë¯¸ì‹œê°„ì£¼ ê·¸ëœë“œë˜í”¼ì¦ˆì˜ ë°ë‹ˆìŠ¤ í•´ë¨¼ë“œ(Dennis Hammond)ì…ë‹ˆë‹¤. ê·¸ëœë“œë˜í”¼ì¦ˆì—ì„œ ê°œì›ì˜ë¡œ ì§„ë£Œí•˜ê³  ìˆìœ¼ë©° 33ë…„ê°„ ì§„ë£Œí•´ ì™”ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ì „ ìˆ˜ë ¨ ê³¼ì • ë•Œë¬¸ì— ì œ ì§„ë£Œì—ëŠ” ë§¤ìš° í™œë°œí•œ í•™ìˆ ì  ì¸¡ë©´ì´ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And I've been involved, as we said, in just about every implant study that's come down the road over the years. I'm very familiar with the technology, designed one of the early expanders. Speaker 10: And that's one of the things that drew me to Motiva, to try to put this in perspective. The silicone crisis of the early 1990s basically halted all innovation related to the use of these things that we call breast implants. Basically at that point it was a silicone bag. We argued a little bit about what the surface should look like but all of that stopped. And that's one of the reasons I became so enamored with Motiva and JJ who deserves a ton of credit for building this company from nothing.</td><td>ê·¸ë¦¬ê³  ì œê°€ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì €ëŠ” ìˆ˜ë…„ê°„ ê±°ì˜ ëª¨ë“  ì„í”Œë€íŠ¸ ì—°êµ¬ì— ì°¸ì—¬í•´ì™”ìŠµë‹ˆë‹¤. ì´ ê¸°ìˆ ì— ë§¤ìš° ìµìˆ™í•˜ë©°, ì´ˆê¸° í™•ì¥ê¸° ì¤‘ í•˜ë‚˜ë¥¼ ì„¤ê³„í•˜ê¸°ë„ í–ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 10: ê·¸ë¦¬ê³  ê·¸ê²ƒì´ ì €ë¥¼ Motivaë¡œ ì´ëˆ ìš”ì¸ ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. ì´ë¥¼ ê´€ì ì—ì„œ ì„¤ëª…í•´ë“œë¦¬ìë©´, 1990ë…„ëŒ€ ì´ˆ ì‹¤ë¦¬ì½˜ ìœ„ê¸°ëŠ” ê¸°ë³¸ì ìœ¼ë¡œ ìš°ë¦¬ê°€ ìœ ë°© ì„í”Œë€íŠ¸ë¼ê³  ë¶€ë¥´ëŠ” ì´ëŸ¬í•œ ì œí’ˆë“¤ì˜ ì‚¬ìš©ê³¼ ê´€ë ¨ëœ ëª¨ë“  í˜ì‹ ì„ ì¤‘ë‹¨ì‹œì¼°ìŠµë‹ˆë‹¤. ê¸°ë³¸ì ìœ¼ë¡œ ê·¸ ì‹œì ì—ì„œëŠ” ì‹¤ë¦¬ì½˜ ë°±ì´ ì „ë¶€ì˜€ìŠµë‹ˆë‹¤. í‘œë©´ì´ ì–´ë–»ê²Œ ìƒê²¨ì•¼ í•˜ëŠ”ì§€ì— ëŒ€í•´ ì•½ê°„ì˜ ë…¼ì˜ëŠ” ìˆì—ˆì§€ë§Œ ê·¸ ëª¨ë“  ê²ƒì´ ì¤‘ë‹¨ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¸ê²ƒì´ ì œê°€ Motivaì™€ JJì—ê²Œ ê·¸í† ë¡ ë§¤ë£Œëœ ì´ìœ  ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. JJëŠ” ì´ íšŒì‚¬ë¥¼ ë¬´ì—ì„œ ìœ ë¡œ ê±´ì„¤í•œ ê³µë¡œë¡œ ì—„ì²­ë‚œ ì¸ì •ì„ ë°›ì„ ìê²©ì´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 10: He said, We need to take innovation forward. It's time. We're past the 90s and here's what we're going to do. And they came up with the implant. The implant, the advantages that you've seen, the silk surface, the rheology, the way that it interacts with the shell. Speaker 10: The expander is that on steroids. So an initial expander in the old days was basically a round balloon with a remote valve and that was it. And the Expander really offered a lot of opportunity to make it better, to make it work better for our patients. So this is what we came up with.</td><td>ë°œí‘œì 10: ê·¸ëŠ” "ìš°ë¦¬ëŠ” í˜ì‹ ì„ ì•ìœ¼ë¡œ ë‚˜ì•„ê°€ê²Œ í•´ì•¼ í•©ë‹ˆë‹¤. ë•Œê°€ ë˜ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 90ë…„ëŒ€ë¥¼ ì§€ë‚˜ì™”ê³ , ì´ì œ ìš°ë¦¬ê°€ í•  ì¼ì€ ì´ê²ƒì…ë‹ˆë‹¤"ë¼ê³  ë§í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¸ë“¤ì€ ì„í”Œë€íŠ¸ë¥¼ ê°œë°œí•´ëƒˆìŠµë‹ˆë‹¤. ì„í”Œë€íŠ¸, ì—¬ëŸ¬ë¶„ì´ ë³´ì‹  ì¥ì ë“¤, ì‹¤í¬ í‘œë©´, ìœ ë³€í•™ì  íŠ¹ì„±, ì‰˜ê³¼ ìƒí˜¸ì‘ìš©í•˜ëŠ” ë°©ì‹ ë§ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 10: ìµìŠ¤íŒ¬ë”ëŠ” ê·¸ê²ƒì„ í•œì¸µ ë” ë°œì „ì‹œí‚¨ ê²ƒì…ë‹ˆë‹¤. ê³¼ê±°ì˜ ì´ˆê¸° ìµìŠ¤íŒ¬ë”ëŠ” ê¸°ë³¸ì ìœ¼ë¡œ ì›í˜• í’ì„ ì— ì›ê²© ë°¸ë¸Œê°€ ë‹¬ë¦° ê²ƒì´ ì „ë¶€ì˜€ìŠµë‹ˆë‹¤. ê·¸ëŸ°ë° ìµìŠ¤íŒ¬ë”ëŠ” ì‹¤ì œë¡œ ë” ë‚˜ì€ ì œí’ˆì„ ë§Œë“¤ê³ , í™˜ìë“¤ì„ ìœ„í•´ ë” ì˜ ì‘ë™í•˜ë„ë¡ ë§Œë“¤ ìˆ˜ ìˆëŠ” ë§ì€ ê¸°íšŒë¥¼ ì œê³µí–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ê²ƒì´ ìš°ë¦¬ê°€ ê°œë°œí•´ë‚¸ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Advantages, it may look simple, but the advantages that you're looking at in this particular device are that it's got a shape. Speaker 10: So when the expander is in the breast after the masticity has been done, the breast has a reasonable looking shape to it as opposed to a round ball which is what it used to in the old days. It's got the silk surface so the silk surface prevents the formation of the scar around the device So it keeps the complication of capsular contracture exceedingly low, which is a<br>huge advantage in reconstruction. And then the other thing is this valve. You can see that metal valve. That's how the expander is filled.</td><td>ì¥ì ë“¤ì„ ì‚´í´ë³´ë©´, ë‹¨ìˆœí•´ ë³´ì¼ ìˆ˜ ìˆì§€ë§Œ ì´ íŠ¹ì • ê¸°ê¸°ê°€ ê°€ì§„ ì¥ì ë“¤ì€ í˜•íƒœë¥¼ ê°–ì¶”ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. <br><br>ë°œí‘œì 10: ìœ ë°©ì ˆì œìˆ  í›„ í™•ì¥ê¸°ê°€ ìœ ë°©ì— ì‚½ì…ë˜ì—ˆì„ ë•Œ, ê³¼ê±°ì— ì‚¬ìš©í•˜ë˜ ë‘¥ê·¼ ê³µ ëª¨ì–‘ê³¼ëŠ” ë‹¬ë¦¬ ìœ ë°©ì´ í•©ë¦¬ì ìœ¼ë¡œ ë³´ì´ëŠ” í˜•íƒœë¥¼ ê°–ê²Œ ë©ë‹ˆë‹¤. ì‹¤í¬ í‘œë©´ì„ ê°€ì§€ê³  ìˆì–´ì„œ ì´ ì‹¤í¬ í‘œë©´ì´ ê¸°ê¸° ì£¼ë³€ì˜ í‰í„° í˜•ì„±ì„ ë°©ì§€í•©ë‹ˆë‹¤. ë”°ë¼ì„œ í”¼ë§‰ êµ¬ì¶•ì´ë¼ëŠ” í•©ë³‘ì¦ì„ ê·¹ë„ë¡œ ë‚®ê²Œ ìœ ì§€í•˜ëŠ”ë°, ì´ëŠ” ì¬ê±´ìˆ ì—ì„œ ì—„ì²­ë‚œ ì¥ì ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë˜ ë‹¤ë¥¸ ê²ƒì€ ì´ ë°¸ë¸Œì…ë‹ˆë‹¤. ì € ê¸ˆì† ë°¸ë¸Œë¥¼ ë³´ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ê²ƒì´ í™•ì¥ê¸°ë¥¼ ì±„ìš°ëŠ” ë°©ì‹ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 10: So when it's in a patient, you find a needle and you can go through the skin into that valve and blow that expander up, inflate it gradually over time so you get to the volume that you want. Traditionally, that valve was external to the device and then it was built into the<br>device but it's metal. And because it's metal that means that the patient can't have an MRI while the device is in place and it really complicates radiation therapy planning because you have to remember these patients are cancer patients. And so we came up with a way to make that valve without using any metal. I know that sounds simple but that's like building the iPhone back in<br>the day.</td><td>ë°œí‘œì 10: í™˜ìì—ê²Œ ì‹œìˆ í•  ë•ŒëŠ” ë°”ëŠ˜ì„ ì°¾ì•„ì„œ í”¼ë¶€ë¥¼ í†µí•´ ê·¸ ë°¸ë¸Œë¡œ ë“¤ì–´ê°€ í™•ì¥ê¸°ë¥¼ ë¶€í’€ë¦¬ê³ , ì‹œê°„ì„ ë‘ê³  ì ì§„ì ìœ¼ë¡œ íŒ½ì°½ì‹œì¼œ ì›í•˜ëŠ” ìš©ëŸ‰ì— ë„ë‹¬í•˜ê²Œ í•©ë‹ˆë‹¤. ì „í†µì ìœ¼ë¡œ ê·¸ ë°¸ë¸ŒëŠ” ê¸°ê¸° ì™¸ë¶€ì— ìˆì—ˆë‹¤ê°€ ë‚˜ì¤‘ì— ê¸°ê¸° ë‚´ë¶€ì— ë‚´ì¥ë˜ì—ˆì§€ë§Œ ê¸ˆì†ìœ¼ë¡œ ë§Œë“¤ì–´ì¡ŒìŠµë‹ˆë‹¤. ê¸ˆì†ì´ê¸° ë•Œë¬¸ì— ê¸°ê¸°ê°€ ì‚½ì…ëœ ìƒíƒœì—ì„œëŠ” í™˜ìê°€ MRIë¥¼ ë°›ì„ ìˆ˜ ì—†ê³ , ë°©ì‚¬ì„  ì¹˜ë£Œ ê³„íšì„ ì„¸ìš°ëŠ” ê²ƒë„ ë§¤ìš° ë³µì¡í•´ì§‘ë‹ˆë‹¤. ì´ í™˜ìë“¤ì´ ì•” í™˜ìë¼ëŠ” ì ì„ ê¸°ì–µí•´ì•¼ í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì €í¬ëŠ” ê¸ˆì†ì„ ì „í˜€ ì‚¬ìš©í•˜ì§€ ì•Šê³  ê·¸ ë°¸ë¸Œë¥¼ ë§Œë“œëŠ” ë°©ë²•ì„ ê°œë°œí–ˆìŠµë‹ˆë‹¤. ê°„ë‹¨í•˜ê²Œ ë“¤ë¦´ì§€ ëª¨ë¥´ì§€ë§Œ, ì´ëŠ” ë§ˆì¹˜ ê³¼ê±°ì— ì•„ì´í°ì„ ë§Œë“œëŠ” ê²ƒê³¼ ê°™ì€ ìˆ˜ì¤€ì˜ í˜ì‹ ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 10: It was a huge step forward in the design of these devices. And then some simple things, putting tabs on the expander so that the expander can't rotate. Another big step. And all that together has created now a device which is uniquely suited for preparation of that pocket for the placement of a Motiva implant. Just real briefly, the way that this valve finder was made, there's a little valve finder you hover over the valve when the expander is in place. Speaker 10: It uses, an RFID coil, which is something that was part of the original Motiva Implants. And there's a signal that's sent to that coil that then comes back to the finder.</td><td>ë°œí‘œì 10: ì´ëŠ” ì´ëŸ¬í•œ ê¸°ê¸° ì„¤ê³„ì— ìˆì–´ ì—„ì²­ë‚œ ì§„ì „ì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ëª‡ ê°€ì§€ ê°„ë‹¨í•œ ê°œì„ ì‚¬í•­ë“¤, ì˜ˆë¥¼ ë“¤ì–´ í™•ì¥ê¸°ê°€ íšŒì „í•˜ì§€ ì•Šë„ë¡ íƒ­ì„ ì¶”ê°€í•˜ëŠ” ê²ƒ ê°™ì€ ê²ƒë“¤ë„ í° ì§„ì „ì´ì—ˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒë“¤ì´ í•©ì³ì ¸ì„œ ì´ì œ Motiva ì„í”Œë€íŠ¸ ì‚½ì…ì„ ìœ„í•œ ì£¼ë¨¸ë‹ˆ ì¤€ë¹„ì— ë…íŠ¹í•˜ê²Œ ì í•©í•œ ê¸°ê¸°ê°€ ë§Œë“¤ì–´ì¡ŒìŠµë‹ˆë‹¤. ê°„ë‹¨íˆ ë§ì”€ë“œë¦¬ë©´, ì´ ë°¸ë¸Œ íŒŒì¸ë”ê°€ ë§Œë“¤ì–´ì§„ ë°©ì‹ì€ í™•ì¥ê¸°ê°€ ì œìë¦¬ì— ìˆì„ ë•Œ ë°¸ë¸Œ ìœ„ì— ì˜¬ë ¤ë†“ëŠ” ì‘ì€ ë°¸ë¸Œ íŒŒì¸ë”ê°€ ìˆìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 10: ì´ ê¸°ê¸°ëŠ” ì›ë˜ Motiva ì„í”Œë€íŠ¸ì˜ ì¼ë¶€ì˜€ë˜ RFID ì½”ì¼ì„ ì‚¬ìš©í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  í•´ë‹¹ ì½”ì¼ì— ì‹ í˜¸ê°€ ì „ì†¡ë˜ë©´ ê·¸ ì‹ í˜¸ê°€ ë‹¤ì‹œ íŒŒì¸ë”ë¡œ ëŒì•„ì˜¤ëŠ” ë°©ì‹ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And that's how you can locate the location of that valve so that you can stick a needle in it successfully and you don't miss and perhaps stick a needle somewhere else and puncture the device. So that took years to develop and God bless them they did. This is an example of the<br><br>planning that goes into somebody who's going to have radiation therapy. Speaker 10: This can happen many times. A patient has a mastectomy because of cancer, lymph nodes are positive, they decide they want to give radiation. Radiation damages tissue. You have to be very careful with how that radiation is delivered to the target area, which is the area where you want to kill cancer cells.</td><td>ê·¸ë¦¬ê³  ê·¸ê²ƒì´ ë°”ë¡œ ë°¸ë¸Œì˜ ìœ„ì¹˜ë¥¼ ì°¾ì•„ì„œ ì„±ê³µì ìœ¼ë¡œ ë°”ëŠ˜ì„ ì‚½ì…í•  ìˆ˜ ìˆê²Œ í•˜ëŠ” ë°©ë²•ì…ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ë¹—ë‚˜ê°€ì§€ ì•Šê³  ë‹¤ë¥¸ ê³³ì— ë°”ëŠ˜ì„ ì°”ëŸ¬ ê¸°ê¸°ë¥¼ ì†ìƒì‹œí‚¤ëŠ” ì¼ì„ ë°©ì§€í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì„ ê°œë°œí•˜ëŠ” ë° ìˆ˜ë…„ì´ ê±¸ë ¸ê³ , ì •ë§ ë‹¤í–‰íˆë„ ê·¸ë“¤ì´ í•´ëƒˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ <br><br>ë°©ì‚¬ì„  ì¹˜ë£Œë¥¼ ë°›ì„ ì˜ˆì •ì¸ í™˜ìë¥¼ ìœ„í•œ ê³„íš ìˆ˜ë¦½ì˜ í•œ ì˜ˆì…ë‹ˆë‹¤. ë°œí‘œì 10: ì´ëŸ° ì¼ì€ ì—¬ëŸ¬ ë²ˆ ë°œìƒí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. í™˜ìê°€ ì•”ìœ¼ë¡œ ì¸í•´ ìœ ë°©ì ˆì œìˆ ì„ ë°›ê³ , ë¦¼í”„ì ˆì´ ì–‘ì„±ìœ¼ë¡œ ë‚˜ì˜¤ë©´, ë°©ì‚¬ì„  ì¹˜ë£Œë¥¼ í•˜ê¸°ë¡œ ê²°ì •í•©ë‹ˆë‹¤. ë°©ì‚¬ì„ ì€ ì¡°ì§ì„ ì†ìƒì‹œí‚µë‹ˆë‹¤. ì•”ì„¸í¬ë¥¼ ì£½ì´ê³ ì í•˜ëŠ” í‘œì  ë¶€ìœ„ì— ë°©ì‚¬ì„ ì´ ì „ë‹¬ë˜ëŠ” ë°©ì‹ì„ ë§¤ìš° ì‹ ì¤‘í•˜ê²Œ ë‹¤ë¤„ì•¼ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>That valve can scatter that radiation. Speaker 10: That metal valve can scatter that radiation and complicate the delivery of that and increase complications. But with no metal in the valve, now all of a sudden that radiation planning process can occur much more seemingly. And as you'll see, studies have already shown this is an advantage. This is an example of an MRI of a patient that has a Motiva expander in. No problems at all with obscuring of the breast tissue or, creating a signal that creates a starburst effect so you can't see the breast. Speaker 10: So again, big step forward. These have been used here in The United States. I've been using them myself.</td><td>í•´ë‹¹ íŒë§‰ì´ ë°©ì‚¬ì„ ì„ ì‚°ë€ì‹œí‚¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë°œí‘œì 10: ê·¸ ê¸ˆì† íŒë§‰ì´ ë°©ì‚¬ì„ ì„ ì‚°ë€ì‹œì¼œ ë°©ì‚¬ì„  ì „ë‹¬ì„ ë³µì¡í•˜ê²Œ ë§Œë“¤ê³  í•©ë³‘ì¦ì„ ì¦ê°€ì‹œí‚¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ íŒë§‰ì— ê¸ˆì†ì´ ì—†ìœ¼ë©´, ì´ì œ ê°‘ìê¸° ë°©ì‚¬ì„  ê³„íš ê³¼ì •ì´ í›¨ì”¬ ë” ì›í™œí•˜ê²Œ ì§„í–‰ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë³´ì‹œê²Œ ë˜ê² ì§€ë§Œ, ì—°êµ¬ë“¤ì´ ì´ë¯¸ ì´ê²ƒì´ ì¥ì ì„ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ Motiva í™•ì¥ê¸°ë¥¼ ì‚½ì…í•œ í™˜ìì˜ MRI ì˜ˆì‹œì…ë‹ˆë‹¤. ìœ ë°© ì¡°ì§ì„ ê°€ë¦¬ê±°ë‚˜ ë³„ ëª¨ì–‘ íš¨ê³¼ë¥¼ ë§Œë“¤ì–´ ìœ ë°©ì„ ë³¼ ìˆ˜ ì—†ê²Œ í•˜ëŠ” ì‹ í˜¸ë¥¼ ìƒì„±í•˜ëŠ” ë¬¸ì œê°€ ì „í˜€ ì—†ìŠµë‹ˆë‹¤. ë°œí‘œì 10: ë‹¤ì‹œ ë§í•´, í° ì§„ì „ì…ë‹ˆë‹¤. ì´ê²ƒë“¤ì€ ë¯¸êµ­ì—ì„œ ì‚¬ìš©ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì € ìì‹ ë„ ì‚¬ìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This comes out of a place no less significant than MD Anderson with Doctor. Clemens, one of the article that's now been published back in 2025. Speaker 10: And one of the things that I would point out here is this right here. Because it was able to allow the radiation beam to hone in more precisely on that tissue, it went from a four centimeter window to a one centimeter window, which means that you could target that radiation much better. And it decreased the radiation to the healthy tissues by 60%. That's massive because radiation damages tissue and we've got to be able to control that to achieve good results. The other thing is a little bit hard to see, but I'll just read it for you.</td><td>ì´ëŠ” MD Andersonì˜ í´ë ˆë©˜ìŠ¤ ë°•ì‚¬ê°€ 2025ë…„ì— ë°œí‘œí•œ ë…¼ë¬¸ì—ì„œ ë‚˜ì˜¨ ê²ƒìœ¼ë¡œ, ê·¸ ì¤‘ìš”ì„±ì´ ê²°ì½” ì‘ì§€ ì•ŠìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 10: ì—¬ê¸°ì„œ ì œê°€ ì§€ì í•˜ê³  ì‹¶ì€ ê²ƒ ì¤‘ í•˜ë‚˜ëŠ” ë°”ë¡œ ì´ ë¶€ë¶„ì…ë‹ˆë‹¤. ë°©ì‚¬ì„  ë¹”ì´ í•´ë‹¹ ì¡°ì§ì— ë”ìš± ì •ë°€í•˜ê²Œ ì§‘ì¤‘í•  ìˆ˜ ìˆê²Œ ë¨ìœ¼ë¡œì¨, 4ì„¼í‹°ë¯¸í„° ë²”ìœ„ì—ì„œ 1ì„¼í‹°ë¯¸í„° ë²”ìœ„ë¡œ ì¤„ì–´ë“¤ì—ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ëŠ” ë°©ì‚¬ì„ ì„ í›¨ì”¬ ë” ì •í™•í•˜ê²Œ í‘œì í™”í•  ìˆ˜ ìˆë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê±´ê°•í•œ ì¡°ì§ì— ëŒ€í•œ ë°©ì‚¬ì„  ë…¸ì¶œì„ 60% ê°ì†Œì‹œì¼°ìŠµë‹ˆë‹¤. ì´ëŠ” ì—„ì²­ë‚œ ì„±ê³¼ì…ë‹ˆë‹¤. ë°©ì‚¬ì„ ì€ ì¡°ì§ì„ ì†ìƒì‹œí‚¤ê¸° ë•Œë¬¸ì—, ì¢‹ì€ ê²°ê³¼ë¥¼ ì–»ê¸° ìœ„í•´ì„œëŠ” ì´ë¥¼ ì œì–´í•  ìˆ˜ ìˆì–´ì•¼ í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë˜ ë‹¤ë¥¸ ë¶€ë¶„ì€ ë³´ê¸°ê°€ ì¡°ê¸ˆ ì–´ë µì§€ë§Œ, ì œê°€ ì½ì–´ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 10: There were six patients in the cohort that had the regular expanders that needed to have an MRI. They had to go back to surgery to have the expander removed because you couldn't get an MRI. Have you ever heard MRI is a very strong magnet and people have<br><br>accidentally brought an oxygen tank by the MRI and the magnetism has smashed the oxygen tank through the wall into the machine. It's extremely dangerous. So you can't get an MRI if there's magnets involved. Speaker 10: No magnet here. There were three patients in the Motiva cohort that just went ahead and had their MRI with no problem because it's MRI conditional.</td><td>ë°œí‘œì 10: ì¼ë°˜ í™•ì¥ê¸°ë¥¼ ì‚¬ìš©í•œ ì½”í˜¸íŠ¸ì—ì„œ 6ëª…ì˜ í™˜ìê°€ MRI ì´¬ì˜ì´ í•„ìš”í–ˆìŠµë‹ˆë‹¤. ì´ë“¤ì€ í™•ì¥ê¸°ë¥¼ ì œê±°í•˜ê¸° ìœ„í•´ ë‹¤ì‹œ ìˆ˜ìˆ ì„ ë°›ì•„ì•¼ í–ˆëŠ”ë°, í™•ì¥ê¸°ê°€ ìˆìœ¼ë©´ MRIë¥¼ ì´¬ì˜í•  ìˆ˜ ì—†ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. MRIëŠ” ë§¤ìš° ê°•ë ¥í•œ ìì„ì´ë¼ëŠ” ê²ƒì„ ë“¤ì–´ë³´ì…¨ì„ ê²ë‹ˆë‹¤. ì‹¤ì œë¡œ ëˆ„êµ°ê°€ê°€ ì‹¤ìˆ˜ë¡œ ì‚°ì†Œí†µì„ MRI ê·¼ì²˜ì— ê°€ì ¸ê°”ë‹¤ê°€ ìê¸°ë ¥ì— ì˜í•´ ì‚°ì†Œí†µì´ ë²½ì„ ëš«ê³  ê¸°ê³„ ì•ˆìœ¼ë¡œ ë‚ ì•„ê°„ ì‚¬ê³ ë„ ìˆì—ˆìŠµë‹ˆë‹¤. ê·¹ë„ë¡œ ìœ„í—˜í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ìì„ì´ í¬í•¨ë˜ì–´ ìˆìœ¼ë©´ MRI ì´¬ì˜ì„ í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 10: ì—¬ê¸°ì—ëŠ” ìì„ì´ ì—†ìŠµë‹ˆë‹¤. Motiva ì½”í˜¸íŠ¸ì˜ 3ëª… í™˜ìë“¤ì€ MRI ì¡°ê±´ë¶€ ìŠ¹ì¸ ì œí’ˆì´ê¸° ë•Œë¬¸ì— ì•„ë¬´ ë¬¸ì œì—†ì´ ë°”ë¡œ MRI ì´¬ì˜ì„ ì§„í–‰í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So you can get the MRI, you can get the radiation plan, huge advantages. As well, there's some basic data from these studies. One just came out today, as a matter of fact, from Austria and another one's coming out from Spain. Speaker 10: The tissue expander is performing beautifully. It's actually holding down complications. So you have less infection, less seroma, and it facilitates really streamlined use. Just to demonstrate visually so that you can see how this works, this is a lady that's going to have a bilateral mastectomy and the markings you can see on the left there, the little purple dot is where the valve is located. That has to stay up here.</td><td>ë”°ë¼ì„œ MRIë¥¼ ë°›ì„ ìˆ˜ ìˆê³ , ë°©ì‚¬ì„  ì¹˜ë£Œ ê³„íšë„ ì„¸ìš¸ ìˆ˜ ìˆì–´ ì—„ì²­ë‚œ ì¥ì ì´ ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì´ëŸ¬í•œ ì—°êµ¬ë“¤ë¡œë¶€í„° ëª‡ ê°€ì§€ ê¸°ë³¸ ë°ì´í„°ê°€ ë‚˜ì˜¤ê³  ìˆìŠµë‹ˆë‹¤. ì‚¬ì‹¤ ì˜¤ëŠ˜ ì˜¤ìŠ¤íŠ¸ë¦¬ì•„ì—ì„œ í•œ ì—°êµ¬ê°€ ë°œí‘œë˜ì—ˆê³ , ìŠ¤í˜ì¸ì—ì„œë„ ë˜ ë‹¤ë¥¸ ì—°êµ¬ê°€ ê³§ ë‚˜ì˜¬ ì˜ˆì •ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 10: ì¡°ì§ í™•ì¥ê¸°ê°€ ë§¤ìš° í›Œë¥­í•˜ê²Œ ì‘ë™í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ í•©ë³‘ì¦ì„ ì¤„ì´ê³  ìˆìŠµë‹ˆë‹¤. ê°ì—¼ì´ ì ê³ , ì¥ì•¡ì¢…ë„ ì ìœ¼ë©°, ì •ë§ ê°„ì†Œí™”ëœ ì‚¬ìš©ì„ ê°€ëŠ¥í•˜ê²Œ í•©ë‹ˆë‹¤. ì´ê²ƒì´ ì–´ë–»ê²Œ ì‘ë™í•˜ëŠ”ì§€ ì‹œê°ì ìœ¼ë¡œ ë³´ì—¬ë“œë¦¬ê¸° ìœ„í•´, ì´ ì—¬ì„±ì€ ì–‘ì¸¡ ìœ ë°©ì ˆì œìˆ ì„ ë°›ì„ ì˜ˆì •ì´ê³  ì™¼ìª½ì— ë³´ì´ëŠ” í‘œì‹œë“¤ ì¤‘ ì‘ì€ ë³´ë¼ìƒ‰ ì ì´ ë°¸ë¸Œê°€ ìœ„ì¹˜í•œ ê³³ì…ë‹ˆë‹¤. ì´ê²ƒì€ ì—¬ê¸° ìœ„ìª½ì— ìˆì–´ì•¼ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 10: That expander has to stay positioned where you want it and it can't rotate around, which is why it's got the tabs on it to hold it in place. This is the expander and that's what it looks like in the patient after she's had the mastectomy. So the skin and the nipple is preserved. There's no reason to take that. That's one of the modern approaches to breast surgery now. Speaker 10: But everything inside is gone. The breast and the fat is gone. So that expander is basically holding that space open but it's doing it with style now. There's no scar, the valve can be easily located and the expander won't rotate. All of those are big advantages.</td><td>ë°œí‘œì 10: ì´ í™•ì¥ê¸°ëŠ” ì›í•˜ëŠ” ìœ„ì¹˜ì— ê³ ì •ë˜ì–´ ìˆì–´ì•¼ í•˜ê³  íšŒì „í•˜ë©´ ì•ˆ ë˜ëŠ”ë°, ê·¸ë˜ì„œ ì œìë¦¬ì— ê³ ì •í•  ìˆ˜ ìˆë„ë¡ íƒ­ì´ ë‹¬ë ¤ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ í™•ì¥ê¸°ì´ê³ , í™˜ìê°€ ìœ ë°©ì ˆì œìˆ ì„ ë°›ì€ í›„ ì²´ë‚´ì—ì„œ ë³´ì´ëŠ” ëª¨ìŠµì…ë‹ˆë‹¤. í”¼ë¶€ì™€ ìœ ë‘ëŠ” ë³´ì¡´ë©ë‹ˆë‹¤. ì œê±°í•  ì´ìœ ê°€ ì—†ê±°ë“ ìš”. ì´ê²ƒì´ í˜„ì¬ ìœ ë°© ìˆ˜ìˆ ì˜ í˜„ëŒ€ì  ì ‘ê·¼ë²• ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 10: í•˜ì§€ë§Œ ë‚´ë¶€ì˜ ëª¨ë“  ê²ƒì€ ì œê±°ë©ë‹ˆë‹¤. ìœ ë°©ê³¼ ì§€ë°©ì´ ì‚¬ë¼ì§‘ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ í™•ì¥ê¸°ëŠ” ê¸°ë³¸ì ìœ¼ë¡œ ê·¸ ê³µê°„ì„ ì—´ì–´ë‘ëŠ” ì—­í• ì„ í•˜ì§€ë§Œ ì´ì œëŠ” ìŠ¤íƒ€ì¼ë¦¬ì‹œí•˜ê²Œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. í‰í„°ê°€ ì—†ê³ , ë°¸ë¸Œë¥¼ ì‰½ê²Œ ì°¾ì„ ìˆ˜ ìˆìœ¼ë©°, í™•ì¥ê¸°ê°€ íšŒì „í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì´ í° ì¥ì ë“¤ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 10: So this is what it looks like then after that expander has set for a bit. And the idea is that expander now just holds that space open while the soft tissue is healing. Then you can<br><br>come back, take that out, put your Motiva implant and that's your reconstruction. So that's the concept, that stage tissue expander, and things like fat grafting. So here's an example of a lady that's had a breast reconstruction. Speaker 10: And as you've heard when Nolan and I went into practice as he's going to tell you, we made bumps. I mean it wasn't anything remotely that looked like a breast. Now we can make people look better after a bilateral mastectomy than when they started.</td><td>ë°œí‘œì 10: ê·¸ë˜ì„œ í™•ì¥ê¸°ê°€ ì–´ëŠ ì •ë„ ìë¦¬ë¥¼ ì¡ì€ í›„ì˜ ëª¨ìŠµì´ ì´ë ‡ìŠµë‹ˆë‹¤. ì´ í™•ì¥ê¸°ì˜ ê°œë…ì€ ì—°ì¡°ì§ì´ ì¹˜ìœ ë˜ëŠ” ë™ì•ˆ ê·¸ ê³µê°„ì„ ì—´ì–´ë‘ëŠ” ì—­í• ì„ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ ë‹¤ìŒì— ë‹¤ì‹œ ì™€ì„œ í™•ì¥ê¸°ë¥¼ ì œê±°í•˜ê³  Motiva ì„í”Œë€íŠ¸ë¥¼ ë„£ìœ¼ë©´ ì¬ê±´ìˆ ì´ ì™„ë£Œë©ë‹ˆë‹¤. ì´ê²ƒì´ ë‹¨ê³„ì  ì¡°ì§ í™•ì¥ê¸°ì˜ ê°œë…ì´ë©°, ì§€ë°© ì´ì‹ìˆ  ê°™ì€ ê²ƒë“¤ë„ í¬í•¨ë©ë‹ˆë‹¤. ì—¬ê¸° ìœ ë°© ì¬ê±´ìˆ ì„ ë°›ì€ ì—¬ì„±ì˜ ì‚¬ë¡€ê°€ ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 10: ê·¸ë¦¬ê³  Nolanê³¼ ì œê°€ ê°œì—…í–ˆì„ ë•Œ ë“¤ìœ¼ì…¨ê² ì§€ë§Œ, ê·¸ê°€ ë§ì”€ë“œë¦´ ê²ƒì²˜ëŸ¼, ì €í¬ëŠ” ë‹¨ìˆœí•œ ëŒì¶œë¶€ë¥¼ ë§Œë“¤ì—ˆìŠµë‹ˆë‹¤. ìœ ë°©ê³¼ ì „í˜€ ë‹®ì§€ ì•Šì€ ê²ƒì´ì—ˆì£ . ì´ì œëŠ” ì–‘ì¸¡ ìœ ë°©ì ˆì œìˆ ì„ ë°›ì€ í™˜ìë“¤ì„ ìˆ˜ìˆ  ì „ë³´ë‹¤ ë” ì¢‹ì•„ ë³´ì´ê²Œ ë§Œë“¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So when you start talking about promoting women's health and making proper treatment with mastectomy acceptable, these are key elements in achieving that goal. Here's another example. Speaker 10: This lady has had a bilateral mastectomy, nipple sparing mastectomy, and she underwent tissue expander, flora tissue expander with implant, reconstruction. And she's got a very beautiful result. She looks almost like our Park Avenue, breast augmentations, that we see. So this is where we're at with, the use of the flora. I think it's a big step forward, and an important part of the portfolio for this particular company. Speaker 10: So thank you very much. Speaker 4: Thank you, Doctor. Hammond.</td><td>ì—¬ì„± ê±´ê°• ì¦ì§„ê³¼ ìœ ë°©ì ˆì œìˆ ì„ í†µí•œ ì ì ˆí•œ ì¹˜ë£Œë¥¼ ìˆ˜ìš© ê°€ëŠ¥í•˜ê²Œ ë§Œë“œëŠ” ê²ƒì— ëŒ€í•´ ì´ì•¼ê¸°í•  ë•Œ, ì´ëŸ¬í•œ ìš”ì†Œë“¤ì´ ê·¸ ëª©í‘œë¥¼ ë‹¬ì„±í•˜ëŠ” ë° í•µì‹¬ì ì…ë‹ˆë‹¤. ë‹¤ìŒì€ ë˜ ë‹¤ë¥¸ ì‚¬ë¡€ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 10: ì´ í™˜ìë¶„ì€ ì–‘ì¸¡ ìœ ë°©ì ˆì œìˆ , ìœ ë‘ë³´ì¡´ ìœ ë°©ì ˆì œìˆ ì„ ë°›ìœ¼ì…¨ê³ , ì¡°ì§ í™•ì¥ê¸°, í”Œë¡œë¼ ì¡°ì§ í™•ì¥ê¸°ì™€ ì„í”Œë€íŠ¸ë¥¼ ì´ìš©í•œ ì¬ê±´ìˆ ì„ ë°›ìœ¼ì…¨ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§¤ìš° ì•„ë¦„ë‹¤ìš´ ê²°ê³¼ë¥¼ ì–»ìœ¼ì…¨ìŠµë‹ˆë‹¤. ë§ˆì¹˜ ìš°ë¦¬ê°€ ë³´ëŠ” íŒŒí¬ ì• ë¹„ë‰´ì˜ ìœ ë°©í™•ëŒ€ìˆ ê³¼ ê°™ì€ ëª¨ìŠµì…ë‹ˆë‹¤. ì´ê²ƒì´ í”Œë¡œë¼ ì‚¬ìš©ì˜ í˜„ì¬ ìˆ˜ì¤€ì…ë‹ˆë‹¤. ì €ëŠ” ì´ê²ƒì´ í° ì§„ì „ì´ë©°, ì´ íšŒì‚¬ì˜ í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œ ì¤‘ìš”í•œ ë¶€ë¶„ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 10: ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ê°ì‚¬í•©ë‹ˆë‹¤, í•´ë¨¼ë“œ ë°•ì‚¬ë‹˜.</td></tr>
<tr><td>Doctor. Karp. Speaker 11: All right. I'm Norman Karp. I'm here in New York, and curiously, Dennis and I, we were talking about it. We started literally the exact same time, and we've gone through all the steps the exact same time, and a lot of things have happened that really have changed things. Obviously, we had to deal with the silicone moratorium, but just in terms of the breast surgery, in about 2006 or 02/07, we started doing nipple springs. Speaker 11: We started to be able to save the nipple. There was no reason to take the nipple if the breast cancer wasn't a nipple. Breast support products came in. There's been tremendous<br><br>amount of innovation in breast support products.</td><td>ë‹¥í„° ì¹´í”„ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 11: ì¢‹ìŠµë‹ˆë‹¤. ì €ëŠ” ë…¸ë¨¼ ì¹´í”„ì´ê³ , ë‰´ìš•ì— ìˆìŠµë‹ˆë‹¤. í¥ë¯¸ë¡­ê²Œë„ ë°ë‹ˆìŠ¤ì™€ ì œê°€ ì´ì•¼ê¸°í–ˆëŠ”ë°, ì €í¬ëŠ” ë§ ê·¸ëŒ€ë¡œ ì •í™•íˆ ê°™ì€ ì‹œê¸°ì— ì‹œì‘í–ˆê³ , ì •í™•íˆ ê°™ì€ ì‹œê¸°ì— ëª¨ë“  ë‹¨ê³„ë¥¼ ê±°ì³ì™”ìœ¼ë©°, ì •ë§ë¡œ ìƒí™©ì„ ë³€í™”ì‹œí‚¨ ë§ì€ ì¼ë“¤ì´ ìˆì—ˆìŠµë‹ˆë‹¤. ë¶„ëª…íˆ ì €í¬ëŠ” ì‹¤ë¦¬ì½˜ ëª¨ë¼í† ë¦¬ì›€ì„ ë‹¤ë¤„ì•¼ í–ˆì§€ë§Œ, ìœ ë°© ìˆ˜ìˆ  ì¸¡ë©´ì—ì„œ ë³´ë©´, ëŒ€ëµ 2006ë…„ì´ë‚˜ 2007ë…„ê²½ì— ì €í¬ëŠ” ìœ ë‘ ë³´ì¡´ìˆ ì„ ì‹œì‘í–ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 11: ì €í¬ëŠ” ìœ ë‘ë¥¼ ë³´ì¡´í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ìœ ë°©ì•”ì´ ìœ ë‘ì— ìˆì§€ ì•Šë‹¤ë©´ ìœ ë‘ë¥¼ ì œê±°í•  ì´ìœ ê°€ ì—†ì—ˆìŠµë‹ˆë‹¤. ìœ ë°© ì§€ì§€ ì œí’ˆë“¤ì´ ë„ì…ë˜ì—ˆìŠµë‹ˆë‹¤. ìœ ë°© ì§€ì§€ ì œí’ˆì—ì„œ ì—„ì²­ë‚œ ì–‘ì˜ í˜ì‹ ì´ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>But, curiously, there was no innovation, none, and a lot dentists touched on having to do with the moratorium, etcetera, on actually breast implants. Speaker 11: So, in the past, I used to spend a great deal of time when I talked to the patients on kind of lowering the bar, trying to set realistic expectations. This was disappointing to the patient. The patient would find out that they were going to get maybe sort of a blob or a mount that looked good in clothes, but when they woke up in the morning and looked in the mirror, it didn't look anything really like a breast.</td><td>í•˜ì§€ë§Œ í¥ë¯¸ë¡­ê²Œë„ í˜ì‹ ì€ ì „í˜€ ì—†ì—ˆìŠµë‹ˆë‹¤. ì „í˜€ìš”. ê·¸ë¦¬ê³  ë§ì€ ì¹˜ê³¼ì˜ì‚¬ë“¤ì´ ìœ ë°© ì„í”Œë€íŠ¸ì— ëŒ€í•œ ëª¨ë¼í† ë¦¬ì—„ ë“±ê³¼ ê´€ë ¨í•´ì„œ ì–¸ê¸‰í–ˆë˜ ë¶€ë¶„ë“¤ì´ ìˆì—ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 11: ê³¼ê±°ì—ëŠ” í™˜ìë“¤ê³¼ ëŒ€í™”í•  ë•Œ ê¸°ëŒ€ì¹˜ë¥¼ ë‚®ì¶”ê³  í˜„ì‹¤ì ì¸ ê¸°ëŒ€ë¥¼ ê°–ë„ë¡ í•˜ëŠ” ë° ìƒë‹¹í•œ ì‹œê°„ì„ í• ì• í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” í™˜ìë“¤ì—ê²Œ ì‹¤ë§ìŠ¤ëŸ¬ìš´ ì¼ì´ì—ˆìŠµë‹ˆë‹¤. í™˜ìë“¤ì€ ì˜·ì„ ì…ì—ˆì„ ë•ŒëŠ” ê´œì°®ì•„ ë³´ì´ì§€ë§Œ, ì•„ì¹¨ì— ì¼ì–´ë‚˜ì„œ ê±°ìš¸ì„ ë³´ë©´ ì‹¤ì œ ìœ ë°©ê³¼ëŠ” ì „í˜€ ë‹¤ë¥´ê²Œ ë³´ì´ëŠ” ê·¸ì € ë©ì–´ë¦¬ë‚˜ ë´‰ê¸‹í•œ ëª¨ì–‘ ì •ë„ë¥¼ ì–»ê²Œ ë  ê²ƒì´ë¼ëŠ” ì‚¬ì‹¤ì„ ì•Œê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>More recently, when we've had all these innovations, again, not in the implants, but in the technique of doing surgery nipple sparing, breast support products, can do the reconstruction a lot of times actually in one stage, sometimes without<br>even using a tissue expander, all these things happen. I started saying to myself, Is it realistic for me to make my reconstructive breast surgery goals and expectations the same as the aesthetic? Speaker 11: And the patients actually expect that. When the patients are thinking about a breast implant, they're looking at magazines and they're seeing the Kylie Jenner. I mean, this is what they see, and we are plastic surgeons.</td><td>ìµœê·¼ì— ì´ëŸ¬í•œ ëª¨ë“  í˜ì‹ ë“¤ì´ ìˆì—ˆëŠ”ë°, ë‹¤ì‹œ ë§í•˜ì§€ë§Œ ì„í”Œë€íŠ¸ ìì²´ì˜ í˜ì‹ ì´ ì•„ë‹ˆë¼ ìˆ˜ìˆ  ê¸°ë²•ì˜ í˜ì‹ ì…ë‹ˆë‹¤. ìœ ë‘ ë³´ì¡´ìˆ , ìœ ë°© ì§€ì§€ ì œí’ˆë“¤ì„ í†µí•´ ë§ì€ ê²½ìš° ì‹¤ì œë¡œ í•œ ë²ˆì˜ ìˆ˜ìˆ ë¡œ ì¬ê±´ìˆ ì„ ì™„ë£Œí•  ìˆ˜ ìˆê³ , ë•Œë¡œëŠ” ì¡°ì§ í™•ì¥ê¸°ë¥¼ ì‚¬ìš©í•˜ì§€ ì•Šê³ ë„ ê°€ëŠ¥í•©ë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒë“¤ì´ ê°€ëŠ¥í•´ì§€ë©´ì„œ ì €ëŠ” ìŠ¤ìŠ¤ë¡œì—ê²Œ ë¬»ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ì¬ê±´ ìœ ë°© ìˆ˜ìˆ ì˜ ëª©í‘œì™€ ê¸°ëŒ€ì¹˜ë¥¼ ë¯¸ìš© ìˆ˜ìˆ ê³¼ ë™ì¼í•˜ê²Œ ì„¤ì •í•˜ëŠ” ê²ƒì´ í˜„ì‹¤ì ì¼ê¹Œìš”?<br><br>ë°œí‘œì 11: ê·¸ë¦¬ê³  í™˜ìë“¤ë„ ì‹¤ì œë¡œ ê·¸ê²ƒì„ ê¸°ëŒ€í•©ë‹ˆë‹¤. í™˜ìë“¤ì´ ìœ ë°© ì„í”Œë€íŠ¸ë¥¼ ìƒê°í•  ë•Œ, ê·¸ë“¤ì€ ì¡ì§€ë¥¼ ë³´ê³  ì¹´ì¼ë¦¬ ì œë„ˆ ê°™ì€ ëª¨ìŠµì„ ë´…ë‹ˆë‹¤. ì´ê²ƒì´ ê·¸ë“¤ì´ ë³´ëŠ” ê²ƒì´ê³ , ìš°ë¦¬ëŠ” ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Ultimately, we want to get the best results for our patients, so which is reconstructive and which is aesthetic? So the goal now, it's not even been 2025, it was even before 2025, but it's become more realistic now, is can we make the reconstructive breast as good or better than the native breasts, as Dennis has shown you in some of his case. Speaker 11: The problem is breast implant technology has not kept up with the patient and marketing expectations. Our implants haven't changed in thirty years, and we're now doing above the muscle reconstruction.</td><td>ê¶ê·¹ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” í™˜ìë“¤ì—ê²Œ ìµœìƒì˜ ê²°ê³¼ë¥¼ ì œê³µí•˜ê³ ì í•˜ë©°, ê·¸ë ‡ë‹¤ë©´ ì¬ê±´ìˆ ê³¼ ë¯¸ìš©ìˆ  ì¤‘ ì–´ëŠ ê²ƒì´ ë” ë‚˜ì€ê°€ìš”? ë”°ë¼ì„œ í˜„ì¬ì˜ ëª©í‘œëŠ” - 2025ë…„ì´ ë˜ê¸° ì „ë¶€í„°ì˜€ì§€ë§Œ, ì§€ê¸ˆì€ ë”ìš± í˜„ì‹¤ì ì´ ë˜ì—ˆìŠµë‹ˆë‹¤ - ë°ë‹ˆìŠ¤ê°€ ê·¸ì˜ ì¼ë¶€ ì‚¬ë¡€ì—ì„œ ë³´ì—¬ì¤€ ê²ƒì²˜ëŸ¼ ì¬ê±´ ìœ ë°©ì„ ìì—° ìœ ë°©ë§Œí¼ ì¢‹ê²Œ ë˜ëŠ” ë” ì¢‹ê²Œ ë§Œë“¤ ìˆ˜ ìˆëŠ”ê°€ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 11: ë¬¸ì œëŠ” ìœ ë°© ì„í”Œë€íŠ¸ ê¸°ìˆ ì´ í™˜ìì™€ ë§ˆì¼€íŒ… ê¸°ëŒ€ì¹˜ë¥¼ ë”°ë¼ê°€ì§€ ëª»í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ì˜ ì„í”Œë€íŠ¸ëŠ” 30ë…„ê°„ ë³€í™”ê°€ ì—†ì—ˆìœ¼ë©°, í˜„ì¬ ìš°ë¦¬ëŠ” ê·¼ìœ¡ ìœ„ ì¬ê±´ìˆ ì„ ì‹œí–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Well, above the muscle reconstruction is a little bit harder than breast augmentation because in breast augmentation, you still have the breast above the<br><br>muscle. So you have skin, you have breast, an implant, and then the muscle. In breast reconstruction, you basically just have the skin and then the implant, so what kind of implant you have actually really matters? Speaker 11: An implant that doesn't ripple, an implant that retains its shape really matters. Why are we interested in Motiva Implants? They feel more natural. So when I started in this study, I saw the Motiva Implant in 2017. Was at a meeting in Korea, and it was unrelated to breast implants.</td><td>ê·¼ìœ¡ ìœ„ ì¬ê±´ìˆ ì€ ìœ ë°© í™•ëŒ€ìˆ ë³´ë‹¤ ì¡°ê¸ˆ ë” ì–´ë µìŠµë‹ˆë‹¤. ìœ ë°© í™•ëŒ€ìˆ ì˜ ê²½ìš°ì—ëŠ” ê·¼ìœ¡ ìœ„ì— ì—¬ì „íˆ ìœ ë°© ì¡°ì§ì´ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì¦‰, í”¼ë¶€, ìœ ë°© ì¡°ì§, ì„í”Œë€íŠ¸, ê·¸ë¦¬ê³  ê·¼ìœ¡ ìˆœìœ¼ë¡œ êµ¬ì„±ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë°˜ë©´ ìœ ë°© ì¬ê±´ìˆ ì—ì„œëŠ” ê¸°ë³¸ì ìœ¼ë¡œ í”¼ë¶€ì™€ ì„í”Œë€íŠ¸ë§Œ ìˆê¸° ë•Œë¬¸ì—, ì–´ë–¤ ì¢…ë¥˜ì˜ ì„í”Œë€íŠ¸ë¥¼ ì‚¬ìš©í•˜ëŠ”ì§€ê°€ ì‹¤ì œë¡œ ë§¤ìš° ì¤‘ìš”í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 11: ì£¼ë¦„ì´ ìƒê¸°ì§€ ì•Šê³  ëª¨ì–‘ì„ ìœ ì§€í•˜ëŠ” ì„í”Œë€íŠ¸ê°€ ì •ë§ ì¤‘ìš”í•©ë‹ˆë‹¤. ì €í¬ê°€ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ì— ê´€ì‹¬ì„ ê°–ëŠ” ì´ìœ ëŠ” ë¬´ì—‡ì¼ê¹Œìš”? ë” ìì—°ìŠ¤ëŸ½ê²Œ ëŠê»´ì§€ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì œê°€ ì´ ì—°êµ¬ë¥¼ ì‹œì‘í–ˆì„ ë•Œ, 2017ë…„ì— ëª¨í‹°ë°” ì„í”Œë€íŠ¸ë¥¼ ì²˜ìŒ ë³´ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. í•œêµ­ì—ì„œ ì—´ë¦° í•™íšŒì—ì„œì˜€ëŠ”ë°, ìœ ë°© ì„í”Œë€íŠ¸ì™€ëŠ” ê´€ë ¨ì´ ì—†ëŠ” íšŒì˜ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 11: It was actually a microsurgical meeting, and there was the Motiva, you know, wrap at a table, and I felt the implants. I'm like, oh my god. These are great. When are we gonna get these in America? I actually went to somebody's office and watched him do five breast augmentations using Motiva Implants, and I was kind of completely hooked on it, but I was just, how can I get involved in this? Speaker 11: So when I enrolled patients, it was super easy to enroll the patients.</td><td>ë°œí‘œì 11: ì‹¤ì œë¡œ ë¯¸ì„¸ìˆ˜ìˆ  íšŒì˜ì˜€ëŠ”ë°, í…Œì´ë¸”ì— Motiva ì œí’ˆë“¤ì´ ì „ì‹œë˜ì–´ ìˆì—ˆê³ , ì €ëŠ” ì„í”Œë€íŠ¸ë¥¼ ì§ì ‘ ë§Œì ¸ë´¤ìŠµë‹ˆë‹¤. ì •ë§ ë†€ë¼ì› ì–´ìš”. ì´ ì œí’ˆë“¤ì´ ì–¸ì œ ë¯¸êµ­ì— ì¶œì‹œë ê¹Œìš”? ì‹¤ì œë¡œ ì–´ë–¤ ë¶„ì˜ ë³‘ì›ì— ê°€ì„œ Motiva ì„í”Œë€íŠ¸ë¥¼ ì‚¬ìš©í•œ ìœ ë°©í™•ëŒ€ìˆ  5ê±´ì„ ì§€ì¼œë´¤ëŠ”ë°, ì™„ì „íˆ ë§¤ë£Œë˜ì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì–´ë–»ê²Œ ì´ ì‚¬ì—…ì— ì°¸ì—¬í•  ìˆ˜ ìˆì„ì§€ ê¶ê¸ˆí–ˆìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 11: í™˜ì ë“±ë¡ì„ ì§„í–‰í•  ë•ŒëŠ” í™˜ìë“¤ì„ ë“±ë¡í•˜ëŠ” ê²ƒì´ ë§¤ìš° ì‰¬ì› ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I just literally sat the patient down, said close your eyes, I put one of the reconstructive implants that we always used and a Motiva implant, one on one hand and one on the other hand, I just said which implant would you like in your body for the next twenty or so years? Ninety five percent<br>of them picked a Motiva implant, and every single one of them wanted to in the study. I've never been in a study where it was so easy to enroll patients. Just said, Give me the paperwork, I want to enroll. Speaker 11: And we're like, Well, you know, it's an FDA study, have to do a little more than that.</td><td>ì €ëŠ” ê·¸ëƒ¥ í™˜ìë¥¼ ì•‰íˆê³  ëˆˆì„ ê°ìœ¼ë¼ê³  í•œ ë‹¤ìŒ, ì €í¬ê°€ í•­ìƒ ì‚¬ìš©í•˜ë˜ ì¬ê±´ìš© ì„í”Œë€íŠ¸ í•˜ë‚˜ì™€ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ í•˜ë‚˜ë¥¼ ê°ê° í•œ ì†ì— í•˜ë‚˜ì”© ë“¤ê³ , "ì•ìœ¼ë¡œ 20ë…„ ì •ë„ ë‹¹ì‹ ì˜ ëª¸ì— ë„£ì„ ì„í”Œë€íŠ¸ë¡œ ì–´ëŠ ê²ƒì„ ì„ íƒí•˜ì‹œê² ìŠµë‹ˆê¹Œ?"ë¼ê³  ë¬¼ì—ˆìŠµë‹ˆë‹¤. 95%ê°€ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ë¥¼ ì„ íƒí–ˆê³ , ëª¨ë“  í™˜ìê°€ ì—°êµ¬ì— ì°¸ì—¬í•˜ê¸°ë¥¼ ì›í–ˆìŠµë‹ˆë‹¤. í™˜ì ë“±ë¡ì´ ì´ë ‡ê²Œ ì‰¬ìš´ ì—°êµ¬ëŠ” ì²˜ìŒì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ëƒ¥ "ì„œë¥˜ ì£¼ì„¸ìš”, ë“±ë¡í•˜ê³  ì‹¶ì–´ìš”"ë¼ê³  í–ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 11: ì €í¬ëŠ” "ìŒ, ì´ê±´ FDA ì—°êµ¬ë¼ì„œ ê·¸ê²ƒë³´ë‹¤ëŠ” ì¢€ ë” í•´ì•¼ í•  ê²Œ ìˆìŠµë‹ˆë‹¤"ë¼ê³  í–ˆì£ .</td></tr>
<tr><td>So besides feeling better, the Motiva Implants ripple less, very rare capsular contraction, I'm not going to go into capsular contraction that much, but scarring around the breast implant, hardening around the breast implant, this is your body saying, hey, this is a foreign body, I'm<br><br>going to make scar around this implant, almost never happens with Motiva implants, whereas with the other implants, you can dispute the data, but it's at least ten or fifteen percent of the time, and it's a big headache when it happens. And in addition, for whatever reason, I've been doing this for we've started this right at COVID in May of twenty twenty, I've not seen a single rupture in a Motiva implant.</td><td>ê·¸ë˜ì„œ ëŠë‚Œì´ ë” ì¢‹ì„ ë¿ë§Œ ì•„ë‹ˆë¼, ëª¨í‹°ë°” ì„í”Œë€íŠ¸ëŠ” ì£¼ë¦„ì´ ëœ ìƒê¸°ê³ , í”¼ë§‰ êµ¬ì¶•ì´ ë§¤ìš° ë“œë­…ë‹ˆë‹¤. í”¼ë§‰ êµ¬ì¶•ì— ëŒ€í•´ì„œëŠ” ìì„¸íˆ ì„¤ëª…í•˜ì§€ ì•Šê² ì§€ë§Œ, ìœ ë°© ì„í”Œë€íŠ¸ ì£¼ë³€ì˜ í‰í„° í˜•ì„±, ì¦‰ ìœ ë°© ì„í”Œë€íŠ¸ ì£¼ë³€ì´ ë”±ë”±í•´ì§€ëŠ” í˜„ìƒì¸ë°, ì´ëŠ” ì‹ ì²´ê°€ 'ì´ê²ƒì€ ì´ë¬¼ì§ˆì´ë‹¤, ì´ ì„í”Œë€íŠ¸ ì£¼ë³€ì— í‰í„°ë¥¼ ë§Œë“¤ê² ë‹¤'ê³  ë°˜ì‘í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ëª¨í‹°ë°” ì„í”Œë€íŠ¸ì—ì„œëŠ” ê±°ì˜ ë°œìƒí•˜ì§€ ì•ŠëŠ” ë°˜ë©´, ë‹¤ë¥¸ ì„í”Œë€íŠ¸ë“¤ì˜ ê²½ìš° ë°ì´í„°ì— ëŒ€í•´ ì´ê²¬ì´ ìˆì„ ìˆ˜ ìˆì§€ë§Œ ìµœì†Œ 10~15%ì˜ í™•ë¥ ë¡œ ë°œìƒí•˜ë©°, ì´ëŸ° ì¼ì´ ìƒê¸°ë©´ ì •ë§ ê³¨ì¹˜ ì•„í”ˆ ë¬¸ì œê°€ ë©ë‹ˆë‹¤. ë˜í•œ ì–´ë–¤ ì´ìœ ì—ì„œì¸ì§€, ì €í¬ê°€ 2020ë…„ 5ì›” ì½”ë¡œë‚˜ ì‹œê¸°ì— ì´ ì‹œìˆ ì„ ì‹œì‘í•œ ì´ë˜ë¡œ ì§€ê¸ˆê¹Œì§€ í•´ì˜¤ê³  ìˆëŠ”ë°, ëª¨í‹°ë°” ì„í”Œë€íŠ¸ì—ì„œ íŒŒì—´ ì‚¬ë¡€ë¥¼ ë‹¨ í•œ ê±´ë„ ë³¸ ì ì´ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We're still early, five years is still early, but we haven't seen a single rupture. So our market, I think this has been touched on by some of the other people, about one hundred thousand cases a year, eighty five percent are implant based. Speaker 11: Some patients are gonna get two implants. They're gonna get tissue expanders, dentist, then an implant. It's concentrated in high volume centers, and so it's a little bit different. Like, if we decide we're going to, you know, if Motiva's approved, and I expect if they are, they will be approved, because they're already approved for the cosmetic cases.</td><td>ì•„ì§ ì´ˆê¸° ë‹¨ê³„ì…ë‹ˆë‹¤. 5ë…„ì€ ì—¬ì „íˆ ì´ˆê¸°ì´ì§€ë§Œ, ë‹¨ í•œ ê±´ì˜ íŒŒì—´ë„ ë°œìƒí•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ ì‹œì¥ì€, ë‹¤ë¥¸ ë¶„ë“¤ë„ ì–¸ê¸‰í•˜ì…¨ì§€ë§Œ, ì—°ê°„ ì•½ 10ë§Œ ê±´ì´ë©°, 85%ê°€ ì„í”Œë€íŠ¸ ê¸°ë°˜ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 11: ì¼ë¶€ í™˜ìë“¤ì€ ë‘ ê°œì˜ ì„í”Œë€íŠ¸ë¥¼ ë°›ê²Œ ë©ë‹ˆë‹¤. ì¡°ì§ í™•ì¥ê¸°ë¥¼ ë¨¼ì € ë°›ê³ , ê·¸ ë‹¤ìŒì— ì„í”Œë€íŠ¸ë¥¼ ë°›ê²Œ ë˜ì£ . ì´ëŠ” ëŒ€ìš©ëŸ‰ ì„¼í„°ì— ì§‘ì¤‘ë˜ì–´ ìˆì–´ì„œ ì¡°ê¸ˆ ë‹¤ë¦…ë‹ˆë‹¤. ë§Œì•½ ìš°ë¦¬ê°€ ê²°ì •í•œë‹¤ë©´, ì¦‰ Motivaê°€ ìŠ¹ì¸ëœë‹¤ë©´ - ê·¸ë¦¬ê³  ì €ëŠ” ìŠ¹ì¸ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ë¯¸ ë¯¸ìš© ì¼€ì´ìŠ¤ì— ëŒ€í•´ì„œëŠ” ìŠ¹ì¸ì„ ë°›ì•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>The reconstructive cases where, I I hate to say it, but you actually need them much more, will get approved. Speaker 11: Like, our institution will switch pretty much overnight. So here's just some sample cases. This is a 41 year old right breast cancer. This was actually still done in the sub pectoral position. This is a round, full profile Motiva implant. Speaker 11: Post op result on the right, one could argue that she actually looks better than she did preoperative. Another patient, a little more challenging, bigger patient.</td><td>ì¬ê±´ ìˆ˜ìˆ  ì¼€ì´ìŠ¤ë“¤ì˜ ê²½ìš°, ë§í•˜ê¸° ì‹«ì§€ë§Œ ì‹¤ì œë¡œ í›¨ì”¬ ë” í•„ìš”í•œ ê²½ìš°ë“¤ì´ ìŠ¹ì¸ì„ ë°›ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 11: ì €í¬ ê¸°ê´€ì€ ê±°ì˜ í•˜ë£»ë°¤ ì‚¬ì´ì— ì „í™˜í•  ê²ƒì…ë‹ˆë‹¤. ì—¬ê¸° ëª‡ ê°€ì§€ ìƒ˜í”Œ ì¼€ì´ìŠ¤ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ 41ì„¸ ìš°ì¸¡ ìœ ë°©ì•” í™˜ìì…ë‹ˆë‹¤. ì´ ì¼€ì´ìŠ¤ëŠ” ì‹¤ì œë¡œ ì—¬ì „íˆ ëŒ€í‰ê·¼í•˜ ìœ„ì¹˜ì—ì„œ ì‹œí–‰ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ ë‘¥ê·¼ í˜•íƒœì˜ í’€ í”„ë¡œíŒŒì¼ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 11: ìš°ì¸¡ì˜ ìˆ˜ìˆ  í›„ ê²°ê³¼ë¥¼ ë³´ë©´, ì‹¤ì œë¡œ ìˆ˜ìˆ  ì „ë³´ë‹¤ ë” ì¢‹ì•„ ë³´ì¸ë‹¤ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜ ë‹¤ë¥¸ í™˜ìëŠ” ì¡°ê¸ˆ ë” ê¹Œë‹¤ë¡œìš´ ì¼€ì´ìŠ¤ë¡œ, ì²´êµ¬ê°€ ë” í° í™˜ìì…ë‹ˆë‹¤.</td></tr>
<tr><td>Again, this is prepectral, so this is now above the muscle, pre op and post op, and this is a slightly complicated case, somebody with a mutation, kind of big breast, double triple D, not really a good candidate for nipple sparing. We did a breast reduction and then a direct implant, one stage implant reconstruction, no tissue expander with the ergonomics Motiva five fifty. So we've done, I've done sixty cases of breast reconstruction Motiva implants, longest follow-up now, probably about fifty four months, probably a little longer than that. Speaker 11: We've had no complications related to implants themselves.</td><td>ë‹¤ì‹œ ë§ì”€ë“œë¦¬ë©´, ì´ê²ƒì€ ëŒ€í‰ê·¼ ì „ë°© ì‚½ì…ìˆ ë¡œ, ê·¼ìœ¡ ìœ„ìª½ì— ìœ„ì¹˜í•˜ë©°, ìˆ˜ìˆ  ì „í›„ ìƒíƒœì…ë‹ˆë‹¤. ì´ëŠ” ë‹¤ì†Œ ë³µì¡í•œ ì¼€ì´ìŠ¤ë¡œ, ëŒì—°ë³€ì´ê°€ ìˆê³  ìƒë‹¹íˆ í° ìœ ë°©(ë”ë¸” íŠ¸ë¦¬í”Œ D ì‚¬ì´ì¦ˆ)ì„ ê°€ì§„ í™˜ìë¡œì„œ ìœ ë‘ ë³´ì¡´ìˆ ì—ëŠ” ì í•©í•˜ì§€ ì•Šì€ ê²½ìš°ì˜€ìŠµë‹ˆë‹¤. ìœ ë°© ì¶•ì†Œìˆ ì„ ì‹œí–‰í•œ í›„ ì¡°ì§ í™•ì¥ê¸° ì—†ì´ ëª¨í‹°ë°” 550 ì—ë¥´ê³ ë…¸ë¯¹ìŠ¤ë¥¼ ì‚¬ìš©í•˜ì—¬ 1ë‹¨ê³„ ì§ì ‘ ì„í”Œë€íŠ¸ ì¬ê±´ìˆ ì„ ì‹¤ì‹œí–ˆìŠµë‹ˆë‹¤. <br><br>ì €ëŠ” ëª¨í‹°ë°” ì„í”Œë€íŠ¸ë¥¼ ì´ìš©í•œ ìœ ë°© ì¬ê±´ìˆ ì„ 60ë¡€ ì‹œí–‰í–ˆìœ¼ë©°, í˜„ì¬ ê°€ì¥ ê¸´ ì¶”ì ê´€ì°° ê¸°ê°„ì€ ì•½ 54ê°œì›”, ì•„ë§ˆë„ ê·¸ë³´ë‹¤ ì¡°ê¸ˆ ë” ê¸¸ ê²ƒì…ë‹ˆë‹¤.<br><br>**ë°œí‘œì 11:** ì„í”Œë€íŠ¸ ìì²´ì™€ ê´€ë ¨ëœ í•©ë³‘ì¦ì€ ì „í˜€ ë°œìƒí•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our complication profile overall for the patients was what we see in breast reconstruction. What we mean by that is you might have complications from the mastectomy or from other components of the operation, but we haven't had complications related to implant. Patient satisfaction, super high, and there were no cases of revision surgery related to pain or discomfort attributed to the implants. My only regret with this study is that unfortunately it ended and, know, we expanded, we started with 30, then went to 50, then went to 60 and then the FDA said, no, you can't let them do any more implants because that's the maximum percentage we can get out of one institution.</td><td>ì „ì²´ì ìœ¼ë¡œ í™˜ìë“¤ì˜ í•©ë³‘ì¦ í”„ë¡œíŒŒì¼ì€ ìœ ë°©ì¬ê±´ìˆ ì—ì„œ ë³´ëŠ” ê²ƒê³¼ ë™ì¼í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì˜ë¯¸í•˜ëŠ” ë°”ëŠ” ìœ ë°©ì ˆì œìˆ ì´ë‚˜ ìˆ˜ìˆ ì˜ ë‹¤ë¥¸ êµ¬ì„±ìš”ì†Œë¡œ ì¸í•œ í•©ë³‘ì¦ì€ ìˆì„ ìˆ˜ ìˆì§€ë§Œ, ì„í”Œë€íŠ¸ì™€ ê´€ë ¨ëœ í•©ë³‘ì¦ì€ ì—†ì—ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. í™˜ì ë§Œì¡±ë„ëŠ” ë§¤ìš° ë†’ì•˜ê³ , ì„í”Œë€íŠ¸ë¡œ ì¸í•œ í†µì¦ì´ë‚˜ ë¶ˆí¸í•¨ê³¼ ê´€ë ¨í•˜ì—¬ ì¬ìˆ˜ìˆ ì„ ë°›ì€ ì‚¬ë¡€ëŠ” ì—†ì—ˆìŠµë‹ˆë‹¤. ì´ ì—°êµ¬ì—ì„œ ì œê°€ ìœ ì¼í•˜ê²Œ ì•„ì‰¬ì›Œí•˜ëŠ” ì ì€ ì•ˆíƒ€ê¹ê²Œë„ ì—°êµ¬ê°€ ì¢…ë£Œë˜ì—ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì €í¬ëŠ” í™•ëŒ€í•´ ë‚˜ê°”ëŠ”ë°, ì²˜ìŒì—ëŠ” 30ëª…ìœ¼ë¡œ ì‹œì‘í•´ì„œ 50ëª…, ê·¸ë‹¤ìŒ 60ëª…ìœ¼ë¡œ ëŠ˜ë ¤ê°”ì§€ë§Œ, FDAì—ì„œ í•œ ê¸°ê´€ì—ì„œ ì–»ì„ ìˆ˜ ìˆëŠ” ìµœëŒ€ ë¹„ìœ¨ì´ê¸° ë•Œë¬¸ì— ë” ì´ìƒ ì„í”Œë€íŠ¸ ì‹œìˆ ì„ í•  ìˆ˜ ì—†ë‹¤ê³  í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 11: So I was just very sad. The minute this ended and I had patients I couldn't offer the Motiva implant to, it was kind of a little bit of a bummer, but that's about it. Thank you. Speaker 4: Thank you, Doctor. Karp. Is this, okay. Question for Doctor. Hammond, and please keep any questions coming. Speaker 4: Malvika has a mic over here. But regarding MRI compatible tissue expanders, why would you not use an MRI compatible tissue expander? And what do you think the market does long term in adopting this technology? Speaker 10: Well, would always use an MRI compatible tissue expander at this point because it's an option. Before the floor, it wasn't.</td><td>ë°œí‘œì 11: ê·¸ë˜ì„œ ì €ëŠ” ì •ë§ ìŠ¬íìŠµë‹ˆë‹¤. ì´ê²ƒì´ ëë‚˜ëŠ” ìˆœê°„ ì œê°€ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ë¥¼ ì œê³µí•  ìˆ˜ ì—†ëŠ” í™˜ìë“¤ì´ ìˆì—ˆëŠ”ë°, ì¡°ê¸ˆ ì‹¤ë§ìŠ¤ëŸ¬ì› ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ê·¸ê²Œ ì „ë¶€ì…ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ê°ì‚¬í•©ë‹ˆë‹¤, ì¹´í”„ ë°•ì‚¬ë‹˜. ì´ì œ í•´ë¨¼ë“œ ë°•ì‚¬ë‹˜ê»˜ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê³„ì†í•´ì„œ ì§ˆë¬¸í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ë§ë¹„ì¹´ê°€ ì—¬ê¸° ë§ˆì´í¬ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. MRI í˜¸í™˜ ì¡°ì§ í™•ì¥ê¸°ì— ê´€í•´ì„œì¸ë°, MRI í˜¸í™˜ ì¡°ì§ í™•ì¥ê¸°ë¥¼ ì‚¬ìš©í•˜ì§€ ì•Šì„ ì´ìœ ê°€ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ì´ ê¸°ìˆ ì„ ì±„íƒí•˜ëŠ” ë° ìˆì–´ ì¥ê¸°ì ìœ¼ë¡œ ì‹œì¥ì´ ì–´ë–»ê²Œ ë  ê²ƒì´ë¼ê³  ìƒê°í•˜ì‹œë‚˜ìš”?<br><br>ë°œí‘œì 10: ìŒ, ì´ ì‹œì ì—ì„œëŠ” í•­ìƒ MRI í˜¸í™˜ ì¡°ì§ í™•ì¥ê¸°ë¥¼ ì‚¬ìš©í•  ê²ƒì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ì œ ì„ íƒ ì˜µì…˜ì´ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. í”Œë¡œì–´ ì´ì „ì—ëŠ” ê·¸ëŸ° ì˜µì…˜ì´ ì—†ì—ˆê±°ë“ ìš”.</td></tr>
<tr><td>That wasn't even on anybody's radar screen, actually, to try to do that. You can get by with it, but like the study showed, there were several patients that literally had to go back to surgery to have their expanders removed in order to allow proper screening. The way that would happen is, say, a patient comes back after the operation and they're having double vision or they're dizzy and you're concerned about whether or they're brain metastasis. Speaker 10: Well, that's way, way, way more important than having your expander. So you've got to have your expander out in order to evaluate for that. That's kind of the medical bit that goes with that.</td><td>ì‚¬ì‹¤ ê·¸ëŸ° ì‹œë„ëŠ” ì•„ë¬´ë„ ê³ ë ¤í•˜ì§€ ì•Šì•˜ë˜ ì‚¬ì•ˆì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ëƒ¥ ë„˜ì–´ê°ˆ ìˆ˜ë„ ìˆì§€ë§Œ, ì—°êµ¬ ê²°ê³¼ì—ì„œ ë³´ë“¯ì´ ì ì ˆí•œ ìŠ¤í¬ë¦¬ë‹ì„ ìœ„í•´ í™•ì¥ê¸°ë¥¼ ì œê±°í•˜ëŠ” ìˆ˜ìˆ ì„ ë‹¤ì‹œ ë°›ì•„ì•¼ í–ˆë˜ í™˜ìë“¤ì´ ì—¬ëŸ¬ ëª… ìˆì—ˆìŠµë‹ˆë‹¤. ì´ëŸ° ìƒí™©ì´ ë°œìƒí•˜ëŠ” ê²½ìš°ëŠ”, ì˜ˆë¥¼ ë“¤ì–´ ìˆ˜ìˆ  í›„ í™˜ìê°€ ë³µì‹œë‚˜ ì–´ì§€ëŸ¼ì¦ì„ í˜¸ì†Œí•˜ë©° ëŒì•„ì™”ì„ ë•Œ ë‡Œì „ì´ ì—¬ë¶€ë¥¼ í™•ì¸í•´ì•¼ í•˜ëŠ” ìƒí™©ì…ë‹ˆë‹¤.<br><br>í™”ì 10: ê·¸ëŸ° ê²½ìš°ì—ëŠ” í™•ì¥ê¸°ë¥¼ ìœ ì§€í•˜ëŠ” ê²ƒë³´ë‹¤ í›¨ì”¬, í›¨ì”¬, í›¨ì”¬ ë” ì¤‘ìš”í•œ ë¬¸ì œì…ë‹ˆë‹¤. ë”°ë¼ì„œ ê·¸ëŸ° í‰ê°€ë¥¼ ìœ„í•´ì„œëŠ” í™•ì¥ê¸°ë¥¼ ì œê±°í•´ì•¼ í•©ë‹ˆë‹¤. ì´ê²ƒì´ ê·¸ì™€ ê´€ë ¨ëœ ì˜í•™ì  ì¸¡ë©´ì…ë‹ˆë‹¤.</td></tr>
<tr><td>So I would always use a MRI compatible expander if I had it available to me, and I do. Speaker 4: Doctor. Karp, a question for you. You mentioned the demands of the reconstructive patient expecting better or at least as good a breast after surgery. What role do recon patients have in selecting their implants, not just with you but with other and this could be a question<br>for you to follow-up on as well, Doctor. Hammond, but what role do patients generally have in that selection process? Speaker 11: It's the same thing as the augmentation patients. Prior to the Motiva Implants, the patients rarely ask sometimes they would ask, but rarely ask which company's implants.</td><td>ë‹¤ìŒì€ í•´ë‹¹ ìˆ˜ìµ ë°œí‘œ ì „í™”íšŒì˜ ë‚´ìš©ì„ í•œêµ­ì–´ë¡œ ë²ˆì—­í•œ ê²ƒì…ë‹ˆë‹¤:<br><br>ë”°ë¼ì„œ ì €ëŠ” MRI í˜¸í™˜ í™•ì¥ê¸°ë¥¼ ì‚¬ìš©í•  ìˆ˜ ìˆë‹¤ë©´ í•­ìƒ ê·¸ê²ƒì„ ì‚¬ìš©í•  ê²ƒì´ë©°, ì‹¤ì œë¡œ ê·¸ë ‡ê²Œ í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 4: ì¹´í”„ ë°•ì‚¬ë‹˜, ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. ì¬ê±´ í™˜ìë“¤ì´ ìˆ˜ìˆ  í›„ ë” ì¢‹ê±°ë‚˜ ìµœì†Œí•œ ê¸°ì¡´ê³¼ ê°™ì€ ìˆ˜ì¤€ì˜ ìœ ë°©ì„ ê¸°ëŒ€í•œë‹¤ê³  ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. ì¬ê±´ í™˜ìë“¤ì´ ì„í”Œë€íŠ¸ë¥¼ ì„ íƒí•˜ëŠ” ê³¼ì •ì—ì„œ ì–´ë–¤ ì—­í• ì„ í•˜ëŠ”ì§€, ë°•ì‚¬ë‹˜ë¿ë§Œ ì•„ë‹ˆë¼ ë‹¤ë¥¸ ì˜ì‚¬ë“¤ê³¼ë„ ê´€ë ¨ëœ ì§ˆë¬¸ì¸ë°ìš”. í•´ë¨¼ë“œ ë°•ì‚¬ë‹˜ê»˜ì„œë„ í›„ì† ë‹µë³€ì„ í•´ì£¼ì‹¤ ìˆ˜ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤ë§Œ, ì¼ë°˜ì ìœ¼ë¡œ í™˜ìë“¤ì´ ê·¸ ì„ íƒ ê³¼ì •ì—ì„œ ì–´ë–¤ ì—­í• ì„ í•˜ë‚˜ìš”?<br><br>ë°œí‘œì 11: í™•ëŒ€ìˆ  í™˜ìë“¤ê³¼ ë™ì¼í•©ë‹ˆë‹¤. ëª¨í‹°ë°” ì„í”Œë€íŠ¸ ì´ì „ì—ëŠ” í™˜ìë“¤ì´ ê±°ì˜ ë¬»ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ë•Œë¡œëŠ” ë¬¼ì–´ë³´ê¸°ë„ í–ˆì§€ë§Œ, ì–´ëŠ íšŒì‚¬ì˜ ì„í”Œë€íŠ¸ì¸ì§€ ê±°ì˜ ë¬»ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>But now that we have the Motiva Implants, a lot of patients come in, well, can I get the Motiva Implant? They know they're approved, and then I have to say to them, they're not approved for breast reconstruction. You can use them, what's called off label. Speaker 11: I've been at an institution that doesn't want us really to do that, so you can use them with the appropriate informed consent that it's off label, but they do ask for that. And I think that we will switch them completely. I mean, we have a bunch of patients who are five years out, so we have like a pretty good track record, not to mention the fact that there's, what, 4,000,000 Motiva implants implanted around the world.</td><td>í•˜ì§€ë§Œ ì´ì œ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ê°€ ìˆìœ¼ë‹ˆê¹Œ, ë§ì€ í™˜ìë“¤ì´ ì™€ì„œ "ëª¨í‹°ë°” ì„í”Œë€íŠ¸ë¥¼ ë°›ì„ ìˆ˜ ìˆë‚˜ìš”?"ë¼ê³  ë¬¼ì–´ë´…ë‹ˆë‹¤. í™˜ìë“¤ì€ ê·¸ê²ƒì´ ìŠ¹ì¸ë˜ì—ˆë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆëŠ”ë°, ê·¸ëŸ¬ë©´ ì €ëŠ” ê·¸ë“¤ì—ê²Œ ìœ ë°©ì¬ê±´ìˆ ì—ëŠ” ìŠ¹ì¸ë˜ì§€ ì•Šì•˜ë‹¤ê³  ë§í•´ì•¼ í•©ë‹ˆë‹¤. ì ì‘ì¦ ì™¸ ì‚¬ìš©(off label)ì´ë¼ê³  í•˜ëŠ” ë°©ì‹ìœ¼ë¡œëŠ” ì‚¬ìš©í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 11: ì €ëŠ” ì‹¤ì œë¡œ ê·¸ëŸ° ê²ƒì„ í•˜ëŠ” ê²ƒì„ ì›í•˜ì§€ ì•ŠëŠ” ê¸°ê´€ì— ìˆì—ˆê¸° ë•Œë¬¸ì—, ì ì‘ì¦ ì™¸ ì‚¬ìš©ì´ë¼ëŠ” ì ì ˆí•œ ì‚¬ì „ë™ì˜ë¥¼ ë°›ìœ¼ë©´ ì‚¬ìš©í•  ìˆ˜ ìˆì§€ë§Œ, ê·¸ë“¤ì€ ê·¸ê²ƒì„ ìš”êµ¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €ëŠ” ìš°ë¦¬ê°€ ì™„ì „íˆ ì „í™˜í•  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì¦‰, ìš°ë¦¬ì—ê²ŒëŠ” 5ë…„ì´ ì§€ë‚œ í™˜ìë“¤ì´ ë§ì´ ìˆì–´ì„œ ê½¤ ì¢‹ì€ ì¶”ì  ê¸°ë¡ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì „ ì„¸ê³„ì ìœ¼ë¡œ 400ë§Œ ê°œì˜ ëª¨í‹°ë°” ì„í”Œë€íŠ¸ê°€ ì´ì‹ë˜ì—ˆë‹¤ëŠ” ì‚¬ì‹¤ì€ ë§í•  ê²ƒë„ ì—†ê³ ìš”.</td></tr>
<tr><td>Even when we started this study, were over a million implants. So it was in 88 or 89 countries, so it was pretty easy to have patients agree to have the implants put in. Speaker 4: Doctor. Hammond, any different in your practice when patients come in and say, want this out of my reconstruction? Are they part of that process? Or do you drive that<br><br>conversation? Speaker 10: We drive the result. We want to try to get the best result we can. And just to dovetail what Nolan said, there's just kind of an inherent desire to kind of keep it all in the same family. So you wouldn't put a Ford transmission and a Dodge drive system, right?</td><td>ì´ ì—°êµ¬ë¥¼ ì‹œì‘í–ˆì„ ë•Œë„ ì´ë¯¸ ë°±ë§Œ ê°œê°€ ë„˜ëŠ” ì„í”Œë€íŠ¸ê°€ ìˆì—ˆìŠµë‹ˆë‹¤. 88ê°œêµ­ ë˜ëŠ” 89ê°œêµ­ì—ì„œ ì‚¬ìš©ë˜ê³  ìˆì—ˆê¸° ë•Œë¬¸ì— í™˜ìë“¤ì´ ì„í”Œë€íŠ¸ ì‚½ì…ì— ë™ì˜í•˜ëŠ” ê²ƒì€ ê½¤ ì‰¬ì› ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 4: í•˜ëª¬ë“œ ë°•ì‚¬ë‹˜, í™˜ìë“¤ì´ ì§„ë£Œì‹¤ì— ì™€ì„œ "ì¬ê±´ìˆ ì—ì„œ ì´ê²ƒì„ ì œê±°í•˜ê³  ì‹¶ë‹¤"ê³  ë§í•  ë•Œ ì„ ìƒë‹˜ì˜ ì§„ë£Œì—ì„œ ì°¨ì´ê°€ ìˆë‚˜ìš”? í™˜ìë“¤ì´ ê·¸ ê³¼ì •ì˜ ì¼ë¶€ì¸ê°€ìš”? ì•„ë‹ˆë©´ ì„ ìƒë‹˜ì´ ê·¸ ëŒ€í™”ë¥¼ ì£¼ë„í•˜ì‹œë‚˜ìš”?<br><br>ë°œí‘œì 10: ì €í¬ê°€ ê²°ê³¼ë¥¼ ì£¼ë„í•©ë‹ˆë‹¤. ê°€ëŠ¥í•œ í•œ ìµœìƒì˜ ê²°ê³¼ë¥¼ ì–»ìœ¼ë ¤ê³  ë…¸ë ¥í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë†€ë€ì´ ë§í•œ ê²ƒì— ë§ë¶™ì´ìë©´, ëª¨ë“  ê²ƒì„ ê°™ì€ ì œí’ˆêµ°ìœ¼ë¡œ ìœ ì§€í•˜ë ¤ëŠ” ë³¸ì§ˆì ì¸ ìš•êµ¬ê°€ ìˆìŠµë‹ˆë‹¤. í¬ë“œ ë³€ì†ê¸°ì— ë‹·ì§€ êµ¬ë™ ì‹œìŠ¤í…œì„ ë„£ì§€ëŠ” ì•Šê² ì£ , ê·¸ë ‡ì§€ ì•Šë‚˜ìš”?</td></tr>
<tr><td>So if you've got a flora tissue expander, then you would want a Motiva implant because it's all the same company. Speaker 10: That just kind of makes sense. Speaker 4: Maybe more of a business question here, but reconstruction is a little different from augmentation where you're dealing with private practitioners who can turn tomorrow, decide they want to use a new device. When you work at a big institution, as you do, what are generally the processes that someone needs to go through if you're a plastic surgeon to get access to these devices? Is it immediate or does it take some time?</td><td>ë”°ë¼ì„œ í”Œë¡œë¼ ì¡°ì§ í™•ì¥ê¸°ë¥¼ ì‚¬ìš©í•œë‹¤ë©´, ëª¨í‹°ë°” ì„í”Œë€íŠ¸ë¥¼ ì›í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ê°™ì€ íšŒì‚¬ ì œí’ˆì´ê¸° ë•Œë¬¸ì´ì£ .<br><br>ë°œí‘œì 10: ê·¸ê²Œ ë§ì´ ë˜ë„¤ìš”.<br><br>ë°œí‘œì 4: ì¢€ ë” ë¹„ì¦ˆë‹ˆìŠ¤ì ì¸ ì§ˆë¬¸ì¼ ìˆ˜ ìˆëŠ”ë°, ì¬ê±´ìˆ ì€ í™•ëŒ€ìˆ ê³¼ëŠ” ì¡°ê¸ˆ ë‹¤ë¦…ë‹ˆë‹¤. í™•ëŒ€ìˆ ì˜ ê²½ìš° ê°œì¸ ê°œì—…ì˜ë“¤ì´ ë‚´ì¼ì´ë¼ë„ ìƒˆë¡œìš´ ê¸°ê¸°ë¥¼ ì‚¬ìš©í•˜ê¸°ë¡œ ê²°ì •í•  ìˆ˜ ìˆê±°ë“ ìš”. ì„ ìƒë‹˜ì²˜ëŸ¼ ëŒ€í˜• ì˜ë£Œê¸°ê´€ì—ì„œ ê·¼ë¬´í•˜ì‹¤ ë•Œ, ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ê°€ ì´ëŸ° ê¸°ê¸°ë“¤ì— ì ‘ê·¼í•˜ê¸° ìœ„í•´ì„œëŠ” ì¼ë°˜ì ìœ¼ë¡œ ì–´ë–¤ ì ˆì°¨ë¥¼ ê±°ì³ì•¼ í•˜ë‚˜ìš”? ì¦‰ì‹œ ê°€ëŠ¥í•œ ê±´ê°€ìš”, ì•„ë‹ˆë©´ ì‹œê°„ì´ ì¢€ ê±¸ë¦¬ë‚˜ìš”?</td></tr>
<tr><td>Speaker 11: I mean, we can get the like, on a case by case basis, we can get the device, but to really we need more than that because it's a headache to do it that way. Like, we need to establish, like, a consignment and a stock of the devices, so we have to kind of negotiate. We have a value based medicine committee. It's not a problem when you have a device that's clearly better. And and actually, the difference in price, if there is a difference in in price, is minimal when you consider the overall cost of a case. Speaker 11: The difference in price might be a few $100 max, whereas the overall cost of these cases is like a 5 figure number, probably $20,000.</td><td>ë°œí‘œì 11: ì¼€ì´ìŠ¤ë³„ë¡œ ê¸°ê¸°ë¥¼ êµ¬í•  ìˆ˜ëŠ” ìˆì§€ë§Œ, ì‹¤ì œë¡œëŠ” ê·¸ê²ƒë³´ë‹¤ ë” ë§ì€ ê²ƒì´ í•„ìš”í•©ë‹ˆë‹¤. ê·¸ëŸ° ì‹ìœ¼ë¡œ í•˜ëŠ” ê²ƒì€ ë²ˆê±°ë¡­ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê¸°ê¸°ì˜ ìœ„íƒ ì¬ê³ ë¥¼ í™•ë³´í•´ì•¼ í•˜ë¯€ë¡œ í˜‘ìƒì„ í•´ì•¼ í•©ë‹ˆë‹¤. ì €í¬ì—ê²ŒëŠ” ê°€ì¹˜ ê¸°ë°˜ ì˜ë£Œ ìœ„ì›íšŒê°€ ìˆìŠµë‹ˆë‹¤. ëª…ë°±íˆ ë” ë‚˜ì€ ê¸°ê¸°ê°€ ìˆì„ ë•ŒëŠ” ë¬¸ì œê°€ ë˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹¤ì œë¡œ ê°€ê²© ì°¨ì´ê°€ ìˆë‹¤ í•˜ë”ë¼ë„, ì¼€ì´ìŠ¤ ì „ì²´ ë¹„ìš©ì„ ê³ ë ¤í•˜ë©´ ê·¸ ì°¨ì´ëŠ” ë¯¸ë¯¸í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 11: ê°€ê²© ì°¨ì´ëŠ” ìµœëŒ€ ëª‡ ë°± ë‹¬ëŸ¬ ì •ë„ì¸ ë°˜ë©´, ì´ëŸ¬í•œ ì¼€ì´ìŠ¤ë“¤ì˜ ì „ì²´ ë¹„ìš©ì€ 5ìë¦¬ ìˆ˜, ì•„ë§ˆë„ 2ë§Œ ë‹¬ëŸ¬ ì •ë„ì…ë‹ˆë‹¤.</td></tr>
<tr><td>It's like maybe 1% of the cost of a case. I don't see it as being I think once they're approved, we'll have them approved, we'll have them available. I think the biggest problem is can you guys put up with the demand because the demand will get bigger faster. I think having been to Costa Rica and having seen the original<br><br>factory, the new factory, I think you guys are ready. Speaker 4: Doctor. Habman, anything to add? There's a question. Okay. Speaker 12: Actually Anthony Petromazu. Thank you for the insights and thanks for sharing your thoughts on reconstruction. Just a follow-up on the business end.</td><td>ì¼€ì´ìŠ¤ ë¹„ìš©ì˜ ì•½ 1% ì •ë„ì…ë‹ˆë‹¤. ì œê°€ ë³´ê¸°ì—ëŠ”... ì¼ë‹¨ ìŠ¹ì¸ì´ ë‚˜ë©´, ì €í¬ê°€ ìŠ¹ì¸ì„ ë°›ê²Œ ë˜ë©´, ì œí’ˆì„ ê³µê¸‰í•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì œê°€ ìƒê°í•˜ëŠ” ê°€ì¥ í° ë¬¸ì œëŠ” ì—¬ëŸ¬ë¶„ë“¤ì´ ìˆ˜ìš”ë¥¼ ê°ë‹¹í•  ìˆ˜ ìˆëŠëƒ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ìˆ˜ìš”ê°€ ë” ë¹ ë¥´ê²Œ ì¦ê°€í•  ê²ƒì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì½”ìŠ¤íƒ€ë¦¬ì¹´ì— ê°€ì„œ ê¸°ì¡´ ê³µì¥ê³¼ ìƒˆë¡œìš´ ê³µì¥ì„ ë‘˜ëŸ¬ë³¸ ê²½í—˜ìœ¼ë¡œëŠ”, ì—¬ëŸ¬ë¶„ë“¤ì´ ì¤€ë¹„ê°€ ë˜ì–´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 4: í•˜ë¸Œë§Œ ë°•ì‚¬ë‹˜, ì¶”ê°€í•˜ì‹¤ ë§ì”€ì´ ìˆìœ¼ì‹ ê°€ìš”? ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. ë„¤.<br><br>ë°œí‘œì 12: ì•ˆí† ë‹ˆ í˜íŠ¸ë¡œë§ˆì£¼ì…ë‹ˆë‹¤. í†µì°°ë ¥ ìˆëŠ” ì˜ê²¬ ê°ì‚¬ë“œë¦¬ê³ , ì¬ê±´ìˆ ì— ëŒ€í•œ ê²¬í•´ë¥¼ ê³µìœ í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì‚¬ì—… ì¸¡ë©´ì— ëŒ€í•œ í›„ì† ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>When you think about reinsurance coverage for mastectomy, with the new platform coming in, does this fall under DRG? Do you think when we get the pre survey that you'll actually need a dedicated sort of reimbursement sort of roll in for a new platform or is it going to kind of slot in under existing kind of codes that are out there? Speaker 12: Thanks. Speaker 11: Preservaes is really an org thing. It's really more for the breast augmentation, it's not so much for the recon. The whole idea is when you're doing a mastectomy, you're taking the whole breast out, whereas Preserva is really about preserving the anatomy when you're doing a breast augmentation.</td><td>ìœ ë°©ì ˆì œìˆ ì— ëŒ€í•œ ì¬ë³´í—˜ ë³´ì¥ì„ ìƒê°í•´ë³´ë©´, ìƒˆë¡œìš´ í”Œë«í¼ì´ ë„ì…ë  ë•Œ ì´ê²ƒì´ DRG í•˜ì— í¬í•¨ë˜ëŠ”ì§€ìš”? ì‚¬ì „ ì¡°ì‚¬ë¥¼ ë°›ì„ ë•Œ ìƒˆë¡œìš´ í”Œë«í¼ì— ëŒ€í•´ ì „ìš© ìƒí™˜ ì—­í• ì´ ì‹¤ì œë¡œ í•„ìš”í•  ê²ƒìœ¼ë¡œ ìƒê°í•˜ì‹œëŠ”ì§€, ì•„ë‹ˆë©´ ê¸°ì¡´ì— ìˆëŠ” ì½”ë“œë“¤ í•˜ì—ì„œ ì²˜ë¦¬ë  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€ìš”?<br><br>í™”ì 12: ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>í™”ì 11: PreservaëŠ” ì‹¤ì œë¡œ ì¥ê¸°ì ì¸ ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì€ ì‹¤ì œë¡œ ìœ ë°© í™•ëŒ€ìˆ ì„ ìœ„í•œ ê²ƒì´ì§€, ì¬ê±´ìˆ ì„ ìœ„í•œ ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. ì „ì²´ì ì¸ ì•„ì´ë””ì–´ëŠ” ìœ ë°©ì ˆì œìˆ ì„ í•  ë•ŒëŠ” ìœ ë°© ì „ì²´ë¥¼ ì œê±°í•˜ëŠ” ê²ƒì¸ ë°˜ë©´, PreservaëŠ” ì‹¤ì œë¡œ ìœ ë°© í™•ëŒ€ìˆ ì„ í•  ë•Œ í•´ë¶€í•™ì  êµ¬ì¡°ë¥¼ ë³´ì¡´í•˜ëŠ” ê²ƒì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>In terms of coverage, we've never had I've at least personally never had any coverage. The federal law, 1998 law, that really very broadly covers breast reconstruction, and we've never had any problems with any of the implants. Speaker 11: I mean, even more expensive than the implants actually are breast support, either devices or implants or dermis, and we've actually never had any trouble with getting any of that covered. Speaker 10: So just to dovetail on that, in Michigan, it doesn't matter what device I use. So what they'll say is, You're doing a tissue expander breast reconstruction? Yes. They don't care what tissue expander I use. That's kind of bundled into the whole system.</td><td>ë³´ì¥ ë²”ìœ„ ì¸¡ë©´ì—ì„œ, ì €í¬ëŠ” ì ì–´ë„ ì œê°€ ê°œì¸ì ìœ¼ë¡œëŠ” ì–´ë–¤ ë³´ì¥ë„ ë°›ì€ ì ì´ ì—†ìŠµë‹ˆë‹¤. 1998ë…„ ì—°ë°©ë²•ì€ ìœ ë°© ì¬ê±´ìˆ ì„ ë§¤ìš° ê´‘ë²”ìœ„í•˜ê²Œ ë³´ì¥í•˜ê³  ìˆìœ¼ë©°, ì €í¬ëŠ” ì–´ë–¤ ì„í”Œë€íŠ¸ì— ëŒ€í•´ì„œë„ ë¬¸ì œë¥¼ ê²ªì€ ì ì´ ì—†ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 11: ì‹¤ì œë¡œ ì„í”Œë€íŠ¸ë³´ë‹¤ ë” ë¹„ì‹¼ ê²ƒì€ ìœ ë°© ì§€ì§€ ì¥ì¹˜ë‚˜ ì„í”Œë€íŠ¸ ë˜ëŠ” ì§„í”¼ì¸ë°, ì €í¬ëŠ” ì´ëŸ° ê²ƒë“¤ì˜ ë³´ì¥ì„ ë°›ëŠ” ë° ì–´ë–¤ ì–´ë ¤ì›€ë„ ê²ªì€ ì ì´ ì—†ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 10: ì´ì— ë§ë¶™ì—¬ ë§ì”€ë“œë¦¬ë©´, ë¯¸ì‹œê°„ì—ì„œëŠ” ì œê°€ ì–´ë–¤ ì¥ì¹˜ë¥¼ ì‚¬ìš©í•˜ë“  ìƒê´€ì—†ìŠµë‹ˆë‹¤. ë³´í—˜ì‚¬ì—ì„œëŠ” "ì¡°ì§ í™•ì¥ê¸°ë¥¼ ì´ìš©í•œ ìœ ë°© ì¬ê±´ìˆ ì„ í•˜ì‹œë‚˜ìš”?"ë¼ê³  ë¬»ìŠµë‹ˆë‹¤. "ë„¤"ë¼ê³  ë‹µí•˜ë©´, ì–´ë–¤ ì¡°ì§ í™•ì¥ê¸°ë¥¼ ì‚¬ìš©í•˜ëŠ”ì§€ëŠ” ì‹ ê²½ ì“°ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ê²ƒì€ ì „ì²´ ì‹œìŠ¤í…œì— ì¼ê´„ì ìœ¼ë¡œ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 10: So to answer your question, no, I don't think there'll be a barrier to using the flora<br><br>versus another one. The barrier will be to get it into the hospital in the place. So what I had to do in my hospital is go sit before the VAC committee and outline all of these advantages. They seem to be very concerned with their floor space for some reason in the hospital. They don't want to clear out room on a shelf to put the devices on. Speaker 10: But I had to explain to them what the advantage was, they vote on it and then you get it into your hospital. Probably at the hospitals, somebody will have to champion that process to make it available in institutions.</td><td>ë°œí‘œì 10: ì§ˆë¬¸ì— ë‹µë³€ë“œë¦¬ìë©´, í”Œë¡œë¼ì™€ ë‹¤ë¥¸ ì œí’ˆ ì‚¬ìš© ê°„ì— ì¥ë²½ì´ ìˆì„ ê²ƒì´ë¼ê³  ìƒê°í•˜ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ì¥ë²½ì€ ë³‘ì› ë‚´ì—ì„œ í•´ë‹¹ ì œí’ˆì„ ë„ì…í•˜ëŠ” ë° ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì œê°€ ê·¼ë¬´í•˜ëŠ” ë³‘ì›ì—ì„œëŠ” VAC ìœ„ì›íšŒ ì•ì— ì•‰ì•„ì„œ ì´ëŸ¬í•œ ëª¨ë“  ì¥ì ë“¤ì„ ì„¤ëª…í•´ì•¼ í–ˆìŠµë‹ˆë‹¤. ë³‘ì›ì—ì„œëŠ” ì–´ë–¤ ì´ìœ ì—ì„œì¸ì§€ ë°”ë‹¥ ê³µê°„ì— ëŒ€í•´ ë§¤ìš° ìš°ë ¤í•˜ëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì„ ë°˜ì— ê¸°ê¸°ë¥¼ ë†“ì„ ê³µê°„ì„ í™•ë³´í•˜ëŠ” ê²ƒì„ ì›í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 10: í•˜ì§€ë§Œ ì €ëŠ” ê·¸ë“¤ì—ê²Œ ì¥ì ì´ ë¬´ì—‡ì¸ì§€ ì„¤ëª…í•´ì•¼ í–ˆê³ , ê·¸ë“¤ì´ íˆ¬í‘œë¥¼ í†µí•´ ê²°ì •í•œ í›„ì—ì•¼ ë³‘ì›ì— ë„ì…í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì•„ë§ˆë„ ê° ë³‘ì›ì—ì„œëŠ” ëˆ„êµ°ê°€ê°€ í•´ë‹¹ ê¸°ê´€ì—ì„œ ì´ë¥¼ ì´ìš©í•  ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ê³¼ì •ì„ ì£¼ë„í•´ì•¼ í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 4: And often that's the plastic surgeon fighting on behalf of his or her patients. So we thank you for that. I'm going turn it over now to Roberta. Thank you very much, panelists. We'll talk a little bit more about the future and the engineering section some of these preservation techniques and how they may apply to breast reconstruction. Speaker 13: Well, hello everyone. Thank you so much for being here.</td><td>í™”ì 4: ê·¸ë¦¬ê³  ì¢…ì¢… ê·¸ê²ƒì€ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ê°€ ìì‹ ì˜ í™˜ìë“¤ì„ ëŒ€ì‹ í•´ì„œ ì‹¸ìš°ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ëŸ° ì ì— ëŒ€í•´ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì´ì œ ë¡œë² ë¥´íƒ€ì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. íŒ¨ë„ë¦¬ìŠ¤íŠ¸ ì—¬ëŸ¬ë¶„, ëŒ€ë‹¨íˆ ê°ì‚¬í•©ë‹ˆë‹¤. ë¯¸ë˜ì™€ ì—”ì§€ë‹ˆì–´ë§ ì„¹ì…˜ì—ì„œ ì´ëŸ¬í•œ ë³´ì¡´ ê¸°ë²•ë“¤ê³¼ ê·¸ê²ƒë“¤ì´ ìœ ë°© ì¬ê±´ìˆ ì— ì–´ë–»ê²Œ ì ìš©ë  ìˆ˜ ìˆëŠ”ì§€ì— ëŒ€í•´ ì¢€ ë” ì´ì•¼ê¸°í•´ë³´ê² ìŠµë‹ˆë‹¤.<br><br>í™”ì 13: ì•ˆë…•í•˜ì„¸ìš”, ì—¬ëŸ¬ë¶„. ì´ ìë¦¬ì— ì°¸ì„í•´ ì£¼ì…”ì„œ ì •ë§ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Being in this company since the very beginning, you can imagine both the feeling of proud and the feeling of how gratifying it is to listen to these surgeons showing their experiences and how our innovations have changed the way that they're doing their procedures and how we have been able to raise the bar for the benefit of our patients. And that is a very gratifying moment for us. I'm very happy to be back here. Speaker 13: Let's see. So I have one of the best jobs in the company which is to lead all the efforts that we do in research, development, and innovation. And it is an honor to be back here to tell you now about what is going to be coming next in our pipeline of innovation.</td><td>íšŒì‚¬ ì°½ë¦½ ì´ˆê¸°ë¶€í„° í•¨ê»˜í•´ì˜¨ ì…ì¥ì—ì„œ, ì´ëŸ¬í•œ ì™¸ê³¼ì˜ì‚¬ë“¤ì´ ìì‹ ë“¤ì˜ ê²½í—˜ì„ ê³µìœ í•˜ê³  ìš°ë¦¬ì˜ í˜ì‹ ì´ ì–´ë–»ê²Œ ê·¸ë“¤ì˜ ìˆ˜ìˆ  ë°©ì‹ì„ ë³€í™”ì‹œì¼°ëŠ”ì§€, ê·¸ë¦¬ê³  ìš°ë¦¬ê°€ ì–´ë–»ê²Œ í™˜ìë“¤ì˜ ì´ìµì„ ìœ„í•´ ê¸°ì¤€ì„ ë†’ì¼ ìˆ˜ ìˆì—ˆëŠ”ì§€ë¥¼ ë“£ëŠ” ê²ƒì´ ì–¼ë§ˆë‚˜ ìë‘ìŠ¤ëŸ½ê³  ë³´ëŒëœ ì¼ì¸ì§€ ìƒìƒí•˜ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ì—ê²Œ ë§¤ìš° ë³´ëŒëœ ìˆœê°„ì…ë‹ˆë‹¤. ë‹¤ì‹œ ì´ ìë¦¬ì— ëŒì•„ì˜¤ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì©ë‹ˆë‹¤.<br><br>ë°œí‘œì 13: ê·¸ëŸ¼ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì €ëŠ” íšŒì‚¬ì—ì„œ ê°€ì¥ ì¢‹ì€ ì—…ë¬´ ì¤‘ í•˜ë‚˜ë¥¼ ë§¡ê³  ìˆëŠ”ë°, ë°”ë¡œ ì—°êµ¬ê°œë°œ ë° í˜ì‹  ë¶„ì•¼ì˜ ëª¨ë“  ë…¸ë ¥ì„ ì´ë„ëŠ” ì¼ì…ë‹ˆë‹¤. ë‹¤ì‹œ ì´ ìë¦¬ì— ëŒì•„ì™€ì„œ ìš°ë¦¬ì˜ í˜ì‹  íŒŒì´í”„ë¼ì¸ì—ì„œ ì•ìœ¼ë¡œ ì„ ë³´ì¼ ë‚´ìš©ë“¤ì— ëŒ€í•´ ë§ì”€ë“œë¦´ ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ê°–ê²Œ ë˜ì–´ ì˜ê´‘ì…ë‹ˆë‹¤.</td></tr>
<tr><td>July is going be seven years that we were standing here precisely to get this going. It was becoming a publicly traded company in order to get the funds to start our clinical trial. Speaker 13: And I want to start here because this does make a difference. We can talk about all<br><br>the technology in the world that we can improve and everything but if we cannot see the outcomes on the real world it would not mean anything. And this it's a very important part of what I'm going to be talking on the future. And it is how not only in the most rigorous study in The United States under the FDA also adding value to the scientific and clinical evidence that we have been building.</td><td>7ì›”ì´ë©´ ìš°ë¦¬ê°€ ì´ ì¼ì„ ì‹œì‘í•˜ê¸° ìœ„í•´ ì •í™•íˆ ì—¬ê¸° ì„œ ìˆì—ˆë˜ ì§€ 7ë…„ì´ ë©ë‹ˆë‹¤. ì„ìƒì‹œí—˜ì„ ì‹œì‘í•  ìê¸ˆì„ í™•ë³´í•˜ê¸° ìœ„í•´ ìƒì¥íšŒì‚¬ê°€ ë˜ëŠ” ê²ƒì´ì—ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 13: ê·¸ë¦¬ê³  ì €ëŠ” ì—¬ê¸°ì„œ ì‹œì‘í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ê²ƒì´ ì°¨ì´ë¥¼ ë§Œë“¤ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ìš°ë¦¬ê°€ ê°œì„ í•  ìˆ˜ ìˆëŠ” ì„¸ìƒì˜ ëª¨ë“  ê¸°ìˆ ì— ëŒ€í•´ ì´ì•¼ê¸°í•  ìˆ˜ ìˆê³  ëª¨ë“  ê²ƒì— ëŒ€í•´ ë§í•  ìˆ˜ ìˆì§€ë§Œ, ì‹¤ì œ ì„¸ê³„ì—ì„œ ê²°ê³¼ë¥¼ ë³¼ ìˆ˜ ì—†ë‹¤ë©´ ì•„ë¬´ ì˜ë¯¸ê°€ ì—†ì„ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì€ ì œê°€ ë¯¸ë˜ì— ëŒ€í•´ ì´ì•¼ê¸°í•  ë‚´ìš©ì˜ ë§¤ìš° ì¤‘ìš”í•œ ë¶€ë¶„ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŠ” FDA í•˜ì—ì„œ ë¯¸êµ­ì—ì„œ ê°€ì¥ ì—„ê²©í•œ ì—°êµ¬ì—ì„œë¿ë§Œ ì•„ë‹ˆë¼ ìš°ë¦¬ê°€ êµ¬ì¶•í•´ì˜¨ ê³¼í•™ì ì´ê³  ì„ìƒì ì¸ ì¦ê±°ì— ê°€ì¹˜ë¥¼ ë”í•˜ëŠ” ë°©ë²•ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And this, more than a decade, there was no implant introduced in this market and coming up with these numbers really makes a difference. Speaker 13: And why? Because it's the platform that we're going to be using to continue innovating. Now that is from The U. S. But I also want to make sure that we all understand that it is consistent around the entire world. Speaker 13: There's more than 160 publications that speaks about Motiva scientifically and clinically that verifies the innovations and the different terms and technology that we're building and bringing into the real world makes a difference. But you can see how consistency these numbers are.</td><td>ê·¸ë¦¬ê³  ì´ê²ƒì€, 10ë…„ ì´ìƒ ë™ì•ˆ ì´ ì‹œì¥ì— ë„ì…ëœ ì„í”Œë€íŠ¸ê°€ ì—†ì—ˆê³ , ì´ëŸ¬í•œ ìˆ˜ì¹˜ë“¤ì„ ì œì‹œí•˜ëŠ” ê²ƒì´ ì •ë§ë¡œ ì°¨ì´ë¥¼ ë§Œë“¤ì–´ëƒ…ë‹ˆë‹¤.<br><br>ë°œí‘œì 13: ê·¸ë¦¬ê³  ì™œì¼ê¹Œìš”? ì´ê²ƒì´ ìš°ë¦¬ê°€ ì§€ì†ì ìœ¼ë¡œ í˜ì‹ í•˜ê¸° ìœ„í•´ ì‚¬ìš©í•  í”Œë«í¼ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ê²ƒì€ ë¯¸êµ­ì—ì„œ ë‚˜ì˜¨ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €ëŠ” ë˜í•œ ìš°ë¦¬ ëª¨ë‘ê°€ ì´ê²ƒì´ ì „ ì„¸ê³„ì ìœ¼ë¡œ ì¼ê´€ë˜ë‹¤ëŠ” ê²ƒì„ ì´í•´í•˜ê¸°ë¥¼ ë°”ëë‹ˆë‹¤.<br><br>ë°œí‘œì 13: Motivaì— ëŒ€í•´ ê³¼í•™ì ì´ê³  ì„ìƒì ìœ¼ë¡œ ì–¸ê¸‰í•˜ëŠ” 160í¸ ì´ìƒì˜ ë…¼ë¬¸ì´ ìˆìœ¼ë©°, ì´ëŠ” ìš°ë¦¬ê°€ êµ¬ì¶•í•˜ê³  ì‹¤ì œ ì„¸ê³„ì— ë„ì…í•˜ê³  ìˆëŠ” í˜ì‹ ê³¼ ë‹¤ì–‘í•œ ê¸°ìˆ ë“¤ì´ ì°¨ì´ë¥¼ ë§Œë“ ë‹¤ëŠ” ê²ƒì„ ê²€ì¦í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ëŸ¬í•œ ìˆ˜ì¹˜ë“¤ì´ ì–¼ë§ˆë‚˜ ì¼ê´€ì„± ìˆëŠ”ì§€ ë³´ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This is a meta analysis removing all the possible bias that there is in the literature. So this is very objective. As well, there's independent registries like in Australia, Sweden, different countries in Europe that resembles and is consistent to these results. Speaker 13: So designing with a purpose for us makes a huge difference. Understanding what are the benefits that we have in our surface to be able to say that we have a less than one percent complication rate makes a huge difference to show us where do we have to keep going and what are the things that we have been doing good and how do we raise the bar even more.</td><td>ì´ëŠ” ë¬¸í—Œì— ì¡´ì¬í•˜ëŠ” ëª¨ë“  ê°€ëŠ¥í•œ í¸í–¥ì„ ì œê±°í•œ ë©”íƒ€ ë¶„ì„ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ë§¤ìš° ê°ê´€ì ì…ë‹ˆë‹¤. ë˜í•œ í˜¸ì£¼, ìŠ¤ì›¨ë´, ìœ ëŸ½ì˜ ì—¬ëŸ¬ êµ­ê°€ì™€ ê°™ì€ ë…ë¦½ì ì¸ ë“±ë¡ ê¸°ê´€ë“¤ì´ ì´ëŸ¬í•œ ê²°ê³¼ì™€ ìœ ì‚¬í•˜ê³  ì¼ì¹˜í•˜ëŠ” ê²°ê³¼ë¥¼ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 13: ëª©ì ì„ ê°€ì§€ê³  ì„¤ê³„í•˜ëŠ” ê²ƒì´ ì €í¬ì—ê²ŒëŠ” í° ì°¨ì´ë¥¼ ë§Œë“­ë‹ˆë‹¤. ì €í¬ í‘œë©´ì´ ê°€ì§„ ì´ì ë“¤ì„ ì´í•´í•˜ì—¬ 1% ë¯¸ë§Œì˜ í•©ë³‘ì¦ë¥ ì„ ê°€ì§€ê³  ìˆë‹¤ê³  ë§í•  ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì€, ì €í¬ê°€ ê³„ì† ë‚˜ì•„ê°€ì•¼ í•  ë°©í–¥ê³¼ ì €í¬ê°€ ì˜í•´ì˜¨ ê²ƒë“¤ì´ ë¬´ì—‡ì¸ì§€, ê·¸ë¦¬ê³  ì–´ë–»ê²Œ ê¸°ì¤€ì„ ë”ìš± ë†’ì¼ ìˆ˜ ìˆëŠ”ì§€ë¥¼ ë³´ì—¬ì£¼ëŠ” ë° í° ì°¨ì´ë¥¼ ë§Œë“­ë‹ˆë‹¤.</td></tr>
<tr><td>So when we think about minimally invasive procedure it's not only about the moment at the Operating Room. It is what is going to happen after the patient leaves that room. So the surface that we build and we have the evidence to show that it's less inflammatory makes at a cell level our point of start and that will make us possible to have a faster healing. Speaker 13: Having a faster healing of the tissues surrounding the breast makes a huge difference on how that patient is going to go back to her lifestyle.</td><td>ìµœì†Œì¹¨ìŠµ ì‹œìˆ ì„ ìƒê°í•  ë•Œ, ì´ëŠ” ë‹¨ìˆœíˆ ìˆ˜ìˆ ì‹¤ì—ì„œì˜ ìˆœê°„ë§Œì„ ì˜ë¯¸í•˜ëŠ” ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. í™˜ìê°€ ê·¸ ìˆ˜ìˆ ì‹¤ì„ ë– ë‚œ í›„ì— ì¼ì–´ë‚  ì¼ë“¤ì„ í¬í•¨í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ê°€ êµ¬ì¶•í•œ í‘œë©´ì´ ì„¸í¬ ìˆ˜ì¤€ì—ì„œ ì—¼ì¦ì„ ëœ ìœ ë°œí•œë‹¤ëŠ” ì¦ê±°ë¥¼ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ ì €í¬ì˜ ì¶œë°œì ì´ ë˜ì–´ ë” ë¹ ë¥¸ ì¹˜ìœ ë¥¼ ê°€ëŠ¥í•˜ê²Œ í•  ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 13: ìœ ë°© ì£¼ë³€ ì¡°ì§ì˜ ë” ë¹ ë¥¸ ì¹˜ìœ ëŠ” í•´ë‹¹ í™˜ìê°€ ì¼ìƒìƒí™œë¡œ ë³µê·€í•˜ëŠ” ë° ìˆì–´ í° ì°¨ì´ë¥¼ ë§Œë“¤ì–´ëƒ…ë‹ˆë‹¤.</td></tr>
<tr><td>And so starting from there, also we needed to make sure that we had the proper technology on the mechanical properties of the surface in order to be able to introduce it to smaller incisions every time possible. How do we make possible to remove any scar from the breast and still have a breast enhancement? So the way that we had to rethink about the chemistry that we were putting our implants and the geometries, the physics, the mechanical properties all got together. Having that purposely designed implants makes a huge difference.</td><td>ì´ëŸ¬í•œ ì¶œë°œì ì—ì„œ ìš°ë¦¬ëŠ” ê°€ëŠ¥í•œ í•œ ë” ì‘ì€ ì ˆê°œë¥¼ í†µí•´ ì„í”Œë€íŠ¸ë¥¼ ì‚½ì…í•  ìˆ˜ ìˆë„ë¡ í‘œë©´ì˜ ê¸°ê³„ì  íŠ¹ì„±ì— ëŒ€í•œ ì ì ˆí•œ ê¸°ìˆ ì„ í™•ë³´í•´ì•¼ í–ˆìŠµë‹ˆë‹¤. ìœ ë°©ì—ì„œ í‰í„°ë¥¼ ì™„ì „íˆ ì œê±°í•˜ë©´ì„œë„ ì—¬ì „íˆ ìœ ë°© í™•ëŒ€ íš¨ê³¼ë¥¼ ì–»ì„ ìˆ˜ ìˆëŠ” ë°©ë²•ì€ ë¬´ì—‡ì¼ê¹Œìš”? ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ì„í”Œë€íŠ¸ì— ì ìš©í•˜ëŠ” í™”í•™ì  ì„±ì§ˆê³¼ ê¸°í•˜í•™ì  êµ¬ì¡°, ë¬¼ë¦¬í•™, ê¸°ê³„ì  íŠ¹ì„±ì„ ëª¨ë‘ í•¨ê»˜ ê³ ë ¤í•˜ì—¬ ë‹¤ì‹œ ìƒê°í•´ì•¼ í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ëª©ì ì— ë§ê²Œ ì„¤ê³„ëœ ì„í”Œë€íŠ¸ë¥¼ ë³´ìœ í•˜ëŠ” ê²ƒì€ ì—„ì²­ë‚œ ì°¨ì´ë¥¼ ë§Œë“¤ì–´ëƒ…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 13: How we can make, as we did when we brought an implant that had a little blue on it that was significantly different from what the industry was used to do. And that was a very clear differentiator. The blue that we brought in our implants making sure that we have a way of identifying that the barrier that is very important for safety over the years it's present in the<br>entire implants. A visual barrier it's equals to better safety. And a geometry that makes a difference, you can see here for the MIA procedure, we were able to create an implant that will project more with less silicone. Speaker 13: At the end, that is extremely beneficial for the patient.</td><td>ë°œí‘œì 13: ìš°ë¦¬ê°€ ì–´ë–»ê²Œ ë§Œë“¤ ìˆ˜ ìˆëŠ”ì§€, ë§ˆì¹˜ ìš°ë¦¬ê°€ ì•½ê°„ì˜ íŒŒë€ìƒ‰ì´ ë“¤ì–´ê°„ ì„í”Œë€íŠ¸ë¥¼ ë„ì…í–ˆì„ ë•Œì²˜ëŸ¼ ë§ì…ë‹ˆë‹¤. ì´ëŠ” ì—…ê³„ê°€ ê¸°ì¡´ì— í•˜ë˜ ê²ƒê³¼ëŠ” ìƒë‹¹íˆ ë‹¤ë¥¸ ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì€ ë§¤ìš° ëª…í™•í•œ ì°¨ë³„í™” ìš”ì†Œì˜€ìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ì„í”Œë€íŠ¸ì— ë„ì…í•œ íŒŒë€ìƒ‰ì€ ìˆ˜ë…„ê°„ ì „ì²´ ì„í”Œë€íŠ¸ì— ì¡´ì¬í•˜ëŠ” ì•ˆì „ì„±ì— ë§¤ìš° ì¤‘ìš”í•œ ì¥ë²½ì„ ì‹ë³„í•  ìˆ˜ ìˆëŠ” ë°©ë²•ì„ í™•ë³´í•˜ë„ë¡ í•´ì¤ë‹ˆë‹¤. ì‹œê°ì  ì¥ë²½ì€ ë” ë‚˜ì€ ì•ˆì „ì„±ê³¼ ê°™ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì°¨ì´ë¥¼ ë§Œë“œëŠ” ê¸°í•˜í•™ì  êµ¬ì¡°, ì—¬ê¸°ì„œ MIA ì‹œìˆ ì„ ìœ„í•´ ë³´ì‹¤ ìˆ˜ ìˆë“¯ì´, ìš°ë¦¬ëŠ” ë” ì ì€ ì‹¤ë¦¬ì½˜ìœ¼ë¡œ ë” ë§ì´ ëŒì¶œë  ìˆ˜ ìˆëŠ” ì„í”Œë€íŠ¸ë¥¼ ë§Œë“¤ ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 13: ê²°êµ­, ì´ê²ƒì€ í™˜ìì—ê²Œ ê·¹ë„ë¡œ ìœ ìµí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Minimizing the touch points during the procedure that the surgeon can have with the implant that will also improve the safety. And all that, we're moving out from just being able to create a platform of a product that is going to be on the patient for many years, raising the bar, being able to increase all the different things that we consider are important for that behavior of the implant, which is the addendum of the breast, to the surrounding natural structures of the breast.</td><td>ìˆ˜ìˆ  ì¤‘ ì™¸ê³¼ì˜ê°€ ì„í”Œë€íŠ¸ì™€ ì ‘ì´‰í•˜ëŠ” ì§€ì ì„ ìµœì†Œí™”í•¨ìœ¼ë¡œì¨ ì•ˆì „ì„±ë„ í–¥ìƒì‹œí‚¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì„ í†µí•´ ìš°ë¦¬ëŠ” ë‹¨ìˆœíˆ í™˜ìì—ê²Œ ìˆ˜ë…„ê°„ ì‚½ì…ë  ì œí’ˆì˜ í”Œë«í¼ì„ ë§Œë“œëŠ” ê²ƒì—ì„œ ë²—ì–´ë‚˜, ê¸°ì¤€ì„ ë†’ì—¬ê°€ê³  ìˆìŠµë‹ˆë‹¤. ì„í”Œë€íŠ¸ì˜ ê±°ë™ì— ìˆì–´ ì¤‘ìš”í•˜ë‹¤ê³  ìƒê°í•˜ëŠ” ëª¨ë“  ë‹¤ì–‘í•œ ìš”ì†Œë“¤, ì¦‰ ìœ ë°©ì˜ ë¶€ì†ë¬¼ì¸ ì„í”Œë€íŠ¸ê°€ ìœ ë°©ì˜ ì£¼ë³€ ìì—° êµ¬ì¡°ë¬¼ë“¤ê³¼ ì–´ë–»ê²Œ ìƒí˜¸ì‘ìš©í•˜ëŠ”ì§€ì— ëŒ€í•œ ëª¨ë“  ì¸¡ë©´ì„ ê°œì„ í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So you can see how we have been raising the bar, increasing our safety, and being able to design with the purpose a shell that will go with the gel to make sure that we can do it under a minimally invasive by enhancing the ergonomic concept, the adaptability, the natural dynamics of the<br><br>breast, and the evolution that we have taken. It is going away from just designing that implant but designing a platform that would allow us to provide a safer, more standardized and replicable procedure. Speaker 13: So with the ergonomics concept, we were able to start our journey on minimally invasive, minimizing the scar, using different tools in order to improve the experience of the patients.</td><td>ë”°ë¼ì„œ ì €í¬ê°€ ì–´ë–»ê²Œ ê¸°ì¤€ì„ ë†’ì—¬ì™”ëŠ”ì§€, ì•ˆì „ì„±ì„ ì¦ëŒ€ì‹œì¼œì™”ëŠ”ì§€, ê·¸ë¦¬ê³  ì ¤ê³¼ í•¨ê»˜ ì‚¬ìš©í•  ì…¸ì„ ëª©ì ì— ë§ê²Œ ì„¤ê³„í•˜ì—¬ ì¸ì²´ê³µí•™ì  ê°œë…, ì ì‘ì„±, ìœ ë°©ì˜ ìì—°ìŠ¤ëŸ¬ìš´ ì—­í•™ì„ í–¥ìƒì‹œí‚´ìœ¼ë¡œì¨ ìµœì†Œì¹¨ìŠµì ìœ¼ë¡œ ì‹œìˆ í•  ìˆ˜ ìˆë„ë¡ í•´ì™”ëŠ”ì§€, ê·¸ë¦¬ê³  ì €í¬ê°€ ì·¨í•´ì˜¨ ë°œì „ ê³¼ì •ì„ ë³´ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ë‹¨ìˆœíˆ ì„í”Œë€íŠ¸ë¥¼ ì„¤ê³„í•˜ëŠ” ê²ƒì—ì„œ ë²—ì–´ë‚˜ ë” ì•ˆì „í•˜ê³  í‘œì¤€í™”ë˜ë©° ì¬í˜„ ê°€ëŠ¥í•œ ì‹œìˆ ì„ ì œê³µí•  ìˆ˜ ìˆëŠ” í”Œë«í¼ì„ ì„¤ê³„í•˜ëŠ” ê²ƒìœ¼ë¡œ ë‚˜ì•„ê°€ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 13: ì¸ì²´ê³µí•™ì  ê°œë…ì„ í†µí•´ ì €í¬ëŠ” ìµœì†Œì¹¨ìŠµ ì—¬ì •ì„ ì‹œì‘í•  ìˆ˜ ìˆì—ˆê³ , í‰í„°ë¥¼ ìµœì†Œí™”í•˜ë©° í™˜ì ê²½í—˜ì„ ê°œì„ í•˜ê¸° ìœ„í•´ ë‹¤ì–‘í•œ ë„êµ¬ë“¤ì„ ì‚¬ìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And this is how we have been evolving to then continue the benefits of the ergonomic platform with the ergonomics too that increases that properties as I've been pointing out. And that's how we were able to create this minimally invasive platform that we are putting in three different pillars. So the one, it's the Mia. It was the one that we started with and it was has been already launched in many cities with great success. Speaker 13: But that allows us to understand the behavior of this technology with the surrounding tissues and the benefits of it. And then after that we were able to create a procedure that will have a larger reach but maintaining the most important principles.</td><td>ê·¸ë¦¬ê³  ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ ì¸ì²´ê³µí•™ì  í”Œë«í¼ì˜ ì´ì ì„ ì§€ì†ì ìœ¼ë¡œ ë°œì „ì‹œì¼œ ì˜¨ ë°©ì‹ì´ë©°, ì œê°€ ì§€ì í•´ì˜¨ ë°”ì™€ ê°™ì´ ê·¸ëŸ¬í•œ íŠ¹ì„±ë“¤ì„ ì¦ëŒ€ì‹œí‚¤ëŠ” ì¸ì²´ê³µí•™ì  ìš”ì†Œë“¤ê³¼ í•¨ê»˜ ë§ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ ì„¸ ê°€ì§€ ì„œë¡œ ë‹¤ë¥¸ ê¸°ë‘¥ìœ¼ë¡œ êµ¬ì„±ëœ ì´ ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì„ ë§Œë“¤ ìˆ˜ ìˆì—ˆë˜ ë°©ë²•ì…ë‹ˆë‹¤. ê·¸ ì¤‘ í•˜ë‚˜ëŠ” Miaì…ë‹ˆë‹¤. ì´ê²ƒì€ ìš°ë¦¬ê°€ ì‹œì‘í•œ ì²« ë²ˆì§¸ ì œí’ˆì´ì—ˆê³  ì´ë¯¸ ë§ì€ ë„ì‹œì—ì„œ í° ì„±ê³µì„ ê±°ë‘ë©° ì¶œì‹œë˜ì—ˆìŠµë‹ˆë‹¤.<br><br>í™”ì 13: í•˜ì§€ë§Œ ì´ë¥¼ í†µí•´ ìš°ë¦¬ëŠ” ì´ ê¸°ìˆ ì´ ì£¼ë³€ ì¡°ì§ê³¼ ì–´ë–»ê²Œ ìƒí˜¸ì‘ìš©í•˜ëŠ”ì§€ ê·¸ í–‰ë™ ì–‘ìƒê³¼ ê·¸ê²ƒì˜ ì´ì ë“¤ì„ ì´í•´í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¸ ì´í›„ì— ìš°ë¦¬ëŠ” ê°€ì¥ ì¤‘ìš”í•œ ì›ì¹™ë“¤ì„ ìœ ì§€í•˜ë©´ì„œë„ ë” ë„“ì€ ì ìš© ë²”ìœ„ë¥¼ ê°€ì§ˆ ìˆ˜ ìˆëŠ” ì‹œìˆ ë²•ì„ ë§Œë“¤ ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The geometries of the implants, how we can reduce the size, having good projections, good outcomes, how can we increase the use of this technology. And then in 2023, we started our clinical trial that I'll be sharing more. But for JEM, for the gluteal like all questioning and all the fears of a gluteal augmentation that is known very, very clearly worldwide, we have been able to maximize the safety of the procedures in a standardized way and a replicable way in order to minimize those risks. Speaker 13: So by creating a very thought platform, we have been able to provide the tools in order to be more precise on how we're doing the procedure.</td><td>ì„í”Œë€íŠ¸ì˜ í˜•íƒœ, í¬ê¸°ë¥¼ ì¤„ì´ëŠ” ë°©ë²•, ì¢‹ì€ íˆ¬ì˜ë„ì™€ ì¢‹ì€ ê²°ê³¼ë¥¼ ì–»ëŠ” ë°©ë²•, ì´ ê¸°ìˆ ì˜ ì‚¬ìš©ì„ ì–´ë–»ê²Œ ì¦ê°€ì‹œí‚¬ ìˆ˜ ìˆëŠ”ì§€ì— ëŒ€í•´ ì—°êµ¬í•´ì™”ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  2023ë…„ì—ëŠ” ì„ìƒì‹œí—˜ì„ ì‹œì‘í–ˆìœ¼ë©°, ì´ì— ëŒ€í•´ì„œëŠ” ë” ìì„¸íˆ ê³µìœ í•˜ê² ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ JEMì˜ ê²½ìš°, ì „ ì„¸ê³„ì ìœ¼ë¡œ ë§¤ìš° ëª…í™•í•˜ê²Œ ì•Œë ¤ì§„ ë‘”ë¶€ í™•ëŒ€ìˆ ì˜ ëª¨ë“  ì˜ë¬¸ì ê³¼ ìš°ë ¤ì‚¬í•­ë“¤ì— ëŒ€í•´, ì €í¬ëŠ” í‘œì¤€í™”ë˜ê³  ì¬í˜„ ê°€ëŠ¥í•œ ë°©ì‹ìœ¼ë¡œ ì‹œìˆ ì˜ ì•ˆì „ì„±ì„ ê·¹ëŒ€í™”í•˜ì—¬ ì´ëŸ¬í•œ ìœ„í—˜ì„ ìµœì†Œí™”í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 13: ë§¤ìš° ì²´ê³„ì ì¸ í”Œë«í¼ì„ êµ¬ì¶•í•¨ìœ¼ë¡œì¨, ì €í¬ëŠ” ì‹œìˆ ì„ ë³´ë‹¤ ì •ë°€í•˜ê²Œ ìˆ˜í–‰í•  ìˆ˜ ìˆëŠ” ë„êµ¬ë“¤ì„ ì œê³µí•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Doctors have been talking about like all these natural structures of the ligaments, sacrum mammary ligaments, Cooper ligaments. Like it is basically rewriting the way that we're thinking about how to bring the addendum of a breast in a safe way that will maximize that behavior between the device and the<br><br>tissue surrounding. And here you see a very comprehensive platform that starts since the marking of the procedure. Like how do we create a way of minimizing the possible errors that a regular plastic surgeon can perform this procedure? Speaker 13: And by doing this we have been able to increase the way that we are educating our surgeons.</td><td>ì˜ì‚¬ë“¤ì€ ì¸ëŒ€, ì²œê³¨ìœ ë°©ì¸ëŒ€, ì¿ í¼ ì¸ëŒ€ì™€ ê°™ì€ ëª¨ë“  ìì—°ì  êµ¬ì¡°ì— ëŒ€í•´ ë…¼ì˜í•´ ì™”ìŠµë‹ˆë‹¤. ì´ëŠ” ê¸°ë³¸ì ìœ¼ë¡œ ê¸°ê¸°ì™€ ì£¼ë³€ ì¡°ì§ ê°„ì˜ ìƒí˜¸ì‘ìš©ì„ ìµœëŒ€í™”í•˜ëŠ” ì•ˆì „í•œ ë°©ì‹ìœ¼ë¡œ ìœ ë°© ë¶€ì†ë¬¼ì„ ì‚½ì…í•˜ëŠ” ë°©ë²•ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì‚¬ê³ ë°©ì‹ì„ ì¬ì •ë¦½í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ê¸°ì„œ ë³´ì‹œëŠ” ê²ƒì€ ì‹œìˆ  í‘œì‹œë¶€í„° ì‹œì‘í•˜ëŠ” ë§¤ìš° í¬ê´„ì ì¸ í”Œë«í¼ì…ë‹ˆë‹¤. ì¼ë°˜ì ì¸ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ê°€ ì´ ì‹œìˆ ì„ ìˆ˜í–‰í•  ë•Œ ë°œìƒí•  ìˆ˜ ìˆëŠ” ì˜¤ë¥˜ë¥¼ ìµœì†Œí™”í•˜ëŠ” ë°©ë²•ì„ ì–´ë–»ê²Œ ë§Œë“¤ ê²ƒì¸ê°€ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 13: ì´ë¥¼ í†µí•´ ìš°ë¦¬ëŠ” ì™¸ê³¼ì˜ì‚¬ë“¤ì„ êµìœ¡í•˜ëŠ” ë°©ì‹ì„ ê°œì„ í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>It is impressive to see surgeons with no experience in transaxillary procedures to be able to do AMIA even faster than the time that it will take an expert surgeon transaxillary<br>trained. And this is to showcase what we see in a AMEA procedure. So clearly you see that the axis is under the armpit and we create the channel separator in order to without damaging the tissue go and create a tunnel, a three-dimensional space that then is going to be used with the balloon and then literally injecting. Just by pressing a button, that implant is propelled into the space that we created.</td><td>ê²½ì¶•ì™€ ìˆ˜ìˆ  ê²½í—˜ì´ ì „í˜€ ì—†ëŠ” ì™¸ê³¼ì˜ë“¤ì´ ê²½ì¶•ì™€ ìˆ˜ìˆ  ì „ë¬¸ í›ˆë ¨ì„ ë°›ì€ ìˆ™ë ¨ëœ ì™¸ê³¼ì˜ë³´ë‹¤ë„ ë” ë¹ ë¥¸ ì‹œê°„ ë‚´ì— AMIA ì‹œìˆ ì„ ìˆ˜í–‰í•  ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì€ ë§¤ìš° ì¸ìƒì ì…ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ AMEA ì‹œìˆ ì—ì„œ ìš°ë¦¬ê°€ ëª©ê²©í•˜ëŠ” í˜„ìƒì„ ë³´ì—¬ì£¼ëŠ” ê²ƒì…ë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ ì¶•ì´ ê²¨ë“œë‘ì´ ì•„ë˜ì— ìœ„ì¹˜í•˜ë©°, ì¡°ì§ ì†ìƒ ì—†ì´ í„°ë„, ì¦‰ 3ì°¨ì› ê³µê°„ì„ ë§Œë“¤ê¸° ìœ„í•´ ì±„ë„ ë¶„ë¦¬ê¸°ë¥¼ ìƒì„±í•©ë‹ˆë‹¤. ì´í›„ ì´ ê³µê°„ì€ í’ì„ ê³¼ í•¨ê»˜ ì‚¬ìš©ë˜ë©°, ë§ ê·¸ëŒ€ë¡œ ë²„íŠ¼ í•˜ë‚˜ë§Œ ëˆ„ë¥´ë©´ ì„í”Œë€íŠ¸ê°€ ìš°ë¦¬ê°€ ë§Œë“  ê³µê°„ìœ¼ë¡œ ì¶”ì§„ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 13: And by doing that, we learned how we could then use it in the pre survey technique that is changing the axis on an infra mammary approach, but the amount of time that it's taking, it's less than five minutes. And what Doctor. Steve said, I think it makes a huge difference. The ability to use local anesthesia, the recovery of that, minimizing that is extremely significant. And you can see the patients here. Speaker 13: Here we're removing any scar from the breast and when you see the armpit it is actually hard to see which are the scars because there's some folds already there. So we're using one of those folds. And in the Preserve case also the scar is very similar.</td><td>í™”ì 13: ê·¸ë¦¬ê³  ê·¸ë ‡ê²Œ í•¨ìœ¼ë¡œì¨, ìš°ë¦¬ëŠ” ìœ ë°©í•˜ ì ‘ê·¼ë²•ì—ì„œ ì¶•ì„ ë³€ê²½í•˜ëŠ” ì‚¬ì „ ì¡°ì‚¬ ê¸°ë²•ì—ì„œ ì´ë¥¼ ì–´ë–»ê²Œ ì‚¬ìš©í•  ìˆ˜ ìˆëŠ”ì§€ ë°°ì› ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì†Œìš”ë˜ëŠ” ì‹œê°„ì€ 5ë¶„ ë¯¸ë§Œì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìŠ¤í‹°ë¸Œ ë°•ì‚¬ê°€ ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼, ì €ëŠ” ì´ê²ƒì´ ì—„ì²­ë‚œ ì°¨ì´ë¥¼ ë§Œë“ ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. êµ­ì†Œë§ˆì·¨ë¥¼ ì‚¬ìš©í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ê³¼ ê·¸ì— ë”°ë¥¸ íšŒë³µ, ì´ë¥¼ ìµœì†Œí™”í•˜ëŠ” ê²ƒì€ ë§¤ìš° ì¤‘ìš”í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ê¸°ì„œ í™˜ìë“¤ì„ ë³´ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>í™”ì 13: ì—¬ê¸°ì„œ ìš°ë¦¬ëŠ” ìœ ë°©ì˜ ëª¨ë“  í‰í„°ë¥¼ ì œê±°í•˜ê³  ìˆìœ¼ë©°, ê²¨ë“œë‘ì´ë¥¼ ë³´ì‹œë©´ ì‹¤ì œë¡œ ì–´ëŠ ê²ƒì´ í‰í„°ì¸ì§€ êµ¬ë³„í•˜ê¸° ì–´ë µìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ë¯¸ ê·¸ê³³ì— ì£¼ë¦„ì´ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ê·¸ ì£¼ë¦„ ì¤‘ í•˜ë‚˜ë¥¼ ì‚¬ìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  Preserve ì¼€ì´ìŠ¤ì—ì„œë„ í‰í„°ëŠ” ë§¤ìš° ìœ ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>So traditional breast augmentation, if you compare like the way that the process is done, we respect it a lot. It is what we have been learning how to improve. Speaker 13: But the way of moving now into a system that will allow us to create these results and using Preserve to go all the way up to four cups, while Mia it's developed in order to do<br><br>one or two cups size up. But the possibility of using the system in order to create a faster recovery for the patient is really making a huge difference for us. And you can see the difference between these two technologies. And this is a summary of the clinical data that we have collected from our study that it was a three year follow-up.</td><td>ë”°ë¼ì„œ ê¸°ì¡´ì˜ ìœ ë°© í™•ëŒ€ìˆ ê³¼ ë¹„êµí•´ë³´ë©´, ê·¸ ê³¼ì •ì´ ìˆ˜í–‰ë˜ëŠ” ë°©ì‹ì„ ìš°ë¦¬ëŠ” ë§¤ìš° ì¡´ì¤‘í•©ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ê°€ ê°œì„  ë°©ë²•ì„ ë°°ì›Œì˜¨ ê²ƒì…ë‹ˆë‹¤.<br><br>í•˜ì§€ë§Œ ì´ì œ Preserveë¥¼ ì‚¬ìš©í•˜ì—¬ ìµœëŒ€ 4ì»µê¹Œì§€ ì˜¬ë¦´ ìˆ˜ ìˆëŠ” ì‹œìŠ¤í…œìœ¼ë¡œ ì „í™˜í•˜ëŠ” ë°©ì‹ìœ¼ë¡œ ë‚˜ì•„ê°€ê³  ìˆìœ¼ë©°, MiaëŠ” 1-2ì»µ ì‚¬ì´ì¦ˆ ì—…ì„ ìœ„í•´ ê°œë°œë˜ì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ í™˜ìì˜ ë” ë¹ ë¥¸ íšŒë³µì„ ìœ„í•´ ì´ ì‹œìŠ¤í…œì„ ì‚¬ìš©í•  ìˆ˜ ìˆëŠ” ê°€ëŠ¥ì„±ì´ ìš°ë¦¬ì—ê²Œ ì •ë§ í° ì°¨ì´ë¥¼ ë§Œë“¤ì–´ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ì€ ì´ ë‘ ê¸°ìˆ  ê°„ì˜ ì°¨ì´ì ì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. <br><br>ì´ê²ƒì€ 3ë…„ê°„ì˜ ì¶”ì  ê´€ì°°ì„ ì§„í–‰í•œ ìš°ë¦¬ ì—°êµ¬ì—ì„œ ìˆ˜ì§‘í•œ ì„ìƒ ë°ì´í„°ì˜ ìš”ì•½ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And when you see the results it's actually hard to believe. Speaker 13: Doctor. Pittman said we used to be called crazy when we started doing this. That we're so used to that word because when you're doing things differently, when you're bringing new technologies, that's exactly the thing that you're going to be called. But with a very good clinical data supporting this, look at the Capcon rate and the rupture rate. Is this a surprise? Speaker 13: It's not. For us it's not because we have been really thinking about how do we minimize.</td><td>ê²°ê³¼ë¥¼ ë³´ë©´ ì‹¤ì œë¡œ ë¯¿ê¸° ì–´ë ¤ìš¸ ì •ë„ì…ë‹ˆë‹¤. <br><br>ë°œí‘œì 13: í”¼íŠ¸ë§Œ ë°•ì‚¬ë‹˜ê»˜ì„œ ë§ì”€í•˜ì…¨ë“¯ì´, ì €í¬ê°€ ì´ ì¼ì„ ì‹œì‘í–ˆì„ ë•Œ ì‚¬ëŒë“¤ì€ ì €í¬ë¥¼ ë¯¸ì³¤ë‹¤ê³  ë¶ˆë €ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê·¸ ë‹¨ì–´ì— ë„ˆë¬´ ìµìˆ™í•´ì¡ŒëŠ”ë°, ì™œëƒí•˜ë©´ ë‹¤ë¥¸ ë°©ì‹ìœ¼ë¡œ ì¼ì„ í•˜ê³  ìƒˆë¡œìš´ ê¸°ìˆ ì„ ë„ì…í•  ë•ŒëŠ” ì •í™•íˆ ê·¸ëŸ° ë§ì„ ë“£ê²Œ ë˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ë¥¼ ë’·ë°›ì¹¨í•˜ëŠ” ë§¤ìš° ìš°ìˆ˜í•œ ì„ìƒ ë°ì´í„°ì™€ í•¨ê»˜, ìº¡ì½˜(Capcon) ë¹„ìœ¨ê³¼ íŒŒì—´ë¥ ì„ ë³´ì‹œê¸° ë°”ëë‹ˆë‹¤. ì´ê²ƒì´ ë†€ë¼ìš´ ì¼ì¸ê°€ìš”?<br><br>ë°œí‘œì 13: ì €í¬ì—ê²ŒëŠ” ê·¸ë ‡ì§€ ì•ŠìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì €í¬ëŠ” ì–´ë–»ê²Œ í•˜ë©´ ìµœì†Œí™”í•  ìˆ˜ ìˆì„ì§€ì— ëŒ€í•´ ì •ë§ë¡œ ê¹Šì´ ìƒê°í•´ì™”ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Even though we had already a very low capsule contraction rate by using a system that will minimize even more the interaction that can possibly bring anything to increase that capcon reducing it. So this is not a surprise. And also having a system that deploys it without the risk of rupturing, of course, also minimizes that. Speaker 13: So like sometimes I know that serials are hard to believe, but this is the information that we have. And I think that that will be in the future also very consistent. And yeah, think that one of the progresses that we're going to be having now is that we're going we're starting to<br>see how the platform that we developed for the breast have other applications.</td><td>ì´ë¯¸ ìº¡ìŠ ìˆ˜ì¶•ë¥ ì´ ë§¤ìš° ë‚®ì•˜ìŒì—ë„ ë¶ˆêµ¬í•˜ê³ , ìº¡ìŠ ìˆ˜ì¶•ì„ ì¦ê°€ì‹œí‚¬ ìˆ˜ ìˆëŠ” ìƒí˜¸ì‘ìš©ì„ ë”ìš± ìµœì†Œí™”í•˜ëŠ” ì‹œìŠ¤í…œì„ ì‚¬ìš©í•¨ìœ¼ë¡œì¨ ì´ë¥¼ ë”ìš± ì¤„ì¼ ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŠ” ë†€ë¼ìš´ ì¼ì´ ì•„ë‹™ë‹ˆë‹¤. ë˜í•œ íŒŒì—´ ìœ„í—˜ ì—†ì´ ë°°ì¹˜í•  ìˆ˜ ìˆëŠ” ì‹œìŠ¤í…œì„ ë³´ìœ í•˜ê³  ìˆì–´ ì´ ì—­ì‹œ ìœ„í—˜ì„ ìµœì†Œí™”í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 13: ë•Œë¡œëŠ” ì—°ì† ë°ì´í„°ë¥¼ ë¯¿ê¸° ì–´ë ¤ìš¸ ìˆ˜ ìˆë‹¤ëŠ” ì ì„ ì•Œê³  ìˆì§€ë§Œ, ì´ê²ƒì´ ìš°ë¦¬ê°€ ë³´ìœ í•œ ì •ë³´ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  í–¥í›„ì—ë„ ì´ëŸ¬í•œ ê²°ê³¼ê°€ ë§¤ìš° ì¼ê´€ë  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë„¤, ì•ìœ¼ë¡œ ìš°ë¦¬ê°€ ì´ë£° ì§„ì „ ì¤‘ í•˜ë‚˜ëŠ” ìœ ë°©ìš©ìœ¼ë¡œ ê°œë°œí•œ í”Œë«í¼ì´ ë‹¤ë¥¸ ì‘ìš© ë¶„ì•¼ì—ë„ í™œìš©ë  ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì„ í™•ì¸í•˜ê¸° ì‹œì‘í•œë‹¤ëŠ” ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And this is some pictures that we use from our clinical study that we started IRB clinical study approved that we started in 2023. So this year we're going to have already two years of follow-up and the patients are doing extremely, extremely nice. Speaker 13: But you can see there's a different tool because we're going between the muscles. So we have to design a tool that will allow us to get to that space. But we're leveraging the<br><br>platform for the injectable that we have for Mia, the injector that we have for Mia. And you can see right there on the table the results that we're getting.</td><td>ê·¸ë¦¬ê³  ì´ê²ƒì€ 2023ë…„ì— ì‹œì‘í•œ IRB ìŠ¹ì¸ ì„ìƒ ì—°êµ¬ì—ì„œ ì‚¬ìš©í•œ ëª‡ ê°€ì§€ ì‚¬ì§„ë“¤ì…ë‹ˆë‹¤. ì˜¬í•´ì—ëŠ” ì´ë¯¸ 2ë…„ê°„ì˜ ì¶”ì  ê´€ì°° ë°ì´í„°ë¥¼ í™•ë³´í•˜ê²Œ ë  ê²ƒì´ë©°, í™˜ìë“¤ì˜ ìƒíƒœëŠ” ë§¤ìš°, ë§¤ìš° ì–‘í˜¸í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 13: í•˜ì§€ë§Œ ê·¼ìœ¡ ì‚¬ì´ë¡œ ì ‘ê·¼í•´ì•¼ í•˜ê¸° ë•Œë¬¸ì— ë‹¤ë¥¸ ë„êµ¬ê°€ í•„ìš”í•˜ë‹¤ëŠ” ê²ƒì„ ì•Œ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ í•´ë‹¹ ë¶€ìœ„ì— ì ‘ê·¼í•  ìˆ˜ ìˆëŠ” ë„êµ¬ë¥¼ ì„¤ê³„í•´ì•¼ í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ëŠ” Miaìš© ì£¼ì‚¬ì œì— ì‚¬ìš©í•˜ëŠ” í”Œë«í¼, ì¦‰ Miaìš© ì£¼ì…ê¸°ë¥¼ í™œìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë°”ë¡œ ì €ê¸° í…Œì´ë¸”ì—ì„œ ìš°ë¦¬ê°€ ì–»ê³  ìˆëŠ” ê²°ê³¼ë¥¼ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And this is a patient, this is six month follow-up but what you can see here is that it's not a huge augmentation. Speaker 13: It's just a little volumization of the gluteal and look at the scar. Traditionally, I don't know if you've seen this, but when you get a gluteal augmentation with an implant you get two scars because of the risk of infection, because of the access to the muscles, and we were able to move all to one scar and the scar is less than three centimeters. And also the procedure is done in less than five minutes itself. And it is no general anesthesia, it's a spinal block and then we do some blocking on the muscle in order to minimize the pain management.</td><td>ì´ê²ƒì€ í™˜ìì˜ 6ê°œì›” ì¶”ì  ê´€ì°° ê²°ê³¼ì¸ë°, ì—¬ê¸°ì„œ ë³´ì‹¤ ìˆ˜ ìˆëŠ” ê²ƒì€ ì´ê²ƒì´ ê³¼ë„í•œ í™•ëŒ€ìˆ ì´ ì•„ë‹ˆë¼ëŠ” ì ì…ë‹ˆë‹¤.<br><br>í™”ì 13: ë‹¨ìˆœíˆ ë‘”ë¶€ì˜ ì•½ê°„ì˜ ë³¼ë¥¨ ì¦ê°€ì¼ ë¿ì´ë©° í‰í„°ë¥¼ ë³´ì„¸ìš”. ì „í†µì ìœ¼ë¡œ, ë³´ì‹  ì ì´ ìˆëŠ”ì§€ ëª¨ë¥´ê² ì§€ë§Œ, ì„í”Œë€íŠ¸ë¥¼ ì´ìš©í•œ ë‘”ë¶€ í™•ëŒ€ìˆ ì„ ë°›ìœ¼ë©´ ê°ì—¼ ìœ„í—˜ê³¼ ê·¼ìœ¡ ì ‘ê·¼ìœ¼ë¡œ ì¸í•´ ë‘ ê°œì˜ í‰í„°ê°€ ìƒê¸°ëŠ”ë°, ì €í¬ëŠ” ëª¨ë“  ê²ƒì„ í•˜ë‚˜ì˜ í‰í„°ë¡œ ì²˜ë¦¬í•  ìˆ˜ ìˆì—ˆê³  í‰í„°ëŠ” 3ì„¼í‹°ë¯¸í„° ë¯¸ë§Œì…ë‹ˆë‹¤. ë˜í•œ ì‹œìˆ  ìì²´ëŠ” 5ë¶„ ì´ë‚´ì— ì™„ë£Œë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì „ì‹ ë§ˆì·¨ê°€ ì•„ë‹Œ ì²™ì¶”ë§ˆì·¨ë¥¼ ì‚¬ìš©í•˜ë©°, í†µì¦ ê´€ë¦¬ë¥¼ ìµœì†Œí™”í•˜ê¸° ìœ„í•´ ê·¼ìœ¡ì— ì¼ë¶€ ì°¨ë‹¨ìˆ ì„ ì‹œí–‰í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And just to finish something that we have been working on since 2010. Speaker 13: We brought the RFID technology into our implants and that was launched in Europe in 2014 and an evolution of this. Well, Doctor. Hammond was explaining how do we use that platform in the flora tissue expander that we're extremely proud of and how it has changed the way that breast reconstruction is being done. And I think that still there's a lot of impact<br>that it will have. But what we did for the breast implant is that we converted that passive technology of radio frequency into the beginning of what it will be a platform to start collecting data like with biosensors.</td><td>ê·¸ë¦¬ê³  2010ë…„ë¶€í„° ì‘ì—…í•´ì˜¨ ê²ƒì„ ë§ˆë¬´ë¦¬í•˜ìë©´, ì €í¬ëŠ” RFID ê¸°ìˆ ì„ ì„í”Œë€íŠ¸ì— ë„ì…í–ˆê³  ì´ëŠ” 2014ë…„ ìœ ëŸ½ì—ì„œ ì¶œì‹œë˜ì—ˆìœ¼ë©° ì´ê²ƒì˜ ë°œì „ëœ í˜•íƒœì…ë‹ˆë‹¤. ìŒ, Hammond ë°•ì‚¬ë‹˜ê»˜ì„œ í”Œë¡œë¼ ì¡°ì§ í™•ì¥ê¸°ì—ì„œ í•´ë‹¹ í”Œë«í¼ì„ ì–´ë–»ê²Œ ì‚¬ìš©í•˜ëŠ”ì§€, ì €í¬ê°€ ë§¤ìš° ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•˜ëŠ” ë¶€ë¶„ê³¼ ì´ê²ƒì´ ìœ ë°© ì¬ê±´ìˆ ì´ ì‹œí–‰ë˜ëŠ” ë°©ì‹ì„ ì–´ë–»ê²Œ ë³€í™”ì‹œì¼°ëŠ”ì§€ ì„¤ëª…í•´ì£¼ì…¨ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ì „íˆ ë§ì€ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. <br><br>í•˜ì§€ë§Œ ìœ ë°© ì„í”Œë€íŠ¸ì— ëŒ€í•´ ì €í¬ê°€ í•œ ì¼ì€ ë¬´ì„  ì£¼íŒŒìˆ˜ì˜ ìˆ˜ë™ì  ê¸°ìˆ ì„ ë°”ì´ì˜¤ì„¼ì„œì™€ ê°™ì€ ë°ì´í„° ìˆ˜ì§‘ì„ ì‹œì‘í•  í”Œë«í¼ì˜ ì‹œì‘ì ìœ¼ë¡œ ì „í™˜í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 13: And we're starting to get our data on the GEM study. All the patients that participated in the GEM study had the temperature sensor and we started collecting information that have never been collected. And also we have some patients that have it in the breast and it is very impressive the difference and the behavior. We have collected the 24 circadian cycle and the capabilities that this platform can bring us to the future. We believe that it will be extremely, extremely valuable for the breast health. Speaker 13: And with that, I would like to now pass it over to Juan Jose Chacon, our founder and captain of all this.</td><td>**í™”ì 13:** ê·¸ë¦¬ê³  ì €í¬ëŠ” GEM ì—°êµ¬ì—ì„œ ë°ì´í„°ë¥¼ ì–»ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. GEM ì—°êµ¬ì— ì°¸ì—¬í•œ ëª¨ë“  í™˜ìë“¤ì´ ì˜¨ë„ ì„¼ì„œë¥¼ ì°©ìš©í–ˆìœ¼ë©°, ì €í¬ëŠ” ì´ì „ì—ëŠ” ìˆ˜ì§‘ëœ ì ì´ ì—†ëŠ” ì •ë³´ë“¤ì„ ìˆ˜ì§‘í•˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ë˜í•œ ìœ ë°©ì— ì„¼ì„œë¥¼ ì°©ìš©í•œ ì¼ë¶€ í™˜ìë“¤ì´ ìˆëŠ”ë°, ê·¸ ì°¨ì´ì™€ í–‰ë™ ì–‘ìƒì´ ë§¤ìš° ì¸ìƒì ì…ë‹ˆë‹¤. ì €í¬ëŠ” 24ì‹œê°„ ì¼ì£¼ê¸° ë¦¬ë“¬ì„ ìˆ˜ì§‘í–ˆìœ¼ë©°, ì´ í”Œë«í¼ì´ ë¯¸ë˜ì— ê°€ì ¸ë‹¤ì¤„ ìˆ˜ ìˆëŠ” ì—­ëŸ‰ë“¤ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ìœ ë°© ê±´ê°•ì— ìˆì–´ ê·¹ë„ë¡œ, ê·¹ë„ë¡œ ê°€ì¹˜ ìˆì„ ê²ƒì´ë¼ê³  ë¯¿ìŠµë‹ˆë‹¤.<br><br>**í™”ì 13:** ì´ì œ ì €í¬ì˜ ì°½ë¦½ìì´ì ì´ ëª¨ë“  ê²ƒì˜ ì„ ì¥ì¸ í›„ì•ˆ í˜¸ì„¸ ì°¨ì½˜(Juan Jose Chacon)ì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And and very nice to be here, and and thank you so much for for being here too. Speaker 14: Thank you, Roberto, and so glad to be here. Last time I was here is 07/19/2018, the day we went public, company from Central America. So it means a lot to be back here, with these amazing plastic surgeons that are here basically to give us the insights that we need, not only on the technology that we have today, but what's coming after. And I think one of the<br>really interesting things is that with the advent of GLP-1s, there's been a profound transformation not only in society but also in the market for medical devices. And for some time probably there was a lumping of aesthetics within that group.</td><td>ì•ˆë…•í•˜ì„¸ìš”, ì´ë ‡ê²Œ ì°¸ì„í•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì˜ê³ , ì—¬ëŸ¬ë¶„ë“¤ë„ í•¨ê»˜í•´ ì£¼ì…”ì„œ ì •ë§ ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>**Speaker 14**: ë¡œë² ë¥´í† , ê°ì‚¬í•©ë‹ˆë‹¤. ì´ê³³ì— ì˜¤ê²Œ ë˜ì–´ ì •ë§ ê¸°ì©ë‹ˆë‹¤. ì œê°€ ë§ˆì§€ë§‰ìœ¼ë¡œ ì´ê³³ì— ì˜¨ ê²ƒì€ 2018ë…„ 7ì›” 19ì¼, ì¤‘ë¯¸ ì¶œì‹  íšŒì‚¬ë¡œì„œ ìƒì¥í•œ ë‚ ì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ë ‡ê²Œ ë‹¤ì‹œ ëŒì•„ì˜¤ê²Œ ëœ ê²ƒì´ ë§¤ìš° ì˜ë¯¸ê°€ ê¹ŠìŠµë‹ˆë‹¤. íŠ¹íˆ ì´ê³³ì— ê³„ì‹  í›Œë¥­í•œ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë¶„ë“¤ê³¼ í•¨ê»˜í•  ìˆ˜ ìˆì–´ì„œìš”. ì´ë¶„ë“¤ì€ ê¸°ë³¸ì ìœ¼ë¡œ ì €í¬ê°€ í˜„ì¬ ë³´ìœ í•œ ê¸°ìˆ ë¿ë§Œ ì•„ë‹ˆë¼ ì•ìœ¼ë¡œ ë‚˜ì˜¬ ê¸°ìˆ ì— ëŒ€í•´ì„œë„ í•„ìš”í•œ í†µì°°ë ¥ì„ ì œê³µí•´ ì£¼ì‹œëŠ” ë¶„ë“¤ì…ë‹ˆë‹¤. <br><br>ì •ë§ í¥ë¯¸ë¡œìš´ ì  ì¤‘ í•˜ë‚˜ëŠ” GLP-1 ì•½ë¬¼ì˜ ë“±ì¥ìœ¼ë¡œ ì‚¬íšŒë¿ë§Œ ì•„ë‹ˆë¼ ì˜ë£Œê¸°ê¸° ì‹œì¥ì—ë„ ê·¼ë³¸ì ì¸ ë³€í™”ê°€ ì¼ì–´ë‚¬ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  í•œë™ì•ˆì€ ì•„ë§ˆë„ ë¯¸ìš© ë¶„ì•¼ë„ ê·¸ ê·¸ë£¹ ì•ˆì— í¬í•¨ë˜ì–´ í•¨ê»˜ ë¬¶ì—¬ì„œ ì¸ì‹ë˜ì—ˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 14: And one of the things we're going do today is we're going to have two amazing plastic surgeons, Doctor. Sachin Sivrani and Doctor. Johnny Franco, who are going to talk about the impact of GLP-one agonist in plastic surgery. So please, both of you, can you come here? And Doctor. Speaker 14: Franco, why don't you come And thank you again. Thank you. Could we have the presentation, please? Speaker 15: Awesome. I'm Doctor. Johnny Franco in Austin, Texas. I'll tell you this. Weight loss revolution has been a personal passion project of mine. Speaker 15: I actually started the journey in about 2022, and I'm down about 90 pounds over the past three years.</td><td>ë°œí‘œì 14: ê·¸ë¦¬ê³  ì˜¤ëŠ˜ ìš°ë¦¬ê°€ í•  ì¼ ì¤‘ í•˜ë‚˜ëŠ” ë‘ ë¶„ì˜ í›Œë¥­í•œ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ì„ ëª¨ì‹œëŠ” ê²ƒì…ë‹ˆë‹¤. ì‚¬ì¹œ ì‹œë¸Œë¼ë‹ˆ(Sachin Sivrani) ë°•ì‚¬ë‹˜ê³¼ ì¡°ë‹ˆ í”„ë‘ì½”(Johnny Franco) ë°•ì‚¬ë‹˜ê»˜ì„œ ì„±í˜•ì™¸ê³¼ì—ì„œ GLP-1 ì‘ìš©ì œì˜ ì˜í–¥ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ì˜ˆì •ì…ë‹ˆë‹¤. ë‘ ë¶„ ëª¨ë‘ ì´ìª½ìœ¼ë¡œ ë‚˜ì™€ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  í”„ë‘ì½” ë°•ì‚¬ë‹˜, ì´ìª½ìœ¼ë¡œ ì™€ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ë‹¤ì‹œ í•œ ë²ˆ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. í”„ë ˆì  í…Œì´ì…˜ì„ ì‹œì‘í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?<br><br>ë°œí‘œì 15: ì¢‹ìŠµë‹ˆë‹¤. ì €ëŠ” í…ì‚¬ìŠ¤ ì˜¤ìŠ¤í‹´ì˜ ì¡°ë‹ˆ í”„ë‘ì½” ë°•ì‚¬ì…ë‹ˆë‹¤. ë§ì”€ë“œë¦¬ìë©´, ì²´ì¤‘ ê°ëŸ‰ í˜ëª…ì€ ì €ì—ê²Œ ê°œì¸ì ì¸ ì—´ì • í”„ë¡œì íŠ¸ì˜€ìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ 2022ë…„ê²½ì— ì´ ì—¬ì •ì„ ì‹œì‘í–ˆê³ , ì§€ë‚œ 3ë…„ ë™ì•ˆ ì•½ 90íŒŒìš´ë“œë¥¼ ê°ëŸ‰í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We integrated this into our practice. At this point, we see anywhere between 1,500 to 2,000 weight loss patients a month in the office. And I think one of the things that's<br>been super unique for us is starting so early on the curve, if you think about 2022 is just a whisper before this kind of wave came in. And I think I've had the fortunate opportunity to, one,<br><br>live it and then, two, be able to see our patients of where they've been in this journey.</td><td>ì €í¬ëŠ” ì´ë¥¼ ì§„ë£Œì— í†µí•©í–ˆìŠµë‹ˆë‹¤. í˜„ì¬ ì €í¬ ë³‘ì›ì—ì„œëŠ” í•œ ë‹¬ì— 1,500ëª…ì—ì„œ 2,000ëª…ì˜ ì²´ì¤‘ ê°ëŸ‰ í™˜ìë¥¼ ì§„ë£Œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ì—ê²Œ ë§¤ìš° ë…íŠ¹í–ˆë˜ ì  ì¤‘ í•˜ë‚˜ëŠ” ì´ ê³¡ì„ ì˜ ì•„ì£¼ ì´ˆê¸°ì— ì‹œì‘í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. 2022ë…„ì„ ìƒê°í•´ë³´ë©´ ì´ëŸ° í° ë¬¼ê²°ì´ ë°€ë ¤ì˜¤ê¸° ì§ì „ì˜ ì†ì‚­ì„ ê°™ì€ ì‹œê¸°ì˜€ì£ . ê·¸ë¦¬ê³  ì €ëŠ” ìš´ ì¢‹ê²Œë„ ì²«ì§¸, ì´ë¥¼ ì§ì ‘ ê²½í—˜í•˜ê³ , ë‘˜ì§¸, ì´ ì—¬ì •ì—ì„œ ì €í¬ í™˜ìë“¤ì´ ì–´ë””ì— ìˆì—ˆëŠ”ì§€ë¥¼ ë³¼ ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ê°€ì¡Œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 15: And I'll give you my case of why I truly think that there's a cosmetic wave coming for those in the industry and for practices that truly adopt this, that truly empower this, but really, really uniquely have to speak to these patients in a different way. There's really just amazing opportunities, but there's real challenges. You've seen some of these, and this is where I think Motiva has a few really unique opportunities to treat some of these challenges that are going to be confronting patients because as great as this is, there's going to be some new frontiers.</td><td>ë°œí‘œì 15: ê·¸ë¦¬ê³  ì €ëŠ” ì™œ ì§„ì •ìœ¼ë¡œ ì´ ì—…ê³„ì— ì¢…ì‚¬í•˜ëŠ” ë¶„ë“¤ê³¼ ì´ë¥¼ ì‹¤ì œë¡œ ë„ì…í•˜ê³ , ì‹¤ì œë¡œ ì´ë¥¼ í™œìš©í•˜ë˜, ì •ë§ë¡œ ë…íŠ¹í•˜ê²Œ ì´ëŸ¬í•œ í™˜ìë“¤ì—ê²Œ ë‹¤ë¥¸ ë°©ì‹ìœ¼ë¡œ ì†Œí†µí•´ì•¼ í•˜ëŠ” ì§„ë£Œì†Œë“¤ì—ê²Œ ì„±í˜• ì›¨ì´ë¸Œê°€ ë‹¤ê°€ì˜¤ê³  ìˆë‹¤ê³  ìƒê°í•˜ëŠ”ì§€ì— ëŒ€í•œ ì œ ê²¬í•´ë¥¼ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì •ë§ ë†€ë¼ìš´ ê¸°íšŒë“¤ì´ ìˆì§€ë§Œ, ì‹¤ì§ˆì ì¸ ë„ì „ê³¼ì œë“¤ë„ ìˆìŠµë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ë“¤ë„ ì´ëŸ¬í•œ ê²ƒë“¤ ì¤‘ ì¼ë¶€ë¥¼ ë³´ì…¨ì„ ê²ƒì´ê³ , ì´ê²ƒì´ ë°”ë¡œ Motivaê°€ í™˜ìë“¤ì´ ì§ë©´í•˜ê²Œ ë  ì´ëŸ¬í•œ ë„ì „ê³¼ì œë“¤ ì¤‘ ì¼ë¶€ë¥¼ í•´ê²°í•  ìˆ˜ ìˆëŠ” ëª‡ ê°€ì§€ ì •ë§ ë…íŠ¹í•œ ê¸°íšŒë¥¼ ê°€ì§€ê³  ìˆë‹¤ê³  ìƒê°í•˜ëŠ” ë¶€ë¶„ì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ê²ƒì´ ì•„ë¬´ë¦¬ í›Œë¥­í•˜ë‹¤ê³  í•´ë„, ìƒˆë¡œìš´ ê°œì²™ ë¶„ì•¼ë“¤ì´ ìˆì„ ê²ƒì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>We're seeing mature issues in really young patients and we have to think about how are going to treat them over the next not twenty, thirty of their years when they came in at 40, 50 or 60, but how are going treat them for next eighty years of their life? So I think a few points have already been made about that. Speaker 15: When you think about this weight loss revolution, why is it such a chord? There's nothing that has ever reached so many people. I don't think that there's been a treatment in the health care field since penicillin that has such a ripple effect in the health care industry. I mean, we're going to see changes because of these medications for the rest of my career at least.</td><td>ì •ë§ ì Šì€ í™˜ìë“¤ì—ê²Œì„œ ì„±ìˆ™í•œ ì§ˆí™˜ë“¤ì„ ë³´ê³  ìˆìœ¼ë©°, 40ì„¸, 50ì„¸, 60ì„¸ì— ë‚´ì›í–ˆì„ ë•Œ í–¥í›„ 20ë…„, 30ë…„ì´ ì•„ë‹ˆë¼ ì•ìœ¼ë¡œ 80ë…„ì˜ ìƒì• ì— ê±¸ì³ ì–´ë–»ê²Œ ì¹˜ë£Œí•  ê²ƒì¸ì§€ì— ëŒ€í•´ ìƒê°í•´ì•¼ í•©ë‹ˆë‹¤. ì´ì— ëŒ€í•´ì„œëŠ” ì´ë¯¸ ëª‡ ê°€ì§€ ìš”ì ë“¤ì´ ì–¸ê¸‰ë˜ì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 15: ì´ ì²´ì¤‘ ê°ëŸ‰ í˜ëª…ì— ëŒ€í•´ ìƒê°í•´ë³´ë©´, ì™œ ì´ë ‡ê²Œ í° ë°˜í–¥ì„ ì¼ìœ¼í‚¤ëŠ” ê±¸ê¹Œìš”? ì´ë ‡ê²Œ ë§ì€ ì‚¬ëŒë“¤ì—ê²Œ ë„ë‹¬í•œ ê²ƒì€ ì „ë¡€ê°€ ì—†ìŠµë‹ˆë‹¤. í˜ë‹ˆì‹¤ë¦° ì´í›„ë¡œ ì˜ë£Œ ì—…ê³„ì—ì„œ ì´ë ‡ê²Œ íŒŒê¸‰ íš¨ê³¼ê°€ í° ì¹˜ë£Œë²•ì€ ì—†ì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì•½ë¬¼ë“¤ë¡œ ì¸í•´ ì ì–´ë„ ì œ ê²½ë ¥ì´ ëë‚  ë•Œê¹Œì§€ëŠ” ë³€í™”ë¥¼ ë³´ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>But so many people are involved. Speaker 15: If you look at how many Americans are interested, at least half, I feel like the other 40% in that group probably just pushed the wrong button. If you look at the aesthetic industry itself, it's one of the things we're looking at is how many people are in it because so many people are trying to just improve this. And you see the indications of these just increasing<br>every day. One of the big changes here, if you think about this, the spend in weight loss, 11% of aesthetic spend is on weight loss medications and lifestyle. A few people, including Doctor. Speaker 15: Steve, already talked about this. You're seeing this pivot, right?</td><td>í•˜ì§€ë§Œ ë„ˆë¬´ ë§ì€ ì‚¬ëŒë“¤ì´ ê´€ë ¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë°œí‘œì 15: ê´€ì‹¬ì„ ë³´ì´ëŠ” ë¯¸êµ­ì¸ë“¤ì˜ ìˆ˜ë¥¼ ë³´ë©´, ìµœì†Œ ì ˆë°˜ì€ ê´€ì‹¬ì´ ìˆê³ , í•´ë‹¹ ê·¸ë£¹ì˜ ë‚˜ë¨¸ì§€ 40%ëŠ” ì•„ë§ˆë„ ì˜ëª»ëœ ë²„íŠ¼ì„ ëˆŒë €ì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë¯¸ìš© ì‚°ì—… ìì²´ë¥¼ ë³´ë©´, ìš°ë¦¬ê°€ ì£¼ëª©í•˜ê³  ìˆëŠ” ê²ƒ ì¤‘ í•˜ë‚˜ëŠ” ì–¼ë§ˆë‚˜ ë§ì€ ì‚¬ëŒë“¤ì´ ì´ ì‚°ì—…ì— ì°¸ì—¬í•˜ê³  ìˆëŠ”ì§€ì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ë„ˆë¬´ ë§ì€ ì‚¬ëŒë“¤ì´ ë‹¨ìˆœíˆ ì´ê²ƒì„ ê°œì„ í•˜ë ¤ê³  ë…¸ë ¥í•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ì§•í›„ë“¤ì´ ë§¤ì¼ ì¦ê°€í•˜ê³  ìˆëŠ” ê²ƒì„ ë³¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œ í° ë³€í™” ì¤‘ í•˜ë‚˜ëŠ”, ì´ê²ƒì— ëŒ€í•´ ìƒê°í•´ë³´ë©´, ì²´ì¤‘ ê°ëŸ‰ ì§€ì¶œì—ì„œ ë¯¸ìš© ì§€ì¶œì˜ 11%ê°€ ì²´ì¤‘ ê°ëŸ‰ ì˜ì•½í’ˆê³¼ ë¼ì´í”„ìŠ¤íƒ€ì¼ì— ì‚¬ìš©ë©ë‹ˆë‹¤. ìŠ¤í‹°ë¸Œ ë°•ì‚¬ë¥¼ í¬í•¨í•œ ëª‡ëª‡ ì‚¬ëŒë“¤ì´ ì´ë¯¸ ì´ì— ëŒ€í•´ ì´ì•¼ê¸°í–ˆìŠµë‹ˆë‹¤. ë°œí‘œì 15: ì´ëŸ¬í•œ ì „í™˜ì ì„ ë³´ê³  ê³„ì‹œëŠ” ê±°ì£ ?</td></tr>
<tr><td>11% in just three<br><br>years. I mean that's a meteoric rise. I mean that's massive. Speaker 15: So you're going to see this whole kind of move. And we've seen it in our practice whether it's BBLs, whether it's GEM, whether it's these things is this different movement in terms of what patients are desiring. This fit and fabulous life because their lifestyle has changed. So they want their appearance to follow that trend. And so I think this is where there's opportunities if you can speak to this. Speaker 15: Little downtime, really subtle sexy changes that follow that lifetime flow I think are huge. The local anesthesia, the subtle changes, the making of the procedures very simple.</td><td>ë‹¨ 3ë…„ ë§Œì— 11%ë¼ëŠ” ê²ƒì€ ì •ë§ ê¸‰ê²©í•œ ìƒìŠ¹ì…ë‹ˆë‹¤. ì—„ì²­ë‚œ ì¦ê°€ì„¸ì£ .<br><br>ë°œí‘œì 15: ì´ëŸ° ì „ë°˜ì ì¸ ë³€í™”ì˜ íë¦„ì„ ë³´ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì €í¬ ì§„ë£Œì—ì„œë„ BBLì´ë“ , GLP-1ì´ë“ , ì´ëŸ° ì‹œìˆ ë“¤ì„ í†µí•´ í™˜ìë“¤ì´ ì›í•˜ëŠ” ê²ƒì´ ë‹¬ë¼ì§€ê³  ìˆìŒì„ ëª©ê²©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¼ì´í”„ìŠ¤íƒ€ì¼ì´ ë³€í™”í•˜ë©´ì„œ ê±´ê°•í•˜ê³  ë©‹ì§„ ì‚¶ì„ ì¶”êµ¬í•˜ëŠ” ì´ëŸ° ë‹¤ë¥¸ ì›€ì§ì„ ë§ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì™¸ëª¨ë„ ê·¸ëŸ° íŠ¸ë Œë“œë¥¼ ë”°ë¥´ê¸¸ ì›í•˜ëŠ” ê²ƒì´ì£ . ì´ ë¶€ë¶„ì— ì–´í•„í•  ìˆ˜ ìˆë‹¤ë©´ ê¸°íšŒê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 15: íšŒë³µ ê¸°ê°„ì´ ì§§ê³ , ì •ë§ ìì—°ìŠ¤ëŸ½ê³  ë§¤ë ¥ì ì¸ ë³€í™”ë¡œ ê·¸ë“¤ì˜ ë¼ì´í”„ìŠ¤íƒ€ì¼ íë¦„ì„ ë”°ë¼ê°€ëŠ” ê²ƒì´ í•µì‹¬ì´ë¼ê³  ë´…ë‹ˆë‹¤. êµ­ì†Œë§ˆì·¨, ìì—°ìŠ¤ëŸ¬ìš´ ë³€í™”, ì‹œìˆ  ê³¼ì •ì„ ë§¤ìš° ê°„ë‹¨í•˜ê²Œ ë§Œë“œëŠ” ê²ƒ ë§ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Some of our surgeons are super talented so I think they downplay their skills of how challenging some of these procedures are. But that's what Motiva has done is really taken a way to decrease complications to make this super easy for patients along this. But I do think there's a ripple effect in this span. Speaker 15: How are you going to actually move them from these aesthetic naive patients along that journey? And this journey here, I think, is complex. And I think it's more complex than<br>most people realize. There's all sorts of places to be along this journey. Anybody who's been in Texas, think about this as a Buc ee's every 90 miles in terms of things.</td><td>ì €í¬ ì™¸ê³¼ì˜ì‚¬ë“¤ ì¤‘ ì¼ë¶€ëŠ” ì •ë§ ë›°ì–´ë‚œ ì‹¤ë ¥ì„ ê°–ì¶”ê³  ìˆì–´ì„œ ì´ëŸ° ì‹œìˆ ë“¤ì´ ì–¼ë§ˆë‚˜ ê¹Œë‹¤ë¡œìš´ì§€ì— ëŒ€í•œ ìì‹ ë“¤ì˜ ê¸°ìˆ ì„ ê³¼ì†Œí‰ê°€í•˜ëŠ” ê²½í–¥ì´ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ Motivaê°€ í•´ë‚¸ ê²ƒì€ ì •ë§ë¡œ í•©ë³‘ì¦ì„ ì¤„ì´ê³  í™˜ìë“¤ì—ê²Œ ì´ ê³¼ì •ì„ ë§¤ìš° ì‰½ê²Œ ë§Œë“œëŠ” ë°©ë²•ì„ ì°¾ì•„ë‚¸ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ ë²”ìœ„ì—ì„œ íŒŒê¸‰íš¨ê³¼ê°€ ìˆì„ ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 15: ë¯¸ìš© ì‹œìˆ ì— ëŒ€í•´ ì˜ ëª¨ë¥´ëŠ” ì´ëŸ° í™˜ìë“¤ì„ ì‹¤ì œë¡œ ì–´ë–»ê²Œ ê·¸ ì—¬ì •ì„ ë”°ë¼ ì´ë™ì‹œí‚¬ ê²ƒì…ë‹ˆê¹Œ? ê·¸ë¦¬ê³  ì—¬ê¸°ì„œ ì´ ì—¬ì •ì€ ë³µì¡í•˜ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ëŒ€ë¶€ë¶„ì˜ ì‚¬ëŒë“¤ì´ ì¸ì‹í•˜ëŠ” ê²ƒë³´ë‹¤ ë” ë³µì¡í•˜ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ ì—¬ì •ì„ ë”°ë¼ ìˆì„ ìˆ˜ ìˆëŠ” ëª¨ë“  ì¢…ë¥˜ì˜ ì§€ì ë“¤ì´ ìˆìŠµë‹ˆë‹¤. í…ì‚¬ìŠ¤ì— ê°€ë³¸ ì ì´ ìˆëŠ” ì‚¬ëŒì´ë¼ë©´, ì´ê²ƒì„ 90ë§ˆì¼ë§ˆë‹¤ ìˆëŠ” Buc-ee'sì²˜ëŸ¼ ìƒê°í•´ë³´ì„¸ìš”.</td></tr>
<tr><td>Speaker 15: But the idea behind this is that there's the weight loss, but it's so much more than this. And there's so many spots to be a part of this journey. And this is where I think, and I'll show you, the Ozempic breast is going to be a massive part. Ozempic butt is going be a massive thing. So those subtle changes that Robert just showed, that's what a lot of our patients are looking for. Speaker 15: They're not looking for a massive change. They're just looking to targetly restore the volume that they had lost in a simple procedure that doesn't have problems, that has little<br><br>downtime, that gets them back right away. Are they living that squat life or that plastic surgery life?</td><td>í™”ì 15: í•˜ì§€ë§Œ ì´ê²ƒì˜ í•µì‹¬ ì•„ì´ë””ì–´ëŠ” ì²´ì¤‘ ê°ëŸ‰ì´ ìˆì§€ë§Œ, ê·¸ê²ƒë³´ë‹¤ í›¨ì”¬ ë” ë§ì€ ê²ƒë“¤ì´ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ ì—¬ì •ì— ì°¸ì—¬í•  ìˆ˜ ìˆëŠ” ì§€ì ë“¤ì´ ë§¤ìš° ë§ìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ì œê°€ ìƒê°í•˜ëŠ” ë¶€ë¶„ì´ê³ , ë³´ì—¬ë“œë¦¬ê² ì§€ë§Œ, ì˜¤ì ¬í”½ ê°€ìŠ´ ì‹œìˆ ì´ ë§¤ìš° í° ë¶€ë¶„ì„ ì°¨ì§€í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì˜¤ì ¬í”½ ì—‰ë©ì´ ì‹œìˆ ë„ ë§¤ìš° í° ì‹œì¥ì´ ë  ê²ƒì…ë‹ˆë‹¤. ë¡œë²„íŠ¸ê°€ ë°©ê¸ˆ ë³´ì—¬ì¤€ ê·¸ëŸ° ë¯¸ë¬˜í•œ ë³€í™”ë“¤, ê·¸ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ í™˜ìë“¤ ëŒ€ë¶€ë¶„ì´ ì°¾ê³  ìˆëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>í™”ì 15: ê·¸ë“¤ì€ ëŒ€ëŒ€ì ì¸ ë³€í™”ë¥¼ ì›í•˜ëŠ” ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. ê·¸ë“¤ì€ ë‹¨ìˆœíˆ ìƒì–´ë²„ë¦° ë³¼ë¥¨ì„ í‘œì í™”í•˜ì—¬ ë³µì›í•˜ëŠ” ê²ƒì„ ì›í•©ë‹ˆë‹¤. ë¬¸ì œê°€ ì—†ê³ , íšŒë³µ ê¸°ê°„ì´ ì§§ìœ¼ë©°, ì¦‰ì‹œ ì¼ìƒìœ¼ë¡œ ë³µê·€í•  ìˆ˜ ìˆëŠ” ê°„ë‹¨í•œ ì‹œìˆ ì„ í†µí•´ì„œ ë§ì…ë‹ˆë‹¤. ê·¸ë“¤ì´ ìŠ¤ì¿¼íŠ¸ ìš´ë™ ìƒí™œì„ í•  ê²ƒì¸ì§€, ì•„ë‹ˆë©´ ì„±í˜•ìˆ˜ìˆ  ìƒí™œì„ í•  ê²ƒì¸ì§€ì˜ ë¬¸ì œì…ë‹ˆë‹¤.</td></tr>
<tr><td>So I think there's a lot of places for plastic surgeons and the aesthetic industry to be a part of this journey. If you think about how many people are part of this and plastic surgeons tend to be a little bit slower adopters, But you see 60% of med spas are doing these. Speaker 15: 35% of aesthetic offices. Even the aesthetic society has made a big push. Doctor. Karp is part of that committee and is committed to training the wellness and those type of things to our members so they can be leaders in this. And so I think there's so many opportunities for us to be leaders of this throughout their entire journey because as a few people said, how do we guide them throughout this?</td><td>ë”°ë¼ì„œ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ê³¼ ë¯¸ìš© ì—…ê³„ê°€ ì´ëŸ¬í•œ ì—¬ì •ì— ì°¸ì—¬í•  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ë§ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ì— ì°¸ì—¬í•˜ëŠ” ì‚¬ëŒë“¤ì˜ ê·œëª¨ë¥¼ ìƒê°í•´ë³´ë©´, ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ì€ ë‹¤ì†Œ ëŠë¦° ë„ì…ìë“¤ì¸ ê²½í–¥ì´ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë©”ë“œ ìŠ¤íŒŒì˜ 60%ê°€ ì´ëŸ¬í•œ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 15: ë¯¸ìš© í´ë¦¬ë‹‰ì˜ 35%ë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ë¯¸ìš©ì™¸ê³¼í•™íšŒ(Aesthetic Society)ë„ ì´ì— ëŒ€í•´ í° ë…¸ë ¥ì„ ê¸°ìš¸ì´ê³  ìˆìŠµë‹ˆë‹¤. ì¹´í”„(Karp) ë°•ì‚¬ë‹˜ì´ í•´ë‹¹ ìœ„ì›íšŒì˜ ì¼ì›ìœ¼ë¡œì„œ ì›°ë‹ˆìŠ¤ ë° ì´ì™€ ìœ ì‚¬í•œ ë¶„ì•¼ì— ëŒ€í•œ êµìœ¡ì„ ìš°ë¦¬ íšŒì›ë“¤ì—ê²Œ ì œê³µí•˜ì—¬ ì´ ë¶„ì•¼ì˜ ë¦¬ë”ê°€ ë  ìˆ˜ ìˆë„ë¡ ìµœì„ ì„ ë‹¤í•˜ê³  ê³„ì‹­ë‹ˆë‹¤. ë”°ë¼ì„œ ëª‡ ë¶„ì´ ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼, ìš°ë¦¬ê°€ ì–´ë–»ê²Œ ê·¸ë“¤ì„ ì „ì²´ ê³¼ì •ì—ì„œ ì•ˆë‚´í•  ê²ƒì¸ê°€ë¼ëŠ” ê´€ì ì—ì„œ ë³¼ ë•Œ, ìš°ë¦¬ê°€ ê·¸ë“¤ì˜ ì „ì²´ ì—¬ì •ì—ì„œ ë¦¬ë” ì—­í• ì„ í•  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ë§¤ìš° ë§ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 15: I mean, it's a perfect world, right? Here's your ultimate goal. Let's take you from step one all the way to the finish line throughout that entire journey. And I think that's really huge. For people that think this is going away, this is a little graph of some of the medications in clinical trials now. Speaker 15: The GGG hit the market likely next year. We have an oral medication coming to the market this year. The GGG will be equivalent to bariatric surgery in terms of weight loss. So the effects that you're going to see are only going to continue to rise over time.</td><td>ë°œí‘œì 15: ì œ ë§ì€, ì´ê²ƒì´ ì™„ë²½í•œ ì„¸ìƒì´ë¼ëŠ” ê±°ì£ , ê·¸ë ‡ì§€ ì•Šë‚˜ìš”? ì—¬ê¸° ì—¬ëŸ¬ë¶„ì˜ ê¶ê·¹ì ì¸ ëª©í‘œê°€ ìˆìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ ë‹¨ê³„ë¶€í„° ê²°ìŠ¹ì„ ê¹Œì§€, ê·¸ ì „ì²´ ì—¬ì •ì„ í†µí•´ ì—¬ëŸ¬ë¶„ì„ ì•ˆë‚´í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €ëŠ” ì´ê²ƒì´ ì •ë§ í° ì˜ë¯¸ê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ê²ƒì´ ì‚¬ë¼ì§ˆ ê²ƒì´ë¼ê³  ìƒê°í•˜ëŠ” ì‚¬ëŒë“¤ì„ ìœ„í•´, ì´ê²ƒì€ í˜„ì¬ ì„ìƒì‹œí—˜ ì¤‘ì¸ ì¼ë¶€ ì˜ì•½í’ˆë“¤ì„ ë³´ì—¬ì£¼ëŠ” ì‘ì€ ê·¸ë˜í”„ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 15: GGGëŠ” ë‚´ë…„ì— ì‹œì¥ì— ì¶œì‹œë  ê°€ëŠ¥ì„±ì´ ë†’ìŠµë‹ˆë‹¤. ì˜¬í•´ ê²½êµ¬ìš© ì˜ì•½í’ˆì´ ì‹œì¥ì— ë‚˜ì˜¬ ì˜ˆì •ì…ë‹ˆë‹¤. GGGëŠ” ì²´ì¤‘ ê°ëŸ‰ ì¸¡ë©´ì—ì„œ ë¹„ë§Œìˆ˜ìˆ ê³¼ ë™ë“±í•œ íš¨ê³¼ë¥¼ ë³´ì¼ ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì—¬ëŸ¬ë¶„ì´ ë³´ê²Œ ë  íš¨ê³¼ë“¤ì€ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ê³„ì†í•´ì„œ ì¦ê°€í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>I've been working<br>on this concept called the Ozempification of aesthetics and this is so exciting because if you think about it, there's so many changes coming. Speaker 15: You have this unique patient population. I used to think this is just our weight loss patients and it's not true because we've never had so many young patients with weight loss issues. We've never had this number of patients coming into the industry. So I think there's really unique challenges. How are we treating these younger patients with mature issues?</td><td>ì €ëŠ” 'ë¯¸ìš©ì˜í•™ì˜ ì˜¤ì ¬í”½í™”(Ozempification of aesthetics)'ë¼ëŠ” ê°œë…ì„ ì—°êµ¬í•´ì™”ëŠ”ë°, ì´ëŠ” ì •ë§ í¥ë¯¸ì§„ì§„í•©ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì•ìœ¼ë¡œ ë§ì€ ë³€í™”ê°€ ì˜¬ ê²ƒì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 15: ë…íŠ¹í•œ í™˜ìêµ°ì„ ë³´ìœ í•˜ê³  ê³„ì‹­ë‹ˆë‹¤. ì €ëŠ” ì´ì „ì— ì´ê²ƒì´ ë‹¨ìˆœíˆ ì²´ì¤‘ ê°ëŸ‰ í™˜ìë“¤ë§Œì˜ ë¬¸ì œë¼ê³  ìƒê°í–ˆëŠ”ë°, ê·¸ê²ƒì€ ì‚¬ì‹¤ì´ ì•„ë‹™ë‹ˆë‹¤. ì²´ì¤‘ ê°ëŸ‰ ë¬¸ì œë¥¼ ê°€ì§„ ì Šì€ í™˜ìë“¤ì´ ì´ë ‡ê²Œ ë§ì•˜ë˜ ì ì´ ì—†ì—ˆê³ , ì´ ì—…ê³„ë¡œ ìœ ì…ë˜ëŠ” í™˜ì ìˆ˜ë„ ì´ë ‡ê²Œ ë§ì•˜ë˜ ì ì´ ì—†ì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì •ë§ ë…íŠ¹í•œ ë„ì „ê³¼ì œë“¤ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì„±ìˆ™í•œ ë¬¸ì œë¥¼ ê°€ì§„ ì´ëŸ° ì Šì€ í™˜ìë“¤ì„ ì–´ë–»ê²Œ ì¹˜ë£Œí•´ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>Speaker 15: But we also have some evolving treatments, and this is where a company like<br><br>Establishment Labs is really looking at how can we treat these new issues in an effective way for them. And I think the people in industry, in plastic surgeons, that adopt these and realize these challenges and really find solutions for them are going to thrive. They're going to be that group that really feeds into that cosmetic wave. If you look at it from a pure business standpoint, the amount of this Ozempiccation our most visited page on our website is Ozempic Face. Ozempic butt skyrocketed.</td><td>**ë°œí‘œì 15:** í•˜ì§€ë§Œ ìš°ë¦¬ëŠ” ë˜í•œ ì¼ë¶€ ì§„í™”í•˜ëŠ” ì¹˜ë£Œë²•ë“¤ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ ë°”ë¡œ Establishment Labsì™€ ê°™ì€ íšŒì‚¬ê°€ ì´ëŸ¬í•œ ìƒˆë¡œìš´ ë¬¸ì œë“¤ì„ íš¨ê³¼ì ìœ¼ë¡œ ì¹˜ë£Œí•  ìˆ˜ ìˆëŠ” ë°©ë²•ì„ ëª¨ìƒ‰í•˜ê³  ìˆëŠ” ë¶„ì•¼ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €ëŠ” ì—…ê³„ì˜ ì‚¬ëŒë“¤, ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ì´ ì´ëŸ¬í•œ ê²ƒë“¤ì„ ì±„íƒí•˜ê³  ì´ëŸ¬í•œ ë„ì „ê³¼ì œë“¤ì„ ì¸ì‹í•˜ë©° ì‹¤ì œë¡œ í•´ê²°ì±…ì„ ì°¾ëŠ” ì‚¬ëŒë“¤ì´ ë²ˆì˜í•  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë“¤ì´ ë°”ë¡œ ë¯¸ìš© ì›¨ì´ë¸Œì— ì‹¤ì§ˆì ìœ¼ë¡œ ê¸°ì—¬í•˜ëŠ” ê·¸ë£¹ì´ ë  ê²ƒì…ë‹ˆë‹¤. ìˆœìˆ˜í•œ ë¹„ì¦ˆë‹ˆìŠ¤ ê´€ì ì—ì„œ ë³´ë©´, ì´ ì˜¤ì ¬í”½í™”(Ozempication)ì˜ ê·œëª¨ëŠ”... ìš°ë¦¬ ì›¹ì‚¬ì´íŠ¸ì—ì„œ ê°€ì¥ ë§ì´ ë°©ë¬¸ë˜ëŠ” í˜ì´ì§€ê°€ ì˜¤ì ¬í”½ í˜ì´ìŠ¤(Ozempic Face)ì…ë‹ˆë‹¤. ì˜¤ì ¬í”½ ë²„íŠ¸(Ozempic butt)ë„ ê¸‰ì¦í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 15: Ozempic Face, 250,000 impressions in the three days it went live, shows you how many people are already searching for these terms. This was mind blowing when I pulled this for a talk recently. Look at this rise of search terms for the Ozempic weight loss. So this isn't the medications themselves. This is just for the treatment. Speaker 15: Ozempic face, Ozempic breast, Ozempic butt, to exactly the things you're talking about, but a straight line up in terms of the amount of people searching for solutions for these Ozempic side effects. So super interesting in terms of things coming. Lastly, just to leave you with something is this idea of aesthetic naive patients.</td><td>ë°œí‘œì 15: ì˜¤ì ¬í”½ í˜ì´ìŠ¤(Ozempic Face)ëŠ” ê²Œì‹œ í›„ 3ì¼ ë§Œì— 25ë§Œ ì¡°íšŒìˆ˜ë¥¼ ê¸°ë¡í–ˆëŠ”ë°, ì´ëŠ” ì´ë¯¸ ì–¼ë§ˆë‚˜ ë§ì€ ì‚¬ëŒë“¤ì´ ì´ëŸ° ìš©ì–´ë“¤ì„ ê²€ìƒ‰í•˜ê³  ìˆëŠ”ì§€ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. ìµœê·¼ ê°•ì—°ì„ ìœ„í•´ ì´ ìë£Œë¥¼ ì¤€ë¹„í•  ë•Œ ì •ë§ ë†€ë¼ì› ìŠµë‹ˆë‹¤. ì˜¤ì ¬í”½ ì²´ì¤‘ ê°ëŸ‰ì— ëŒ€í•œ ê²€ìƒ‰ì–´ ì¦ê°€ ì¶”ì´ë¥¼ ë³´ì‹œê¸° ë°”ëë‹ˆë‹¤. ì´ê²ƒì€ ì•½ë¬¼ ìì²´ê°€ ì•„ë‹™ë‹ˆë‹¤. ì´ê²ƒì€ ë‹¨ì§€ ì¹˜ë£Œì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. <br><br>ë°œí‘œì 15: ì˜¤ì ¬í”½ í˜ì´ìŠ¤, ì˜¤ì ¬í”½ ë¸Œë ˆìŠ¤íŠ¸, ì˜¤ì ¬í”½ ë²„íŠ¸ ë“±, ì—¬ëŸ¬ë¶„ì´ ë§ì”€í•˜ì‹  ê²ƒë“¤ê³¼ ì •í™•íˆ ì¼ì¹˜í•˜ëŠ”ë°, ì´ëŸ¬í•œ ì˜¤ì ¬í”½ ë¶€ì‘ìš©ì— ëŒ€í•œ í•´ê²°ì±…ì„ ì°¾ëŠ” ì‚¬ëŒë“¤ì˜ ìˆ˜ê°€ ì§ì„ ì ìœ¼ë¡œ ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ë‹¤ê°€ì˜¬ ê²ƒë“¤ì„ ê³ ë ¤í•  ë•Œ ë§¤ìš° í¥ë¯¸ë¡œìš´ í˜„ìƒì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì—¬ëŸ¬ë¶„ê»˜ ë‚¨ê²¨ë“œë¦¬ê³  ì‹¶ì€ ê²ƒì€ ë¯¸ìš© ì¹˜ë£Œ ë¯¸ê²½í—˜ í™˜ì(aesthetic naive patients)ë¼ëŠ” ê°œë…ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Have forty percent to sixty percent of patients that are on these GLPs are new to the aesthetic industry, new to your office. I'll tell you, it's hard to move them over. Speaker 15: It's challenging and it's got to be specific. And this is why I think when you can do unique things that speak to them in a very good way, I think it's going be on us as providers, as surgeons in the industry to help guide that and train people. But yes, speak to them in a way that truly resonates and helps guide them through this. You see this demand coming. You truly see the wave.</td><td>ì´ëŸ¬í•œ GLP ì•½ë¬¼ì„ ë³µìš©í•˜ëŠ” í™˜ìì˜ 40%ì—ì„œ 60%ê°€ ë¯¸ìš© ì‚°ì—…ì— ì²˜ìŒ ì ‘í•˜ëŠ” ë¶„ë“¤ì´ê³ , ê·€í•˜ì˜ ë³‘ì›ì—ë„ ì²˜ìŒ ì˜¤ì‹œëŠ” ë¶„ë“¤ì…ë‹ˆë‹¤. ë§ì”€ë“œë¦¬ìë©´, ì´ë¶„ë“¤ì„ ì „í™˜ì‹œí‚¤ê¸°ê°€ ì‰½ì§€ ì•ŠìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 15: ë§¤ìš° ì–´ë ¤ìš´ ì¼ì´ê³  êµ¬ì²´ì ì¸ ì ‘ê·¼ì´ í•„ìš”í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ë¶„ë“¤ì—ê²Œ ë§¤ìš° ì¢‹ì€ ë°©ì‹ìœ¼ë¡œ ì–´í•„í•  ìˆ˜ ìˆëŠ” ë…íŠ¹í•œ ê²ƒë“¤ì„ í•  ìˆ˜ ìˆì„ ë•Œ, ì €ëŠ” ì˜ë£Œì§„ìœ¼ë¡œì„œ, ì—…ê³„ì˜ ì™¸ê³¼ì˜ì‚¬ë¡œì„œ ì´ë¥¼ ì•ˆë‚´í•˜ê³  ì‚¬ëŒë“¤ì„ êµìœ¡í•˜ëŠ” ê²ƒì´ ìš°ë¦¬ì˜ ëª«ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ê·¸ë ‡ìŠµë‹ˆë‹¤, ì´ë¶„ë“¤ì—ê²Œ ì§„ì •ìœ¼ë¡œ ê³µê°ì„ ë¶ˆëŸ¬ì¼ìœ¼í‚¤ê³  ì´ ê³¼ì •ì„ ì•ˆë‚´í•˜ëŠ” ë° ë„ì›€ì´ ë˜ëŠ” ë°©ì‹ìœ¼ë¡œ ì†Œí†µí•´ì•¼ í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ìˆ˜ìš”ê°€ ì˜¤ê³  ìˆëŠ” ê²ƒì„ ë³´ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì •ë§ë¡œ ì´ ë¬¼ê²°ì„ ëª©ê²©í•˜ê³  ê³„ì‹­ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 15: There's a few other studies out there that are starting to show some of these trends of people looking for solutions for this. So super excited to be a part of this. I think that we're<br><br>only scratching the surface. I think there's a massive wave of cosmetics coming to the industry for those people that really embrace this. Thank you guys. Speaker 16: Thanks so much, Johnny. I think Doctor. Franco's enthusiasm and passion always shines through in a great way. So my name is Sachin Sheridharani. I'm a plastic surgeon based here in New York City.</td><td>ë°œí‘œì 15: ì´ëŸ¬í•œ íŠ¸ë Œë“œë¥¼ ë³´ì—¬ì£¼ëŠ” ëª‡ ê°€ì§€ ë‹¤ë¥¸ ì—°êµ¬ë“¤ì´ ë‚˜ì˜¤ê¸° ì‹œì‘í•˜ê³  ìˆìœ¼ë©°, ì‚¬ëŒë“¤ì´ ì´ì— ëŒ€í•œ ì†”ë£¨ì…˜ì„ ì°¾ê³  ìˆë‹¤ëŠ” ê²ƒì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë¶„ì•¼ì— ì°¸ì—¬í•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì•„ì§ í‘œë©´ë§Œ ê¸ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ë¥¼ ì§„ì •ìœ¼ë¡œ ë°›ì•„ë“¤ì´ëŠ” ì‚¬ëŒë“¤ì„ ìœ„í•œ í™”ì¥í’ˆì˜ ê±°ëŒ€í•œ ë¬¼ê²°ì´ ì—…ê³„ì— ë‹¤ê°€ì˜¤ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 16: ì •ë§ ê°ì‚¬í•©ë‹ˆë‹¤, ì¡°ë‹ˆ. í”„ë‘ì½” ë°•ì‚¬ë‹˜ì˜ ì—´ì •ê³¼ ì—´ì˜ê°€ í•­ìƒ í›Œë¥­í•œ ë°©ì‹ìœ¼ë¡œ ë¹›ì„ ë°œí•œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì œ ì´ë¦„ì€ ì‚¬ì¹œ ì…°ë¦¬ë‹¤ë¼ë‹ˆì…ë‹ˆë‹¤. ì €ëŠ” ë‰´ìš•ì‹œì— ê¸°ë°˜ì„ ë‘” ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 16: And also I'm excited to talk to you about something we've been incredibly enthusiastic about, which is understanding the GLP-1s and their impacts on plastic surgery. Just take you kind of through a little bit of a journey with our practice. So firstly, I wear a few have a few different roles in the world of aesthetics. I'm the founder of Lux Surgery with a confluence of luxury and aesthetic surgery and have a true focus on really curating experience that we try to think is unlike any other in aesthetic medicine and aesthetic plastic surgery. I'm also Associate Clinical Professor of Plastic Surgery at Wash U. Speaker 16: And then finally, Chief Medical Officer of Skin Spirit.</td><td>ë°œí‘œì 16: ê·¸ë¦¬ê³  ì €í¬ê°€ ë§¤ìš° ì—´ì •ì ìœ¼ë¡œ ì—°êµ¬í•´ì˜¨ ì£¼ì œì¸ GLP-1 ì•½ë¬¼ë“¤ê³¼ ì„±í˜•ì™¸ê³¼ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. ì €í¬ ì§„ë£Œì†Œì—ì„œì˜ ê²½í—˜ì„ ê°„ë‹¨íˆ ì†Œê°œí•´ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € ì œê°€ ë¯¸ìš©ì˜í•™ ë¶„ì•¼ì—ì„œ ì—¬ëŸ¬ ì—­í• ì„ ë§¡ê³  ìˆë‹¤ëŠ” ì ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì €ëŠ” ëŸ­ì…”ë¦¬ì™€ ë¯¸ìš©ì™¸ê³¼ì˜ ìœµí•©ì„ ì¶”êµ¬í•˜ëŠ” Lux Surgeryì˜ ì°½ë¦½ìë¡œì„œ, ë¯¸ìš©ì˜í•™ê³¼ ë¯¸ìš©ì„±í˜•ì™¸ê³¼ ë¶„ì•¼ì—ì„œ ê·¸ ì–´ëŠ ê³³ê³¼ë„ ë‹¤ë¥¸ íŠ¹ë³„í•œ ê²½í—˜ì„ ì œê³µí•˜ëŠ” ë° ì§„ì •ìœ¼ë¡œ ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì›Œì‹±í„´ ëŒ€í•™êµ ì„±í˜•ì™¸ê³¼ ë¶€êµìˆ˜ë¡œë„ ì¬ì§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë°œí‘œì 16: ê·¸ë¦¬ê³  ë§ˆì§€ë§‰ìœ¼ë¡œ Skin Spiritì˜ ìµœê³ ì˜ë£Œì±…ì„ì(CMO)ë¡œë„ í™œë™í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We partnered with private equity and are backed by KKR and L'Oreal recently bought a sizable stake in our organization, six fifty employees, 55 clinics throughout The U. S. And focus on nonsurgical aesthetics along with minimally invasive aesthetics. So really all three of those different roles afford me the opportunity to see people that come into the clinic in a few different lights. Speaker 16: Do we see them as a patient? Do we see them as a customer? Or do we see them as a client? And one of the things that all three of these individuals seeking aesthetic procedures have in common or that they have they pose us as clinicians with a challenge.</td><td>ì €í¬ëŠ” ì‚¬ëª¨í€ë“œì™€ íŒŒíŠ¸ë„ˆì‹­ì„ ë§ºê³  ìˆìœ¼ë©° KKRì˜ ì§€ì›ì„ ë°›ê³  ìˆê³ , ìµœê·¼ ë¡œë ˆì•Œì´ ì €í¬ ì¡°ì§ì— ìƒë‹¹í•œ ì§€ë¶„ì„ ì¸ìˆ˜í–ˆìŠµë‹ˆë‹¤. ì§ì› 650ëª…, ë¯¸êµ­ ì „ì—­ì— 55ê°œ í´ë¦¬ë‹‰ì„ ìš´ì˜í•˜ë©° ë¹„ìˆ˜ìˆ  ë¯¸ìš©ì‹œìˆ ê³¼ ìµœì†Œì¹¨ìŠµ ë¯¸ìš©ì‹œìˆ ì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì„¸ ê°€ì§€ ì—­í•  ëª¨ë‘ í´ë¦¬ë‹‰ì— ì˜¤ì‹œëŠ” ë¶„ë“¤ì„ ëª‡ ê°€ì§€ ë‹¤ë¥¸ ê´€ì ì—ì„œ ë³¼ ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ì œê³µí•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 16: ì €í¬ê°€ ê·¸ë¶„ë“¤ì„ í™˜ìë¡œ ë³´ëŠ”ì§€, ê³ ê°ìœ¼ë¡œ ë³´ëŠ”ì§€, ì•„ë‹ˆë©´ ì˜ë¢°ì¸ìœ¼ë¡œ ë³´ëŠ”ì§€ ë§ì…ë‹ˆë‹¤. ë¯¸ìš©ì‹œìˆ ì„ ì›í•˜ëŠ” ì´ ì„¸ ë¶€ë¥˜ì˜ ê°œì¸ë“¤ì´ ê³µí†µì ìœ¼ë¡œ ê°€ì§€ê³  ìˆëŠ” ê²ƒ ì¤‘ í•˜ë‚˜ëŠ”, ê·¸ë“¤ì´ ì„ìƒì˜ë¡œì„œ ì €í¬ì—ê²Œ ê³¼ì œë¥¼ ì œì‹œí•œë‹¤ëŠ” ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And those challenges are basically, I want the most effective treatment that you have, the least amount of downtime, minimal to no adverse events performed by the most experienced person in the world, and finally, is it free? Speaker 16: That's what patients are often seeking.</td><td>ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ê³¼ì œë“¤ì€ ê¸°ë³¸ì ìœ¼ë¡œ, í™˜ìë“¤ì´ ì›í•˜ëŠ” ê²ƒì€ ê°€ì¥ íš¨ê³¼ì ì¸ ì¹˜ë£Œ, ê°€ì¥ ì ì€ ë‹¤ìš´íƒ€ì„, ìµœì†Œí•œì˜ ë¶€ì‘ìš© ë˜ëŠ” ë¶€ì‘ìš©ì´ ì „í˜€ ì—†ëŠ” ì¹˜ë£Œë¥¼ ì„¸ê³„ì—ì„œ ê°€ì¥ ê²½í—˜ì´ í’ë¶€í•œ ì˜ë£Œì§„ì—ê²Œ ë°›ëŠ” ê²ƒì´ë©°, ë§ˆì§€ë§‰ìœ¼ë¡œëŠ” ê·¸ê²ƒì´ ë¬´ë£Œì¸ì§€ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>í™”ì 16: ì´ê²ƒì´ í™˜ìë“¤ì´ ì¢…ì¢… ì¶”êµ¬í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And so of course, these challenges then we have imposed to our partners in industry, for example, like JJ and Nick Lewin and the folks at Establishment Labs to come up with complex solutions to this problem to give us incredibly innovative technologies with tremendously low amount of downtime and again a phenomenal safety profile because really the industry is impacted at a very global level by anything that is a poor outcome. The margin for error in aesthetics is incredibly minimal. Patients really have tremendously high expectations. So it helps us think about how do we curate what I call in the treatment phase which is patients are tremendously vulnerable.</td><td>ë¬¼ë¡  ì´ëŸ¬í•œ ë„ì „ ê³¼ì œë“¤ì€ ìš°ë¦¬ê°€ ì—…ê³„ íŒŒíŠ¸ë„ˆë“¤, ì˜ˆë¥¼ ë“¤ì–´ JJì™€ Nick Lewin, ê·¸ë¦¬ê³  Establishment Labsì˜ ë™ë£Œë“¤ì—ê²Œ ë¶€ê³¼í•œ ê²ƒë“¤ë¡œ, ì´ ë¬¸ì œì— ëŒ€í•œ ë³µì¡í•œ ì†”ë£¨ì…˜ì„ ê°œë°œí•˜ì—¬ ìš°ë¦¬ì—ê²Œ ë§¤ìš° í˜ì‹ ì ì¸ ê¸°ìˆ ì„ ì œê³µí•˜ë„ë¡ í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ê·¹ë„ë¡œ ì ì€ ë‹¤ìš´íƒ€ì„ê³¼ ë‹¤ì‹œ í•œë²ˆ ë§ì”€ë“œë¦¬ì§€ë§Œ ë†€ë¼ìš´ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ì„ ê°–ì¶˜ ê¸°ìˆ ì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì‹¤ì œë¡œ ì—…ê³„ëŠ” ë¶€ì •ì ì¸ ê²°ê³¼ê°€ ë°œìƒí•  ê²½ìš° ì „ ì„¸ê³„ì  ì°¨ì›ì—ì„œ ì˜í–¥ì„ ë°›ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë¯¸ìš© ë¶„ì•¼ì—ì„œì˜ ì˜¤ì°¨ í—ˆìš© ë²”ìœ„ëŠ” ê·¹ë„ë¡œ ì œí•œì ì…ë‹ˆë‹¤. í™˜ìë“¤ì€ ì •ë§ë¡œ ë§¤ìš° ë†’ì€ ê¸°ëŒ€ì¹˜ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŠ” ì œê°€ ì¹˜ë£Œ ë‹¨ê³„ë¼ê³  ë¶€ë¥´ëŠ” ê³¼ì •ì—ì„œ ì–´ë–»ê²Œ íë ˆì´ì…˜í•  ê²ƒì¸ê°€ì— ëŒ€í•´ ìƒê°í•˜ëŠ” ë° ë„ì›€ì´ ë©ë‹ˆë‹¤. ì´ ë‹¨ê³„ì—ì„œ í™˜ìë“¤ì€ ê·¹ë„ë¡œ ì·¨ì•½í•œ ìƒíƒœì— ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 16: They're really looking to create a bond during this time point. Why this ties in is just sort of a walkthrough of portion of our clinic. What it really starts to lend ways, we think about true innovation and how now GLP-1s are going to impact plastic surgery. We already realize at a top line level that excisional procedures are on the rise unlike any other. We started to see tremendous amounts of growth in the injectable sector over the last several years. Speaker 16: Neuromodulator treatments are the most frequently performed cosmetic treatments followed by dermal fillers.</td><td>ë°œí‘œì 16: ê·¸ë“¤ì€ ì´ ì‹œì ì—ì„œ ì •ë§ë¡œ ìœ ëŒ€ê°ì„ í˜•ì„±í•˜ë ¤ê³  í•©ë‹ˆë‹¤. ì´ê²ƒì´ ì—°ê´€ë˜ëŠ” ì´ìœ ëŠ” ì €í¬ í´ë¦¬ë‹‰ ì¼ë¶€ì— ëŒ€í•œ ì•ˆë‚´ì™€ ê°™ìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì§„ì •í•œ í˜ì‹ ì— ëŒ€í•´ ìƒê°í•˜ê¸° ì‹œì‘í•˜ëŠ” ê³„ê¸°ê°€ ë˜ë©°, ì´ì œ GLP-1ì´ ì„±í˜•ì™¸ê³¼ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹ ì§€ì— ëŒ€í•œ ê²ƒì…ë‹ˆë‹¤. ì €í¬ëŠ” ì´ë¯¸ ìµœìƒìœ„ ìˆ˜ì¤€ì—ì„œ ì ˆì œ ì‹œìˆ ì´ ê·¸ ì–´ëŠ ë•Œë³´ë‹¤ë„ ì¦ê°€í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ ì¸ì‹í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë…„ê°„ ì£¼ì‚¬ ë¶€ë¬¸ì—ì„œ ì—„ì²­ë‚œ ì„±ì¥ì„ ë³´ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 16: ì‹ ê²½ì¡°ì ˆì œ ì¹˜ë£ŒëŠ” ê°€ì¥ ë¹ˆë²ˆí•˜ê²Œ ì‹œí–‰ë˜ëŠ” ë¯¸ìš© ì¹˜ë£Œì´ë©°, ê·¸ ë‹¤ìŒì´ í”¼ë¶€ í•„ëŸ¬ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And as we've seen the GLP-1s now being introduced into aesthetics, we're starting to see that there's a slight correction there but surgical procedures that we historically were not performing nearly that much of have come onto a shocking increase in rise which is obviously something that makes us the surgeons who use our scalpel instead of a syringe incredibly happy. So what impact does that have in general for patients during that treatment phase? Phase? Firstly, the advent of GLP-one is something incredibly interesting to me.</td><td>GLP-1ì´ ì´ì œ ë¯¸ìš© ë¶„ì•¼ì— ë„ì…ë˜ë©´ì„œ, ê·¸ ë¶€ë¶„ì—ì„œëŠ” ì•½ê°„ì˜ ì¡°ì •ì´ ìˆëŠ” ê²ƒì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ê³¼ê±°ì—ëŠ” ê±°ì˜ ì‹œí–‰í•˜ì§€ ì•Šì•˜ë˜ ìˆ˜ìˆ ì  ì‹œìˆ ë“¤ì´ ë†€ë¼ìš¸ ì •ë„ë¡œ ê¸‰ê²©íˆ ì¦ê°€í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì£¼ì‚¬ê¸° ëŒ€ì‹  ë©”ìŠ¤ë¥¼ ì‚¬ìš©í•˜ëŠ” ì €í¬ ì™¸ê³¼ì˜ë“¤ì—ê²ŒëŠ” ë‹¹ì—°íˆ ë§¤ìš° ê¸°ìœ ì¼ì…ë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ì´ê²ƒì´ ì¹˜ë£Œ ë‹¨ê³„ì— ìˆëŠ” í™˜ìë“¤ì—ê²Œ ì¼ë°˜ì ìœ¼ë¡œ ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹˜ëŠ” ê²ƒì¼ê¹Œìš”? ìš°ì„ , GLP-1ì˜ ë“±ì¥ì€ ì €ì—ê²Œ ë§¤ìš° í¥ë¯¸ë¡œìš´ í˜„ìƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 16: Out of my practice, we published the paper in the plastic surgery literature as a systematic review just on kind of the impact that we would have on or what the impact of these processes or these medications will have on aesthetic plastic surgery. You already heard some<br><br>really great top line data from Johnny, so I'll spare you from having to hear those points again. But really and fundamentally, there is tremendous amount of value that we're seeing in GLP-1s. But with that said, that volume loss and the overall weight loss that occurs leaves patients with a new problem that they really weren't maybe expecting before.</td><td>ë°œí‘œì 16: ì œ ì§„ë£Œ ê²½í—˜ì„ ë°”íƒ•ìœ¼ë¡œ, ì €í¬ëŠ” ì„±í˜•ì™¸ê³¼ ë¬¸í—Œì— ì²´ê³„ì  ê²€í†  ë…¼ë¬¸ì„ ë°œí‘œí–ˆëŠ”ë°, ì´ëŠ” ì´ëŸ¬í•œ ê³¼ì •ë“¤ì´ë‚˜ ì•½ë¬¼ë“¤ì´ ë¯¸ìš© ì„±í˜•ì™¸ê³¼ì— ë¯¸ì¹  ì˜í–¥ì— ê´€í•œ ë‚´ìš©ì´ì—ˆìŠµë‹ˆë‹¤. ì´ë¯¸ Johnnyë¡œë¶€í„° í›Œë¥­í•œ í•µì‹¬ ë°ì´í„°ë¥¼ ë“¤ìœ¼ì…¨ìœ¼ë‹ˆ, ê°™ì€ ë‚´ìš©ì„ ë°˜ë³µí•´ì„œ ë§ì”€ë“œë¦¬ì§€ëŠ” ì•Šê² ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ê·¼ë³¸ì ìœ¼ë¡œ GLP-1ì—ì„œ ì—„ì²­ë‚œ ê°€ì¹˜ë¥¼ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë ‡ê¸´ í•˜ì§€ë§Œ, ë³¼ë¥¨ ì†ì‹¤ê³¼ ì „ë°˜ì ì¸ ì²´ì¤‘ ê°ì†Œë¡œ ì¸í•´ í™˜ìë“¤ì€ ì´ì „ì—ëŠ” ì˜ˆìƒí•˜ì§€ ëª»í–ˆë˜ ìƒˆë¡œìš´ ë¬¸ì œì— ì§ë©´í•˜ê²Œ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>And that's where as JJ already astutely mentioned, this whole concept of weight loss and wellness and thinking about decline in aesthetics is actually quite the opposite. Speaker 16: After patients go through that initial decline in 10%, 15%, 20% of body mass index and subcutaneous fat, They're left with something that is basically an empty balloon. Think about the skin of the breast analogous to the rubber of the balloon. The air filling that balloon is like the glandular tissue and fat filling the skin. So if we let air out of a balloon very simply, it starts to droop and sag.</td><td>ê·¸ë¦¬ê³  JJê°€ ì´ë¯¸ ì˜ˆë¦¬í•˜ê²Œ ì–¸ê¸‰í•œ ë°”ì™€ ê°™ì´, ì²´ì¤‘ ê°ì†Œì™€ ì›°ë‹ˆìŠ¤, ê·¸ë¦¬ê³  ë¯¸ìš© ë¶„ì•¼ì˜ ì‡ í‡´ì— ëŒ€í•œ ì´ëŸ¬í•œ ì „ì²´ì ì¸ ê°œë…ì€ ì‹¤ì œë¡œëŠ” ì •ë°˜ëŒ€ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 16: í™˜ìë“¤ì´ ì²´ì§ˆëŸ‰ì§€ìˆ˜ì™€ í”¼í•˜ì§€ë°©ì˜ 10%, 15%, 20%ì— í•´ë‹¹í•˜ëŠ” ì´ˆê¸° ê°ì†Œë¥¼ ê²ªê³  ë‚œ í›„ì—ëŠ” ê¸°ë³¸ì ìœ¼ë¡œ ë¹ˆ í’ì„ ê³¼ ê°™ì€ ìƒíƒœê°€ ë©ë‹ˆë‹¤. ìœ ë°©ì˜ í”¼ë¶€ë¥¼ í’ì„ ì˜ ê³ ë¬´ì— ë¹„ìœ í•´ì„œ ìƒê°í•´ë³´ì„¸ìš”. í’ì„ ì„ ì±„ìš°ëŠ” ê³µê¸°ëŠ” í”¼ë¶€ë¥¼ ì±„ìš°ëŠ” ì„ ì¡°ì§ê³¼ ì§€ë°©ê³¼ ê°™ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ í’ì„ ì—ì„œ ê³µê¸°ë¥¼ ë¹¼ë©´ ì•„ì£¼ ê°„ë‹¨í•˜ê²Œ ì²˜ì§€ê³  ëŠ˜ì–´ì§€ê¸° ì‹œì‘í•©ë‹ˆë‹¤.</td></tr>
<tr><td>So although patients are really excited about the new overall body shape they have, they're coming in now and saying, what am I going to do with this loose skin? Speaker 16: So there's a tremendous amount of interest in volumization in these areas and then thinking about how can we use novel technologies, minimally invasive technologies that optimize the patient experience and safety and efficacy but still give the patient what they're looking for. So we're starting to satisfy those new challenges that we're seeing that are coming to us in an incredibly rapid fire fashion because of the fact that these GLP-1s have exploded on the scene and are clearly not going anywhere anytime soon.</td><td>ë”°ë¼ì„œ í™˜ìë“¤ì´ ìƒˆë¡œìš´ ì „ì²´ì ì¸ ì²´í˜•ì— ëŒ€í•´ì„œëŠ” ì •ë§ ë§Œì¡±í•´í•˜ê³  ìˆì§€ë§Œ, ì´ì œëŠ” ë‚´ì›í•´ì„œ "ì´ ëŠ˜ì–´ì§„ í”¼ë¶€ë¥¼ ì–´ë–»ê²Œ í•´ì•¼ í•˜ë‚˜ìš”?"ë¼ê³  ë¬»ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 16: ê·¸ë˜ì„œ ì´ëŸ¬í•œ ë¶€ìœ„ì˜ ë³¼ë¥¨í™”ì— ëŒ€í•œ ì—„ì²­ë‚œ ê´€ì‹¬ì´ ìˆìœ¼ë©°, í™˜ì ê²½í—˜ê³¼ ì•ˆì „ì„± ë° íš¨ëŠ¥ì„ ìµœì í™”í•˜ë©´ì„œë„ í™˜ìê°€ ì›í•˜ëŠ” ê²°ê³¼ë¥¼ ì œê³µí•  ìˆ˜ ìˆëŠ” ìƒˆë¡œìš´ ê¸°ìˆ , ìµœì†Œì¹¨ìŠµì  ê¸°ìˆ ì„ ì–´ë–»ê²Œ í™œìš©í•  ìˆ˜ ìˆì„ì§€ì— ëŒ€í•´ ê³ ë¯¼í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” GLP-1 ì•½ë¬¼ë“¤ì´ ì‹œì¥ì— í­ë°œì ìœ¼ë¡œ ë“±ì¥í•˜ì—¬ ì¡°ë§Œê°„ ì‚¬ë¼ì§ˆ ê¸°ë¯¸ê°€ ì „í˜€ ë³´ì´ì§€ ì•ŠëŠ”ë‹¤ëŠ” ì‚¬ì‹¤ë¡œ ì¸í•´ ë§¤ìš° ë¹ ë¥¸ ì†ë„ë¡œ ìš°ë¦¬ì—ê²Œ ë‹¤ê°€ì˜¤ê³  ìˆëŠ” ì´ëŸ¬í•œ ìƒˆë¡œìš´ ê³¼ì œë“¤ì„ í•´ê²°í•˜ê¸° ì‹œì‘í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So now our technologies have to start to rise and knowing that we have a tremendous and robust pipeline that you heard from Roberto about already tells us that we are very, very well poised to be able to help volumize these patients, treat them with these areas that are deflated and give them a really beautiful outcome with minimal downtime and minimal adverse events. This is just an example of a patient. This is actually though a massive weight loss patient, not a GLP-one patient. Speaker 16: But one of the things that you can see is that there are tremendous challenges at<br><br>times with the volume loss.</td><td>ì´ì œ ìš°ë¦¬ì˜ ê¸°ìˆ ë“¤ì´ ë¶€ìƒí•˜ê¸° ì‹œì‘í•´ì•¼ í•˜ê³ , Robertoê°€ ì´ë¯¸ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ ìš°ë¦¬ê°€ ì—„ì²­ë‚˜ê³  ê²¬ê³ í•œ íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆê¸° ë•Œë¬¸ì—, ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ í™˜ìë“¤ì˜ ë³¼ë¥¨ì„ íšŒë³µì‹œí‚¤ê³ , ìœ„ì¶•ëœ ë¶€ìœ„ë¥¼ ì¹˜ë£Œí•˜ë©°, ìµœì†Œí•œì˜ ë‹¤ìš´íƒ€ì„ê³¼ ìµœì†Œí•œì˜ ë¶€ì‘ìš©ìœ¼ë¡œ ì •ë§ ì•„ë¦„ë‹¤ìš´ ê²°ê³¼ë¥¼ ì œê³µí•  ìˆ˜ ìˆëŠ” ë§¤ìš° ìœ ë¦¬í•œ ìœ„ì¹˜ì— ìˆë‹¤ê³  ë§í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ í™˜ìì˜ í•œ ì˜ˆì‹œì…ë‹ˆë‹¤. ì‹¤ì œë¡œëŠ” GLP-1 í™˜ìê°€ ì•„ë‹Œ ëŒ€ëŸ‰ ì²´ì¤‘ ê°ì†Œ í™˜ìì…ë‹ˆë‹¤.<br><br>í™”ì 16: í•˜ì§€ë§Œ ë³¼ ìˆ˜ ìˆëŠ” ê²ƒ ì¤‘ í•˜ë‚˜ëŠ” ë•Œë•Œë¡œ ë³¼ë¥¨ ì†ì‹¤ê³¼ ê´€ë ¨í•˜ì—¬ ì—„ì²­ë‚œ ë„ì „ê³¼ì œë“¤ì´ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>This patient comes in and says, I've never looked better in clothes but I feel incredibly a loss of femininity, a loss of my overall volume and I don't feel like myself. I have this amazing overall volume loss journey, weight loss journey but I still have issues and concerns about intimacy or being in clothes that would try to make me feel a bit more comfortable. So what can we do?</td><td>ì´ í™˜ìê°€ ì™€ì„œ ì´ë ‡ê²Œ ë§í•©ë‹ˆë‹¤. "ì˜·ì„ ì…ì—ˆì„ ë•Œ ì´ë ‡ê²Œ ì¢‹ì•„ ë³´ì¸ ì ì´ ì—†ì§€ë§Œ, ì—¬ì„±ìŠ¤ëŸ¬ì›€ì„ ìƒì€ ê²ƒ ê°™ê³  ì „ì²´ì ì¸ ë³¼ë¥¨ê°ì„ ìƒì–´ì„œ ì œ ìì‹  ê°™ì§€ ì•Šì•„ìš”. ë†€ë¼ìš´ ì „ì²´ì ì¸ ë³¼ë¥¨ ê°ì†Œ ì—¬ì •, ì²´ì¤‘ ê°ëŸ‰ ì—¬ì •ì„ ê²ªì—ˆì§€ë§Œ ì—¬ì „íˆ ì¹œë°€ê°ì´ë‚˜ ì¢€ ë” í¸ì•ˆí•¨ì„ ëŠë‚„ ìˆ˜ ìˆê²Œ í•´ì£¼ëŠ” ì˜·ì„ ì…ëŠ” ê²ƒì— ëŒ€í•œ ë¬¸ì œì™€ ìš°ë ¤ê°€ ìˆì–´ìš”. ê·¸ëŸ¼ ìš°ë¦¬ê°€ ë¬´ì—‡ì„ í•  ìˆ˜ ìˆì„ê¹Œìš”?"</td></tr>
<tr><td>Being able to treat these patients in a single treatment fashion, volumizing the breast for example with our Vimotiva implants and being able to do a lift simultaneously and knowing that we have a tremendous overall safety profile in these otherwise challenging cases is something that gives us a lot of confidence as plastic surgeons<br>to be able to partner and use these products because again of the safety, efficacy, data and the ability to have them not have as aggressive of a procedure. Speaker 16: So just an example again of one of the patients here. You can see them approximately six months out with the Motiva implants. So these are just case examples of that in general.</td><td>ì´ëŸ¬í•œ í™˜ìë“¤ì„ ë‹¨ì¼ ì¹˜ë£Œ ë°©ì‹ìœ¼ë¡œ ì¹˜ë£Œí•  ìˆ˜ ìˆë‹¤ëŠ” ì , ì˜ˆë¥¼ ë“¤ì–´ ì €í¬ Vimotiva ì„í”Œë€íŠ¸ë¡œ ìœ ë°©ì„ ë³¼ë¥¨í™”í•˜ë©´ì„œ ë™ì‹œì— ë¦¬í”„íŒ…ì„ í•  ìˆ˜ ìˆê³ , ì´ëŸ¬í•œ ê¹Œë‹¤ë¡œìš´ ì¼€ì´ìŠ¤ë“¤ì—ì„œë„ ë›°ì–´ë‚œ ì „ë°˜ì ì¸ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ì„ í™•ë³´í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ ì•„ëŠ” ê²ƒì€ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë¡œì„œ ì´ëŸ¬í•œ ì œí’ˆë“¤ê³¼ íŒŒíŠ¸ë„ˆì‹­ì„ ë§ºê³  ì‚¬ìš©í•  ìˆ˜ ìˆëŠ” í° í™•ì‹ ì„ ì£¼ëŠ” ìš”ì†Œì…ë‹ˆë‹¤. ë‹¤ì‹œ ë§í•´, ì•ˆì „ì„±, íš¨ëŠ¥, ë°ì´í„° ê·¸ë¦¬ê³  í™˜ìë“¤ì´ ëœ ê³µê²©ì ì¸ ì‹œìˆ ì„ ë°›ì„ ìˆ˜ ìˆë‹¤ëŠ” ëŠ¥ë ¥ ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 16: ë‹¤ì‹œ í•œ ë²ˆ í™˜ì ì‚¬ë¡€ë¥¼ ì˜ˆë¡œ ë“¤ì–´ë³´ê² ìŠµë‹ˆë‹¤. Motiva ì„í”Œë€íŠ¸ ì‹œìˆ  í›„ ì•½ 6ê°œì›” ê²½ê³¼í•œ ëª¨ìŠµì„ ë³´ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒë“¤ì€ ì¼ë°˜ì ì¸ ì¼€ì´ìŠ¤ ì˜ˆì‹œë“¤ì…ë‹ˆë‹¤.</td></tr>
<tr><td>So with summary, our GLP-1s are here to stay. You already heard about how they're going to be combined with multimodal type of approaches or multiple medications packed into the weight loss component. Speaker 16: Injectables are going to turn into one of those elements with the weight loss medication where we will look at greater longevity so patients don't have to do them weekly. You are seeing oral formulations that will start to rival the efficacy of the injectable formulation.</td><td>ìš”ì•½í•˜ìë©´, ìš°ë¦¬ì˜ GLP-1 ì œì œë“¤ì€ ì§€ì†ë  ê²ƒì…ë‹ˆë‹¤. ì´ë¯¸ ë©€í‹°ëª¨ë‹¬ ì ‘ê·¼ë²•ì´ë‚˜ ì²´ì¤‘ ê°ëŸ‰ ì„±ë¶„ì— ì—¬ëŸ¬ ì•½ë¬¼ì„ ê²°í•©í•˜ëŠ” ë°©ì‹ìœ¼ë¡œ ì–´ë–»ê²Œ ì¡°í•©ë  ê²ƒì¸ì§€ì— ëŒ€í•´ ë“¤ìœ¼ì…¨ì„ ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 16: ì£¼ì‚¬ì œëŠ” ì²´ì¤‘ ê°ëŸ‰ ì•½ë¬¼ì˜ êµ¬ì„± ìš”ì†Œ ì¤‘ í•˜ë‚˜ê°€ ë  ê²ƒì´ë©°, í™˜ìë“¤ì´ ë§¤ì£¼ ì£¼ì‚¬í•  í•„ìš”ê°€ ì—†ë„ë¡ ë” ê¸´ ì§€ì†ì„±ì„ ì¶”êµ¬í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì£¼ì‚¬ ì œí˜•ì˜ íš¨ëŠ¥ì— í•„ì í•  ìˆ˜ ìˆëŠ” ê²½êµ¬ìš© ì œí˜•ë“¤ì´ ë‚˜íƒ€ë‚˜ê¸° ì‹œì‘í•˜ëŠ” ê²ƒì„ ë³´ê³  ê³„ì‹¤ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>All of that means that we are well poised as plastic surgeons to see a tremendous amount of influx because patients want to look good in and out of their clothes and they are not going to walk around with an empty balloon. So that is what's going to give us a unique opportunity to use, again, novel technologies with high efficacy, high safety profile, minimal downtime. Unfortunately, they probably won't be free. Speaker 16: So with that said, thank you all very much. Speaker 14: Okay. So I would like to call Doctor. Steve, Doctor. Epstein, and Doctor. Pittman back here to the stage. Speaker 14: And I think I'll give it to you guys here and I'll move over here so I can give you some room.</td><td>ì´ ëª¨ë“  ê²ƒì€ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë¡œì„œ ìš°ë¦¬ê°€ ì—„ì²­ë‚œ í™˜ì ìœ ì…ì„ ë³¼ ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆë‹¤ëŠ” ê²ƒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. í™˜ìë“¤ì€ ì˜·ì„ ì…ì—ˆì„ ë•Œë‚˜ ë²—ì—ˆì„ ë•Œë‚˜ ì¢‹ì•„ ë³´ì´ê¸°ë¥¼ ì›í•˜ê³ , ë¹ˆ í’ì„ ì„ ê°€ì§€ê³  ë‹¤ë‹ˆì§€ëŠ” ì•Šì„ ê²ƒì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ê²ƒì´ ìš°ë¦¬ì—ê²Œ ë‹¤ì‹œ í•œë²ˆ ìƒˆë¡œìš´ ê¸°ìˆ ë“¤ì„ ì‚¬ìš©í•  ìˆ˜ ìˆëŠ” ë…íŠ¹í•œ ê¸°íšŒë¥¼ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤ - ë†’ì€ íš¨ëŠ¥, ë†’ì€ ì•ˆì „ì„± í”„ë¡œíŒŒì¼, ìµœì†Œí•œì˜ ë‹¤ìš´íƒ€ì„ì„ ê°€ì§„ ê¸°ìˆ ë“¤ ë§ì…ë‹ˆë‹¤. ì•ˆíƒ€ê¹ê²Œë„ ì•„ë§ˆ ë¬´ë£ŒëŠ” ì•„ë‹ ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 16: ê·¸ë ‡ë‹¤ë©´, ëª¨ë“  ë¶„ë“¤ê»˜ ëŒ€ë‹¨íˆ ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 14: ì¢‹ìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ìŠ¤í‹°ë¸Œ ë°•ì‚¬ë‹˜, ì—¡ìŠ¤íƒ€ì¸ ë°•ì‚¬ë‹˜, ê·¸ë¦¬ê³  í”¼íŠ¸ë§Œ ë°•ì‚¬ë‹˜ì„ ë‹¤ì‹œ ë¬´ëŒ€ë¡œ ëª¨ì‹œê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 14: ì—¬ê¸° ìë¦¬ë¥¼ ë“œë¦´ í…Œë‹ˆ ì œê°€ ì´ìª½ìœ¼ë¡œ ì´ë™í•´ì„œ ê³µê°„ì„ ë§Œë“¤ì–´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And in this next panel, I think what we would like to do is to have a discussion around market expansion, because I think it's one of the most important things, plastic surgery for many years has suffered from the lack of innovation. And of course that has had an impact in the size of the market for plastic surgery treatments. And we saw today in that presentation that Roberto gave about that minimally invasive platform and where that is going. I would like to hear what you guys have to say when you see that platform and you think about the future. Speaker 14: And as know, me as already in the market is in more than 50 cities around the world and growing every month.</td><td>ë‹¤ìŒ íŒ¨ë„ì—ì„œëŠ” ì‹œì¥ í™•ì¥ì— ëŒ€í•œ ë…¼ì˜ë¥¼ í•´ë³´ê³ ì í•©ë‹ˆë‹¤. ì´ëŠ” ë§¤ìš° ì¤‘ìš”í•œ ì£¼ì œë¼ê³  ìƒê°í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì„±í˜•ì™¸ê³¼ëŠ” ì˜¤ë«ë™ì•ˆ í˜ì‹  ë¶€ì¡±ìœ¼ë¡œ ì–´ë ¤ì›€ì„ ê²ªì–´ì™”ìŠµë‹ˆë‹¤. ë¬¼ë¡  ì´ëŠ” ì„±í˜•ì™¸ê³¼ ì¹˜ë£Œ ì‹œì¥ ê·œëª¨ì—ë„ ì˜í–¥ì„ ë¯¸ì³¤ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ë¡œë² ë¥´í† ê°€ ë°œí‘œí•œ ìµœì†Œì¹¨ìŠµ í”Œë«í¼ê³¼ ê·¸ ë°œì „ ë°©í–¥ì— ëŒ€í•œ í”„ë ˆì  í…Œì´ì…˜ì„ ë³´ì•˜ìŠµë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ê»˜ì„œ ê·¸ í”Œë«í¼ì„ ë³´ì‹œê³  ë¯¸ë˜ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ì‹œëŠ”ì§€ ì˜ê²¬ì„ ë“£ê³  ì‹¶ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 14: ì•„ì‹œë‹¤ì‹œí”¼, ì €í¬ëŠ” ì´ë¯¸ ì „ ì„¸ê³„ 50ê°œ ì´ìƒì˜ ë„ì‹œì—ì„œ ì‹œì¥ì— ì§„ì¶œí•´ ìˆìœ¼ë©° ë§¤ì›” ì„±ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Pressurvey has been launched in many regions and select markets. And we are under clinical study when it comes GEM. So these things are real. How do you think those will impact your practice and how do you think it will mean to the way you price this and also you communicate those? Speaker 14: I think you have<br><br><br>Speaker 15: But I would say in our practice, interesting since I had the chance to go to Costa Rica, was actually with a couple of you is I actually started doing more local procedures after we chatted and it was super interesting to me. One, how big of an obstacle anesthesia was for patients, how receptive they were. For us, we haven't decreased our prices.</td><td>ì‚¬ì „ ì¡°ì‚¬ê°€ ë§ì€ ì§€ì—­ê³¼ ì„ ë³„ëœ ì‹œì¥ì—ì„œ ì‹œì‘ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  GEMê³¼ ê´€ë ¨í•´ì„œëŠ” ì„ìƒ ì—°êµ¬ë¥¼ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ° ê²ƒë“¤ì€ ì‹¤ì œì ì¸ ê²ƒë“¤ì…ë‹ˆë‹¤. ì´ê²ƒë“¤ì´ ê·€í•˜ì˜ ì§„ë£Œì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒì´ë¼ê³  ìƒê°í•˜ì‹œëŠ”ì§€, ê·¸ë¦¬ê³  ì´ê²ƒì´ ê°€ê²© ì±…ì • ë°©ì‹ê³¼ ì†Œí†µ ë°©ì‹ì— ì–´ë–¤ ì˜ë¯¸ê°€ ë  ê²ƒì´ë¼ê³  ìƒê°í•˜ì‹œëŠ”ì§€ìš”? <br><br>ë°œí‘œì 14: ì €ëŠ” ìƒê°í•˜ê¸°ì—<br><br>ë°œí‘œì 15: í•˜ì§€ë§Œ ì €í¬ ì§„ë£Œì—ì„œ ë§ì”€ë“œë¦¬ìë©´, í¥ë¯¸ë¡œìš´ ì ì€ ì œê°€ ì½”ìŠ¤íƒ€ë¦¬ì¹´ì— ê°ˆ ê¸°íšŒê°€ ìˆì—ˆëŠ”ë°, ì‹¤ì œë¡œ ì—¬ëŸ¬ë¶„ ì¤‘ ëª‡ ë¶„ê³¼ í•¨ê»˜ì˜€ëŠ”ë°, ì €í¬ê°€ ëŒ€í™”ë¥¼ ë‚˜ëˆˆ í›„ ì‹¤ì œë¡œ ë” ë§ì€ êµ­ì†Œ ì‹œìˆ ì„ ì‹œì‘í•˜ê²Œ ë˜ì—ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¸ê²ƒì´ ì €ì—ê²ŒëŠ” ë§¤ìš° í¥ë¯¸ë¡œì› ìŠµë‹ˆë‹¤. ì²«ì§¸ë¡œ, ë§ˆì·¨ê°€ í™˜ìë“¤ì—ê²Œ ì–¼ë§ˆë‚˜ í° ì¥ë²½ì´ì—ˆëŠ”ì§€, ê·¸ë“¤ì´ ì–¼ë§ˆë‚˜ ìˆ˜ìš©ì ì´ì—ˆëŠ”ì§€ ë§ì…ë‹ˆë‹¤. ì €í¬ì˜ ê²½ìš°, ê°€ê²©ì„ ì¸í•˜í•˜ì§€ëŠ” ì•Šì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We've considered it a premium package in terms of doing this. But it goes to the whole movement of rapid<br>recovery, people don't want any downtime. Speaker 15: Sometimes people just don't want somebody to have to take care of them for an extended period of time. Anesthesia is the biggest reason that people have a little bit of that<br><br>hangover. It takes them a little bit longer to get going. So I think that's been super exciting. Also as a plastic surgeon this has been a really exciting time. Speaker 15: I mean between the transparency trend which has taken off like wildfire and you see more of this coming to life, people sharing their journeys.</td><td>ì €í¬ëŠ” ì´ë¥¼ í”„ë¦¬ë¯¸ì—„ íŒ¨í‚¤ì§€ë¡œ ê°„ì£¼í•´ì™”ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ëŠ” ë¹ ë¥¸ íšŒë³µì´ë¼ëŠ” ì „ì²´ì ì¸ ì›€ì§ì„ê³¼ ê´€ë ¨ì´ ìˆìœ¼ë©°, ì‚¬ëŒë“¤ì€ ì–´ë–¤ ë‹¤ìš´íƒ€ì„ë„ ì›í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 15: ë•Œë¡œëŠ” ì‚¬ëŒë“¤ì´ ë‹¨ìˆœíˆ ëˆ„êµ°ê°€ê°€ ì¥ê¸°ê°„ ìì‹ ì„ ëŒë´ì£¼ëŠ” ê²ƒì„ ì›í•˜ì§€ ì•Šê¸°ë„ í•©ë‹ˆë‹¤. ë§ˆì·¨ê°€ ì‚¬ëŒë“¤ì´ ì•½ê°„ì˜ ìˆ™ì·¨ê°ì„ ê°–ê²Œ ë˜ëŠ” ê°€ì¥ í° ì´ìœ ì…ë‹ˆë‹¤. ë§ˆì·¨ë¡œ ì¸í•´ íšŒë³µí•˜ëŠ” ë° ì¡°ê¸ˆ ë” ì˜¤ë˜ ê±¸ë¦¬ê²Œ ë©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ê²ƒì´ ë§¤ìš° í¥ë¯¸ì§„ì§„í–ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë˜í•œ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë¡œì„œ ì´ëŠ” ì •ë§ í¥ë¯¸ë¡œìš´ ì‹œê¸°ì˜€ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 15: íˆ¬ëª…ì„± íŠ¸ë Œë“œê°€ ë“¤ë¶ˆì²˜ëŸ¼ ë²ˆì ¸ë‚˜ê°€ê³  ìˆê³ , ì‚¬ëŒë“¤ì´ ìì‹ ì˜ ì—¬ì •ì„ ê³µìœ í•˜ë©´ì„œ ì´ëŸ¬í•œ í˜„ìƒì´ ë”ìš± í˜„ì‹¤í™”ë˜ëŠ” ê²ƒì„ ëª©ê²©í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I think with Motiva really changing things and just having great conversations, whether people agree or not, the fact that we're talking about this I think is absolutely huge. You've seen and obviously I'm biased, but truly believe that the GLPs have led to this huge conversation because you've seen this movement. The timing couldn't have been better for you guys because in terms of this whole fit and fabulous change stuff and the movement away from being so big and something this subtle sexy has really taken off. So I think that the timing has been a perfect storm that you guys probably couldn't have planned any better.</td><td>ëª¨í‹°ë°”ê°€ ì •ë§ë¡œ ìƒí™©ì„ ë°”ê¾¸ê³  ìˆê³  í›Œë¥­í•œ ëŒ€í™”ë“¤ì„ ë‚˜ëˆ„ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì‚¬ëŒë“¤ì´ ë™ì˜í•˜ë“  ê·¸ë ‡ì§€ ì•Šë“ , ìš°ë¦¬ê°€ ì´ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ê³  ìˆë‹¤ëŠ” ì‚¬ì‹¤ ìì²´ê°€ ì •ë§ ì—„ì²­ë‚œ ì¼ì´ë¼ê³  ë´…ë‹ˆë‹¤. ì œê°€ í¸í–¥ì ì¼ ìˆ˜ë„ ìˆì§€ë§Œ, GLPë“¤ì´ ì´ëŸ° ê±°ëŒ€í•œ ëŒ€í™”ë¥¼ ì´ëŒì–´ëƒˆë‹¤ê³  ì§„ì‹¬ìœ¼ë¡œ ë¯¿ìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ëŸ° ì›€ì§ì„ì„ ë³´ì…¨ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ì—ê²ŒëŠ” íƒ€ì´ë°ì´ ì •ë§ ì™„ë²½í–ˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  'ê±´ê°•í•˜ê³  ë©‹ì§„' ë³€í™”ì™€ ë„ˆë¬´ í° ê²ƒì—ì„œ ë²—ì–´ë‚˜ ë¯¸ë¬˜í•˜ê³  ì„¹ì‹œí•œ ê²ƒìœ¼ë¡œì˜ ì›€ì§ì„ì´ ì •ë§ë¡œ ì£¼ëª©ë°›ê³  ìˆëŠ” ì‹œì ì—ì„œ ë§ì´ì£ . ë”°ë¼ì„œ ì´ íƒ€ì´ë°ì€ ì—¬ëŸ¬ë¶„ì´ ì•„ë§ˆ ë” ì˜ ê³„íší•  ìˆ˜ë„ ì—†ì—ˆì„ ì™„ë²½í•œ í­í’ì´ì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 7: And I think the one thing that stuck with me was when we were in Costa Rica the time, we were asking how we're gonna incorporate Prezerva and Mia into our practice. And your answer was you haven't seen those people yet. And I think that's something that's really exciting is that there are all of these women who are wearing push up bras who are sitting in their home saying if there was only a way to kind of fill this bra out and not have surgery under anesthesia, I'd love that. And so that's what's exciting is that there are all of these women that we're going to be able to open the market to who we don't even see in our practice yet. Speaker 16: Sure.</td><td>**ë°œí‘œì 7:** ê·¸ë¦¬ê³  ì œê°€ ê¸°ì–µì— ë‚¨ëŠ” í•œ ê°€ì§€ëŠ” ì½”ìŠ¤íƒ€ë¦¬ì¹´ì— ìˆì„ ë•Œ, ì €í¬ê°€ Prezervaì™€ Miaë¥¼ ì–´ë–»ê²Œ ì§„ë£Œì— ë„ì…í•  ê²ƒì¸ì§€ ë¬¼ì–´ë´¤ì„ ë•Œ, ë‹¹ì‹ ì˜ ë‹µë³€ì´ "ì•„ì§ ê·¸ëŸ° í™˜ìë“¤ì„ ë³¸ ì ì´ ì—†ë‹¤"ëŠ” ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €ëŠ” ê·¸ê²ƒì´ ì •ë§ í¥ë¯¸ì§„ì§„í•œ ë¶€ë¶„ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì™œëƒí•˜ë©´ í‘¸ì‹œì—… ë¸Œë¼ë¥¼ ì°©ìš©í•˜ê³  ì§‘ì— ì•‰ì•„ì„œ "ë§ˆì·¨ í•˜ì— ìˆ˜ìˆ ì„ ë°›ì§€ ì•Šê³ ë„ ì´ ë¸Œë¼ë¥¼ ì±„ìš¸ ìˆ˜ ìˆëŠ” ë°©ë²•ë§Œ ìˆë‹¤ë©´ ì •ë§ ì¢‹ê² ë‹¤"ê³  ë§í•˜ëŠ” ëª¨ë“  ì—¬ì„±ë“¤ì´ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ í¥ë¯¸ë¡œìš´ ì ì€ ì €í¬ê°€ ì•„ì§ ì§„ë£Œì‹¤ì—ì„œ ë§Œë‚˜ë³´ì§€ë„ ëª»í•œ ì´ ëª¨ë“  ì—¬ì„±ë“¤ì—ê²Œ ì‹œì¥ì„ ì—´ì–´ì¤„ ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>**ë°œí‘œì 16:** ë§ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So I think those are two incredible points. And I think if we just take kind of a bigger step back and take a look at this. When you talk about market expansion innovation, these are two elements that have been incredibly lacking in aesthetics. Most of the innovation has come in the nonsurgical sector because surgical procedures, really the innovation are just expansion of new techniques, not necessarily new technologies per se. Speaker 16: That's why you've seen so much in the injectables, new neurotoxins, new dermal fillers, new devices, tightening. All of those things are device based that actually have a lot of science to drive them.</td><td>ì´ ë‘ ê°€ì§€ëŠ” ì •ë§ ë†€ë¼ìš´ í¬ì¸íŠ¸ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì¢€ ë” í° ê´€ì ì—ì„œ í•œ ê±¸ìŒ ë¬¼ëŸ¬ì„œì„œ ì‚´í´ë³´ë©´, ì‹œì¥ í™•ì¥ í˜ì‹ ì— ëŒ€í•´ ë§ì”€í•˜ì‹¤ ë•Œ, ì´ ë‘ ìš”ì†ŒëŠ” ë¯¸ìš© ë¶„ì•¼ì—ì„œ ê·¹ë„ë¡œ ë¶€ì¡±í–ˆë˜ ë¶€ë¶„ë“¤ì…ë‹ˆë‹¤. ëŒ€ë¶€ë¶„ì˜ í˜ì‹ ì€ ë¹„ìˆ˜ìˆ  ë¶€ë¬¸ì—ì„œ ë‚˜ì™”ëŠ”ë°, ì´ëŠ” ìˆ˜ìˆ ì  ì‹œìˆ ì˜ ê²½ìš° í˜ì‹ ì´ë¼ëŠ” ê²ƒì´ ìƒˆë¡œìš´ ê¸°ìˆ  ìì²´ê°€ ì•„ë‹ˆë¼ ë‹¨ìˆœíˆ ìƒˆë¡œìš´ ê¸°ë²•ì˜ í™•ì¥ì— ë¶ˆê³¼í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>í™”ì 16: ê·¸ë˜ì„œ ì£¼ì‚¬ì œ ë¶„ì•¼ì—ì„œ ê·¸ë ‡ê²Œ ë§ì€ ë°œì „ì„ ë³´ê²Œ ëœ ê²ƒì…ë‹ˆë‹¤. ìƒˆë¡œìš´ ì‹ ê²½ë…ì†Œ, ìƒˆë¡œìš´ í”¼ë¶€ í•„ëŸ¬, ìƒˆë¡œìš´ ê¸°ê¸°ë“¤, íƒ€ì´íŠ¸ë‹ ë“± ì´ ëª¨ë“  ê²ƒë“¤ì€ ì‹¤ì œë¡œ ì´ë¥¼ ë’·ë°›ì¹¨í•  ë§ì€ ê³¼í•™ì  ê·¼ê±°ë¥¼ ê°€ì§„ ê¸°ê¸° ê¸°ë°˜ ê¸°ìˆ ë“¤ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Surgical innovation usually just occurs in advancement and techniques until you have something truly novel like a new device or a new implant that's being used in a completely different way. So the word innovation gets thrown around quite a bit. And it's why even this multibillion dollar industry has still been so underpenetrated. Speaker 16: If you look at the data, six percent to eight percent of Americans undergo an aesthetic procedure. That's it. So when you think about the number of people, as Doctor.</td><td>ìˆ˜ìˆ  í˜ì‹ ì€ ì¼ë°˜ì ìœ¼ë¡œ ì™„ì „íˆ ìƒˆë¡œìš´ ë°©ì‹ìœ¼ë¡œ ì‚¬ìš©ë˜ëŠ” ìƒˆë¡œìš´ ê¸°ê¸°ë‚˜ ìƒˆë¡œìš´ ì„í”Œë€íŠ¸ì™€ ê°™ì´ ì§„ì •ìœ¼ë¡œ ì°¸ì‹ í•œ ê²ƒì´ ë‚˜ì˜¬ ë•Œê¹Œì§€ëŠ” ë‹¨ìˆœíˆ ê¸°ìˆ ì˜ ë°œì „ ìˆ˜ì¤€ì—ì„œë§Œ ì¼ì–´ë‚©ë‹ˆë‹¤. ê·¸ë˜ì„œ í˜ì‹ ì´ë¼ëŠ” ë‹¨ì–´ê°€ ìƒë‹¹íˆ ë‚¨ìš©ë˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ìˆ˜ì‹­ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì´ ì‚°ì—…ì´ ì—¬ì „íˆ ì‹œì¥ ì¹¨íˆ¬ìœ¨ì´ ë‚®ì€ ì´ìœ ì´ê¸°ë„ í•©ë‹ˆë‹¤. <br><br>ë°œí‘œì 16: ë°ì´í„°ë¥¼ ë³´ì‹œë©´, ë¯¸êµ­ì¸ì˜ 6%ì—ì„œ 8%ë§Œì´ ë¯¸ìš© ì‹œìˆ ì„ ë°›ìŠµë‹ˆë‹¤. ê·¸ê²Œ ì „ë¶€ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì˜ì‚¬ê°€ ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ ì‚¬ëŒë“¤ì˜ ìˆ˜ë¥¼ ìƒê°í•´ë³´ë©´...</td></tr>
<tr><td>Pittman already alluded to, that are out there waiting for a different type of technology or a different procedure with less downtime that they would that taps into what they're looking for, there's a huge opportunity in market expansion as opposed to what we usually do, which is just cannibalize our internal databases and just keep offering the same people multiple different types of procedures. And that's what's historically happened. Speaker 16: So there's an unmet need which can be met because of these novel advances. Speaker 14: And let me add something more to that.</td><td>í”¼íŠ¸ë§Œì´ ì´ë¯¸ ì–¸ê¸‰í–ˆë“¯ì´, ë‹¤ë¥¸ ìœ í˜•ì˜ ê¸°ìˆ ì´ë‚˜ ë‹¤ìš´íƒ€ì„ì´ ì ì€ ë‹¤ë¥¸ ì‹œìˆ ì„ ê¸°ë‹¤ë¦¬ê³  ìˆëŠ” ê³ ê°ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì´ë“¤ì´ ì°¾ê³  ìˆëŠ” ê²ƒì„ ì¶©ì¡±ì‹œí‚¬ ìˆ˜ ìˆë‹¤ë©´, ìš°ë¦¬ê°€ ë³´í†µ í•˜ëŠ” ê²ƒì²˜ëŸ¼ ë‹¨ìˆœíˆ ë‚´ë¶€ ë°ì´í„°ë² ì´ìŠ¤ë¥¼ ì ì‹í•˜ê³  ê°™ì€ ì‚¬ëŒë“¤ì—ê²Œ ì—¬ëŸ¬ ê°€ì§€ ë‹¤ë¥¸ ìœ í˜•ì˜ ì‹œìˆ ì„ ê³„ì† ì œê³µí•˜ëŠ” ê²ƒê³¼ëŠ” ë‹¬ë¦¬, ì‹œì¥ í™•ì¥ì— ìˆì–´ ì—„ì²­ë‚œ ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ì—­ì‚¬ì ìœ¼ë¡œ ì¼ì–´ë‚¬ë˜ ì¼ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 16: ê·¸ëŸ¬ë‹ˆê¹Œ ì´ëŸ¬í•œ ìƒˆë¡œìš´ ë°œì „ìœ¼ë¡œ ì¸í•´ ì¶©ì¡±ë  ìˆ˜ ìˆëŠ” ë¯¸ì¶©ì¡± ìˆ˜ìš”ê°€ ìˆë‹¤ëŠ” ë§ì”€ì´êµ°ìš”.<br><br>ë°œí‘œì 14: ê±°ê¸°ì— í•œ ê°€ì§€ ë” ë§ë¶™ì´ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I think one of the most exciting things from today was the announcement that we will begin early experience with press survey this year here in The United States, which I think it's way ahead of the expectations that many people had. And when we look at already, we had the launch in Brazil in February, followed by launches in Europe, Middle East, then we launched in more select countries in Latin America and now The United States. So I would like to add Doctor. Steve and Doctor. Speaker 14: Epstein about like breast tissue preservation, Doctor. Pittman presented on it, but I think the wave towards preservation in these type of patients and what it could mean.</td><td>ì˜¤ëŠ˜ ë°œí‘œ ì¤‘ ê°€ì¥ í¥ë¯¸ë¡œìš´ ê²ƒ ì¤‘ í•˜ë‚˜ëŠ” ì˜¬í•´ ë¯¸êµ­ì—ì„œ ìœ ë°© ì¡°ì‚¬(press survey)ë¥¼ í†µí•œ ì´ˆê¸° ê²½í—˜ì„ ì‹œì‘í•œë‹¤ëŠ” ë°œí‘œì˜€ìŠµë‹ˆë‹¤. ì´ëŠ” ë§ì€ ì‚¬ëŒë“¤ì´ ì˜ˆìƒí–ˆë˜ ê²ƒë³´ë‹¤ í›¨ì”¬ ì•ì„  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ë¯¸ 2ì›” ë¸Œë¼ì§ˆì—ì„œì˜ ì¶œì‹œë¥¼ ì‹œì‘ìœ¼ë¡œ, ìœ ëŸ½ê³¼ ì¤‘ë™ì—ì„œì˜ ì¶œì‹œ, ê·¸ë¦¬ê³  ë¼í‹´ ì•„ë©”ë¦¬ì¹´ì˜ ì¼ë¶€ ì„ ë³„ëœ êµ­ê°€ë“¤ì—ì„œì˜ ì¶œì‹œì— ì´ì–´ ì´ì œ ë¯¸êµ­ê¹Œì§€ ì§„ì¶œí•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ Steve ë°•ì‚¬ì™€ Epstein ë°•ì‚¬ì—ê²Œ ìœ ë°© ì¡°ì§ ë³´ì¡´ì— ëŒ€í•´ ì§ˆë¬¸í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. Pittman ë°•ì‚¬ê°€ ì´ì— ëŒ€í•´ ë°œí‘œí–ˆì§€ë§Œ, ì´ëŸ¬í•œ ìœ í˜•ì˜ í™˜ìë“¤ì—ì„œ ë³´ì¡´ ì¹˜ë£Œë¡œì˜ íë¦„ê³¼ ê·¸ê²ƒì´ ì˜ë¯¸í•˜ëŠ” ë°”ì— ëŒ€í•´ ë” ìì„¸íˆ ë“£ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 5: Well, I think the information is out there, and it's readily obtainable, and women are<br><br>going to drive this. They're going to find the information, and they're going to be the ones asking for the procedure. So there are going be those who adopt it and those who don't. And those who don't, they're going to see their practices decline dramatically. Those who do adopt the procedure, this is what's, just like open to laparoscopic surgery, this is where the future is going, and the Motiva device is engineered to be most ideal for the minimally invasive preservation approach, and that's gonna become the gold standard.</td><td>ë°œí‘œì 5: ìŒ, ì •ë³´ëŠ” ì´ë¯¸ ê³µê°œë˜ì–´ ìˆê³  ì‰½ê²Œ ì ‘ê·¼í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ì„±ë“¤ì´ ì´ë¥¼ ì£¼ë„í•  ê²ƒì…ë‹ˆë‹¤. ì—¬ì„±ë“¤ì´ ì •ë³´ë¥¼ ì°¾ì•„ë³¼ ê²ƒì´ê³ , ì‹œìˆ ì„ ìš”ì²­í•˜ëŠ” ê²ƒë„ ì—¬ì„±ë“¤ì´ ë  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ë¥¼ ë„ì…í•˜ëŠ” ì˜ì‚¬ë“¤ê³¼ ê·¸ë ‡ì§€ ì•Šì€ ì˜ì‚¬ë“¤ë¡œ ë‚˜ë‰  ê²ƒì…ë‹ˆë‹¤. ë„ì…í•˜ì§€ ì•ŠëŠ” ì˜ì‚¬ë“¤ì€ ì§„ë£ŒëŸ‰ì´ ê¸‰ê²©íˆ ê°ì†Œí•˜ëŠ” ê²ƒì„ ë³´ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ë°˜ë©´ ì‹œìˆ ì„ ë„ì…í•˜ëŠ” ì˜ì‚¬ë“¤ì—ê²ŒëŠ”, ì´ê²ƒì´ ë°”ë¡œ ê°œë³µìˆ˜ìˆ ì—ì„œ ë³µê°•ê²½ìˆ˜ìˆ ë¡œì˜ ì „í™˜ê³¼ ë§ˆì°¬ê°€ì§€ë¡œ ë¯¸ë˜ê°€ í–¥í•˜ëŠ” ë°©í–¥ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  Motiva ê¸°ê¸°ëŠ” ìµœì†Œì¹¨ìŠµì  ë³´ì¡´ ì ‘ê·¼ë²•ì— ê°€ì¥ ì´ìƒì ìœ¼ë¡œ ì„¤ê³„ë˜ì—ˆìœ¼ë©°, ì´ê²ƒì´ ê³¨ë“œ ìŠ¤íƒ ë‹¤ë“œê°€ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 6: You know, I think we're all surgeons, and we love surgery, but no patient loves surgery. So if you can have an injectable breast implant, which is exactly what's coming, I think that's a huge market expansion for women who otherwise wouldn't have even considered surgery. And then I would say before I spoke about having two primary types of patients, I would add a in that the weight loss patients, they look like postpartum women in the amount of volume loss they have.</td><td>ë°œí‘œì 6: ì €í¬ëŠ” ëª¨ë‘ ì™¸ê³¼ì˜ì‚¬ì´ê³  ìˆ˜ìˆ ì„ ì¢‹ì•„í•˜ì§€ë§Œ, ìˆ˜ìˆ ì„ ì¢‹ì•„í•˜ëŠ” í™˜ìëŠ” ì—†ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì£¼ì‚¬ ê°€ëŠ¥í•œ ìœ ë°© ì„í”Œë€íŠ¸ê°€ ë‚˜ì˜¨ë‹¤ë©´, ê·¸ë¦¬ê³  ì´ê²ƒì´ ë°”ë¡œ ë‹¤ê°€ì˜¤ê³  ìˆëŠ” ê²ƒì¸ë°, ì´ëŠ” ê¸°ì¡´ì— ìˆ˜ìˆ ì„ ì „í˜€ ê³ ë ¤í•˜ì§€ ì•Šì•˜ì„ ì—¬ì„±ë“¤ì—ê²Œ ì—„ì²­ë‚œ ì‹œì¥ í™•ì¥ì´ ë  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•ì„œ ë‘ ê°€ì§€ ì£¼ìš” í™˜ì ìœ í˜•ì— ëŒ€í•´ ë§ì”€ë“œë ¸ëŠ”ë°, ì—¬ê¸°ì— ì¶”ê°€í•˜ê³  ì‹¶ì€ ê²ƒì€ ì²´ì¤‘ ê°ëŸ‰ í™˜ìë“¤ì…ë‹ˆë‹¤. ì´ë“¤ì€ ë³¼ë¥¨ ì†ì‹¤ ì •ë„ê°€ ì‚°í›„ ì—¬ì„±ë“¤ê³¼ ë¹„ìŠ·í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And in my practice, even with the Park Avenue look and these very lean women, at least sixty to seventy percent of our patients are taking these medications even when they're very fit women just to be a little bit thinner. And the consequences of that are those women have dramatic volume loss that they don't want to tolerate from the perspective<br>of feeling like they're too young to look that way. Speaker 14: Yeah, one additional thing we wanted to add is, just last weekend, we were in Paris in the minimally invasive breast meeting worldwide. And this was an amazing opportunity because it had two tracks.</td><td>ì´ í…ìŠ¤íŠ¸ëŠ” ìˆ˜ìµ ë°œí‘œ ì „í™”íšŒì˜ ë‚´ìš©ì´ ì•„ë‹Œ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì˜ë£Œì§„ì´ í™˜ìë“¤ì˜ ì²´ì¤‘ ê°ëŸ‰ ì•½ë¬¼ ì‚¬ìš©ê³¼ ê·¸ë¡œ ì¸í•œ ë³¼ë¥¨ ì†ì‹¤ì— ëŒ€í•´ ë…¼ì˜í•˜ê³ , íŒŒë¦¬ì—ì„œ ì—´ë¦° ìµœì†Œì¹¨ìŠµ ìœ ë°© ê´€ë ¨ íšŒì˜ì— ëŒ€í•´ ì–¸ê¸‰í•˜ëŠ” ë‚´ìš©ì…ë‹ˆë‹¤.<br><br>ìˆ˜ìµ ë°œí‘œ ì „í™”íšŒì˜ transcriptë¥¼ ì œê³µí•´ ì£¼ì‹œë©´, ê¸ˆìœµ ì „ë¬¸ ìš©ì–´ì™€ í™”ìì˜ ì–´ì¡°ë¥¼ ë³´ì¡´í•˜ë©´ì„œ ìì—°ìŠ¤ëŸ½ê³  ì •í™•í•œ í•œêµ­ì–´ë¡œ ë²ˆì—­í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>One was breast reconstruction with robotics, endoscopy, and then the other track was pretty much all about Motiva's incorporation of minimally invasive into aesthetics. But one of the interesting things is that in that meeting, we had people presenting<br>on the use of Mia in breast reconstruction. And I think that's something that we should all remember is that if you're doing, for instance, robotic breast surgery, eventually an injectable implant is a huge solution for that type of technique and beyond. Speaker 14: And there's also this changing of expectations of the recon patients that is looking more and more like aesthetics.</td><td>í•œ íŠ¸ë™ì€ ë¡œë´‡ê³µí•™ê³¼ ë‚´ì‹œê²½ì„ í™œìš©í•œ ìœ ë°©ì¬ê±´ìˆ ì´ì—ˆê³ , ë‹¤ë¥¸ íŠ¸ë™ì€ ì£¼ë¡œ Motivaì˜ ìµœì†Œì¹¨ìŠµ ê¸°ìˆ ì„ ë¯¸ìš© ë¶„ì•¼ì— ì ‘ëª©í•˜ëŠ” ê²ƒì— ê´€í•œ ë‚´ìš©ì´ì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ í¥ë¯¸ë¡œìš´ ì  ì¤‘ í•˜ë‚˜ëŠ” ê·¸ íšŒì˜ì—ì„œ ìœ ë°©ì¬ê±´ìˆ ì— Miaë¥¼ ì‚¬ìš©í•˜ëŠ” ê²ƒì— ëŒ€í•´ ë°œí‘œí•˜ëŠ” ì‚¬ëŒë“¤ì´ ìˆì—ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ ëª¨ë‘ê°€ ê¸°ì–µí•´ì•¼ í•  ì ì€, ì˜ˆë¥¼ ë“¤ì–´ ë¡œë´‡ ìœ ë°©ìˆ˜ìˆ ì„ ì‹œí–‰í•  ë•Œ ì£¼ì…í˜• ì„í”Œë€íŠ¸ê°€ ê·¸ëŸ¬í•œ ê¸°ìˆ ê³¼ ê·¸ ì´ìƒì˜ ì˜ì—­ì—ì„œ ë§¤ìš° ì¤‘ìš”í•œ ì†”ë£¨ì…˜ì´ ëœë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 14: ê·¸ë¦¬ê³  ì¬ê±´ í™˜ìë“¤ì˜ ê¸°ëŒ€ì¹˜ê°€ ë³€í™”í•˜ê³  ìˆëŠ”ë°, ì ì  ë” ë¯¸ìš© ë¶„ì•¼ì™€ ìœ ì‚¬í•´ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>But beyond that commercial, what I would like to do is go further into, GEM because that's been an indication that's been only for a very few, very courageous plastic surgeons, usually one or two per city. And then you have had access to the procedure and seeing it. And I would like to see like not only on the GLP-one population, but also in the day to day patients, what impact it could have on that. Speaker 15: I'm someone that does butt implants and it's interesting because we'll have people come visit our office because in training most people didn't see it, didn't do it.</td><td>í•˜ì§€ë§Œ ìƒì—…ì ì¸ ì¸¡ë©´ì„ ë„˜ì–´ì„œ, ì œê°€ ë” ê¹Šì´ ë“¤ì–´ê°€ê³  ì‹¶ì€ ê²ƒì€ GEMì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ê²ƒì€ ì§€ê¸ˆê¹Œì§€ ë§¤ìš° ì†Œìˆ˜ì˜, ë§¤ìš° ìš©ê°í•œ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤, ë³´í†µ ë„ì‹œë‹¹ í•œë‘ ëª… ì •ë„ë§Œì´ ì‹œí–‰í•´ì˜¨ ì ì‘ì¦ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¸ë“¤ë§Œì´ ì´ ì‹œìˆ ì— ì ‘ê·¼í•  ìˆ˜ ìˆì—ˆê³  ì‹¤ì œë¡œ ë³´ì•„ì™”ìŠµë‹ˆë‹¤. ì €ëŠ” GLP-1 í™˜ìêµ°ë¿ë§Œ ì•„ë‹ˆë¼ ì¼ìƒì ì¸ í™˜ìë“¤ì—ê²Œë„ ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆëŠ”ì§€ ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 15: ì €ëŠ” ë‘”ë¶€ ì„í”Œë€íŠ¸ ì‹œìˆ ì„ í•˜ëŠ” ì‚¬ëŒì¸ë°, í¥ë¯¸ë¡œìš´ ì ì€ ì‚¬ëŒë“¤ì´ ì €í¬ ë³‘ì›ì„ ë°©ë¬¸í•˜ëŠ” ì´ìœ ê°€ ëŒ€ë¶€ë¶„ì˜ ì˜ì‚¬ë“¤ì´ ìˆ˜ë ¨ ê³¼ì •ì—ì„œ ì´ë¥¼ ë³´ì§€ë„ ëª»í–ˆê³  ì‹œí–‰í•´ë³´ì§€ë„ ëª»í–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And one of the things that I think is so exciting when I've talked to your team about this is that I think this is another huge opportunity for market expansion because a lot of people don't do it because of our moral compass that if we haven't been trained we don't feel good like we can do this reproducibly. We're typically not gonna offer it to patients. But when you make this very systematic that it's step by step in terms of this, I think you're going to have so many people wanting to because I have people come up to me all the time or they DM me and they're like, hey can I come watch and learn this? I have so many patients that need this now that they've lost weight.</td><td>ê·¸ë¦¬ê³  ì œê°€ ê·€í•˜ì˜ íŒ€ê³¼ ì´ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ë©´ì„œ ì •ë§ í¥ë¯¸ë¡­ê²Œ ìƒê°í•˜ëŠ” ê²ƒ ì¤‘ í•˜ë‚˜ëŠ”, ì´ê²ƒì´ ì‹œì¥ í™•ì¥ì„ ìœ„í•œ ë˜ ë‹¤ë¥¸ ê±°ëŒ€í•œ ê¸°íšŒë¼ëŠ” ì ì…ë‹ˆë‹¤. ë§ì€ ì‚¬ëŒë“¤ì´ ì´ ì‹œìˆ ì„ í•˜ì§€ ì•ŠëŠ” ì´ìœ ëŠ” ìš°ë¦¬ì˜ ë„ë•ì  ë‚˜ì¹¨ë°˜ ë•Œë¬¸ì¸ë°, í›ˆë ¨ì„ ë°›ì§€ ì•Šì•˜ë‹¤ë©´ ì´ê²ƒì„ ì¬í˜„ ê°€ëŠ¥í•˜ê²Œ í•  ìˆ˜ ìˆë‹¤ëŠ” í™•ì‹ ì´ ì„œì§€ ì•Šê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì¼ë°˜ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” í™˜ìë“¤ì—ê²Œ ì´ëŸ° ì‹œìˆ ì„ ì œì•ˆí•˜ì§€ ì•Šì„ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ê²ƒì„ ë§¤ìš° ì²´ê³„ì ìœ¼ë¡œ, ë‹¨ê³„ë³„ë¡œ ë§Œë“¤ì–´ ë†“ìœ¼ë©´, ì •ë§ ë§ì€ ì‚¬ëŒë“¤ì´ í•˜ê³  ì‹¶ì–´í•  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì™œëƒí•˜ë©´ í•­ìƒ ì‚¬ëŒë“¤ì´ ì €ì—ê²Œ ë‹¤ê°€ì™€ì„œ DMì„ ë³´ë‚´ë©° "ì œê°€ ê°€ì„œ ë³´ê³  ë°°ìš¸ ìˆ˜ ìˆì„ê¹Œìš”? ì²´ì¤‘ì„ ê°ëŸ‰í•œ í›„ ì´ëŸ° ì‹œìˆ ì´ í•„ìš”í•œ í™˜ìë“¤ì´ ë„ˆë¬´ ë§ì•„ìš”"ë¼ê³  ë§í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 15: But I don't want to just jump in and try this. And so I think having a standard approach and then you guys would roll it out just like you're doing now. We're like hey here's to be some center of excellences. Here's some of the trip stuff and then being able to do that. And I think the Ozempic bot, it's been absolutely mind blowing to me how many people have asked for this. Speaker 15: People ask me all the time because a big part of my practice is lipo fat transfers. Have BBLs gone away? I'm like absolutely not. We'll do more BBLs this year than I ever have in my career. And most people what they want is changed in terms of desires.</td><td>í™”ì 15: í•˜ì§€ë§Œ ì €ëŠ” ê·¸ëƒ¥ ë›°ì–´ë“¤ì–´ì„œ ì‹œë„í•˜ê³  ì‹¶ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ í‘œì¤€í™”ëœ ì ‘ê·¼ë²•ì„ ê°–ì¶”ê³  ì—¬ëŸ¬ë¶„ë“¤ì´ ì§€ê¸ˆ í•˜ê³  ê³„ì‹  ê²ƒì²˜ëŸ¼ ë‹¨ê³„ì ìœ¼ë¡œ ë„ì…í•˜ëŠ” ê²ƒì´ ì¢‹ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë§ˆì¹˜ 'ì—¬ê¸° ëª‡ ê°œì˜ ìš°ìˆ˜ ì„¼í„°ë“¤ì´ ìˆê³ , ì—¬ê¸° ëª‡ ê°€ì§€ ì‹œë²” ì‚¬ë¡€ë“¤ì´ ìˆë‹¤'ëŠ” ì‹ìœ¼ë¡œ ë§ì´ì£ . ê·¸ë¦¬ê³  ê·¸ëŸ° ë°©ì‹ìœ¼ë¡œ ì§„í–‰í•  ìˆ˜ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¤ì ¬í”½ ê´€ë ¨ ê±´ì— ëŒ€í•´ì„œëŠ”, ì–¼ë§ˆë‚˜ ë§ì€ ì‚¬ëŒë“¤ì´ ì´ê²ƒì— ëŒ€í•´ ë¬¸ì˜í•˜ëŠ”ì§€ ì •ë§ ë†€ë¼ìš¸ ì •ë„ì…ë‹ˆë‹¤.<br><br>í™”ì 15: ì œ ì§„ë£Œì˜ ìƒë‹¹ ë¶€ë¶„ì´ ì§€ë°© ì´ì‹ìˆ ì´ë‹¤ ë³´ë‹ˆ ì‚¬ëŒë“¤ì´ í•­ìƒ ì €ì—ê²Œ ë¬»ìŠµë‹ˆë‹¤. BBL(ë¸Œë¼ì§ˆë¦¬ì–¸ ì—‰ë©ì´ ë¦¬í”„íŠ¸)ì´ ì‚¬ë¼ì¡ŒëŠëƒê³ ìš”. ì €ëŠ” ì ˆëŒ€ ê·¸ë ‡ì§€ ì•Šë‹¤ê³  ë‹µí•©ë‹ˆë‹¤. ì˜¬í•´ ì œ ì»¤ë¦¬ì–´ì—ì„œ ê·¸ ì–´ëŠ ë•Œë³´ë‹¤ ë” ë§ì€ BBLì„ ì‹œìˆ í•  ì˜ˆì •ì…ë‹ˆë‹¤. ëŒ€ë¶€ë¶„ì˜ ì‚¬ëŒë“¤ì´ ì›í•˜ëŠ” ê²ƒì€ ìš•êµ¬ ì¸¡ë©´ì—ì„œ ë³€í™”í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 15: It's more shape over size now, and this is I think falls right in line with Jim. Speaker 7: Well, I think to your point, one of the things we see all the time with women who have deflated breasts who come into the office and they say, I wanna have fat put in my breast is we can't shape your breasts with fat. We need to use something like an implant to shape the breast. And it's the same thing with the Ozempic butt. It's a there's so much skin laxity that just filling that with fat is not gonna work. We have to have something more projecting. Speaker 14: Yeah.</td><td>í™”ì 15: ì´ì œëŠ” í¬ê¸°ë³´ë‹¤ëŠ” ëª¨ì–‘ì´ ë” ì¤‘ìš”í•´ì¡ŒìŠµë‹ˆë‹¤. ì´ëŠ” Jimì˜ ì˜ê²¬ê³¼ ì¼ì¹˜í•œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>í™”ì 7: ë§ìŠµë‹ˆë‹¤. ì €í¬ê°€ í•­ìƒ ë³´ëŠ” ê²ƒ ì¤‘ í•˜ë‚˜ëŠ” ê°€ìŠ´ì´ ì²˜ì§„ ì—¬ì„±ë“¤ì´ ë³‘ì›ì— ì™€ì„œ "ê°€ìŠ´ì— ì§€ë°©ì„ ë„£ê³  ì‹¶ë‹¤"ê³  ë§í•˜ëŠ” ê²½ìš°ì¸ë°, ì§€ë°©ìœ¼ë¡œëŠ” ê°€ìŠ´ ëª¨ì–‘ì„ ë§Œë“¤ ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ê°€ìŠ´ ëª¨ì–‘ì„ ë§Œë“¤ê¸° ìœ„í•´ì„œëŠ” ì„í”Œë€íŠ¸ ê°™ì€ ê²ƒì„ ì‚¬ìš©í•´ì•¼ í•©ë‹ˆë‹¤. ì˜¤ì ¬í”½ ì—‰ë©ì´(Ozempic butt)ì˜ ê²½ìš°ë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. í”¼ë¶€ ì´ì™„ì´ ë„ˆë¬´ ì‹¬í•´ì„œ ë‹¨ìˆœíˆ ì§€ë°©ìœ¼ë¡œ ì±„ìš°ëŠ” ê²ƒë§Œìœ¼ë¡œëŠ” íš¨ê³¼ê°€ ì—†ìŠµë‹ˆë‹¤. ë” ëŒì¶œëœ í˜•íƒœì˜ ë¬´ì–¸ê°€ê°€ í•„ìš”í•©ë‹ˆë‹¤.<br><br>í™”ì 14: ë„¤.</td></tr>
<tr><td>And then there's the other part that<br><br><br>Speaker 3: I think it would be<br><br><br>Speaker 14: interesting to discuss, which is, you know, the gem can be used for women but also for men. And I think that's something that has been overlooked and because we've been primarily devoted to women's health, but as part of everything that we are developing, I think that's the other very interesting part. Speaker 5: Offering a minimally invasive procedure has a huge impact on your practice. Thirty years ago, I was doing a lot of hand surgery, and I was doing carpal tunnel releases.</td><td>ê·¸ë¦¬ê³  ë˜ ë‹¤ë¥¸ ë¶€ë¶„ì´ ìˆëŠ”ë°<br><br>ë°œí‘œì 3: ì œê°€ ìƒê°í•˜ê¸°ì— í¥ë¯¸ë¡­ê²Œ ë…¼ì˜í•  ë§Œí•œ ë¶€ë¶„ì´ ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 14: ë°”ë¡œ ì ¬(gem)ì´ ì—¬ì„±ë¿ë§Œ ì•„ë‹ˆë¼ ë‚¨ì„±ì—ê²Œë„ ì‚¬ìš©ë  ìˆ˜ ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì €ëŠ” ì´ ë¶€ë¶„ì´ ê°„ê³¼ë˜ì–´ ì™”ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ìš°ë¦¬ê°€ ì£¼ë¡œ ì—¬ì„± ê±´ê°•ì— ì§‘ì¤‘í•´ì™”ê¸° ë•Œë¬¸ì´ì£ . í•˜ì§€ë§Œ ìš°ë¦¬ê°€ ê°œë°œí•˜ê³  ìˆëŠ” ëª¨ë“  ê²ƒì˜ ì¼í™˜ìœ¼ë¡œì„œ, ì´ê²ƒì´ ë˜ ë‹¤ë¥¸ ë§¤ìš° í¥ë¯¸ë¡œìš´ ë¶€ë¶„ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ìµœì†Œì¹¨ìŠµ ì‹œìˆ ì„ ì œê³µí•˜ëŠ” ê²ƒì€ ì§„ë£Œì— ì—„ì²­ë‚œ ì˜í–¥ì„ ë¯¸ì¹©ë‹ˆë‹¤. 30ë…„ ì „ì— ì €ëŠ” ìˆ˜ë¶€ ìˆ˜ìˆ ì„ ë§ì´ í–ˆê³ , ìˆ˜ê·¼ê´€ ì¦í›„êµ° í•´ì œìˆ ì„ ì‹œí–‰í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>When I went to endoscopic, where my patients had minimal discomfort and a mechanic could work a day or two later, my volume, in twelve months, went up tenfold, and it stayed that way until I stopped doing hand surgery. So why should this be any different than that? And I think once we're offering the MIA procedure with sedation or local, however you wanna do it, and the Preserve, I expect the same thing in my practice, a very, very substantial uptick in volume.</td><td>ë‚´ì‹œê²½ ìˆ˜ìˆ ë¡œ ì „í™˜í–ˆì„ ë•Œ, í™˜ìë“¤ì˜ ë¶ˆí¸í•¨ì´ ìµœì†Œí™”ë˜ê³  ê¸°ê³„ê³µì´ í•˜ë£¨ë‚˜ ì´í‹€ í›„ì— ë°”ë¡œ ì¼í•  ìˆ˜ ìˆê²Œ ë˜ë©´ì„œ, 12ê°œì›” ë§Œì— ìˆ˜ìˆ ëŸ‰ì´ 10ë°° ì¦ê°€í–ˆê³ , ì œê°€ ìˆ˜ë¶€ ìˆ˜ìˆ ì„ ì¤‘ë‹¨í•  ë•Œê¹Œì§€ ê·¸ ìˆ˜ì¤€ì„ ìœ ì§€í–ˆìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ì´ë²ˆ ê²½ìš°ê°€ ì™œ ë‹¤ë¥¼ ì´ìœ ê°€ ìˆê² ìŠµë‹ˆê¹Œ? ì§„ì •ì œë“  êµ­ì†Œë§ˆì·¨ë“  ì›í•˜ëŠ” ë°©ì‹ìœ¼ë¡œ MIA ì‹œìˆ ê³¼ Preserveë¥¼ ì œê³µí•˜ê²Œ ë˜ë©´, ì œ ì§„ë£Œì—ì„œë„ ë™ì¼í•œ ê²°ê³¼, ì¦‰ ë§¤ìš° ìƒë‹¹í•œ ìˆ˜ìˆ ëŸ‰ ì¦ê°€ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 6: And I think being a women's health company, there are a lot of similarities in where you entered the market with a breast implant that was safer in a time when there was a lot of concern and hesitation and mistrust of the implant industry. And I think similarly, there is<br><br>concern around the safety of things like BBL, which is the fat transfer to the buttock. And so there are a lot of similarities in the ability to bring a safer product to the market, which I think is a really valuable thing for not only women's health, but also just creating opportunities for patients that they see these aesthetic solutions as something that's less risky. Speaker 14: Yes.</td><td>**ë°œí‘œì 6:** ê·¸ë¦¬ê³  ì €ëŠ” ì—¬ì„± ê±´ê°• íšŒì‚¬ë¡œì„œ, ì‹œì¥ì— ì§„ì…í–ˆë˜ ë°©ì‹ê³¼ ë§ì€ ìœ ì‚¬ì ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì„í”Œë€íŠ¸ ì—…ê³„ì— ëŒ€í•œ ë§ì€ ìš°ë ¤ì™€ ì£¼ì €í•¨, ë¶ˆì‹ ì´ ìˆë˜ ì‹œê¸°ì— ë” ì•ˆì „í•œ ìœ ë°© ì„í”Œë€íŠ¸ë¡œ ì‹œì¥ì— ì§„ì…í–ˆë˜ ê²ƒì²˜ëŸ¼ ë§ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§ˆì°¬ê°€ì§€ë¡œ í˜„ì¬ BBL, ì¦‰ ì—‰ë©ì´ë¡œì˜ ì§€ë°© ì´ì‹ê³¼ ê°™ì€ ì‹œìˆ ë“¤ì˜ ì•ˆì „ì„±ì— ëŒ€í•œ ìš°ë ¤ê°€ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë” ì•ˆì „í•œ ì œí’ˆì„ ì‹œì¥ì— ì¶œì‹œí•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì—ì„œ ë§ì€ ìœ ì‚¬ì ì´ ìˆìœ¼ë©°, ì´ëŠ” ì—¬ì„± ê±´ê°•ë¿ë§Œ ì•„ë‹ˆë¼ í™˜ìë“¤ì´ ì´ëŸ¬í•œ ë¯¸ìš© ì†”ë£¨ì…˜ì„ ëœ ìœ„í—˜í•œ ê²ƒìœ¼ë¡œ ì¸ì‹í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ ì°½ì¶œí•œë‹¤ëŠ” ì ì—ì„œ ì •ë§ ê°€ì¹˜ ìˆëŠ” ì¼ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>**ë°œí‘œì 14:** ë„¤.</td></tr>
<tr><td>At this point, because we have a few minutes, anyone wants to ask any questions from the audience? Josh? Speaker 9: Thanks a lot. Josh Jenning from TD Cowen. Appreciate the insights and the outlook for GLP-1s creating a next wave of aesthetic procedures. I was just hoping to get a sense of what you're seeing already. I know we're still early in the adoption of GLP-1s in The United States. Speaker 9: I think the metric you shared was twelve percent of the population have or the adult population has trialed. Are you seeing the beginnings of this wave? And any percentages of cases of GLP-1s outside of maybe the lean population that's using GLP-1s to get even leaner on the Park Avenue side?</td><td>ì´ ì‹œì ì—ì„œ ëª‡ ë¶„ì˜ ì‹œê°„ì´ ìˆìœ¼ë‹ˆ, ì²­ì¤‘ ì¤‘ì—ì„œ ì§ˆë¬¸í•˜ì‹¤ ë¶„ì´ ê³„ì‹ ê°€ìš”? ì¡°ì‹œ?<br><br>ë°œí‘œì 9: ê°ì‚¬í•©ë‹ˆë‹¤. TD Cowenì˜ ì¡°ì‹œ ì œë‹ì…ë‹ˆë‹¤. í†µì°°ë ¥ ìˆëŠ” ë¶„ì„ê³¼ GLP-1ì´ ì°¨ì„¸ëŒ€ ë¯¸ìš© ì‹œìˆ ì˜ ë¬¼ê²°ì„ ë§Œë“¤ì–´ë‚¼ ê²ƒì´ë¼ëŠ” ì „ë§ì— ëŒ€í•´ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. í˜„ì¬ ì–´ë–¤ ìƒí™©ì„ ëª©ê²©í•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ GLP-1 ë„ì…ì´ ì•„ì§ ì´ˆê¸° ë‹¨ê³„ë¼ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 9: ë§ì”€í•´ì£¼ì‹  ì§€í‘œê°€ ì„±ì¸ ì¸êµ¬ì˜ 12%ê°€ ì‹œë„í•´ë´¤ë‹¤ëŠ” ê²ƒì´ì—ˆëŠ”ë°, ì´ëŸ¬í•œ ë¬¼ê²°ì˜ ì‹œì‘ì„ ë³´ê³  ê³„ì‹ ê°€ìš”? ê·¸ë¦¬ê³  íŒŒí¬ ì• ë¹„ë‰´ ìª½ì—ì„œ ë” ë‚ ì”¬í•´ì§€ê¸° ìœ„í•´ GLP-1ì„ ì‚¬ìš©í•˜ëŠ” ë§ˆë¥¸ ì²´í˜• ì¸êµ¬ ì™¸ì—, GLP-1 ì‚¬ìš© ì‚¬ë¡€ì˜ ë¹„ìœ¨ì´ ì–´ëŠ ì •ë„ì¸ì§€ ì•Œ ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Speaker 15: I'll tell you, our practice, you know, since we've been doing this for about three years, the journey for our patient is typically this. They'll come in and at the very beginning because at the very beginning right it was your own patients, but now we just get patients from all over. So the very new ones is aesthetic naive, the forty, sixty percent that are new to the practice. They'll be like, oh, I'm not interested in any of that foo foo stuff. I'm just here to lose a little weight just trying to get into a spot. Speaker 15: The two things that we've seen is one, we've seen more men come into our offices for sure.</td><td>ë°œí‘œì 15: ë§ì”€ë“œë¦¬ìë©´, ì €í¬ê°€ ì´ ì‚¬ì—…ì„ ì•½ 3ë…„ê°„ í•´ì˜¤ë©´ì„œ ì¶•ì í•œ ê²½í—˜ì— ë”°ë¥´ë©´, í™˜ìë“¤ì˜ ì—¬ì •ì€ ë³´í†µ ì´ëŸ° ì‹ì…ë‹ˆë‹¤. ì²˜ìŒì—ëŠ” ì €í¬ ê¸°ì¡´ í™˜ìë“¤ì´ì—ˆì§€ë§Œ, ì´ì œëŠ” ì „êµ­ ê°ì§€ì—ì„œ í™˜ìë“¤ì´ ì˜¤ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ìƒˆë¡œìš´ í™˜ìë“¤ ì¤‘ 40~60%ëŠ” ë¯¸ìš© ì‹œìˆ  ê²½í—˜ì´ ì „í˜€ ì—†ëŠ” ë¶„ë“¤ì…ë‹ˆë‹¤. ì´ëŸ° ë¶„ë“¤ì€ "ì•„, ì €ëŠ” ê·¸ëŸ° í—ˆí™©ëœ ê²ƒë“¤ì—ëŠ” ê´€ì‹¬ ì—†ì–´ìš”. ê·¸ëƒ¥ ì‚´ ì¢€ ë¹¼ì„œ ëª¸ë§¤ ê´€ë¦¬ë§Œ í•˜ë ¤ê³  ì™”ì–´ìš”"ë¼ê³  ë§ì”€í•˜ì‹œì£ .<br><br>ë°œí‘œì 15: ì €í¬ê°€ ëª©ê²©í•œ ë‘ ê°€ì§€ ë³€í™” ì¤‘ í•˜ë‚˜ëŠ”, í™•ì‹¤íˆ ë‚¨ì„± ê³ ê°ë“¤ì´ ì €í¬ í´ë¦¬ë‹‰ì„ ë” ë§ì´ ì°¾ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>It's almost eight to ten percent and this is the new wave and then it's the same thing two or three years from now. But I truly think that's going to change. From a timeline, I'll tell<br><br>you what happens is that it takes about six to nine months to move them into your injectable med spa treatment stuff. And the better you can be about speaking to them and happy to answer questions about that because it was a learning curve for us. Speaker 15: And then from surgery, it was about a year. And some of that is us making sure that people are stable, not having the rebound.</td><td>ê±°ì˜ 8~10%ì— ë‹¬í•˜ë©°, ì´ê²ƒì´ ìƒˆë¡œìš´ ë¬¼ê²°ì´ê³  2~3ë…„ í›„ì—ë„ ë™ì¼í•œ ìƒí™©ì´ ë  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €ëŠ” ì •ë§ë¡œ ì´ê²ƒì´ ë³€í™”í•  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. íƒ€ì„ë¼ì¸ ì¸¡ë©´ì—ì„œ ë§ì”€ë“œë¦¬ë©´,<br><br>ì£¼ì‚¬í˜• ë©”ë“œìŠ¤íŒŒ ì¹˜ë£Œë¡œ ì´ë“¤ì„ ì „í™˜ì‹œí‚¤ëŠ” ë° ì•½ 6~9ê°œì›”ì´ ì†Œìš”ë©ë‹ˆë‹¤. ì´ì— ëŒ€í•´ ë” ì˜ ì†Œí†µí•  ìˆ˜ ìˆì„ìˆ˜ë¡ ì¢‹ìœ¼ë©°, ì´ ë¶€ë¶„ì— ëŒ€í•œ ì§ˆë¬¸ì— ê¸°êº¼ì´ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì €í¬ì—ê²Œë„ í•™ìŠµ ê³¡ì„ ì´ ìˆì—ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 15: ê·¸ë¦¬ê³  ìˆ˜ìˆ ì˜ ê²½ìš°ì—ëŠ” ì•½ 1ë…„ì´ ê±¸ë ¸ìŠµë‹ˆë‹¤. ì´ ì¤‘ ì¼ë¶€ëŠ” í™˜ìë“¤ì´ ì•ˆì •ì ì¸ ìƒíƒœë¥¼ ìœ ì§€í•˜ê³  ìˆëŠ”ì§€, ë°˜ë™ í˜„ìƒì´ ì—†ëŠ”ì§€ í™•ì¸í•˜ëŠ” ì €í¬ì˜ ê³¼ì •ì´ê¸°ë„ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Because if you're going to do a bigger surgery and depending on how much weight they lost, there is a few medical things that we make people accomplish, meet and stabilize before we do some of these surgeries. I'll tell you in our practice personally, I used to do, we're talking about this earlier, one or two of these kind of circumferential lifts, arm lifts, thigh lifts a month. It was funny, yesterday in our office I did a circumferential lift and then a thigh lift on another patient. Speaker 15: My partner did a thigh lift in the room next door and then did a butt lift.</td><td>ë” í° ìˆ˜ìˆ ì„ ì§„í–‰í•  ì˜ˆì •ì´ê³  í™˜ìê°€ ì–¼ë§ˆë‚˜ ì²´ì¤‘ì„ ê°ëŸ‰í–ˆëŠ”ì§€ì— ë”°ë¼, ì´ëŸ¬í•œ ìˆ˜ìˆ ë“¤ì„ ì‹œí–‰í•˜ê¸° ì „ì— í™˜ìë“¤ì´ ë‹¬ì„±í•˜ê³  ì¶©ì¡±í•˜ë©° ì•ˆì •í™”ì‹œì¼œì•¼ í•˜ëŠ” ëª‡ ê°€ì§€ ì˜í•™ì  ìš”ê±´ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì €í¬ ì§„ë£Œì†Œì—ì„œ ê°œì¸ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, ì˜ˆì „ì—ëŠ” - ì´ì— ëŒ€í•´ ì•ì„œ ì´ì•¼ê¸°í–ˆë“¯ì´ - ì´ëŸ° ì¢…ë¥˜ì˜ ì „ì‹  ë¦¬í”„íŒ…, íŒ” ë¦¬í”„íŒ…, í—ˆë²…ì§€ ë¦¬í”„íŒ…ì„ í•œ ë‹¬ì— í•œë‘ ê±´ ì •ë„ ì‹œí–‰í–ˆìŠµë‹ˆë‹¤. ì¬ë¯¸ìˆê²Œë„, ì–´ì œ ì €í¬ ë³‘ì›ì—ì„œ ì œê°€ ì „ì‹  ë¦¬í”„íŒ…ì„ í•œ ê±´ í•˜ê³ , ë‹¤ë¥¸ í™˜ìì—ê²ŒëŠ” í—ˆë²…ì§€ ë¦¬í”„íŒ…ì„ í–ˆìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 15: ì œ ë™ë£ŒëŠ” ì˜† ìˆ˜ìˆ ì‹¤ì—ì„œ í—ˆë²…ì§€ ë¦¬í”„íŒ…ì„ í•œ ê±´ í•˜ê³ , ê·¸ ë‹¤ìŒì— ì—‰ë©ì´ ë¦¬í”„íŒ…ì„ í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And I mean typically those individually would be one surgery that happens a month and here it was in one day we did four of them. And that has become a routine spot in our practice. So I think it's changing. I think the big timeline is six to nine months for like med spa, about a year for surgeries. Speaker 15: But I think this is where it's gonna be on us to educate those new patients and really have that conversation going because not just going to magically move. Sachin? Speaker 16: Sure, so I think I'd echo a lot of what Doctor. Franco said. The use of these medications can be used to optimize patients, right?</td><td>ì¼ë°˜ì ìœ¼ë¡œ ì´ëŸ° ìˆ˜ìˆ ë“¤ì€ ê°œë³„ì ìœ¼ë¡œ í•œ ë‹¬ì— í•œ ë²ˆì”© ì‹œí–‰ë˜ëŠ”ë°, ì—¬ê¸°ì„œëŠ” í•˜ë£¨ì— ë„¤ ê±´ì„ í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ì €í¬ ì§„ë£Œì—ì„œ ì¼ìƒì ì¸ ë¶€ë¶„ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë³€í™”í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. í° íƒ€ì„ë¼ì¸ìœ¼ë¡œ ë³´ë©´ ë©”ë“œ ìŠ¤íŒŒì˜ ê²½ìš° 6~9ê°œì›”, ìˆ˜ìˆ ì˜ ê²½ìš° ì•½ 1ë…„ ì •ë„ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 15: í•˜ì§€ë§Œ ì´ ë¶€ë¶„ì—ì„œ ì €í¬ê°€ ìƒˆë¡œìš´ í™˜ìë“¤ì„ êµìœ¡í•˜ê³  ì‹¤ì œë¡œ ê·¸ëŸ° ëŒ€í™”ë¥¼ ì´ì–´ê°€ëŠ” ê²ƒì´ ì €í¬ì˜ ëª«ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì €ì ˆë¡œ ë§ˆë²•ì²˜ëŸ¼ ë³€í™”ê°€ ì¼ì–´ë‚˜ì§€ëŠ” ì•Šì„ í…Œë‹ˆê¹Œìš”. ì‚¬ì¹œ?<br><br>ë°œí‘œì 16: ë„¤, í”„ë‘ì½” ë°•ì‚¬ë‹˜ì´ ë§ì”€í•˜ì‹  ë‚´ìš©ì— ë§ì´ ë™ì˜í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì•½ë¬¼ë“¤ì˜ ì‚¬ìš©ì€ í™˜ìë“¤ì„ ìµœì í™”í•˜ëŠ” ë° í™œìš©ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So what I mean by medical optimization is elevated BMIs, having patients on these medications, allowing them to get to a healthy weight where we know that their body mass index falls within a range where we can then mitigate and offset some of the complications and adverse events that we're accustomed to seeing. We started prescribing these quite some time ago over the last couple of years. Speaker 16: And so it's not just for the lean patient who wants to be leaner. We keep talking about we're talking about the Park Avenue element. It's New York City, the ongoing joke, you can never be too skinny or too rich. Patients want to be leaner.</td><td>ì œê°€ ì˜í•™ì  ìµœì í™”ë¼ê³  ë§í•˜ëŠ” ê²ƒì€ ë†’ì€ BMIë¥¼ ê°€ì§„ í™˜ìë“¤ì—ê²Œ ì´ëŸ¬í•œ ì•½ë¬¼ì„ íˆ¬ì—¬í•˜ì—¬ ê±´ê°•í•œ ì²´ì¤‘ì— ë„ë‹¬í•˜ë„ë¡ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì²´ì§ˆëŸ‰ì§€ìˆ˜ê°€ ìš°ë¦¬ê°€ ì¼ë°˜ì ìœ¼ë¡œ ë³´ë˜ í•©ë³‘ì¦ê³¼ ë¶€ì‘ìš©ë“¤ì„ ì™„í™”í•˜ê³  ìƒì‡„í•  ìˆ˜ ìˆëŠ” ë²”ìœ„ ë‚´ì— ë“¤ì–´ê°€ë„ë¡ í•˜ëŠ” ê²ƒì´ì£ . ì €í¬ëŠ” ì§€ë‚œ ëª‡ ë…„ê°„ ê½¤ ì˜¤ë˜ì „ë¶€í„° ì´ëŸ¬í•œ ì•½ë¬¼ë“¤ì„ ì²˜ë°©í•´ ì™”ìŠµë‹ˆë‹¤.<br><br>í™”ì 16: ê·¸ë¦¬ê³  ì´ê²ƒì€ ë‹¨ìˆœíˆ ë” ë‚ ì”¬í•´ì§€ê³  ì‹¶ì–´í•˜ëŠ” ë§ˆë¥¸ í™˜ìë“¤ë§Œì„ ìœ„í•œ ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. ì €í¬ê°€ ê³„ì† ì´ì•¼ê¸°í•˜ê³  ìˆëŠ” ê²ƒì€ íŒŒí¬ ì• ë¹„ë‰´ ìš”ì†Œì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ë‰´ìš•ì‹œì—ì„œ í”íˆ í•˜ëŠ” ë†ë‹´ì´ ìˆì£ , ë„ˆë¬´ ë§ˆë¥´ê±°ë‚˜ ë„ˆë¬´ ë¶€ìœ í•  ìˆ˜ëŠ” ì—†ë‹¤ëŠ”. í™˜ìë“¤ì€ ë” ë‚ ì”¬í•´ì§€ê¸°ë¥¼ ì›í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Now we're taking a look at patients who are slightly heavier set, optimizing them, getting to something that's stable, using that then as a maintenance dose and carrying them through the journey and allowing them to get a safer surgical procedure. Speaker 16: And the answer is yes. We are seeing this consistently higher. I think you'll start to see data and statistics that we put out from American Society of Plastic Surgeons, American Society of Aesthetic Plastic Surgeons, sort of our governing bodies. And you'll start to see that a lot of these surgical procedures are on the rise that either plateaued or declined over the last decade plus.</td><td>ì´ì œ ìš°ë¦¬ëŠ” ì•½ê°„ ë” ì²´ì¤‘ì´ ë‚˜ê°€ëŠ” í™˜ìë“¤ì„ ì‚´í´ë³´ê³  ìˆìœ¼ë©°, ì´ë“¤ì„ ìµœì í™”í•˜ì—¬ ì•ˆì •ì ì¸ ìƒíƒœë¡œ ë§Œë“  ë‹¤ìŒ, ì´ë¥¼ ìœ ì§€ ìš©ëŸ‰ìœ¼ë¡œ ì‚¬ìš©í•˜ì—¬ ì¹˜ë£Œ ê³¼ì • ì „ë°˜ì— ê±¸ì³ í™˜ìë“¤ì„ ê´€ë¦¬í•˜ê³  ë” ì•ˆì „í•œ ìˆ˜ìˆ  ì ˆì°¨ë¥¼ ë°›ì„ ìˆ˜ ìˆë„ë¡ ë•ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë°œí‘œì 16: ê·¸ë¦¬ê³  ë‹µì€ 'ì˜ˆ'ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ í˜„ìƒì´ ì§€ì†ì ìœ¼ë¡œ ë” ë†’ê²Œ ë‚˜íƒ€ë‚˜ëŠ” ê²ƒì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì„±í˜•ì™¸ê³¼í•™íšŒ(American Society of Plastic Surgeons), ë¯¸êµ­ë¯¸ìš©ì„±í˜•ì™¸ê³¼í•™íšŒ(American Society of Aesthetic Plastic Surgeons) ë“± ìš°ë¦¬ì˜ ê´€ë¦¬ ê¸°êµ¬ë“¤ì—ì„œ ë°œí‘œí•˜ëŠ” ë°ì´í„°ì™€ í†µê³„ë¥¼ ë³´ê¸° ì‹œì‘í•˜ì‹¤ ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§€ë‚œ 10ë…„ ì´ìƒ ë™ì•ˆ ì •ì²´ë˜ê±°ë‚˜ ê°ì†Œí–ˆë˜ ë§ì€ ìˆ˜ìˆ  ì ˆì°¨ë“¤ì´ ì¦ê°€ì„¸ì— ìˆë‹¤ëŠ” ê²ƒì„ í™•ì¸í•˜ê¸° ì‹œì‘í•˜ì‹¤ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>So that's really where we're starting to see that explosion occur, which gives us again unique opportunities for novel technologies. Speaker 17: Next question. Mike Matson, Needham and Company. Just with regard to the GLP-one patients that get the breast augmentation procedures, are you able to use MIA, Preservay or do you feel like there's a need for to develop some type of other, you know, more specialized procedure for those patients?</td><td>ê·¸ë˜ì„œ ë°”ë¡œ ê·¸ ì§€ì ì—ì„œ í­ë°œì ì¸ ì„±ì¥ì´ ì‹œì‘ë˜ëŠ” ê²ƒì„ ë³´ê³  ìˆìœ¼ë©°, ì´ëŠ” ë‹¤ì‹œ í•œë²ˆ ìƒˆë¡œìš´ ê¸°ìˆ ë“¤ì— ëŒ€í•œ ë…íŠ¹í•œ ê¸°íšŒë¥¼ ì œê³µí•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 17: ë‹¤ìŒ ì§ˆë¬¸ì…ë‹ˆë‹¤. ë‹ˆë¤ ì•¤ ì»´í¼ë‹ˆì˜ ë§ˆì´í¬ ë§·ìŠ¨ì…ë‹ˆë‹¤. GLP-1 í™˜ìë“¤ì´ ìœ ë°© í™•ëŒ€ìˆ ì„ ë°›ëŠ” ê²½ìš°ì™€ ê´€ë ¨í•´ì„œ, MIAë‚˜ Preservayë¥¼ ì‚¬ìš©í•  ìˆ˜ ìˆëŠ”ì§€, ì•„ë‹ˆë©´ í•´ë‹¹ í™˜ìë“¤ì„ ìœ„í•´ ë” ì „ë¬¸í™”ëœ ë‹¤ë¥¸ ìœ í˜•ì˜ ì‹œìˆ ì„ ê°œë°œí•  í•„ìš”ê°€ ìˆë‹¤ê³  ìƒê°í•˜ì‹œëŠ”ì§€ìš”?</td></tr>
<tr><td>Speaker 6: So I find very unique is that the shape of the Ergo implant actually spares a lot of women the need for a breast lift because that implant placed above the muscle means that they actually don't need that incision pattern of a traditional breast lift. So a lot of patients come in thinking that they need a breast lift and they really don't want those scars. And with volume restoration using the right shaped implant, they don't actually need that. So I think that the technology to meet the need already exists.</td><td>ë°œí‘œì 6: ì œê°€ ë§¤ìš° ë…íŠ¹í•˜ë‹¤ê³  ìƒê°í•˜ëŠ” ì ì€ Ergo ì„í”Œë€íŠ¸ì˜ í˜•íƒœê°€ ì‹¤ì œë¡œ ë§ì€ ì—¬ì„±ë“¤ì—ê²Œ ìœ ë°© ê±°ìƒìˆ ì˜ í•„ìš”ì„±ì„ ì—†ì• ì¤€ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¼ìœ¡ ìœ„ì— ë°°ì¹˜ë˜ëŠ” ì´ ì„í”Œë€íŠ¸ëŠ” ê¸°ì¡´ ìœ ë°© ê±°ìƒìˆ ì˜ ì ˆê°œ íŒ¨í„´ì´ ì‹¤ì œë¡œ í•„ìš”í•˜ì§€ ì•Šë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤. ë§ì€ í™˜ìë“¤ì´ ìœ ë°© ê±°ìƒìˆ ì´ í•„ìš”í•˜ë‹¤ê³  ìƒê°í•˜ê³  ë‚´ì›í•˜ì§€ë§Œ ê·¸ëŸ° í‰í„°ëŠ” ì •ë§ ì›í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ëŸ°ë° ì ì ˆí•œ í˜•íƒœì˜ ì„í”Œë€íŠ¸ë¥¼ ì‚¬ìš©í•œ ë³¼ë¥¨ ë³µì›ì„ í†µí•´ ì‹¤ì œë¡œëŠ” ê·¸ëŸ° ìˆ˜ìˆ ì´ í•„ìš”í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ ë‹ˆì¦ˆë¥¼ ì¶©ì¡±í•  ê¸°ìˆ ì€ ì´ë¯¸ ì¡´ì¬í•œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And I think there is also a whole another culture way of coming of longevity medicine and people taking these GLP-1s not for weight loss but<br>for cardio protective benefits and the idea of longevity medicine and I think that is also coming<br><br>with a consequence of still these volume loss changes that a large portion of the population is suffering from. Speaker 15: And Mark brought up a great point because those patients are challenging because the tissues are already so thin and somewhat been destroyed by the inflation and deflation, but<br>if you think about it, if you can minimize the trauma to that, you're preserving whatever is left even if it's been stretched just a little bit.</td><td>ê·¸ë¦¬ê³  ì¥ìˆ˜ ì˜í•™(longevity medicine)ì´ë¼ëŠ” ì™„ì „íˆ ë‹¤ë¥¸ ë¬¸í™”ì  ì ‘ê·¼ ë°©ì‹ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì‚¬ëŒë“¤ì´ ì²´ì¤‘ ê°ëŸ‰ì´ ì•„ë‹Œ ì‹¬í˜ˆê´€ ë³´í˜¸ íš¨ê³¼ë¥¼ ìœ„í•´ ì´ëŸ¬í•œ GLP-1 ì•½ë¬¼ì„ ë³µìš©í•˜ê³  ìˆìœ¼ë©°, ì¥ìˆ˜ ì˜í•™ì´ë¼ëŠ” ê°œë…ì´ ë“±ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒ ì—­ì‹œ ì¸êµ¬ì˜ ìƒë‹¹ ë¶€ë¶„ì´ ê²ªê³  ìˆëŠ” ë³¼ë¥¨ ì†ì‹¤ ë³€í™”ë¼ëŠ” ê²°ê³¼ë¥¼ ë™ë°˜í•œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 15: ë§ˆí¬ê°€ í›Œë¥­í•œ ì§€ì ì„ í–ˆëŠ”ë°, ê·¸ëŸ° í™˜ìë“¤ì€ ë„ì „ì ì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì¡°ì§ì´ ì´ë¯¸ ë§¤ìš° ì–‡ì•„ì ¸ ìˆê³  íŒ½ì°½ê³¼ ìˆ˜ì¶•ì— ì˜í•´ ì–´ëŠ ì •ë„ ì†ìƒë˜ì—ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìƒê°í•´ë³´ë©´, ê·¸ ì¡°ì§ì— ëŒ€í•œ ì™¸ìƒì„ ìµœì†Œí™”í•  ìˆ˜ ìˆë‹¤ë©´, ì¡°ê¸ˆ ëŠ˜ì–´ë‚¬ë”ë¼ë„ ë‚¨ì•„ìˆëŠ” ê²ƒì€ ë¬´ì—‡ì´ë“  ë³´ì¡´í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I think we're just scratching the surface of maximizing. Speaker 5: Yeah. I think you asked an incredible question, and I'm gonna tell you why. Separate minimally invasive in your mind from amount of scar. Okay? So let's say I have a patient who's lost weight, and the breast clearly even a blind person can look, face them, and say, you need a lift, Okay? Speaker 5: Would I do the minimally invasive? And the answer is yes, and I'll tell you why. Yes, I'm going to make big incisions for the lift. But remember, the minimally invasive, a side benefit is the small scar. The real purpose to do it is the preservation of the internal anatomy.</td><td>ì €í¬ëŠ” ì•„ì§ ìµœëŒ€í™”ì˜ í‘œë©´ë§Œ ê±´ë“œë¦¬ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. <br><br>ë°œí‘œì 5: ë„¤. ì •ë§ ë†€ë¼ìš´ ì§ˆë¬¸ì„ í•´ì£¼ì…¨ëŠ”ë°, ê·¸ ì´ìœ ë¥¼ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìµœì†Œì¹¨ìŠµê³¼ í‰í„°ì˜ í¬ê¸°ë¥¼ ë¨¸ë¦¿ì†ì—ì„œ ë¶„ë¦¬í•´ì„œ ìƒê°í•´ë³´ì„¸ìš”. ì˜ˆë¥¼ ë“¤ì–´, ì²´ì¤‘ì´ ê°ì†Œí•œ í™˜ìê°€ ìˆê³ , ê°€ìŠ´ì„ ë³´ë©´ ì‹œê°ì¥ì• ì¸ì´ë¼ë„ í™˜ìë¥¼ ë§ˆì£¼ë³´ê³  ë¦¬í”„íŒ…ì´ í•„ìš”í•˜ë‹¤ê³  ë§í•  ìˆ˜ ìˆì„ ì •ë„ë¼ê³  ê°€ì •í•´ë´…ì‹œë‹¤. <br><br>ë°œí‘œì 5: ê·¸ëŸ° ê²½ìš°ì— ìµœì†Œì¹¨ìŠµ ë°©ë²•ì„ ì‚¬ìš©í•  ê²ƒì¸ê°€ìš”? ë‹µì€ 'ì˜ˆ'ì…ë‹ˆë‹¤. ê·¸ ì´ìœ ë¥¼ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë„¤, ë¦¬í”„íŒ…ì„ ìœ„í•´ì„œëŠ” í° ì ˆê°œë¥¼ í•  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ê¸°ì–µí•˜ì„¸ìš”, ìµœì†Œì¹¨ìŠµì—ì„œ ì‘ì€ í‰í„°ëŠ” ë¶€ìˆ˜ì ì¸ ì´ì ì¼ ë¿ì…ë‹ˆë‹¤. ìµœì†Œì¹¨ìŠµì„ í•˜ëŠ” ì§„ì§œ ëª©ì ì€ ë‚´ë¶€ í•´ë¶€í•™ì  êµ¬ì¡°ì˜ ë³´ì¡´ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 5: And when you do a lift, you are not technically in the breast. There's a very fine layer of fascia on the surface of the breast that separates it from the skin and the subcutaneous fat. So the fat right under the skin is not breast tissue. It's fat. So if you're in that plane, you can do that lift. Speaker 5: You've already put the implant in. You've preserved all the ligaments. So now you've got a preserved breast, and now you're just rearranging the skin envelope. It's a separate issue. So it's not about the the issue with the scars.</td><td>ë°œí‘œì 5: ê·¸ë¦¬ê³  ë¦¬í”„íŠ¸ë¥¼ ì‹œí–‰í•  ë•ŒëŠ” ê¸°ìˆ ì ìœ¼ë¡œ ìœ ë°© ë‚´ë¶€ì— ìˆì§€ ì•ŠìŠµë‹ˆë‹¤. ìœ ë°© í‘œë©´ì—ëŠ” ë§¤ìš° ì–‡ì€ ê·¼ë§‰ì¸µì´ ìˆì–´ì„œ ì´ê²ƒì´ í”¼ë¶€ì™€ í”¼í•˜ì§€ë°©ì„ ë¶„ë¦¬í•©ë‹ˆë‹¤. ë”°ë¼ì„œ í”¼ë¶€ ë°”ë¡œ ì•„ë˜ì˜ ì§€ë°©ì€ ìœ ë°© ì¡°ì§ì´ ì•„ë‹™ë‹ˆë‹¤. ê·¸ê²ƒì€ ì§€ë°©ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ê·¸ í‰ë©´ì—ì„œ ì‘ì—…í•œë‹¤ë©´ ë¦¬í”„íŠ¸ë¥¼ í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ì´ë¯¸ ì„í”Œë€íŠ¸ë¥¼ ì‚½ì…í–ˆìŠµë‹ˆë‹¤. ëª¨ë“  ì¸ëŒ€ë¥¼ ë³´ì¡´í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ì œ ë³´ì¡´ëœ ìœ ë°©ì„ ê°–ê²Œ ë˜ì—ˆê³ , ì´ì œëŠ” ë‹¨ìˆœíˆ í”¼ë¶€ ì™¸í”¼ë¥¼ ì¬ë°°ì—´í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì€ ë³„ê°œì˜ ë¬¸ì œì…ë‹ˆë‹¤. ë”°ë¼ì„œ í‰í„° ë¬¸ì œì™€ëŠ” ê´€ë ¨ì´ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 5: It's about how can you put the implant into the breast in the least destructive way to preserve the long term results, and the lift is just going to redress the skin on top. What<br><br>happens with that breast long term is not gonna be due to whether you removed too much skin or the skin loosens up, whatever. It's gonna be, did you destroy the ligaments inside that breast, and are you gonna get a change in the breast parenchyma now slipping off that implant? And that's where I would still advocate for the minimally invasive approach, using the preserved approach. You don't need the preserved to put that implant in and then do the lift at the same time of the same surgery.</td><td>ë°œí‘œì 5: ì´ëŠ” ì¥ê¸°ì ì¸ ê²°ê³¼ë¥¼ ë³´ì¡´í•˜ê¸° ìœ„í•´ ê°€ì¥ íŒŒê´´ì ì´ì§€ ì•Šì€ ë°©ì‹ìœ¼ë¡œ ì„í”Œë€íŠ¸ë¥¼ ìœ ë°©ì— ì‚½ì…í•˜ëŠ” ë°©ë²•ì— ê´€í•œ ê²ƒì´ë©°, ë¦¬í”„íŠ¸ëŠ” ë‹¨ìˆœíˆ ìœ„ìª½ í”¼ë¶€ë¥¼ ì¬ì •ë ¬í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. <br><br>í•´ë‹¹ ìœ ë°©ì˜ ì¥ê¸°ì ì¸ ê²°ê³¼ëŠ” í”¼ë¶€ë¥¼ ë„ˆë¬´ ë§ì´ ì œê±°í–ˆëŠ”ì§€ ë˜ëŠ” í”¼ë¶€ê°€ ëŠìŠ¨í•´ì§€ëŠ”ì§€ ë“±ê³¼ëŠ” ê´€ë ¨ì´ ì—†ì„ ê²ƒì…ë‹ˆë‹¤. í•µì‹¬ì€ ìœ ë°© ë‚´ë¶€ì˜ ì¸ëŒ€ë¥¼ íŒŒê´´í–ˆëŠ”ì§€, ê·¸ë¦¬ê³  ìœ ë°© ì‹¤ì§ˆì´ ì„í”Œë€íŠ¸ì—ì„œ ë¯¸ë„ëŸ¬ì ¸ ë‚´ë ¤ê°€ëŠ” ë³€í™”ê°€ ìƒê¸¸ ê²ƒì¸ì§€ì— ë‹¬ë ¤ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ì œê°€ ì—¬ì „íˆ ë³´ì¡´ì  ì ‘ê·¼ë²•ì„ ì‚¬ìš©í•œ ìµœì†Œì¹¨ìŠµì  ì ‘ê·¼ë²•ì„ ì˜¹í˜¸í•˜ëŠ” ì´ìœ ì…ë‹ˆë‹¤. ì„í”Œë€íŠ¸ë¥¼ ì‚½ì…í•˜ê³  ë™ì¼í•œ ìˆ˜ìˆ ì—ì„œ ë™ì‹œì— ë¦¬í”„íŠ¸ë¥¼ ì‹œí–‰í•˜ëŠ” ë° ë³´ì¡´ì  ë°©ë²•ì´ ë°˜ë“œì‹œ í•„ìš”í•œ ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 5: So you brought up an absolutely awesome question. Thank you. Speaker 14: And to be clear, PreSurvey is augmentation up to four sizes, but also, which was very pertinent to that question, it also includes the hybrid you know, breast tissue preservation augmentation and the mastopexy breast tissue preservation. So it does have that opportunity. I think there's another Alan? Speaker 18: Thanks for the question. Alan Gong, JPMorgan. You kind of actually addressed part of my question here, but my question was kind of around if you do, again, like a Google search of minimally invasive breast augmentation, you will get practices advertising their procedures being minimally invasive.</td><td>**ë°œí‘œì 5:** ì •ë§ í›Œë¥­í•œ ì§ˆë¬¸ì„ í•´ì£¼ì…¨ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>**ë°œí‘œì 14:** ëª…í™•íˆ ë§ì”€ë“œë¦¬ë©´, PreSurveyëŠ” ìµœëŒ€ 4ì‚¬ì´ì¦ˆê¹Œì§€ì˜ í™•ëŒ€ìˆ ë¿ë§Œ ì•„ë‹ˆë¼, ë°©ê¸ˆ ì§ˆë¬¸ê³¼ ë§¤ìš° ê´€ë ¨ì´ ìˆëŠ” ë¶€ë¶„ì¸ë°, í•˜ì´ë¸Œë¦¬ë“œ ìœ ë°© ì¡°ì§ ë³´ì¡´ í™•ëŒ€ìˆ ê³¼ ìœ ë°©ê±°ìƒìˆ  ì¡°ì§ ë³´ì¡´ë„ í¬í•¨í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ê·¸ëŸ° ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤. ë˜ ë‹¤ë¥¸... ì•¨ëŸ°?<br><br>**ë°œí‘œì 18:** ì§ˆë¬¸í•´ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. JPëª¨ê±´ì˜ ì•¨ëŸ° ê³µì…ë‹ˆë‹¤. ì‚¬ì‹¤ ì œ ì§ˆë¬¸ì˜ ì¼ë¶€ë¥¼ ì´ë¯¸ ë‹¤ë¤„ì£¼ì…¨ëŠ”ë°, ì œ ì§ˆë¬¸ì€ êµ¬ê¸€ì—ì„œ 'ìµœì†Œì¹¨ìŠµ ìœ ë°©í™•ëŒ€ìˆ 'ì„ ê²€ìƒ‰í•´ë³´ë©´ ìì‹ ë“¤ì˜ ì‹œìˆ ì´ ìµœì†Œì¹¨ìŠµì ì´ë¼ê³  ê´‘ê³ í•˜ëŠ” ë³‘ì›ë“¤ì„ ë³¼ ìˆ˜ ìˆë‹¤ëŠ” ì ì— ê´€í•œ ê²ƒì´ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And there have been, you know, techniques like transaxial that are arguably less invasive over the years. You've talked about how it's like, you know, it's not just about having the smaller scar, it's about the preservation. Speaker 18: But, you know, when it comes to changing, you know, the hearts and minds of other physicians who will say, you know, I already have a approach that works for me, you know, my skill level is higher than everyone else, what would you do to kind of convince those doctors? Speaker 5: Were you a surgeon in your past life?</td><td>ê·¸ë¦¬ê³  ìˆ˜ë…„ì— ê±¸ì³ ê²½ì¶•(transaxial) ê°™ì€ ê¸°ë²•ë“¤ì´ ìˆì—ˆëŠ”ë°, ì´ëŠ” í‹€ë¦¼ì—†ì´ ëœ ì¹¨ìŠµì ì…ë‹ˆë‹¤. ë‹¹ì‹ ì€ ì´ê²ƒì´ ë‹¨ìˆœíˆ ë” ì‘ì€ í‰í„°ë¥¼ ê°–ëŠ” ê²ƒì— ê´€í•œ ê²ƒì´ ì•„ë‹ˆë¼ ë³´ì¡´ì— ê´€í•œ ê²ƒì´ë¼ê³  ë§ì”€í•˜ì…¨ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 18: í•˜ì§€ë§Œ ë‹¤ë¥¸ ì˜ì‚¬ë“¤ì˜ ë§ˆìŒê³¼ ìƒê°ì„ ë°”ê¾¸ëŠ” ê²ƒì— ê´€í•´ì„œëŠ”, ê·¸ë“¤ì´ "ë‚˜ëŠ” ì´ë¯¸ ë‚˜ì—ê²Œ íš¨ê³¼ì ì¸ ì ‘ê·¼ë²•ì„ ê°€ì§€ê³  ìˆê³ , ë‚´ ê¸°ìˆ  ìˆ˜ì¤€ì€ ë‹¤ë¥¸ ëˆ„êµ¬ë³´ë‹¤ë„ ë†’ë‹¤"ê³  ë§í•  ë•Œ, ê·¸ëŸ° ì˜ì‚¬ë“¤ì„ ì„¤ë“í•˜ê¸° ìœ„í•´ ì–´ë–»ê²Œ í•˜ì‹œê² ìŠµë‹ˆê¹Œ?<br><br>ë°œí‘œì 5: ë‹¹ì‹ ì€ ì „ìƒì— ì™¸ê³¼ì˜ì‚¬ì˜€ë‚˜ìš”?</td></tr>
<tr><td>Because surgeons tend to be very egotistical, And there are those who change and evolve with the market and with technology, and everyone<br><br>on this panel is like that. And there are those who say, hey, this is the way I do it. I've done it this way because in my hands that's the expression. In my hands, it's always work. Speaker 5: Now, you mentioned minimally invasive small incision. Yes, small incision clearly is minimally invasive. Years ago, I used to do transaxillary breast aug, small incision, but inside I was doing all the same destructive stuff, destroying the ligaments to create the pocket.</td><td>ì™¸ê³¼ì˜ë“¤ì€ ë§¤ìš° ìì¡´ì‹¬ì´ ê°•í•œ ê²½í–¥ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹œì¥ê³¼ ê¸°ìˆ ì˜ ë³€í™”ì— ë”°ë¼ ë³€í™”í•˜ê³  ë°œì „í•˜ëŠ” ì‚¬ëŒë“¤ì´ ìˆëŠ”ë°, ì´ íŒ¨ë„ì˜ ëª¨ë“  ë¶„ë“¤ì´ ê·¸ëŸ° ë¶„ë“¤ì…ë‹ˆë‹¤. ë°˜ë©´ì— "ì´ê²Œ ë‚´ê°€ í•˜ëŠ” ë°©ì‹ì´ì•¼. ë‚´ ì†ìœ¼ë¡œëŠ”"ì´ë¼ëŠ” í‘œí˜„ì„ ì“°ë©° "ë‚´ ì†ìœ¼ë¡œëŠ” í•­ìƒ ì˜ ë˜ê±°ë“ "ì´ë¼ê³  ë§í•˜ëŠ” ì‚¬ëŒë“¤ë„ ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ë°©ê¸ˆ ìµœì†Œì¹¨ìŠµ ì†Œì ˆê°œì— ëŒ€í•´ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°ìš”. ë„¤, ì†Œì ˆê°œëŠ” ë¶„ëª…íˆ ìµœì†Œì¹¨ìŠµì ì…ë‹ˆë‹¤. ëª‡ ë…„ ì „ì— ì €ëŠ” ê²½ì•¡ì™€ ìœ ë°©í™•ëŒ€ìˆ ì„ í–ˆì—ˆëŠ”ë°, ì†Œì ˆê°œì˜€ì§€ë§Œ ë‚´ë¶€ì—ì„œëŠ” ë™ì¼í•œ íŒŒê´´ì ì¸ ì‘ì—…ë“¤ì„ í•˜ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ì£¼ë¨¸ë‹ˆë¥¼ ë§Œë“¤ê¸° ìœ„í•´ ì¸ëŒ€ë“¤ì„ íŒŒê´´í•˜ëŠ” ê²ƒì´ì£ .</td></tr>
<tr><td>So now you have so if if if someone said, well, I do Transacts minimally invasive, and I use some dissectors, and I make my pocket. Yes. Speaker 5: You're doing a minimally invasive procedure. I'm doing a minimally invasive procedure, but unlike you, I'm preserving the internal ligamentous anatomy of the breast. So going forward, my results are gonna last better and look last longer and look better than your results will. And that's the difference. It's not just the small scar. Speaker 5: The whole key that is up that is turning everything upside down here is the idea that you can completely preserve the circumambulatory ligament and all the ligaments inside.</td><td>ì´ì œ ë§Œì•½ ëˆ„êµ°ê°€ê°€ "ì €ëŠ” ìµœì†Œì¹¨ìŠµì ìœ¼ë¡œ ì‹œìˆ í•˜ê³ , ì¼ë¶€ ë°•ë¦¬ê¸°ë¥¼ ì‚¬ìš©í•˜ì—¬ ì£¼ë¨¸ë‹ˆë¥¼ ë§Œë“­ë‹ˆë‹¤"ë¼ê³  ë§í•œë‹¤ë©´, ë„¤.<br><br>ë°œí‘œì 5: ë‹¹ì‹ ë„ ìµœì†Œì¹¨ìŠµ ì‹œìˆ ì„ í•˜ê³  ìˆê³ , ì €ë„ ìµœì†Œì¹¨ìŠµ ì‹œìˆ ì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë‹¹ì‹ ê³¼ ë‹¬ë¦¬ ì €ëŠ” ìœ ë°©ì˜ ë‚´ë¶€ ì¸ëŒ€ í•´ë¶€í•™ì  êµ¬ì¡°ë¥¼ ë³´ì¡´í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì•ìœ¼ë¡œ ì œ ê²°ê³¼ëŠ” ë” ì˜¤ë˜ ì§€ì†ë˜ê³  ë” ì˜¤ë˜ ì¢‹ì€ ëª¨ìŠµì„ ìœ ì§€í•  ê²ƒì´ë©°, ë‹¹ì‹ ì˜ ê²°ê³¼ë³´ë‹¤ ë” ë‚˜ì€ ì™¸ê´€ì„ ë³´ì¼ ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì´ ì°¨ì´ì ì…ë‹ˆë‹¤. ë‹¨ìˆœíˆ ì‘ì€ í‰í„°ë§Œì˜ ë¬¸ì œê°€ ì•„ë‹™ë‹ˆë‹¤.<br><br>ë°œí‘œì 5: ì—¬ê¸°ì„œ ëª¨ë“  ê²ƒì„ ë’¤ë°”ê¾¸ê³  ìˆëŠ” í•µì‹¬ ì•„ì´ë””ì–´ëŠ” ë‘˜ë ˆ ì¸ëŒ€(circumambulatory ligament)ì™€ ë‚´ë¶€ì˜ ëª¨ë“  ì¸ëŒ€ë¥¼ ì™„ì „íˆ ë³´ì¡´í•  ìˆ˜ ìˆë‹¤ëŠ” ê°œë…ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Speaker 15: I think patients are what's gonna change, you know, a surgeon's mind because when when doctor Steve and doctor Pittman are scheduled off for six or nine months and they're doing two fifty breast dogs a year and somebody else is doing 20 because patients are demanding, patients are asking for this and they're not doing it, that's what's going move them. Speaker 6: I think that is the total shift that comes along with this culture of transparency is you could have surgeons egos clashing forever, but we live in an era where patients know more than they've ever known about the technology. And that is really aligned with the direct to consumer marketing.</td><td>ë°œí‘œì 15: ì œ ìƒê°ì—ëŠ” í™˜ìë“¤ì´ ì™¸ê³¼ì˜ì‚¬ë“¤ì˜ ë§ˆìŒì„ ë°”ê¾¸ê²Œ í•  ê²ƒì…ë‹ˆë‹¤. ìŠ¤í‹°ë¸Œ ë°•ì‚¬ì™€ í”¼íŠ¸ë¨¼ ë°•ì‚¬ê°€ 6ê°œì›”ì´ë‚˜ 9ê°œì›” ë™ì•ˆ ìˆ˜ìˆ  ì¼ì •ì´ ì¡í˜€ ìˆê³  ì—°ê°„ 250ê±´ì˜ ìœ ë°© ìˆ˜ìˆ ì„ í•˜ê³  ìˆëŠ”ë°, ë‹¤ë¥¸ ì˜ì‚¬ëŠ” 20ê±´ë°–ì— í•˜ì§€ ì•ŠëŠ” ìƒí™©ì—ì„œ í™˜ìë“¤ì´ ì´ë¥¼ ìš”êµ¬í•˜ê³  ìˆê³  ê·¸ ì˜ì‚¬ëŠ” ì´ë¥¼ ì‹œí–‰í•˜ì§€ ì•Šê³  ìˆë‹¤ë©´, ë°”ë¡œ ê·¸ê²ƒì´ ê·¸ë“¤ì„ ì›€ì§ì´ê²Œ í•  ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 6: ì €ëŠ” ì´ê²ƒì´ íˆ¬ëª…ì„± ë¬¸í™”ì™€ í•¨ê»˜ ì˜¤ëŠ” ì™„ì „í•œ ë³€í™”ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì™¸ê³¼ì˜ì‚¬ë“¤ì˜ ìì¡´ì‹¬ ì‹¸ì›€ì€ ì˜ì›íˆ ê³„ì†ë  ìˆ˜ ìˆì§€ë§Œ, ìš°ë¦¬ëŠ” í™˜ìë“¤ì´ ê¸°ìˆ ì— ëŒ€í•´ ê·¸ ì–´ëŠ ë•Œë³´ë‹¤ ë§ì´ ì•Œê³  ìˆëŠ” ì‹œëŒ€ì— ì‚´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŠ” ì§ì ‘ ì†Œë¹„ì ë§ˆì¼€íŒ…ê³¼ ì •ë§ ì˜ ë§ì•„ë–¨ì–´ì§‘ë‹ˆë‹¤.</td></tr>
<tr><td>Patients are going to demand this of surgeons and those who don't evolve will be left behind because patients are more knowledgeable than they've ever been. Speaker 14: I'm good. All right. Well, look, on that note, I think we'd like to thank you all for participating in this panel. So, let's give you a hand of a round of applause. And I think next we are planning the Q and A from management. Speaker 14: So these boys will get up here. Speaker 1: Yeah, we have a few minutes here just to wrap up if anybody had any questions for management. If you don't, that's fine too, but we thought maybe we'd give you a couple minutes. So we have question right here. Speaker 19: Harrison Parsons, Stevens.</td><td>í™˜ìë“¤ì€ ì™¸ê³¼ì˜ì‚¬ë“¤ì—ê²Œ ì´ë¥¼ ìš”êµ¬í•  ê²ƒì´ê³ , ì§„í™”í•˜ì§€ ì•ŠëŠ” ì˜ì‚¬ë“¤ì€ ë’¤ì²˜ì§€ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ í™˜ìë“¤ì´ ê·¸ ì–´ëŠ ë•Œë³´ë‹¤ ë§ì€ ì§€ì‹ì„ ê°–ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 14: ì¢‹ìŠµë‹ˆë‹¤. ì, ê·¸ëŸ¼ ì´ ì‹œì ì—ì„œ ì´ë²ˆ íŒ¨ë„ì— ì°¸ì—¬í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦°ë‹¤ê³  ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ë°•ìˆ˜ë¥¼ ë³´ë‚´ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ë‹¤ìŒìœ¼ë¡œëŠ” ê²½ì˜ì§„ê³¼ì˜ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê³„íší•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 14: ê·¸ëŸ¼ ì´ë¶„ë“¤ì´ ì˜¬ë¼ì˜¤ì‹œê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ë„¤, ì—¬ê¸°ì„œ ë§ˆë¬´ë¦¬í•˜ê¸° ì „ì— ëª‡ ë¶„ ì •ë„ ì‹œê°„ì´ ìˆìœ¼ë‹ˆ ê²½ì˜ì§„ì—ê²Œ ì§ˆë¬¸ì´ ìˆìœ¼ì‹œë©´ í•´ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ì—†ìœ¼ì‹œë©´ ê·¸ê²ƒë„ ê´œì°®ì§€ë§Œ, ëª‡ ë¶„ ì •ë„ ì‹œê°„ì„ ë“œë¦¬ëŠ” ê²ƒì´ ì¢‹ì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì—¬ê¸° ì§ˆë¬¸ì´ ìˆë„¤ìš”.<br><br>ë°œí‘œì 19: ìŠ¤í‹°ë¸ìŠ¤ì˜ í•´ë¦¬ìŠ¨ íŒŒìŠ¨ìŠ¤ì…ë‹ˆë‹¤.</td></tr>
<tr><td>At a recent conference, you noted that ergonomics makes up nearly or up around 60% of The US implant volume. Has that trend stayed relatively consistent over the past few months? And how does that mix help you better understand the The US consumer from a competitive standpoint given you've noted most of competition is based on primarily around pricing discounts? Speaker 3: Yes. So I'll take that question. So that that ratio sixty forty ergonomic to round has pretty much stayed very consistent since day one. It moves around a little bit as we bring on new surgeons and each surgeon like you heard from Doctor.</td><td>ìµœê·¼ ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ì¸ì²´ê³µí•™ì  ì œí’ˆì´ ë¯¸êµ­ ì„í”Œë€íŠ¸ ë³¼ë¥¨ì˜ ê±°ì˜ 60% ë˜ëŠ” ì•½ 60%ë¥¼ ì°¨ì§€í•œë‹¤ê³  ì–¸ê¸‰í•˜ì…¨ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¶”ì„¸ê°€ ì§€ë‚œ ëª‡ ë‹¬ ë™ì•ˆ ë¹„êµì  ì¼ê´€ë˜ê²Œ ìœ ì§€ë˜ì—ˆë‚˜ìš”? ê·¸ë¦¬ê³  ê²½ìŸì—…ì²´ë“¤ì´ ì£¼ë¡œ ê°€ê²© í• ì¸ì— ê¸°ë°˜í•œ ê²½ìŸì„ í•˜ê³  ìˆë‹¤ê³  ì–¸ê¸‰í•˜ì‹  ì ì„ ê³ ë ¤í•  ë•Œ, ì´ëŸ¬í•œ ì œí’ˆ ë¯¹ìŠ¤ê°€ ê²½ìŸì  ê´€ì ì—ì„œ ë¯¸êµ­ ì†Œë¹„ìë¥¼ ë” ì˜ ì´í•´í•˜ëŠ” ë° ì–´ë–»ê²Œ ë„ì›€ì´ ë˜ë‚˜ìš”?<br><br>ë°œí‘œì 3: ë„¤, ê·¸ ì§ˆë¬¸ì— ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì¸ì²´ê³µí•™ì  ì œí’ˆ ëŒ€ ë¼ìš´ë“œ ì œí’ˆì˜ 60ëŒ€ 40 ë¹„ìœ¨ì€ ì²«ë‚ ë¶€í„° ë§¤ìš° ì¼ê´€ë˜ê²Œ ìœ ì§€ë˜ì–´ ì™”ìŠµë‹ˆë‹¤. ìƒˆë¡œìš´ ì™¸ê³¼ì˜ë“¤ì„ ì˜ì…í•˜ë©´ì„œ ì•½ê°„ì”© ë³€ë™ì€ ìˆì§€ë§Œ, ê° ì™¸ê³¼ì˜ëŠ” ë°•ì‚¬ë‹˜ê»˜ì„œ ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼...</td></tr>
<tr><td>Steve has a certain sort of look that they go for that type of patient in their practice. Speaker 3: That's a very different look if you're in Dallas, Texas, right? So that regional difference or the actual practice that that surgeon has that comes into the equation with us does move it around a little bit, but it's one or two percentage points one way or the other. And then what the part of the question? Speaker 19: Just around how that mix informs your strategy from a competitive perspective given the price points between the rounds and ergonomics implants. Speaker 3: Yeah.</td><td>ìŠ¤í‹°ë¸ŒëŠ” ìì‹ ì˜ ì§„ë£Œì—ì„œ ì¶”êµ¬í•˜ëŠ” íŠ¹ì •í•œ í™˜ì ìœ í˜•ì— ëŒ€í•œ ì–´ë–¤ ì™¸ëª¨ì  ê¸°ì¤€ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 3: í…ì‚¬ìŠ¤ ë‹¬ë¼ìŠ¤ì— ìˆë‹¤ë©´ ê·¸ê²ƒì€ ë§¤ìš° ë‹¤ë¥¸ ì™¸ëª¨ê°€ ë  ê²ƒì…ë‹ˆë‹¤, ë§ì£ ? ë”°ë¼ì„œ ì§€ì—­ì  ì°¨ì´ë‚˜ í•´ë‹¹ ì™¸ê³¼ì˜ì‚¬ê°€ ê°€ì§„ ì‹¤ì œ ì§„ë£Œ ë°©ì‹ì´ ìš°ë¦¬ì™€ì˜ ê´€ê³„ì—ì„œ ê³ ë ¤ë˜ëŠ” ìš”ì†Œë¡œ ì‘ìš©í•˜ì—¬ ì•½ê°„ì˜ ë³€ë™ì„ ê°€ì ¸ì˜¤ì§€ë§Œ, ì´ëŠ” í•œë‘ í¼ì„¼íŠ¸ í¬ì¸íŠ¸ ì •ë„ì˜ ì°¨ì´ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§ˆë¬¸ì˜ ë‚˜ë¨¸ì§€ ë¶€ë¶„ì€ ë¬´ì—‡ì´ì—ˆë‚˜ìš”?<br><br>ë°œí‘œì 19: ë¼ìš´ë“œí˜•ê³¼ ì¸ì²´ê³µí•™ì  ì„í”Œë€íŠ¸ ê°„ì˜ ê°€ê²©ëŒ€ë¥¼ ê³ ë ¤í•  ë•Œ, ê·¸ëŸ¬í•œ ì œí’ˆ êµ¬ì„±ì´ ê²½ìŸ ê´€ì ì—ì„œ ê·€í•˜ì˜ ì „ëµì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹˜ëŠ”ì§€ì— ê´€í•œ ê²ƒì´ì—ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ë„¤.</td></tr>
<tr><td>I don't know if it really affects our particular strategy in terms of we're trying to satisfy the market demands of that particular practice or patient is looking for a full upper pole round look, we're happy to provide that device to them. If somebody is looking for a more natural teardrop shape, we're obviously happy to do that as well. I don't know if we're really going to try to steer that one way or the other versus just try to satisfy the demand. Speaker 8: Sam Iver, BTIG. Just a clarification question on the regulatory submission for PRESIVAY. Do you also need the ergonomics two implant to enable the PRESIVAY procedure? Can you use the existing round and ergonomics implants?</td><td>ì €í¬ì˜ íŠ¹ì • ì „ëµì— ì‹¤ì œë¡œ ì˜í–¥ì„ ë¯¸ì¹˜ëŠ”ì§€ëŠ” ì˜ ëª¨ë¥´ê² ìŠµë‹ˆë‹¤. ì €í¬ëŠ” í•´ë‹¹ ì‹œìˆ ì´ë‚˜ í™˜ìê°€ ì°¾ëŠ” ì‹œì¥ ìˆ˜ìš”ë¥¼ ì¶©ì¡±ì‹œí‚¤ë ¤ê³  ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§Œì•½ ëˆ„êµ°ê°€ê°€ í’€ ì–´í¼ í´ ë¼ìš´ë“œ ë£©ì„ ì›í•œë‹¤ë©´, ì €í¬ëŠ” ê¸°êº¼ì´ ê·¸ ê¸°ê¸°ë¥¼ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. ë§Œì•½ ëˆ„êµ°ê°€ê°€ ë³´ë‹¤ ìì—°ìŠ¤ëŸ¬ìš´ í‹°ì–´ë“œë¡­ ëª¨ì–‘ì„ ì›í•œë‹¤ë©´, ì €í¬ëŠ” ë‹¹ì—°íˆ ê·¸ê²ƒë„ ê¸°êº¼ì´ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. ì €í¬ê°€ í•œìª½ ë°©í–¥ìœ¼ë¡œ ìœ ë„í•˜ë ¤ê³  í•˜ê¸°ë³´ë‹¤ëŠ” ê·¸ëƒ¥ ìˆ˜ìš”ë¥¼ ì¶©ì¡±ì‹œí‚¤ë ¤ê³  ë…¸ë ¥í•  ê²ƒì¸ì§€ëŠ” ì˜ ëª¨ë¥´ê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 8: BTIGì˜ ìƒ˜ ì•„ì´ë²„ì…ë‹ˆë‹¤. PRESIVAYì˜ ê·œì œ ìŠ¹ì¸ ì‹ ì²­ì— ëŒ€í•œ ëª…í™•í™” ì§ˆë¬¸ì…ë‹ˆë‹¤. PRESIVAY ì‹œìˆ ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ê¸° ìœ„í•´ ì—ë¥´ê³ ë…¸ë¯¹ìŠ¤ íˆ¬ ì„í”Œë€íŠ¸ë„ í•„ìš”í•œê°€ìš”? ê¸°ì¡´ì˜ ë¼ìš´ë“œ ë° ì—ë¥´ê³ ë…¸ë¯¹ìŠ¤ ì„í”Œë€íŠ¸ë¥¼ ì‚¬ìš©í•  ìˆ˜ ìˆë‚˜ìš”?</td></tr>
<tr><td>And then in terms of the commercial strategy, are you going to be taking a meal like approach where you're certifying centers and they're buying into the program? Speaker 8: Or is it going be a broad based sort of launch? Speaker 14: So on the regulatory piece, I think it's important to realize that PRESUVEY can be done with the ergonomics implant and with the ergonomics two implant. The ergonomics two implant allows for more advanced applications that are very specific, but you can do breast augmentation up to four cups with breast tissue preservation with the ergonomics device that has been already approved in The U. S.</td><td>ê·¸ë¦¬ê³  ìƒì—…ì  ì „ëµ ì¸¡ë©´ì—ì„œëŠ”, ì„¼í„°ë“¤ì„ ì¸ì¦í•˜ê³  ê·¸ë“¤ì´ í”„ë¡œê·¸ë¨ì— ì°¸ì—¬í•˜ëŠ” ë°©ì‹ì˜ ë‹¨ê³„ì  ì ‘ê·¼ë²•ì„ ì·¨í•˜ì‹¤ ê±´ê°€ìš”?<br><br>ë°œí‘œì 8: ì•„ë‹ˆë©´ ê´‘ë²”ìœ„í•œ ì¶œì‹œ ë°©ì‹ì´ ë  ê±´ê°€ìš”?<br><br>ë°œí‘œì 14: ê·œì œ ë¶€ë¶„ì— ëŒ€í•´ì„œëŠ”, PRESUVEYê°€ ì—ë¥´ê³ ë…¸ë¯¹ìŠ¤ ì„í”Œë€íŠ¸ì™€ ì—ë¥´ê³ ë…¸ë¯¹ìŠ¤ íˆ¬ ì„í”Œë€íŠ¸ ëª¨ë‘ì™€ í•¨ê»˜ ì‚¬ìš©ë  ìˆ˜ ìˆë‹¤ëŠ” ì ì„ ì´í•´í•˜ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤. ì—ë¥´ê³ ë…¸ë¯¹ìŠ¤ íˆ¬ ì„í”Œë€íŠ¸ëŠ” ë§¤ìš° êµ¬ì²´ì ì¸ ê³ ê¸‰ ì‘ìš© ë¶„ì•¼ë¥¼ ê°€ëŠ¥í•˜ê²Œ í•˜ì§€ë§Œ, ì´ë¯¸ ë¯¸êµ­ì—ì„œ ìŠ¹ì¸ëœ ì—ë¥´ê³ ë…¸ë¯¹ìŠ¤ ê¸°ê¸°ë¥¼ ì‚¬ìš©í•˜ì—¬ ìœ ë°© ì¡°ì§ ë³´ì¡´ê³¼ í•¨ê»˜ ìµœëŒ€ 4ì»µê¹Œì§€ì˜ ìœ ë°© í™•ëŒ€ìˆ ì„ ì‹œí–‰í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Plus the other like mastopexy breast tissue preservation and the hybrid breast tissue preservation. So those will be part of this. Speaker 14: The important thing also is to realize that as we do this early experience, we will be getting a lot of information back from these centers and that will be used to tailor the strategy<br>for the eventual launch. Speaker 3: Yes.</td><td>ë˜í•œ ìœ ë°©ê³ ì •ìˆ , ìœ ë°©ì¡°ì§ ë³´ì¡´ìˆ , í•˜ì´ë¸Œë¦¬ë“œ ìœ ë°©ì¡°ì§ ë³´ì¡´ìˆ ê³¼ ê°™ì€ ë‹¤ë¥¸ ì‹œìˆ ë“¤ë„ í¬í•¨ë  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì‹œìˆ ë“¤ì´ ì´ë²ˆ í”„ë¡œê·¸ë¨ì— í¬í•¨ë  ê²ƒì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 14: ì¤‘ìš”í•œ ì ì€ ì´ëŸ¬í•œ ì´ˆê¸° ê²½í—˜ì„ ì§„í–‰í•˜ë©´ì„œ í•´ë‹¹ ì„¼í„°ë“¤ë¡œë¶€í„° ë§ì€ ì •ë³´ë¥¼ ì–»ê²Œ ë  ê²ƒì´ê³ , ì´ ì •ë³´ë“¤ì´ ìµœì¢… ì¶œì‹œë¥¼ ìœ„í•œ ì „ëµì„ ë§ì¶¤í™”í•˜ëŠ” ë° í™œìš©ë  ê²ƒì´ë¼ëŠ” ì ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ë„¤.</td></tr>
<tr><td>And just to be very clear because we've sort of mentioned it this early experience groups, so some of the surgeons here as well They will gain access to the tools in advance of the broad general launch that will happen early next year and as JJ said that will<br><br>help inform our strategy from what's the training necessary to get somebody off the ground, what's the pricing, what are the cost savings in terms of the procedure time, the OR time anesthesia etcetera, etcetera that will help inform our overall pricing strategy as well. Speaker 2: Yes, as I mentioned earlier today, think a lot of the learnings that we get is from what's going on outside The U. S.</td><td>ë§¤ìš° ëª…í™•íˆ ë§ì”€ë“œë¦¬ìë©´, ì•ì„œ ì–¸ê¸‰í–ˆë˜ ì´ˆê¸° ê²½í—˜ ê·¸ë£¹ë“¤, ì¦‰ ì—¬ê¸° ê³„ì‹  ì¼ë¶€ ì™¸ê³¼ì˜ì‚¬ë¶„ë“¤ê»˜ì„œë„ ë‚´ë…„ ì´ˆì— ìˆì„ ê´‘ë²”ìœ„í•œ ì¼ë°˜ ì¶œì‹œì— ì•ì„œ ë„êµ¬ë“¤ì— ë¯¸ë¦¬ ì ‘ê·¼í•˜ì‹¤ ìˆ˜ ìˆê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  JJê°€ ë§í–ˆë“¯ì´, ì´ëŠ” ìš°ë¦¬ì˜ ì „ëµ ìˆ˜ë¦½ì— ë„ì›€ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì¦‰, ëˆ„êµ°ê°€ë¥¼ ì‹œì‘ì‹œí‚¤ê¸° ìœ„í•´ í•„ìš”í•œ êµìœ¡ì´ ë¬´ì—‡ì¸ì§€, ê°€ê²© ì±…ì •ì€ ì–´ë–»ê²Œ í•  ê²ƒì¸ì§€, ìˆ˜ìˆ  ì‹œê°„, ìˆ˜ìˆ ì‹¤ ì‹œê°„, ë§ˆì·¨ ë“±ë“±ì˜ ì¸¡ë©´ì—ì„œ ì–´ë–¤ ë¹„ìš© ì ˆê°ì´ ìˆëŠ”ì§€ ë“±ì„ íŒŒì•…í•˜ì—¬ ìš°ë¦¬ì˜ ì „ë°˜ì ì¸ ê°€ê²© ì „ëµ ìˆ˜ë¦½ì—ë„ ë„ì›€ì´ ë  ê²ƒì…ë‹ˆë‹¤.<br><br>í™”ì 2: ë„¤, ì˜¤ëŠ˜ ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´, ìš°ë¦¬ê°€ ì–»ëŠ” ë§ì€ í•™ìŠµë“¤ì´ ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ ì¼ì–´ë‚˜ê³  ìˆëŠ” ìƒí™©ë“¤ë¡œë¶€í„° ë‚˜ì˜¨ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And we just launched Preserve and as we launch in each region, we've been adapting that strategy And we're going to apply a lot of those learnings in terms of how we launch it in The U. S. From a strategic standpoint. Speaker 2: Thanks<br><br><br>Speaker 12: for presentation feedback. Two questions. One on revision. The revision pricing is double that of augmentation. So maybe just a little bit on how that's going to play in the gross margins next couple of years as that comes into play. Speaker 12: So that would be question one. And then question two is on Prezurve, the economics for practice economics.</td><td>ê·¸ë¦¬ê³  ì €í¬ëŠ” ë°©ê¸ˆ Preserveë¥¼ ì¶œì‹œí–ˆê³ , ê° ì§€ì—­ì—ì„œ ì¶œì‹œí•  ë•Œë§ˆë‹¤ í•´ë‹¹ ì „ëµì„ ì¡°ì •í•´ì™”ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¯¸êµ­ì—ì„œ ì¶œì‹œí•  ë•Œ ì „ëµì  ê´€ì ì—ì„œ ì´ëŸ¬í•œ í•™ìŠµ ë‚´ìš©ë“¤ì„ ë§ì´ ì ìš©í•  ì˜ˆì •ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 2: í”„ë ˆì  í…Œì´ì…˜ í”¼ë“œë°± ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 12: ë‘ ê°€ì§€ ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ëŠ” ì¬ìˆ˜ìˆ ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ì¬ìˆ˜ìˆ  ê°€ê²©ì´ í™•ëŒ€ìˆ ì˜ ë‘ ë°°ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ê²ƒì´ í–¥í›„ ëª‡ ë…„ê°„ ë§¤ì¶œì´ì´ìµë¥ ì— ì–´ë–»ê²Œ ì˜í–¥ì„ ë¯¸ì¹ ì§€ì— ëŒ€í•´ ì¡°ê¸ˆ ì„¤ëª…í•´ ì£¼ì‹œë©´ ì¢‹ê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 12: ì´ê²ƒì´ ì²« ë²ˆì§¸ ì§ˆë¬¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‘ ë²ˆì§¸ ì§ˆë¬¸ì€ Preserveì— ê´€í•œ ê²ƒìœ¼ë¡œ, ì§„ë£Œì†Œ ê²½ì œì„±ì— ëŒ€í•œ ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>I think with the MIA centers, the price point was about<br>$3,500 meaning revenue to establishment labs. The price point was about $10,000 $12,000 for practices. Is that sort of the right way to think about a Preservaix clinic once we start to get going there? Speaker 12: Thanks. Speaker 1: So I can answer the question on the reconstruction approval. So much like augmentation in The United States, that the cost of making these devices for us for The United States is essentially the same, right, as it is everywhere. The reconstruction approval, it's the same devices, right? And as was noted, the prices in reconstruction are significantly higher.</td><td>MIA ì„¼í„°ì˜ ê²½ìš°, ê°€ê²©ëŒ€ê°€ ì•½ 3,500ë‹¬ëŸ¬ì˜€ëŠ”ë° ì´ëŠ” ì„¤ë¦½ ì—°êµ¬ì†Œë“¤ì— ëŒ€í•œ ìˆ˜ìµì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ê°œì¸ ë³‘ì›ë“¤ì˜ ê²½ìš° ê°€ê²©ëŒ€ëŠ” ì•½ 10,000ë‹¬ëŸ¬ì—ì„œ 12,000ë‹¬ëŸ¬ì˜€ìŠµë‹ˆë‹¤. Preservaix í´ë¦¬ë‹‰ì´ ë³¸ê²©ì ìœ¼ë¡œ ìš´ì˜ë˜ê¸° ì‹œì‘í•˜ë©´ ì´ëŸ° ì‹ìœ¼ë¡œ ìƒê°í•˜ëŠ” ê²ƒì´ ë§ëŠ” ë°©í–¥ì¼ê¹Œìš”?<br><br>ë°œí‘œì 12: ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ì¬ê±´ìˆ  ìŠ¹ì¸ì— ëŒ€í•œ ì§ˆë¬¸ì— ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œì˜ í™•ëŒ€ìˆ ê³¼ ë§ˆì°¬ê°€ì§€ë¡œ, ë¯¸êµ­ì„ ìœ„í•´ ì´ëŸ¬í•œ ê¸°ê¸°ë“¤ì„ ì œì¡°í•˜ëŠ” ë¹„ìš©ì€ ë³¸ì§ˆì ìœ¼ë¡œ ë‹¤ë¥¸ ì§€ì—­ê³¼ ë™ì¼í•©ë‹ˆë‹¤. ì¬ê±´ìˆ  ìŠ¹ì¸ì˜ ê²½ìš°, ë™ì¼í•œ ê¸°ê¸°ë“¤ì´ì£ . ê·¸ë¦¬ê³  ì–¸ê¸‰ëœ ë°”ì™€ ê°™ì´, ì¬ê±´ìˆ ì˜ ê°€ê²©ì€ ìƒë‹¹íˆ ë†’ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So the price for an implant can be well north of $1,000 in reconstruction, where it's $650 or so for<br><br>us on average in aesthetics, so quite a bit higher. Speaker 1: So gross margins will be higher, right, significantly higher in reconstruction. You asked about Preserve as well, the pricing on Preserve. Speaker 3: Don't know if you<br><br><br>Speaker 1: want to take that. Speaker 14: Well, I think it's early to talk about pricing of Preserve in The United States. But I think as Pete was saying, we are collecting a wealth of information from the international market from the launch of PRESUVEY.</td><td>ì¬ê±´ ìˆ˜ìˆ ì—ì„œ ì„í”Œë€íŠ¸ ê°€ê²©ì€ 1,000ë‹¬ëŸ¬ë¥¼ í›¨ì”¬ ë„˜ì„ ìˆ˜ ìˆëŠ” ë°˜ë©´, ë¯¸ìš© ìˆ˜ìˆ ì—ì„œëŠ” í‰ê·  650ë‹¬ëŸ¬ ì •ë„ì´ë¯€ë¡œ ìƒë‹¹íˆ ë†’ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ë”°ë¼ì„œ ì¬ê±´ ìˆ˜ìˆ ì—ì„œ ì´ ë§ˆì§„ì´ ë” ë†’ì„ ê²ƒì…ë‹ˆë‹¤. ìƒë‹¹íˆ ë†’ì„ ê²ƒì´ì£ . Preserveì˜ ê°€ê²©ì— ëŒ€í•´ì„œë„ ì§ˆë¬¸í•˜ì…¨ëŠ”ë°ìš”.<br><br>ë°œí‘œì 3: ì˜ ëª¨ë¥´ê² ëŠ”ë°...<br><br>ë°œí‘œì 1: ë‹µë³€í•˜ì‹œê² ìŠµë‹ˆê¹Œ?<br><br>ë°œí‘œì 14: ë¯¸êµ­ì—ì„œ Preserveì˜ ê°€ê²©ì— ëŒ€í•´ ë…¼í•˜ê¸°ì—ëŠ” ì•„ì§ ì´ë¥´ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ Peteê°€ ë§í–ˆë“¯ì´, ì €í¬ëŠ” PRESERVEì˜ í•´ì™¸ ì‹œì¥ ì¶œì‹œë¥¼ í†µí•´ í’ë¶€í•œ ì •ë³´ë¥¼ ìˆ˜ì§‘í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And some of the early learnings from the international market is that when practices adopt PRESUVEY, what they are doing is upselling those procedures. And with all the benefits that the patients see in breast tissue preservation and also the downtime changes, speed of the procedure itself, then that allows those practices to charge about 20% to 30% more than they're charging for their normal augmentations. Remember, PreSurvey is more for your day to day. Speaker 14: Mia is market expansion. PreSurvey is really more for the day to day. So the willingness to pay of those two patients is different.</td><td>í•´ì™¸ ì‹œì¥ì—ì„œ ì–»ì€ ì´ˆê¸° í•™ìŠµ ê²°ê³¼ ì¤‘ í•˜ë‚˜ëŠ” ì˜ë£Œì§„ë“¤ì´ PRESUVEYë¥¼ ë„ì…í•  ë•Œ í•´ë‹¹ ì‹œìˆ ì˜ ìƒí–¥ íŒë§¤ë¥¼ í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. í™˜ìë“¤ì´ ìœ ë°© ì¡°ì§ ë³´ì¡´ê³¼ íšŒë³µ ì‹œê°„ ë‹¨ì¶•, ì‹œìˆ  ì†ë„ ê°œì„  ë“±ì˜ ëª¨ë“  ì´ì ì„ ê²½í—˜í•˜ê²Œ ë˜ë©´ì„œ, í•´ë‹¹ ì˜ë£Œì§„ë“¤ì€ ì¼ë°˜ì ì¸ í™•ëŒ€ìˆ  ëŒ€ë¹„ ì•½ 20%ì—ì„œ 30% ë” ë†’ì€ ê°€ê²©ì„ ì±…ì •í•  ìˆ˜ ìˆê²Œ ë©ë‹ˆë‹¤. PRESUVEYëŠ” ì¼ìƒì ì¸ ì‹œìˆ ì— ë” ì í•©í•˜ë‹¤ëŠ” ì ì„ ê¸°ì–µí•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>ë°œí‘œì 14: MiaëŠ” ì‹œì¥ í™•ì¥ìš©ì…ë‹ˆë‹¤. PRESUVEYëŠ” ì‹¤ì œë¡œ ì¼ìƒì ì¸ ì‹œìˆ ì— ë” ì í•©í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ë‘ í™˜ìêµ°ì˜ ì§€ë¶ˆ ì˜í–¥ì€ ë‹¤ë¦…ë‹ˆë‹¤.</td></tr>
<tr><td>And going back to what Pete was saying, with all of that information that we are gathering, we will be collecting it and with the information from the group in The U. S, we'll put together something. Speaker 14: But I think I gave you an indication of where this is going. Speaker 9: Josh Shank from TD Cowen. Just wanted to ask about the reception of the pricing strategy. I mean, seems from all the trends you guys have laid out over the last number of months and today that there isn't much friction. You're having strong adoption ramp. Think you said over 1,000 surgeons already are in the customer base. Speaker 9: But when there is friction, how much is there, or has not been an issue at all?</td><td>Peteê°€ ë§í•œ ë‚´ìš©ìœ¼ë¡œ ëŒì•„ê°€ì„œ, ìš°ë¦¬ê°€ ìˆ˜ì§‘í•˜ê³  ìˆëŠ” ëª¨ë“  ì •ë³´ë¥¼ ì·¨í•©í•˜ì—¬ ë¯¸êµ­ ë‚´ ê·¸ë£¹ìœ¼ë¡œë¶€í„° ì–»ì€ ì •ë³´ì™€ í•¨ê»˜ ì¢…í•©ì ì¸ ìë£Œë¥¼ ë§Œë“¤ ì˜ˆì •ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 14: í•˜ì§€ë§Œ ì´ê²ƒì´ ì–´ëŠ ë°©í–¥ìœ¼ë¡œ ê°€ê³  ìˆëŠ”ì§€ì— ëŒ€í•œ ë°©í–¥ì„±ì€ ì œì‹œí•´ë“œë¦° ê²ƒ ê°™ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 9: TD Cowenì˜ Josh Shankì…ë‹ˆë‹¤. ê°€ê²© ì „ëµì— ëŒ€í•œ ì‹œì¥ ë°˜ì‘ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë‹¬ê°„ ê·¸ë¦¬ê³  ì˜¤ëŠ˜ ì œì‹œí•´ì£¼ì‹  ëª¨ë“  íŠ¸ë Œë“œë¥¼ ë³´ë©´ í° ë§ˆì°°ì´ ì—†ëŠ” ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ê°•ë ¥í•œ ë„ì… ì¦ê°€ì„¸ë¥¼ ë³´ì´ê³  ê³„ì‹œê³ , ì´ë¯¸ 1,000ëª… ì´ìƒì˜ ì™¸ê³¼ì˜ì‚¬ë“¤ì´ ê³ ê° ê¸°ë°˜ì— í¬í•¨ë˜ì–´ ìˆë‹¤ê³  ë§ì”€í•˜ì‹  ê²ƒ ê°™ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 9: í•˜ì§€ë§Œ ë§ˆì°°ì´ ìˆì„ ë•ŒëŠ” ì–´ëŠ ì •ë„ì¸ì§€, ì•„ë‹ˆë©´ ì „í˜€ ë¬¸ì œê°€ ë˜ì§€ ì•Šì•˜ëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>I think there were some concerns before the launch of a premium product. Then are these plastic surgeons using the adoption of Motiva as an opportunity to take their procedure pricing up? And is that a big is that actually creating a tailwind, the premium price strategy for ergonomics at least? Thanks. Speaker 3: Yes. We have not had significant pushback on our pricing strategy. We've been very transparent about what that strategy is. It does command a bit of a premium relative to the<br>other products in the category. It's hard to say exactly what that is because the other companies actually allow their individual reps to negotiate price. Speaker 3: We've taken that out of the equation.</td><td>í”„ë¦¬ë¯¸ì—„ ì œí’ˆ ì¶œì‹œ ì „ì— ì¼ë¶€ ìš°ë ¤ê°€ ìˆì—ˆë˜ ê²ƒìœ¼ë¡œ ìƒê°ë©ë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ì´ëŸ¬í•œ ì„±í˜•ì™¸ê³¼ ì˜ì‚¬ë“¤ì´ Motivaì˜ ë„ì…ì„ ì‹œìˆ  ê°€ê²©ì„ ì¸ìƒí•  ê¸°íšŒë¡œ í™œìš©í•˜ê³  ìˆìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  ì´ê²ƒì´ ì‹¤ì œë¡œ ìˆœí’ì„ ë§Œë“¤ì–´ë‚´ê³  ìˆìŠµë‹ˆê¹Œ? ì ì–´ë„ ì¸ì²´ê³µí•™ì  ì¸¡ë©´ì—ì„œ í”„ë¦¬ë¯¸ì—„ ê°€ê²© ì „ëµì´ ë§ì…ë‹ˆê¹Œ? ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ë„¤. ì €í¬ì˜ ê°€ê²© ì „ëµì— ëŒ€í•´ì„œëŠ” í° ë°˜ë°œì„ ë°›ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê·¸ ì „ëµì´ ë¬´ì—‡ì¸ì§€ì— ëŒ€í•´ ë§¤ìš° íˆ¬ëª…í•˜ê²Œ ê³µê°œí•´ì™”ìŠµë‹ˆë‹¤. ì´ ì œí’ˆì€ í•´ë‹¹ ì¹´í…Œê³ ë¦¬ì˜ ë‹¤ë¥¸ ì œí’ˆë“¤ ëŒ€ë¹„ ì–´ëŠ ì •ë„ í”„ë¦¬ë¯¸ì—„ì„ ìš”êµ¬í•˜ëŠ” ê²ƒì´ ì‚¬ì‹¤ì…ë‹ˆë‹¤. ì •í™•íˆ ê·¸ í”„ë¦¬ë¯¸ì—„ì´ ì–¼ë§ˆì¸ì§€ ë§ì”€ë“œë¦¬ê¸°ëŠ” ì–´ë ¤ìš´ë°, ë‹¤ë¥¸ íšŒì‚¬ë“¤ì€ ì‹¤ì œë¡œ ê°œë³„ ì˜ì—…ë‹´ë‹¹ìë“¤ì´ ê°€ê²©ì„ í˜‘ìƒí•  ìˆ˜ ìˆë„ë¡ í—ˆìš©í•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ì €í¬ëŠ” ê·¸ëŸ° ìš”ì†Œë¥¼ ë°°ì œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We have very transparent three tier structure based on the volume that of commitment that they have with us. And that seems to have gone very well in the marketplace and enabled us to command that premium. Relative to that, nearly all practices are and it somewhat depends on how they do the actual pricing within their practice because that can vary. But in general, yes, surgeons are taking a premium on procedures that are done with Motiva relative to the other products in the category. Speaker 3: Generally, it's about $1,000 but for some of them, it's as much as $3,000 more for that procedure. So, yes, probably a bit of a tailwind for us. Speaker 17: Mike Matson, Needham and Company.</td><td>ì €í¬ëŠ” ê³ ê°ë“¤ê³¼ì˜ ì•½ì • ê·œëª¨ì— ê¸°ë°˜í•œ ë§¤ìš° íˆ¬ëª…í•œ 3ë‹¨ê³„ êµ¬ì¡°ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì‹œì¥ì—ì„œ ë§¤ìš° ì¢‹ì€ ë°˜ì‘ì„ ì–»ì—ˆìœ¼ë©° ì €í¬ê°€ í”„ë¦¬ë¯¸ì—„ì„ ë°›ì„ ìˆ˜ ìˆê²Œ í•´ì£¼ì—ˆìŠµë‹ˆë‹¤. ì´ì™€ ê´€ë ¨í•˜ì—¬, ê±°ì˜ ëª¨ë“  ì˜ë£Œì§„ë“¤ì´ - ì´ëŠ” ê·¸ë“¤ì´ ì§„ë£Œì†Œ ë‚´ì—ì„œ ì‹¤ì œ ê°€ê²©ì„ ì–´ë–»ê²Œ ì±…ì •í•˜ëŠëƒì— ë”°ë¼ ë‹¤ì†Œ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤ë§Œ - ì¼ë°˜ì ìœ¼ë¡œëŠ” ê·¸ë ‡ìŠµë‹ˆë‹¤. ì™¸ê³¼ì˜ë“¤ì€ í•´ë‹¹ ì¹´í…Œê³ ë¦¬ì˜ ë‹¤ë¥¸ ì œí’ˆë“¤ ëŒ€ë¹„ Motivaë¡œ ì‹œí–‰í•˜ëŠ” ì‹œìˆ ì— ëŒ€í•´ í”„ë¦¬ë¯¸ì—„ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ì¼ë°˜ì ìœ¼ë¡œ ì•½ 1,000ë‹¬ëŸ¬ ì •ë„ì´ì§€ë§Œ, ì¼ë¶€ì˜ ê²½ìš° í•´ë‹¹ ì‹œìˆ ì— ëŒ€í•´ ìµœëŒ€ 3,000ë‹¬ëŸ¬ê¹Œì§€ ë” ë°›ê¸°ë„ í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ë„¤, ì €í¬ì—ê²ŒëŠ” ë‹¤ì†Œ ìˆœí’ì´ë¼ê³  í•  ìˆ˜ ìˆê² ìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 17: Needham and Companyì˜ Mike Matsonì…ë‹ˆë‹¤.</td></tr>
<tr><td>It was good to to hear from the the the super fans you had here from in terms of surgeons, but I guess what what are you hearing from the<br>the surgeons that are kind of reluctant to adopt Motiva for whatever reason? What's the common objections and, what can you do to sort of overcome that? I mean, seems like the data is really strong. Seem to have a better product. Speaker 17: Or is it just simply classic case of like early adopters versus<br><br>Speaker 3: That's exactly the answer right.</td><td>ìˆ˜ìˆ ì˜ë“¤ë¡œë¶€í„° ì—´ë ¬í•œ ì§€ì§€ë¥¼ ë°›ê³  ìˆë‹¤ëŠ” ì†Œì‹ì„ ë“£ê²Œ ë˜ì–´ ì¢‹ì•˜ìŠµë‹ˆë‹¤ë§Œ, ì–´ë–¤ ì´ìœ ë¡œë“  Motiva ë„ì…ì„ ì£¼ì €í•˜ëŠ” ìˆ˜ìˆ ì˜ë“¤ë¡œë¶€í„°ëŠ” ì–´ë–¤ ì˜ê²¬ì„ ë“£ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì£¼ìš” ë°˜ëŒ€ ì˜ê²¬ë“¤ì€ ë¬´ì—‡ì´ê³ , ì´ë¥¼ ì–´ë–»ê²Œ ê·¹ë³µí•  ìˆ˜ ìˆì„ê¹Œìš”? ë°ì´í„°ë„ ì •ë§ ê°•ë ¥í•´ ë³´ì´ê³ , ë” ë‚˜ì€ ì œí’ˆì„ ë³´ìœ í•˜ê³  ê³„ì‹  ê²ƒ ê°™ì€ë°ìš”.<br><br>**í™”ì 17:** ì•„ë‹ˆë©´ ë‹¨ìˆœíˆ ì–¼ë¦¬ ì–´ë‹µí„° ëŒ€ ì¼ë°˜ ë„ì…ìë“¤ ê°„ì˜ ì „í˜•ì ì¸ ì‚¬ë¡€ì¸ ê±´ê°€ìš”?<br><br>**í™”ì 3:** ë°”ë¡œ ê·¸ê²Œ ë‹µì…ë‹ˆë‹¤.</td></tr>
<tr><td>You've heard some very progressive cutting edge surgeons here today that obviously have been early adopters but I would say it's falling exactly into that sort of typical pattern right early early adopters and innovators and we're probably at the tail end of that sort of part of the curve and we're starting to gain sort of the general masses. But you heard Doctor. Epstein talk about people say, well, in my hands, I'm doing great work with whatever this thing is. And that's the late adopter crowd and we'll get<br><br>Speaker 14: to them at some point. But right now there's not really significant pushback that we don't feel like we have a very solid answer for.</td><td>ì˜¤ëŠ˜ ì—¬ê¸°ì„œ ë§¤ìš° ì§„ë³´ì ì´ê³  ìµœì²¨ë‹¨ì˜ ì™¸ê³¼ì˜ì‚¬ë“¤ì„ ë§Œë‚˜ì…¨ëŠ”ë°, ì´ë“¤ì€ ëª…ë°±íˆ ì–¼ë¦¬ ì–´ë‹µí„°ë“¤ì´ì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì €ëŠ” ì´ê²ƒì´ ì „í˜•ì ì¸ íŒ¨í„´ì„ ì •í™•íˆ ë”°ë¥´ê³  ìˆë‹¤ê³  ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ë°”ë¡œ ì–¼ë¦¬ ì–´ë‹µí„°ë“¤ê³¼ í˜ì‹ ê°€ë“¤ì˜ ë‹¨ê³„ì´ê³ , ìš°ë¦¬ëŠ” ì•„ë§ˆë„ ê·¸ëŸ¬í•œ ê³¡ì„  ë¶€ë¶„ì˜ ëìë½ì— ìˆìœ¼ë©° ì¼ë°˜ ëŒ€ì¤‘ë“¤ì„ í™•ë³´í•˜ê¸° ì‹œì‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì—¡ìŠ¤íƒ€ì¸ ë°•ì‚¬ê»˜ì„œ ì‚¬ëŒë“¤ì´ "ë‚´ ì†ìœ¼ë¡œëŠ” ì´ ê¸°ìˆ ë¡œ í›Œë¥­í•œ ìˆ˜ìˆ ì„ í•˜ê³  ìˆë‹¤"ê³  ë§í•˜ëŠ” ê²ƒì— ëŒ€í•´ ì–¸ê¸‰í•˜ì‹  ê²ƒì„ ë“¤ìœ¼ì…¨ì„ ê²ƒì…ë‹ˆë‹¤. ê·¸ê²ƒì´ ë°”ë¡œ í›„ë°œ ë„ì…ì ì§‘ë‹¨ì´ê³  ìš°ë¦¬ëŠ” ì–¸ì  ê°€ëŠ” ê·¸ë“¤ì—ê²Œë„ ë„ë‹¬í•  ê²ƒì…ë‹ˆë‹¤.<br><br>í™”ì 14: í•˜ì§€ë§Œ í˜„ì¬ë¡œì„œëŠ” ìš°ë¦¬ê°€ í™•ì‹¤í•œ ë‹µë³€ì„ ê°€ì§€ê³  ìˆì§€ ì•Šë‹¤ê³  ëŠë¼ëŠ” ì‹¬ê°í•œ ë°˜ë°œì€ ì‹¤ì œë¡œ ì—†ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>But one really important thing is that the speed of adoption that we've seen over the last fifteen years per market and how fast we become market leaders is definitely turbocharged by the ability of consumers to ask for Motiva. So I think one of the things you heard today very clearly is that not only you have this wave of transparency, you also have this wave of patient education. So the fact that these patients are coming and asking for Motiva by name, eventually if you're not a user, what you do is like how many patients am I losing for not using Motiva? Speaker 14: And that's where that group starts to break out. Speaker 12: I'll follow-up just on the broader market trends.</td><td>í•˜ì§€ë§Œ ì •ë§ ì¤‘ìš”í•œ í•œ ê°€ì§€ëŠ” ì§€ë‚œ 15ë…„ê°„ ì‹œì¥ë³„ë¡œ ìš°ë¦¬ê°€ ëª©ê²©í•œ ë„ì… ì†ë„ì™€ ìš°ë¦¬ê°€ ì‹œì¥ ë¦¬ë”ê°€ ë˜ëŠ” ì†ë„ê°€ ì†Œë¹„ìë“¤ì´ ëª¨í‹°ë°”ë¥¼ ìš”ì²­í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì— ì˜í•´ í™•ì‹¤íˆ ê°€ì†í™”ë˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì˜¤ëŠ˜ ì—¬ëŸ¬ë¶„ì´ ë§¤ìš° ëª…í™•í•˜ê²Œ ë“¤ìœ¼ì‹  ê²ƒ ì¤‘ í•˜ë‚˜ëŠ” íˆ¬ëª…ì„±ì˜ ë¬¼ê²°ë¿ë§Œ ì•„ë‹ˆë¼ í™˜ì êµìœ¡ì˜ ë¬¼ê²°ë„ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ í™˜ìë“¤ì´ ì™€ì„œ ëª¨í‹°ë°”ë¥¼ ì§€ëª…í•´ì„œ ìš”ì²­í•œë‹¤ëŠ” ì‚¬ì‹¤ì€, ê²°êµ­ ì‚¬ìš©ìê°€ ì•„ë‹ˆë¼ë©´ 'ëª¨í‹°ë°”ë¥¼ ì‚¬ìš©í•˜ì§€ ì•Šì•„ì„œ ì–¼ë§ˆë‚˜ ë§ì€ í™˜ìë¥¼ ìƒê³  ìˆëŠ”ê°€?'ë¼ê³  ìƒê°í•˜ê²Œ ë©ë‹ˆë‹¤.<br><br>ë°œí‘œì 14: ê·¸ë¦¬ê³  ë°”ë¡œ ê·¸ ì§€ì ì—ì„œ í•´ë‹¹ ê·¸ë£¹ì´ ëŒíŒŒêµ¬ë¥¼ ì°¾ê¸° ì‹œì‘í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 12: ë” ê´‘ë²”ìœ„í•œ ì‹œì¥ íŠ¸ë Œë“œì— ëŒ€í•´ í›„ì† ì§ˆë¬¸ì„ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Just where do you think we are in the cycle for aesthetics broadly, breast augmentation? How much, I guess, pent up demand do you think there is out there just considering it's been a slow market? And do you think we need a rate cut to sort of get things going? Thanks. Speaker 2: I think it depends on the market. I think when you look at The U. S, I don't think that that's one of the obstacles. Think we've seen a little bit different in lot of the markets. I think there's been a lot different fluctuation in the macroeconomic standpoint. Speaker 2: But like we said before, I mean, think it's, for the most part, it's stabilized.</td><td>ë¯¸ìš© ì „ë°˜, íŠ¹íˆ ìœ ë°©í™•ëŒ€ìˆ  ì‹œì¥ì—ì„œ í˜„ì¬ ì‚¬ì´í´ìƒ ì–´ëŠ ì§€ì ì— ìˆë‹¤ê³  ë³´ì‹œëŠ”ì§€ìš”? ì‹œì¥ì´ ì¹¨ì²´ë˜ì–´ ìˆì—ˆë˜ ì ì„ ê³ ë ¤í•  ë•Œ ì–µëˆŒë¦° ìˆ˜ìš”ê°€ ì–¼ë§ˆë‚˜ ìˆë‹¤ê³  ìƒê°í•˜ì‹œëŠ”ì§€, ê·¸ë¦¬ê³  ì‹œì¥ì´ ë‹¤ì‹œ í™œì„±í™”ë˜ë ¤ë©´ ê¸ˆë¦¬ ì¸í•˜ê°€ í•„ìš”í•˜ë‹¤ê³  ë³´ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 2: ì‹œì¥ì— ë”°ë¼ ë‹¤ë¥´ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë¯¸êµ­ ì‹œì¥ì„ ë³´ë©´, ê·¸ê²ƒì´ ì¥ì•  ìš”ì¸ ì¤‘ í•˜ë‚˜ë¼ê³ ëŠ” ìƒê°í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë§ì€ ì‹œì¥ì—ì„œ ì¡°ê¸ˆ ë‹¤ë¥¸ ì–‘ìƒì„ ë³´ì´ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê±°ì‹œê²½ì œì  ê´€ì ì—ì„œ ìƒë‹¹íˆ ë‹¤ë¥¸ ë³€ë™ì´ ìˆì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 2: í•˜ì§€ë§Œ ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ëŒ€ë¶€ë¶„ ì•ˆì •í™”ë˜ì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>I think<br><br>there's still some questions out there, especially with all the tariff discussions. But I think certainly on a global basis, think we see it fairly stable and I don't think it's something that we need to kind of to drive the growth. Speaker 3: Yes, specifically in The U. S, we're not seeing any slowdown at all right now. And in fact, we're seeing the opposite. The surgeons we engage with are talking about very long booking times, three months, six months, some outside of a year to get a consult with them. So I think the market in The U. Speaker 3: S. Is very healthy and only getting better. Speaker 18: Alan Gong, JPMorgan.</td><td>ì €ëŠ” ì—¬ì „íˆ ëª‡ ê°€ì§€ ì˜ë¬¸ì ë“¤ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. íŠ¹íˆ ëª¨ë“  ê´€ì„¸ ë…¼ì˜ë“¤ê³¼ ê´€ë ¨í•´ì„œ ë§ì´ì£ . í•˜ì§€ë§Œ í™•ì‹¤íˆ ê¸€ë¡œë²Œ ê¸°ì¤€ìœ¼ë¡œëŠ” ìƒë‹¹íˆ ì•ˆì •ì ìœ¼ë¡œ ë³´ê³  ìˆìœ¼ë©°, ì„±ì¥ì„ ê²¬ì¸í•˜ê¸° ìœ„í•´ íŠ¹ë³„íˆ ë¬´ì–¸ê°€ë¥¼ í•´ì•¼ í•  í•„ìš”ëŠ” ì—†ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ë„¤, êµ¬ì²´ì ìœ¼ë¡œ ë¯¸êµ­ì—ì„œëŠ” í˜„ì¬ ì „í˜€ ë‘”í™”ë¥¼ ë³´ì§€ ëª»í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‚¬ì‹¤ ì •ë°˜ëŒ€ í˜„ìƒì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ë§Œë‚˜ëŠ” ì™¸ê³¼ì˜ì‚¬ë“¤ì€ ë§¤ìš° ê¸´ ì˜ˆì•½ ëŒ€ê¸° ì‹œê°„ì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ê³  ìˆìŠµë‹ˆë‹¤. 3ê°œì›”, 6ê°œì›”, ì¼ë¶€ëŠ” 1ë…„ ì´ìƒ ê±¸ë ¤ì•¼ ìƒë‹´ì„ ë°›ì„ ìˆ˜ ìˆë‹¤ê³  í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ë¯¸êµ­ ì‹œì¥ì€ ë§¤ìš° ê±´ê°•í•˜ë©° ì ì  ë” ë‚˜ì•„ì§€ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 18: ì•¨ëŸ° ê³µ, JPëª¨ê±´ì…ë‹ˆë‹¤.</td></tr>
<tr><td>I guess I just had a quick question on kind of the competitive landscape. You're kind of entering a market that was dominated by two much larger diversified players. And I'm just kind of curious, in reaction to having a new entrant, the disruption that's happening around the player on the market, if you're seeing kind of any renewed activity or anything of note on the competitive front just kind of in response to the launch that you're having? Speaker 3: In short, not really.</td><td>ê²½ìŸ í™˜ê²½ì— ëŒ€í•´ ê°„ë‹¨í•œ ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. ê·€í•˜ê»˜ì„œëŠ” ë‘ ê°œì˜ í›¨ì”¬ í° ë‹¤ê°í™”ëœ ê¸°ì—…ë“¤ì´ ì§€ë°°í•˜ê³  ìˆë˜ ì‹œì¥ì— ì§„ì…í•˜ê³  ê³„ì‹ ë°ìš”. ìƒˆë¡œìš´ ì§„ì…ìê°€ ë“±ì¥í•˜ê³ , ì‹œì¥ ë‚´ ê¸°ì¡´ ì—…ì²´ë“¤ ì£¼ë³€ì—ì„œ ì¼ì–´ë‚˜ê³  ìˆëŠ” ë³€í™”ì— ëŒ€í•œ ë°˜ì‘ìœ¼ë¡œ, ê·€í•˜ì˜ ì¶œì‹œì— ëŒ€ì‘í•˜ì—¬ ê²½ìŸ ì¸¡ë©´ì—ì„œ ìƒˆë¡œìš´ í™œë™ì´ë‚˜ ì£¼ëª©í•  ë§Œí•œ ì›€ì§ì„ì„ ë³´ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.<br><br>í™”ì 3: ê°„ë‹¨íˆ ë§ì”€ë“œë¦¬ë©´, ê·¸ë ‡ì§€ ì•ŠìŠµë‹ˆë‹¤.</td></tr>
<tr><td>If you really look at where those companies are right now, they're all either deemphasizing their breast and plant portfolio or they're sort of like in the case of Mentor sort of nothing really new from them for a long time although they do the booster device which is actually done fairly well for them. But Sientra, Tiger is definitely in a withdrawal from the breast implant space, so much so that they've really deemphasized it in their sales reps comp plan. So, if reps not getting paid on it, they're probably not talking about it, right.</td><td>ì´ëŸ¬í•œ íšŒì‚¬ë“¤ì˜ í˜„ì¬ ìƒí™©ì„ ì‹¤ì œë¡œ ì‚´í´ë³´ë©´, ëª¨ë“  íšŒì‚¬ë“¤ì´ ìœ ë°© ë° ì‹ë¬¼ì„± í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì¶•ì†Œí•˜ê³  ìˆê±°ë‚˜, Mentorì˜ ê²½ìš°ì²˜ëŸ¼ ì˜¤ë«ë™ì•ˆ ì‹¤ì§ˆì ìœ¼ë¡œ ìƒˆë¡œìš´ ì œí’ˆì´ ì—†ëŠ” ìƒí™©ì…ë‹ˆë‹¤. ë¬¼ë¡  ê·¸ë“¤ì´ ì¶œì‹œí•œ ë¶€ìŠ¤í„° ë””ë°”ì´ìŠ¤ëŠ” ì‹¤ì œë¡œ ê½¤ ì¢‹ì€ ì„±ê³¼ë¥¼ ê±°ë‘ê³  ìˆê¸´ í•˜ì§€ë§Œìš”. í•˜ì§€ë§Œ Sientraì™€ TigerëŠ” í™•ì‹¤íˆ ìœ ë°© ì„í”Œë€íŠ¸ ë¶„ì•¼ì—ì„œ ì² ìˆ˜í•˜ê³  ìˆìœ¼ë©°, ì‹¬ì§€ì–´ ì˜ì—… ë‹´ë‹¹ìë“¤ì˜ ë³´ìƒ ê³„íšì—ì„œë„ ì´ ë¶€ë¶„ì„ í¬ê²Œ ì¶•ì†Œí–ˆìŠµë‹ˆë‹¤. ì˜ì—… ë‹´ë‹¹ìë“¤ì´ í•´ë‹¹ ì œí’ˆìœ¼ë¡œ ì¸ì„¼í‹°ë¸Œë¥¼ ë°›ì§€ ëª»í•œë‹¤ë©´, ì•„ë§ˆ ê·¸ ì œí’ˆì— ëŒ€í•´ ì´ì•¼ê¸°í•˜ì§€ë„ ì•Šì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And then Allergan has just gone through a major reshuffle across their entire organization again sort of deemphasizing that part of their portfolio even further. Speaker 3: So for us I think it's ideal time to enter the marketplace. Speaker 1: Well, if there are no more questions, we wanna thank everyone for joining us here in the room and also on the webcast. And we'll be here for a few minutes also if anybody wants to have some refreshments and chat, we'll be here for the next few minutes. So thank you again for joining us.</td><td>ê·¸ë¦¬ê³  Allerganì€ ì „ì²´ ì¡°ì§ì— ê±¸ì³ ëŒ€ëŒ€ì ì¸ ê°œí¸ì„ ë‹¨í–‰í–ˆìœ¼ë©°, ì´ëŠ” í•´ë‹¹ í¬íŠ¸í´ë¦¬ì˜¤ ë¶€ë¬¸ì— ëŒ€í•œ ë¹„ì¤‘ì„ ë”ìš± ì¶•ì†Œí•˜ëŠ” ë°©í–¥ìœ¼ë¡œ ì§„í–‰ë˜ì—ˆìŠµë‹ˆë‹¤.<br><br>ë°œí‘œì 3: ì €í¬ì—ê²ŒëŠ” ì‹œì¥ì— ì§„ì…í•˜ê¸°ì— ì´ìƒì ì¸ ì‹œê¸°ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ë°œí‘œì 1: ë” ì´ìƒ ì§ˆë¬¸ì´ ì—†ìœ¼ì‹œë‹¤ë©´, ì˜¤ëŠ˜ ì´ ìë¦¬ì— ì°¸ì„í•´ ì£¼ì‹  ë¶„ë“¤ê³¼ ì›¹ìºìŠ¤íŠ¸ë¡œ ì°¸ì—¬í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ë‹¤ê³¼ë¥¼ ë“œì‹œë©° ëŒ€í™”ë¥¼ ë‚˜ëˆ„ê³  ì‹¶ìœ¼ì‹  ë¶„ë“¤ì„ ìœ„í•´ ì €í¬ê°€ ëª‡ ë¶„ ë” ì´ ìë¦¬ì— ìˆì„ ì˜ˆì •ì´ë‹ˆ, ì•ìœ¼ë¡œ ëª‡ ë¶„ê°„ ì´ ìë¦¬ì— ìˆê² ìŠµë‹ˆë‹¤. ë‹¤ì‹œ í•œë²ˆ ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">Here's a summary of the key points from the Establishment Labs Investor Day transcript in Korean:<br><br>â€¢ ì‹¤ì  ë° ì„±ì¥<br>- 2025ë…„ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ $2.05-2.1B ë‹¬ì„± ì „ë§<br>- ë¯¸êµ­ ì‹œì¥ì—ì„œ $35M ëª©í‘œë¥¼ í¬ê²Œ ìƒíšŒí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒ (Q2 ë§¤ì¶œ $9.5M ì´ìƒ ì „ë§)<br>- í–¥í›„ 3ë…„ê°„ ì—°í‰ê·  20% ì„±ì¥ë¥  ëª©í‘œ<br><br>â€¢ ì œí’ˆ ë° ê¸°ìˆ  í˜ì‹ <br>- Motiva ì„í”Œë€íŠ¸ì˜ ìš°ìˆ˜í•œ ì•ˆì „ì„± ì…ì¦ (í•©ë³‘ì¦ ë°œìƒë¥  1% ë¯¸ë§Œ)<br>- ìµœì†Œ ì¹¨ìŠµ í”Œë«í¼(Mia, Preservay) ì¶œì‹œë¡œ ì‹œì¥ í™•ëŒ€ <br>- 2026ë…„ë¶€í„° ë¯¸êµ­ì—ì„œ ìƒˆë¡œìš´ ì œí’ˆ/ì ì‘ì¦ ìˆœì°¨ ì¶œì‹œ ì˜ˆì •<br><br>â€¢ ì‹œì¥ ê¸°íšŒ<br>- GLP-1 ì•½ë¬¼ ì‚¬ìš© ì¦ê°€ë¡œ ì¸í•œ ìƒˆë¡œìš´ ìˆ˜ìš” ì°½ì¶œ ì „ë§<br>- ì˜ì‚¬ë“¤ì˜ ë†’ì€ ì œí’ˆ ë§Œì¡±ë„ì™€ ê°•ë ¥í•œ ì„ìƒ ë°ì´í„°<br>- íˆ¬ëª…ì„± ì¦ê°€ì™€ ì†Œë¹„ì ì¸ì‹ ê°œì„ ìœ¼ë¡œ ì‹œì¥ í™•ëŒ€ ê¸°ëŒ€<br><br>â€¢ ì¬ë¬´ ì „ë§<br>- ë¯¸êµ­ ì‚¬ì—… ì„±ì¥ê³¼ ìš´ì˜ íš¨ìœ¨í™”ë¡œ ìˆ˜ìµì„± ê°œì„ <br>- 2025ë…„ EBITDA í‘ìì „í™˜, 2026ë…„ í˜„ê¸ˆíë¦„ í‘ì ëª©í‘œ<br>- í”„ë¦¬ë¯¸ì—„ ê°€ê²© ì „ëµ ìœ ì§€ ì¤‘ì´ë©° ì‹œì¥ ìˆ˜ìš©ë„ ì–‘í˜¸</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Question-and-Answer Session</td><td>ì§ˆì˜ì‘ë‹µ ì‹œê°„</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">I don't see any transcript to analyze. Could you please provide the earnings call transcript that you'd like me to summarize in Korean? Once you share the content, I'll help create 3-5 clear bullet points focusing on:<br><br>- ì£¼ìš” ì¬ë¬´ ì§€í‘œ<br>- ê°€ì´ë˜ìŠ¤ ì—…ë°ì´íŠ¸<br>- ê²½ì˜ì§„ì˜ í†¤<br>- ì ì¬ì  ë¦¬ìŠ¤í¬ì™€ ê°•ì </p>
    <hr style="margin:50px 0;">
    
</body></html>